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ABSTRACT 
 
Chronic kidney disease (CKD) is a common and serious problem causing a significant burden to 
healthcare systems and, most importantly, the affected individual. Despite this, few successful 
treatments exist for CKD. Understanding the pathophysiological features that are common to 
chronic kidney pathologies is vital to identify targets for treatment. Oxidative stress has been 
implicated in all chronic diseases, acting via highly conserved pathways of disease progression. 
However, evidence to date shows limited benefit of antioxidants as therapies for CKD patients, 
suggesting a need to better identify the pathways that are stimulated. 
This thesis focuses on the role of oxidative stress, the regulation of mitochondrial homeostasis, the 
action of antioxidant compounds, and the disruption of oxidant signalling networks in chronic 
kidney pathologies (reviewed in Chapter 1). The aims of this project were to: (1) to use an in vitro 
model of oxidative stress-induced kidney injury to determine how a failure in balance between 
oxidative stress and oxidant control causes the cellular characteristics of CKD, then to determine 
whether exogenous antioxidants can prevent and restore renal cell bioenergetics and reduce cell 
injury; (2) to use an in vivo model of oxidative stress-induced kidney injury with molecular and 
metabolic imaging to measure potential biomarkers identified in Aim 1, in association with changes 
in kidney structure and function, and determine whether treatment with an antioxidant therapy 
modulates kidney disease pathology; and (3) to explore the links between biomarkers of oxidative 
stress and clinical characteristics of CKD in patients to determine whether a lifestyle intervention in 
conjunction with standard nephrology care improve systemic oxidative stress and whether this 
influences kidney function. The renal specific in vitro, in vivo, and clinical models and the methods 
used are explained in Chapter 2. 
 
Chapter 3 reports the separate and cumulative effects of oxidative stress, mitochondrial 
dysfunction and cell senescence in promoting loss of renal cells in an in vitro model of kidney 
disease. The results demonstrate that oxidative stress and cell senescence cause mitochondrial 
destabilization and kidney tubular epithelial cell loss. This may contribute to the development of 
cellular and tissue atrophy seen in CKD. 
 
Chapter 4 further defines the role of mitochondrial alterations as a consequence of a specifically-
impaired oxidant signalling regulatory mechanism, namely, peroxisome proliferator-activated 
receptor-gamma (PPARγ)-regulated mitochondrial biogenesis. Oxidative stress promoted 
mitochondrial destabilisation in kidney proximal tubular epithelial cells, in association with 
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increased PPARγ Serine 112 phosphorylation. Despite their positive effects in other tissues, PPARγ 
agonists failed to protect proximal tubular epithelial (PTE) cells, and appear to be detrimental to 
kidney PTE cell health when oxidative stress induces the cell damage. 
 
Chapter 5 examined mediators of oxidative stress in an in vivo model of acute to chronic kidney 
injury progression, in a spatial and temporal manner via intravital multiphoton microscopy (MPM) 
in the mouse kidney. Fluorescence lifetime imaging microscopy (FLIM) coupled MPM identified 
significant and dynamic metabolic substrate utilisation by kidney tubular cells promoting oxidative 
stress in progressive CKD. Mitochondrial dysfunction is persistent in structurally-normal tubules of 
the chronically-damaged kidney, potentially enhancing free radical production in a progressive 
manner. 
 
Chapter 6 examined the influence of antioxidants in reducing oxidative stress-induced kidney 
damage using in vitro and in vivo models. In vitro studies revealed that NAC was superior in 
reducing oxidative stress-induced PTE cell apoptosis, compared to Coenzyme Q10, alpha(α)-
tocopherol or trolox. In vivo studies utilised 4-6 week old C57Bl6 mice on a 5% NAC diet that 
underwent bilateral ischaemia-reperfusion injury (20 min). Intravital MPM, histopathology, and 
protein analysis revealed that NAC protects against early kidney damage, but enhances the 
progression of chronic kidney pathology by eliminating redox-sensitive endogenous cytoprotective 
signalling. FLIM of cortex and medulla highlight mitochondrial dysfunction and the negative 
effects of NAC. This does not support general antioxidants for the treatment of CKD. 
 
Chapter 7 examined systemic biomarkers of oxidative stress in stage 3-4 CKD patients. 136 
patients from the LANDMARK-III cohort underwent standard nephrology care with or without an 
exercise and lifestyle intervention. Clinical tests and oxidative stress biomarkers (plasma 
isoprostanes, glutathione peroxidase, total antioxidant capacity) were taken at baseline and at 12 
months. No significant differences were identified over 12-months in systemic oxidative stress 
markers, or eGFR. The results highlight the biological variability of systemic oxidative stress 
biomarkers in CKD patients. 
 
In summary (Chapter 8), this thesis presents oxidative stress as a common and unifying concept of 
pathophysiological change in chronic kidney pathology at a cellular level. Oxidative stress actively 
promotes cell death and cell cycle arrest in PTE cells whilst enhancing the secretion of pro-fibrotic 
factors to increase tubulointerstitial fibrosis. Correcting this process requires are targeted approach, 
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however is increasingly difficult given the complexity of the cellular, physiological, and systemic 
responses to oxidative stress. 
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CHAPTER 1 
 
Literature Review, Hypotheses and Aims 
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This thesis is presented as a literature review (Chapter 1) followed by a chapter detailing general 
materials and methods (Chapter 2), five original research sections that have, in some cases, been 
published (Chapters 3-7) and a general discussion of the results (Chapter 8). Copies of the published 
review articles relevant to this thesis and original research publications can be found in Appendices 
A. The review articles contribute to, and were updated, for Chapter 1.  
 
1.1 GENERAL INTRODUCTION 
 
Chronic disease is an increasingly important concern to health systems worldwide. Kidney disease 
is no exception to this, with increasing incidence and prevalence of chronic kidney disease (CKD) 
in developed and developing nations (Saran et al., 2010). The population prevalence of CKD 
exceeds 10 % in most countries and is more than 50 % in high-risk subpopulations (Hallan et al., 
2012; Levey and Coresh, 2012; Matsushita et al., 2012; Eckardt et al., 2013). Recent evidence from 
the Australian population shows that 1 in 10 adults has CKD (ABS, 2013) while 1 in 3 is at 
increased risk of developing CKD throughout their life (KHA, 2014). The insidious nature of CKD 
is evident in that less than 10 % of people with CKD are aware they have symptoms of CKD (ABS, 
2012; Radhakrishnan et al., 2014). Most importantly, since 2000 there has been a dramatic increase 
in the prevalence of end stage kidney disease (ESKD) suggesting that current therapies that target 
progressive CKD have limited impact (White and Chadban, 2014). The identification of 
therapeutics that target particular mechanisms or molecular pathways is hindered by the disparate 
aetiology of CKD. A growing body of evidence demonstrates that the kidneys are not only target 
organs of many diseases but also can initiate a systemic pathophysiological process owing to their 
complex functions and effects on body homeostasis. Even with no other overt pathology such as 
hypertension or diabetes, age per se is a major risk factor for development of CKD (Radhakrishnan 
et al., 2014), further adding to the health burden in our increasingly ageing population. Research 
investigating the development and progression of CKD is increasingly necessary. 
 
CKD is primarily defined by a reduction in glomerular filtration rate (GFR) and increased urinary 
albumin excretion. It was originally categorised into five different stages, usually according to the 
estimated glomerular filtration rate (eGFR), but stage 3 CKD has now been separated into two 
stages, 3a and 3b (Fig. 1.1) (Johnson et al., 2013). An eGFR of at least 90 mL/min/1.73m
2
 with 
other indicators of kidney damage over three months is classified as stage 1 and represents early 
evidence of developing CKD, but not at a level that is dangerous to human health. However, this 
early development of CKD may be exacerbated by other superimposed causes of renal injury, such 
as high blood pressure, high blood lipids, diabetes and high blood glucose, chronic systemic 
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Figure 1.1: Factors that influence the development of chronic kidney disease 
Chronic kidney disease (CKD) has many modifiable and non-modifiable causes. Ageing is one of 
the non-modifiable causes and its effects are accelerated by the presence of other age-related 
diseases like type 2 diabetes and hypertension. CKD is graded in stages from 1 to 5, according to an 
estimated glomerular filtration rate (GFR). Cardiovascular disease, infections and anaemia all 
exacerbate outcomes of CKD. The final stage, end stage kidney disease, causes uraemia at toxic 
levels and is treatable only with renal replacement therapies such as dialysis or transplantation. 
(AKI, acute kidney injury) 
 
inflammation, or a build-up of environmental toxins. The functional impairment of the kidney is 
accompanied by pathological changes including increased tubular atrophy, interstitial fibrosis, 
glomerulosclerosis, renal vasculopathy and reduced regenerative capabilities of renal cells 
(Pannarale et al., 2010). 
 
The structural changes of CKD result in a stochastic deleterious effect on renal function. Over time, 
the renal damage may progress to stage 5 CKD, also known as ESKD, when renal function needs to 
be supplemented with dialysis, or renal transplant is necessary. Common health problems of the 
general population, including obesity, diabetes and cardiovascular disease (CVD), have a causative 
and/or synergistic relationship with CKD development. The aptly named cardio-renal syndrome is 
becoming increasingly defined as a disorder in itself, caused by an acute or chronic dysfunction of 
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the heart or kidneys leading to an acute or chronic dysfunction of the other organ (Ronco et al., 
2010). Although the aetiology and details of this disorder have yet to be validated, the outcomes of 
patients with CKD who develop co-morbid CVD are significantly poorer. 
 
The kidneys are highly susceptible to age-related degeneration (Beeson et al., 2010). They are one 
of the hardest working organs in the body, highly metabolising and reliant on a high energy 
production right throughout human life. In ageing, the kidneys show greater development of chronic 
pathology compared with brain, liver and heart, and this may relate to the gradual loss of renal 
energy through loss of mitochondrial function with ageing (Percy et al., 2009). The aetiology of 
CKD is far reaching and includes specific diseases, such as diabetes, hypertension, or 
glomerulonephritis, or environmental factors such as those that influence metabolic syndrome or 
acute kidney injury (AKI). Each cause of CKD may have unique mechanisms that drive the 
progression of CKD, but often an underlying mechanism relates to mitochondrial dysfunction and 
oxidative stress. Oxidative stress, therefore, presents a useful target to slow the progression of CKD. 
However, oxidative stress is difficult to define at a cellular level, given its ubiquitous nature 
systemically.  
 
The following literature review will initially describe oxidative stress, the involvement of 
mitochondrial dysfunction and the associated molecular pathways, the role of oxidative stress in 
CKD pathogenesis, how oxidative stress may be measured, and will give an update on the 
amelioration of CKD using antioxidant therapies. 
 
1.2 LITERATURE REVIEW 
 
1.2.1  Oxidative stress: role in kidney disease 
Oxidative stress may be defined as a disturbance in regular cellular and molecular function caused 
by an imbalance between production of reactive oxygen species (ROS) and similar molecules, 
reactive nitrogen species (RNS), and the natural antioxidant ability of our cells (Pias and Aw, 2002; 
Zhuang et al., 2007; Gomes et al., 2009). Examples of the endogenous and exogenous sources of 
cellular ROS are listed in Table 1.1 and a list of the common reactive species is found in Table 1.2. 
Free radicals normally have a tightly regulated role as effectors of intracellular signalling pathways, 
by the activation of downstream targets for the maintenance of healthy tissue functionality. For 
example, physiological ligands act at specific targets to induce small bursts of ROS that control 
many physiological functions (Blanchetot et al., 2002; Meng et al., 2002; Rao and Clayton, 2002). 
Thus, the oxidative stress theories of disease development are controversial (Linnane and Eastwood, 
5 
 
2004, 2006; Linnane et al., 2007b). Nonetheless, theories involving oxidative stress, as distinct 
from oxidant metabolism, explain many of the accumulated cellular deficits of disease 
pathogenesis. 
 
 
 
 
 
 
 
 
 
 
 
a
 A free radical is defined as any molecule that has a spare electron in its outer shell. 
b
 A non-radical does not contain a spare electron but is either an oxidizing agent or is easily 
converted to a free radical. 
 
The kidney is highly energetic and therefore relies heavily on aerobic metabolism for the production 
of adenosine triphosphate (ATP) by oxidative phosphorylation (Beeson et al., 2010). The reduction 
of molecular oxygen along the electron transport chain (ETC) within mitochondria is vital for 
cellular function, yet potentially devastating long-term. Highly reactive molecules that contain extra 
Table 1.1: Endogenous and exogenous sources of reactive species 
Endogenous factors Exogenous factors 
 
Mitochondrial oxidative phosphorylation 
Xanthine oxidase, NADPH oxidase 
Inflammatory cells 
Endosome/lysosome degradation 
Angiotensin II 
Fibroblasts 
Endoplasmic reticulum 
Peroxisomes 
 
Environmental pollutants and toxins 
Cigarette smoke 
Hypoxia 
Hyperoxia 
Radiation (sunlight, UV radiation) 
Infectious microbes 
High calorie diet 
Glucotoxicity 
Table 1.2: Common reactive species 
 Free Radicals
a 
Non-Radical
b
 
Reactive Oxygen Species Superoxide (O2
•-
) 
Hydroxyl (OH
•
) 
Peroxyl (R-O
-
) 
Hydrogen peroxide (H2O2) 
Organic peroxides (R-OOH) 
e.g. lipid peroxides 
Hypochlorous acid (HOCl) 
Reactive Nitrogen Species Nitric Oxide (NO
•
) 
Nitrogen dioxide (NO2) 
Peroxynitrite (ONOO
-
) 
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electrons in their outer-shell are produced as by-products of oxidative phosphorylation. These ROS 
have the ability to damage lipids, deoxyribose nucleic acid (DNA) and proteins (Nemoto et al., 
2000). By-products of oxidative damage are increasingly found in various tissues with age. These 
by-products are believed to be a result of disturbances in the normal physiological oxidant pathways 
in young healthy renal cells, over time (Qiao et al., 2005; Choksi et al., 2007; Miyazawa et al., 
2009; Park et al., 2011). 
 
It is likely that, in a multifactorial process like a chronic disease, no theories for development of 
structural and functional deficit are mutually exclusive. The effect of age on kidney function has 
been well documented in a large range of mammalian models (Goyal, 1982; Clark, 2000; Esposito 
et al., 2007; Pannarale et al., 2010). Renal function is, in fact, considered a good predictor of 
longevity, with a close association found between a reduction in renal function and increase in all-
cause mortality (Chien et al., 2008; Liao et al., 2009). CKD patients display increased biomarkers 
of oxidative stress compared to the non-CKD population (Dounousi et al., 2006). Interestingly, 
other age-related diseases, such as neurodegenerative disease, which are also influenced by 
oxidative stress (Mancuso et al., 2006) also have an increased incidence in the CKD population 
(Post et al., 2010). This perhaps demonstrates oxidative stress as an important pathogenic factor in 
the development of multiple chronic diseases in the one patient. 
 
1.2.2 Role of the mitochondria and reactive oxygen species 
Fig. 1.2 demonstrates pathways to, and natural antioxidant neutralisation of, common ROS. The 
main ROS are superoxide (O2
•-
), the hydroxyl radical (OH
•
) and hydrogen peroxide (H2O2). 
Although the mitochondria are considered the major source of ROS, other contributing sites of ROS 
generation include the endoplasmic reticulum, peroxisomes and lysosomes (Fig. 1.2) (Madesh and 
Hajnoczky, 2001; Soubannier and McBride, 2009; Vay et al., 2009). Estimated levels of ROS 
within mitochondria are 5-10 fold higher than cystolic and nuclear compartments (Cadenas and 
Davies, 2000) due to the presence of the ETC within the mitochondrial inner membrane. 1-3 % of 
inspired molecular oxygen (O2) is converted to the most common of the ROS, O2
•-
 (Boveris and 
Chance, 1973; Nohl and Hegner, 1978), a powerful precursor of H2O2. Although cellular H2O2 is 
stable in this form, it has the potential to interact with a variety of substrates to cause damage, 
especially in the presence of the ferrous iron (Fe
2+
), which leads to cleavage and formation of the 
most reactive and damaging of the ROS, the OH
•
. In healthy metabolic cells, the production of the 
potentially harmful H2O2 is countered by the catalysing actions of mitochondrial or cystolic catalase 
(CAT), or thiol peroxidases, into water and O2. 
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Figure 1.2: Cellular sites of free radical generation and interactions 
The mitochondrion produces high levels of the superoxide anion (O2
•-
) as a by-product of oxidative 
phosphorylation. O2
•-
 is converted to stable hydrogen peroxide (H2O2) by manganese superoxide 
dismutase (MnSOD). Protein assemblage by the endoplasmic reticulum and fatty acid breakdown 
by peroxisomes also account for O2
•-
 generation, whereby conversion to H2O2 occurs due to 
copper/zinc superoxide dismutase (Cu/ZnSOD). Catalase (CAT) is able to neutralise H2O2 into 
water (H2O) and oxygen (O2). In the presence of high amounts of H2O2, heavy metals (Fe
+2
 or Cu
+2
) 
can form the highly reactive hydroxyl anion (OH
•
). Nitric oxide (NO
•
) and O2
•-
 have the ability to 
form the highly reactive nitrogen species, peroxynitrite (ONOO
-
), which, in the presence of carbon 
dioxide (CO2) forms nitrogen dioxide (NO2) and the reactive carbonyl species, the carboxyl anion 
(CO3
-
). 
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The ETC consists of 5 multi-enzyme complexes responsible for maintaining the mitochondrial 
membrane potential and ATP generation. Each of these complexes presents a site of ROS 
generation, however complexes I and III have been identified as primary sites of O2
•-
 generation 
(Cadenas et al., 1977; Turrens and Boveris, 1980; Turrens et al., 1985; Turrens, 2003). ROS 
generation from mitochondrial complexes increases with age in mice (Choksi et al., 2007). In 
humans, Granata and colleagues (2009) have reported that patients with CKD and haemodialysis 
patients display impaired mitochondrial respiration. 
 
Oxidative phosphorylation is a highly orchestrated process and involves the pumping of protons 
into the inter-membrane space to create the mitochondrial membrane potential which is harnessed 
to synthesize ATP. Complex I, also known as nicotinamide adenine dinucleotide (NADH) 
dehydrogenase, or NADH-CoenzymeQ (NADH-CoQ) reductase, facilitates the transfer of electrons 
between NADH to CoQ10 (sometimes known as ubiquinone). Complex I has been identified as a 
major site of O2
•-
 production (Liu et al., 2002), increasing with age (Choksi et al., 2007). Inhibition 
of complex I with rotenone reduces O2
•-
  production significantly (Lenaz, 2001). The potential for 
alterations at this site with age favour the use of exogenous CoQ10 as an electron acceptor of 
excessive NADH derived radicals. Ubiquinol-cytochrome C oxidoreductase (Complex III) has also 
been identified as a major site of oxidant production. Furthermore, in an altered state, complex II 
can exhibit properties that would allow the reduction of O2 to O2
•-
 (Ishii et al., 1998). Two 
mitochondrial oxidoreductase enzymes, glycerol-1-phosphate dehydrogenase and dihydroorotate 
dehydrogenase are also involved in the production of ROS. However, O’Toole and colleagues 
(2010) demonstrated recently that defects in oxidative phosphorylation may be due to the use of 
substrates in the respiratory chain, such as the reduced NADH and NADH oxidase, and not due to 
alterations in the proteins of the respiratory complexes. Thus, it is likely that both altered respiratory 
complexes and substrates lead to an inefficiency of electron transport and subsequent increased 
ROS generation, decreased ATP production and a loss of the mitochondrial membrane potential. 
Continual damage of this system with age produces a vicious cycle of increasing ROS generation 
and cell dysfunction. 
 
Given that ROS are likely to be highly damaging molecules to cells, why have the mitochondria not 
evolved more efficient systems that limit mitochondrial oxidants? One possible answer is they are 
also involved in highly conserved basic physiological processes and are effectors of downstream 
pathways. Although there is evidence for this (Nemoto et al., 2000; Werner and Werb, 2002), the 
specific mechanisms are difficult to define because of the rapidity of oxidant signalling (Cadenas 
and Davies, 2000). For example, protein tyrosine phosphatases are major targets for oxidant 
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signalling since they contain the amino acid residue cysteine that is highly susceptible to oxidative 
modification (Cooper et al., 2002). Meng and colleagues (2002) demonstrated the oxidation of the 
SH2 domain of the platelet-derived growth factor (PDGF) receptor, which contains protein tyrosine 
phosphatases, in response to PDGF binding. This may indicate the induction of free radicals in 
response to receptor activation by a cognate ligand in a process that is similar to phosphorylation 
cascades of intracellular signalling. 
 
Free radical damage to mitochondria with increasing age may not increase the generation of ROS, 
but instead inhibit mitochondrial function and ROS generation (de Grey, 2000, 2002). This theory 
relies on free radical damage to mitochondrial DNA (mtDNA) that causes mutations and therefore 
defects to complexes I and III of the ETC. This reduces mitochondrial ROS generation, and also 
enables mitochondria defective in mtDNA to avoid autophagy, a process traditionally believed to 
control intracellular removal and recycling of dysfunctional mitochondria within the cellular 
lysosome system. By inhibiting oxidative phosphorylation as an option for cellular energy 
metabolism and ATP synthesis, the cell has to utilize alternate forms of electron transport to 
reoxidize NADH and generate NAD+ to sustain ATP production by glycolysis. Thus, the plasma 
membrane redox system may facilitate the transfer of electrons from NADH inside the cell to 
outside the cell, and in doing so regenerate NAD+ to NADH and contribute to extracellular ROS 
(Close et al., 2007). However, no experimental evidence exists for this theory. 
 
Mitochondria are intimately linked to metabolism since they act, principally, as the main site for 
metabolism. However, there are recent and interesting investigations that highlight the importance 
of mitochondria during cell stress. The mitochondrial oasis hypothesis states that the NAD+ content 
and energetics of mitochondria determine cell survival in the fate of genotoxic stress and DNA 
damage, independent of the state of the cytoplasm or nucleus (Yang et al., 2007a). This is achieved 
through an increase in mitochondrial nicotinamide phosphoribosyltransferase (Nampt), which is the 
biosynthetic enzyme needed to create NAD+, as well as mitochondrial NAD+-dependent 
deacetylases sirtuin 3 (Sirt3) and Sirt4. Furthermore, with age there is a specific loss of 
mitochondrial, and not nuclear, encoded oxidative phosphorylation sub-units. Thus, the decline in 
NAD+ that occurs with age is facilitated by a loss of nuclear-mitochondrial communication. This 
leads to a pseudo hypoxic state that contributes to the decline in mitochondrial function with age 
(Gomes et al., 2013). 
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1.2.3 Natural defences: endogenous antioxidants 
The production of ROS is usually in balance with the availability and cellular localisation of 
antioxidant enzymes such as superoxide dismutase (SOD), CAT and glutathione peroxidase (GPX) 
(Fig. 1.2). In vivo studies have found accumulated oxidative damage occurs from decreased levels 
of these enzymes rather than increased ROS production (Kokoszka et al., 2001; Meng et al., 2007). 
However, adequate levels of both are likely to be vital for normal cell function. Mitochondria 
possess their own pool of antioxidants to counteract their generation of ROS. Mitochondrial 
manganese-SOD (Mn-SOD) converts O2
•-
 to H2O2 which is then decomposed to harmless H2O and 
O2 by CAT and Gpx (Raha et al., 2000). Copper/zinc-SOD (Cu/Zn-SOD) has been implicated in 
stabilizing O2
•-
 within other cellular compartments, especially peroxisomes, and must be considered 
in maintenance of the redox state of the whole cell (Angermuller et al., 2009; Islinger et al., 2009). 
Limited antioxidant actions of Cu/Zn-SOD may also occur within the inter-membrane space (Sturtz 
et al., 2001). There is no evidence to indicate that glutathione synthesis occurs within mitochondria, 
however the mitochondria have their own distinct pool of glutathione required for the formation of 
Gpx (Soderdahl et al., 2003). 
 
Among the various endogenous defences against ROS, glutathione homeostasis is critical for a 
cellular redox environment and works in a critical coordinated fashion. Glutathione-linked 
enzymatic defences of this family include GPX, glutathione-S-transferase (GST), glutaredoxins 
(Grx), thioredoxins (Trx), and peroxiredoxins (Prx) (Godoy et al., 2011). Many of these proteins are 
known to interact with each other, forming redox networks which have come under investigation 
for their contribution to dysfunctional oxidant pathways. Mitochondrial-specific isoforms of these 
proteins also exist and include Grx2, Grx5, Trx2 and Prx3 (Lillig and Holmgren, 2007; Lonn et al., 
2008; Hanschmann et al., 2010) which may be more critical for cell survival compared to 
their cytosolic counterparts (Soderdahl et al., 2003). Mitochondrial dysfunction, resulting in 
depleted ATP synthesis, has the potential to reduce the redox control of glutathione since the rate of 
glutathione synthesis is ATP dependent (Lash et al., 2002). Intracellular synthesis of glutathione 
from amino acid derivatives (glycine, glutamic acid and cysteine) accounts for the majority of 
cellular glutathione compared with, for example, the uptake of extracellular glutathione from the 
bicollateral membrane in epithelial tubular cells of the renal nephron (Visarius et al., 1996). This 
characteristic may account for different segments of the nephron being differently-susceptible to the 
same insult, since proximal tubular epithelial (PTE) cells lack the ability to synthesise glutathione, 
compared with other segments of the nephron which have that ability (Hall et al., 2009). There may 
also be “antioxidant networks” in which there is interplay, crosstalk, and synergism to efficiently 
and specifically scavenge ROS. If this is the case, these antioxidant networks could be harnessed by 
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researchers to develop polytherapeutic antioxidant supplements to combat oxidant-related 
pathologies, like CKD. 
 
1.2.4 Mitochondrial biogenesis and degradation: molecular pathways 
Although oxidative stress has been recorded as a mechanistic factor in many forms of kidney 
disease, including CKD, the role of mitochondrial dysfunction and the molecular pathways that are 
involved in this process, have received little attention. Here, characteristics and molecular pathways 
of mitochondrial biogenesis and degradation are described. Some of these will receive attention in 
the research of this thesis. 
 
Mitochondrial biogenesis and the degradation of mitochondria (mitophagy) usually occur in balance 
within healthy cells, including those of the kidney (Gunst et al., 2013). The imbalance between 
mitochondrial biogenesis and mitophagy has come under investigation recently as a major 
contributor to oxidative stress and cellular metabolic decline (Kirkin et al., 2009). It was 
traditionally believed that autophagy (literally, “self-eating”) was a non-selective cell regulatory 
mechanism for the degradation of dysfunctional organelles within the cellular lysosome system 
(Kurz et al., 2007). However, the discovery of the autophagy genes, particularly Atg32, as 
mitochondrial transmembrane receptors directing autophagosome formation, has uncovered a 
highly selective process of removal of damaged mitochondria (Okamoto et al., 2009). A major 
pathway for injury-induced mitochondrial degradation is the phosphate and tensin homology-
induced kinase 1 (PINK1) - Parkin 2 (Park2) pathway. Park2 is an E3 ubiquitin ligase that 
translocates to mitochondria and mediates mitochondrial degradation (Narendra et al., 2008; Cai et 
al., 2012). The adaptor protein p62 facilitates selective autophagy into the light chain-2 beta 
(LC3β)-regulated machinery for lysosomal degradation (Bjorkoy et al., 2005; Geisler et al., 2010). 
p62 is not required for Park2 translocation to damaged mitochondria, but is essential for final 
autophagic clearance (Geisler et al., 2010). This response is enhanced by a decrease in ATP 
production due to dysfunctional mitochondria, and is regulated by the intracellular energy sensor, 
adenosine monophosphate-activated protein kinase (AMPK) (Egan et al., 2011). These pathways 
are summarised in Figure 1.3. 
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Figure 1.3: Degradation of mitochondria via autophagy (mitophagy) 
Parkin is an E3 ubiquitin ligase that translocates to defective mitochondria, effectively labelling 
them for degradation. Autophagy is initiated by folding of the endoplasmic reticulum membrane 
and formation of the isolation membrane expressing light chain 3-II (LC3-II). The adapter protein 
p62 facilitates sequestration of parkin-labelled mitochondria into the autophagosome through LC3-
II binding. Following closure of the autophagosome, lysosomes fuse to the autophagosome to form 
the autolysosome, and the intra-autophagosomal contents are degraded by lysosomal hydrolases.   
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Failure to restore mitochondrial homeostasis and function can lead to a progressive increase in ROS 
and ensuing oxidative stress. Peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
(PGC-1α) is a nuclear transcription factor shown to mediate almost all aspects of mitochondrial 
biogenesis, and is considered a master regulator of biogenesis (Hock and Kralli, 2009). Therefore, 
PGC-1α activation presents a crucial target for mitochondrial preservation. Previous studies have 
demonstrated pharmacological peroxisome proliferator-activated receptor gamma (PPARγ) 
activation and induction of mitochondrial biogenesis (Hondares et al., 2006; Rasbach and 
Schnellmann, 2007). Increasing mitochondrial biogenesis is an attractive target to reduce cellular 
metabolic injury and improve recovery. However, it must be realised that increasing the number of 
mitochondria could possibly worsen tissue hypoxia due to increased oxygen consumption. 
 
1.2.5 Cellular apoptosis, regeneration and senescence 
One of the frequently-seen structural characteristics of CKD is tubular atrophy. This involves cell 
deletion via apoptosis, a process first described in the kidney by Gobe and Axelsen (1987) but 
which has been extensively studied since. Along with the atrophic tubules, foci of regenerating 
tubules are often seen histologically in the kidneys of CKD patients. Although very important in 
maintaining renal function in the presence of significant tissue deletion, this has received less 
attention than apoptosis (Yang et al., 2014). Finally, one of the least studied of the characteristics of 
tubular atrophy in CKD is the development of cell senescence (Melk et al., 2004). Apoptosis and 
cell senescence both have some links with mitochondrial dysfunction. The characteristics of 
apoptosis and the balance of regeneration, and cell senescence, will be discussed in the following 
section. They will also form part of the analyses in the original research chapters of this thesis. 
 
1.2.5.1 Apoptosis 
Apoptosis is a rapid, highly conserved process of gene-driven, programmed cell death required for 
normal physiological homeostasis (Kerr et al., 1972). Apoptosis is also central to many diseases, 
including CKD (Yang et al., 2007b; Hughson et al., 2008) where the general loss of functioning 
renal mass of up to 25 % is attributed, at least in part, to apoptosis (Percy et al., 2008). Pro-
apoptotic proteases, known as caspases, play essential roles in apoptosis. ROS generation may 
cause suppression of phosphorylation of the anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein and 
loss of mitochondrial membrane potential. Thus, mitochondrial dysfunction, oxidative stress and 
ROS are closely associated with renal apoptosis, and as a consequence, the development of CKD 
(Sanz et al., 2008; Miyazawa et al., 2009). 
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Figure 1.4 demonstrates some of the molecular pathways involved in apoptosis. The extrinsic 
pathways start, in general, with ligation of death receptors, like Fas, with ligands, like FasL and 
tumour necrosis factor-α (TNFα), from outside the cell. The intrinsic apoptotic pathway involves 
action at the mitochondria, and this might be initiated by ROS. Both pathways can impact in 
mitochondrial function through activation of members of the Bcl-2 family of proteins. This family 
has anti-apoptotic (Bcl-2, the long Bcl isoform Bcl-xl, Mcl-1) and pro-apoptotic (Bcl-2-associated x 
protein/Bax; Bcl-2 antagonist killer/Bak; Bid) members. Bid is crucial for the induction of death 
receptor-mediated apoptosis in primary tissues; but Bax is more generally recognised as a pro-
apoptotic Bcl-2 protein acting at the mitochondria (Lindsay et al., 2011). Once the mitochondrial 
membrane is injured, another set of molecules is released (cytochrome C/Cyt C) or activated 
(apoptotic peptidase activating factor-1/Apaf-1, caspases 9 and 3), and the structural characteristics 
of apoptosis become evident. 
 
The intrinsic pathway to apoptosis is of particular importance to age-related CKD since it involves 
mitochondrial dysfunction and excessive ROS generation (Madesh and Hajnoczky, 2001; Ott et al., 
2007). Opening of the mitochondrial permeability transition pore (PTP) releases Cyt C, which had 
been previously bound to the inner mitochondrial membrane by an association with the anionic 
phospholipid, cardiolipan. Increased oxidative stress results in increased amounts of Cyt C in the 
cytosol, suggesting that ROS causes a dissociation of Cyt C from cardiolipan (Miyazawa et al., 
2009). Cytoplasmic Cyt C binds and activates caspase-9, one of the proteases known to act in the 
apoptotic pathways. Activated caspase-9 forms an apoptosome with Apaf-1, leading to 
phosphorylation and cleavage of caspase-3 and subsequent morphological changes of apoptosis (Li 
et al., 1997; Allan and Clarke, 2009). 
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Figure 1.4: Apoptotic pathway involving cytochrome c release 
During apoptosis processing using intrinsic or extrinsic pathways, cytochrome c moves from its 
location between the outer and inner membranes of mitochondria and is rapidly released into the 
cytosol. Activation and translocation of pro-apoptotic Bcl-2 family members such as Bax and Bak 
to the mitochondria cause the opening of the channels in the outer and inner mitochondrial 
membranes, thereby inducing a permeability transition. Once released, cytochrome c forms a 
complex with apoptotic peptidase activating factor-1 (Apaf-1) and procaspase-9, termed the 
apoptosome. This interaction causes cleavage and activation of caspase -9, which in turn activates 
the executioner caspase-3, which then induces the structural changes that are characteristic of 
apoptosis. (Small and Gobe, 2012) 
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The translocation of the Bcl-2 family proteins, especially pro-apoptotic Bax and Bak, to the 
mitochondria of kidney cells is the precursor to opening of the mitochondrial PTP, release of Cyt C 
and resultant apoptosis (Degenhardt et al., 2002). Bax and Bak interact with the outer mitochondrial 
membrane, causing its permeabilization, however endogenous anti-apoptotic proteins (like Bcl-2 or 
Bcl-xl) also translocate from the cytoplasm to the mitochondrial membrane, protecting renal tubular 
epithelial cells against oxidative stress (Cuttle et al., 2001). Apoptosis inducible factor (AIF) 
possesses an oxidoreductase domain which aids in the scavenging of ROS when localised within 
the mitochondria. However, cytosolic localisation of AIF triggers apoptosis via pro-apoptotic Bcl-2 
proteins and caspase activation. This characteristic is also noted with Cyt C within and outside 
mitochondria which presents a possible cellular location-specific function of ROS-induced proteins 
as well as mitochondrial-cystolic communication by mitochondrial oxidants. 
 
1.2.5.2 Regeneration 
The regenerative ability of the kidney is limited by its own general health. It is well known that the 
proximal tubule has a substantial repair capacity after injury (Witzgall et al., 1994), however 
whether a stem cell population is responsible for this proliferative response or not remains 
controversial. The classical model of repair after injury in epithelial cells of the proximal tubule 
involves a process of initial dedifferentiation and then proliferation of all surviving epithelial cells 
(Witzgall et al., 1994; Vogetseder et al., 2008). Numerous studies have also suggested a scattered 
intratubular progenitor cell population that is responsible for proliferation following injury (Loverre 
et al., 2008; Lindgren et al., 2011; Angelotti et al., 2012). However, a recent study by Kusaba et al. 
(2014) using genetic lineage analysis, demonstrates that populations of fully differentiated PTE 
cells undergo dedifferentiation, to upregulate apparent stem cell markers and proliferate after injury. 
This provides strong evidence that epithelial dedifferentiation is responsible for regeneration rather 
than a resident adult stem cell population. AKI mouse models have primarily been used to define 
kidney regeneration, and little is known regarding this process in progressive CKD, as well a 
species between mouse and human. 
 
1.2.5.3 Senescence 
Most differentiated cells, as are found in the adult kidney, cannot divide indefinitely due to cellular 
senescence. One theory of cell senescence implicates telomeres, specialized structures that function 
in the protection, positioning and replication of chromosomes. Telomeres shorten after every 
mitotic division. The rate of telomere shortening is determined, at least in part, by the accumulation 
of DNA damage induced by ROS, further implicating the mitochondria in induction of senescence 
(Passos and Von Zglinicki, 2006). However, senescence is also associated with irreversible cell 
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cycle arrest, mainly in the G1 phase of the cell cycle. The senescent cells acquire a large, flat 
morphology, senescence-activated (acidic) β-galactosidase (β-gal) activity, and the upregulation of 
cyclin dependent kinase inhibitors, such as p53, p21
waf
 and p16
ink
 (Stein et al., 1999). Oxidative 
stress plays a role in cell senescence: H2O2 downregulates casein kinase II which is required for 
phosphorylation of DNA-binding proteins, nuclear oncoproteins and transcription factors needed 
for cell proliferation and growth (Ryu et al., 2006). Premature senescence also involves 
modification of the cellular signal transduction pathways (Goldenthal and Marin-Garcia, 2004), and 
a question remains as to the role of ROS and mitochondria in this modification. Lee et al (2010) 
recently demonstrated that increased pro-apoptotic c-Jun N-terminal kinase (JNK) was involved in 
the premature senescence of fibroblasts and breast carcinoma cells, accompanied by a rapid increase 
in mitochondrial ROS production. Basal JNK expression was also necessary for maintaining 
healthy levels of anti-apoptotic proteins, mitochondrial health and inhibition of cell senescence. 
This type of study has not been repeated in the ageing kidney, and needs investigation. 
 
Cell senescence is a defining characteristic of CKD in ageing (Melk, 2003), yet the exact role of 
oxidative stress in renal cell senescence has yet to be defined. Oxidative stress induces premature 
senescence in fibroblast cultures (Frippiat et al., 2001), and retinal epithelium during development 
of macular degeneration (Glotin et al., 2008). The prevention of premature cell senescence with the 
antioxidants quercetin and vitamin E also demonstrates the essential role of oxidative stress in cell 
senescence (Volonte et al., 2002). Given the evidence supporting increased oxidative stress with 
age due to increasing numbers of dysfunctional mitochondria, mitochondria may also play a novel 
and significant role in the premature senescence of kidney cells in CKD, but this has yet to be 
studied. 
 
 
1.2.6 Genes driven by oxidative stress in chronic kidney disease 
Knowledge of the regulatory molecular networks that determine renal health is far from complete. 
Understanding the transcriptional networks that maintain oxidant balance in the mature kidney will 
provide promising entry points for future therapeutic interventions, including for CKD. The 
following paragraphs summarise key aspects of transcriptional regulation in oxidative-stress 
induced CKD. Note that it was not possible for all regulatory molecules that are discussed here to 
be studied in this thesis. 
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1.2.6.1 Peroxisome proliferator activated receptors 
Peroxisome proliferator activated receptors (PPARs) are a class of highly conserved nuclear 
hormone receptor superfamily of ligand-dependent transcription factors that are important 
regulators of metabolism (Ahmadian et al., 2013). There have been three PPAR isoforms identified 
and characterised – PPARα, PPARγ, and PPARβ/δ. PPARα is expressed primarily in liver, heart 
and brown adipose tissue, where it is a major activator of fatty acid oxidation pathways (Evans et 
al., 2004). PPARβ/δ plays a similar role to PPARα however PPARβ/δ is ubiquitously expressed, 
playing more of a role in skeletal muscle, liver and heart (Barish et al., 2006). PPARγ exists as two 
isoforms – PPARγ1 and PPARγ2 – with PPARγ1 being expressed in many tissues including kidney, 
and PPARγ2 expression restricted to adipose tissue, however, has been shown to be induced in 
other tissues by a high fat diet (Medina-Gomez et al., 2007; Tontonoz and Spiegelman, 2008). 
Ligand binding of PPARγ induces heterodimer formation with the retinoic acid receptor and 
complex binding to the peroxisome-proliferator response element within the promoter region of 
target genes involved in lipid metabolism, glucose homeostasis, cell proliferation and inflammation 
(Guan et al., 2002). PPARγ also positively regulates mitochondrial biogenesis through the 
activation of PGC-1α (Portilla et al., 2002; Weinberg, 2011). Therefore PPARγ may influence 
mitochondrial function and the maintenance of mitochondrial homeostasis to restore the 
intracellular redox environment (Funk et al., 2010; Chiang et al., 2013; Zhan et al., 2013). Post-
translational modifications of PPARγ have been shown to regulate its activity including 
phosphorylation (Hu et al., 1996; Leff, 2003), acetylation (Qiang et al., 2012), sumoylation 
(Shimizu et al., 2006), and ubiquitination (Hauser et al., 2000). Each modification has the potential 
to impart distinct features for cell or tissue specific activity of PPARγ. Specific endogenous ligands 
of PPARγ have not been clearly defined, however synthetic ligands such as thiazolidinediones 
(TZDs), are potent activators of PPARγ and are commonly used for their insulin-sensitising 
activities in the management of type 2 diabetes (Kung and Henry, 2012). PPAYγ expression has 
been shown to be increased in kidney biopsies from CKD patients of diverse aetiologies (Lepenies 
et al., 2010) implicating a possible pathological influence in kidney disease. Nephroprotective 
mechanisms independent of inulin-sensitisation have been reported following PPARγ activation, 
including kidney structural and functional preservation in a mouse model of diabetic nephropathy 
despite no change in glucose, insulin or lipid levels (Calkin et al., 2006); and a reduction in 
proteinuria in non-diabetic CKD patients (Kincaid-Smith et al., 2008). However, human TZD trials 
in renal disease often report disparate results (Agarwal et al., 2005; Pistrosch et al., 2005). 
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1.2.6.2 The stress induced Nrf2/Keap1 axis 
Nuclear factor-E2-related factor-2 (Nrf2) has received much attention over the past decade due to 
its ubiquitous protective regulation against cellular stress. As such, Nrf2 has formed the target of 
many trial therapies for common diseases (Zhao et al., 2010; Joshi and Johnson, 2012; Miyata et 
al., 2013; Yang et al., 2013). Nrf2 is a transcription factor that modulates the expression of vital 
cytoprotective enzymes such as hemeoxygenase-1 (HO-1), PPARγ, SOD1/2, GST, and 
NAD(P)H:quinine oxidoreductase (NQO1) (Hybertson et al., 2011). The transcriptional activation 
of these enzymes occurs through the binding of Nrf2 to a nucleotide motif sequence known as the 
antioxidant response element (ARE) (Rushmore et al., 1991). During basal conditions, Nrf2 is 
constitutively degraded via a cullin-3-dependent pathway, following ubiquitylation labelling that 
appears to be promoted by the interaction with Kelch-like ECH-associated protein 1 (Keap1) 
(McMahon et al., 2003; Zhang et al., 2004). Keap1 is a strong regulator of Nrf2 activity and is vital 
for responding to oxidative stress to promote Nrf2 binding to ARE. Overexpression of Keap1 leads 
to increased levels of ubiquitin-conjugated forms of Nrf2 in cells (Nguyen et al., 2005), and in 
keap1
-/-
 animals, increased steady-state levels of Nrf2 (Wakabayashi et al., 2003). The regulation of 
the Keap1-Nrf2 interaction in response to oxidative stress has yet to be fully characterised. The 
promotion of Nrf2 stabilisation by Keap1 disassociation and subsequent DNA binding of ARE is 
important (Nguyen et al., 2005; Fourquet et al., 2010). However, strong evidence suggests the 
modification of Keap1 cysteine residues by thiol-reactive chemical species, such as ROS (Dinkova-
Kostova et al., 2002; Zhang and Hannink, 2003; Yamamoto et al., 2008; Fourquet et al., 2010). 
Given the large numbers of cysteine residues within the primary structure of Keap1, this may 
prevent the interaction, or aid the disassociation, with Nrf2. Major protein kinase pathways have 
been implicated in Nrf2 regulation and although phosphorylation of Nrf2 has been demonstrated, it 
cannot be linked to its stabilisation (Kang et al., 2001; Bloom and Jaiswal, 2003; Numazawa et al., 
2003). Furthermore, the cAMP response element-binding (CREB) protein can induce acetylation of 
Nrf2 and increase binding of Nrf2 to ARE, which can be decreased by sirtuin-1 (Sirt1) deacetylase 
(Kawai et al., 2011). The hypothesis that Keap1 binding of Nrf2 occurs exclusively in the 
cytoplasm, and upon modification, allows Nrf2 nuclear translocation has been discarded. This 
outcome is in agreement with evidence that Nrf2 ARE binding occurs constitutively in healthy 
conditions (Nguyen et al., 2005). Modulation of the Keap1-Nrf2 pathway in the kidney has been 
shown attenuate various pathologies that involve oxidative stress, including ischaemia-reperfusion 
injury, remnant kidney models, and in vitro models. Despite these positive benefits, the application 
of the potent Nrf2 activator, bardoxolone methyl, to pre-dialysis diabetic nephropathy patients 
resulted in increased mortality and serious adverse effects (de et al., 2013). The outcome of this trial 
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highlights the need for more basic research into the Nrf-Keap1 pathway to harness its proven 
cytoprotective properties therapeutically.  
 
1.2.6.3 Nuclear factor-kappa B 
Nuclear factor-kappa B (NF-κB) comprises a family of rapid-acting nuclear transcription factors 
that transcriptionally-regulate a wide variety of genes involved in inflammation, immunity, 
apoptosis, cell proliferation and differentiation. In oxidative stress-induced kidney disease, NF-κB 
is activated by ROS and initiates signalling pathways involved in renal fibrosis (Greiber et al., 
2002; Morigi et al., 2002; Sanz et al., 2010) and age-related CKD (Percy et al., 2009). NF-κB 
consists of homo- or heterodimers from five possible units of the Rel family, with the p65/p50 
heterodimer being the most common form. The inhibitory protein, IκB, is associated with, and 
inactivates, NF-κB within the cytoplasm (Baeuerle and Henkel, 1994). Mitochondrial stress and 
subsequent ROS generation activates NF-κB (Morigi et al., 2002). NF-κB activation in CKD is not 
isolated to one cell type within the kidney and has been demonstrated in podocytes, tubular cells, 
and mesangial cells (Massy et al., 1999; Greiber et al., 2002; Queisser et al., 2011). It has been 
implicated in the transcriptional activation of the cell cycle inhibitor p21 (Pennington et al., 2001; 
Savickiene et al., 2004), linking the transcriptional regulator with renal cell senescence.  
 
1.2.6.4 Forkhead (FoxO) proteins  
The Forkhead (FoxO) proteins are a family of transcription factors believed to play a critical role in 
the regulation of genes in ageing (van der Horst and Burgering, 2007). They comprise FoxO1 to 
FoxO4, and FoxO6, however FoxO1 has most association with CKD. FoxO1 has increased levels of 
phosphorylation in the kidneys of elderly overweight humans with type 2 diabetes and CKD 
(Mussig et al., 2009) and old hypertensive rats with CKD (Percy et al., 2009). Increased ROS could 
regulate FoxO activity. Overexpression of FoxO proteins increases stress resistance including that 
induced by ROS (Guarente and Kenyon, 2000). Moreover, they have been linked to the 
upregulation of antioxidants involved in the detoxification of the harmful O2
•-
 and H2O2 (Kops et 
al., 2002; Nemoto and Finkel, 2002). Upregulation of FoxO also induces cell cycle arrest through 
the regulation of p27
kip1
 and its associated cyclin dependant kinases (Kops et al., 2002; van der 
Horst and Burgering, 2007). H2O2 can induce FoxO transcriptional activity and this is further 
confirmed by the observation that H2O2 treatment results in translocation of FoxOs from the cytosol 
to the nucleus. In addition, cell death ligands like Fas and TNFα, known to increase cellular H2O2 
levels, also activate FoxO transcriptional activity. FoxOs induce apoptosis mainly by upregulation 
of pro-apoptotic genes such as those of the Bcl-2 family (Dijkers et al., 2000; van der Horst and 
Burgering, 2007), yet they can also detoxify harmful cellular oxidants and protect cells. FoxOs can 
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also function in a negative feedback loop to control the cellular level of ROS and oxidative stress 
(Wang et al., 2007). 
 
1.2.6.5 Adapter protein p66
shc
  
The adapter protein p66
shc
 is a relatively newly-recognised mediator of mitochondrial dysfunction, 
first described in 1999 (Migliaccio et al., 1999). Knock-out mouse models of the p66
shc
 gene have 
shown an increase in lifespan of 30 %, indicating an important role for this protein in ageing 
(Menini et al., 2006). An isoform of the ShcA protein, p66
shc
 antagonises the actions of two other 
isoforms, p46
shc
 and p52
shc
, on cell proliferation. Cellular oxidative stress induces the 
phosphorylation of serine 36 of p66
shc 
by protein kinase C beta (PKCβ) prior to translocation of 
p66
shc
 into the mitochondria. Here, it translates oxidative stress into Ca
2+
-mediated mitochondrial 
damage and subsequent apoptosis (Pinton et al., 2007; Arany et al., 2010). As well as the general 
cytoplasmic location of p66
shc
, a large proportion also exists in the mitochondria bound to heat 
shock protein 70. This has been shown to dissociate during stressful conditions, thereby increasing 
mitochondrial ROS generation and resulting in apoptosis (Orsini et al., 2004). H2O2-induced cell 
injury is dependent upon a loss of mitochondrial membrane potential which can occur due to 
increased ROS. Ablation of the p66
shc
 gene decreased H2O2, oxidative damage and mitochondrial-
mediated apoptosis (Pinton et al., 2007). Activated (phosphorylated) p66
shc
 may increase 
mitochondrial ROS by the oxidation of Cyt C, also causing its release into the cytoplasm and 
induction of apoptosis (Giorgio et al., 2005). Activation or opening of the PTP by ROS also induces 
mitochondrial dysfunction leading to apoptosis (Mather and Rottenberg, 2000). This suggests that 
ROS production by mitochondria is the cause and not a consequence of loss of membrane 
permeability transition; however, the causes and consequences of mitochondrial ROS remain 
elusive. Recently, histone acetylation and methylation of the p66
shc
 promoter was shown to induce 
both premature and replicative senescence, indicating a role of altered p66shc expression and 
subsequent cellular dysfunction (Zhang et al., 2010). Although the role of p66
shc
 has been noted in 
glomerulopathies and diabetes (Menini et al., 2006; Menini et al., 2007) and its differential 
expression has been demonstrated in ageing kidneys (Percy et al., 2009), the functional significance 
of p66
shc
 in age-related CKD has not received detailed attention. 
 
 
1.2.7 Concomitant pathologies: effects on the kidneys and relationship with oxidative stress 
In CKD, functional impairment correlates with tubulointerstitial fibrosis that can be characterised 
by inflammation, accumulation of extracellular matrix, tubular atrophy and loss of peritubular 
capillaries. The causes of these global CKD characteristics are, as mentioned previously, 
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multifactorial. In this section, the relationship between CKD and concomitant illnesses, like CVD 
and the interrelated epidemic of obesity in our societies, and diabetes, are briefly discussed. 
 
An overwhelmingly large proportion of populations in Western societies is overweight or obese, 
and this proportion is increasing (Flegal et al., 2002). Obesity is seen as a chronic disease state due 
to its epidemiological significance of co-morbidity and mortality, and is the most common risk 
factor for diabetes and CVD, both of which predispose individuals to CKD especially in ageing 
(Kalaitzidis and Siamopoulos, 2011). Obesity raises blood pressure by increasing renal tubular 
sodium reabsorption, impairing pressure natriuresis, and causing volume expansion via activation of 
the sympathetic nervous system and renin-angiotensin-aldosterone system and by physical 
compression of the kidneys, especially when there is increased visceral adiposity (Hall et al., 2014). 
Obesity is also likely to have a direct mechanistic effect on metabolism or endocrine function, and 
through these, on the kidneys. Factors such as inflammation, oxidative stress, and lipotoxicity are 
known to contribute to obesity-mediated CKD and CVD.  
 
Obese individuals are more likely to develop CKD and commonly show increased markers of 
oxidative stress, supporting redox dysregulation as a mechanism in CKD (Fox et al., 2004; Noeman 
et al., 2011). Recently, there has been interest in the novel biomarkers adiponectin and leptin in the 
CKD population (Kaisar et al., 2008). Adipose tissue is now recognised not just as a storage system 
for triglycerides but as a highly active metabolic organ involved in the secretion of various 
adipokines. Adiponectin is a cytokine and the most common adipocyte-derived protein. This protein 
acts through stimulation of AMPK, inducing glucose transport (Zoccali and Mallamaci, 2011). The 
direct mechanistic action of adiponectin on the kidneys is yet to be defined, but serum adiponectin 
levels are inversely related to markers of inflammation such as C-reactive protein, TNF-α, and 
interleukin-6 (IL-6), in healthy individuals and those with Type-2 diabetes and CVD.  
 
Efficient vascular and renal function relies on a healthy cellular redox balance. NO
•
 regulates 
vascular tone yet is also highly susceptible to oxidant insult. In a redox balanced state, NO synthase 
(NOS) converts L-arginine into NO
•
. However, increases in O2
•-
 due to systemic oxidative stress 
can cause a reduction of NOS and, upon reaction with NO
•
, the formation of the highly reactive 
peroxynitrite. A systemic inflammatory response commonly observed in CKD and hypertensive 
patients can result in elevated leukocyte count. Leukocyte and vascular smooth muscle cells are 
sources of ROS which can contribute to the contraction and growth of vascular smooth muscle 
cells, thereby increasing systemic blood pressure (Gonzalez-Pacheco et al., 2002). The role of the 
renin-angiotensin-aldosterone system (RAAS) is also highly relevant to CKD since angiotensin II 
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induces apoptosis in renal PTE cells via a process involving ROS and pro-fibrotic transforming 
growth factor-β (TGF-β) (Bhaskaran et al., 2003).  
 
Diabetes can cause harmful effects by mechanisms that include increasing oxidative stress, 
producing advanced glycation end products (AGE) and activation of PKC (Brownlee, 2001). It can 
cause the activation of pro-inflammatory growth factors and cytokines, such as IL-1, TNF-α, TGF-β 
and PDGF (Vlassara et al., 1988; Doi et al., 1992). Plasma oxidative stress levels are further 
elevated in CKD patients with diabetes and hypercholesterolemia, providing a causative or 
progressive role for systemic oxidative stress (Oberg et al., 2004). The overproduction of ROS by 
the mitochondrial ETC due to increased hyperglycaemic-dependant availability of electron donors 
by the citric acid cycle, such as NADH and FADH2, is thought to be responsible for initiating this 
increase in oxidative stress (Du et al., 2000; Munusamy and MacMillan-Crow, 2009). Furthermore, 
overexpression of MnSOD attenuates the overproduction of mitochondrial O2
•-
 (Du et al., 2001). 
AGE has a major pathogenic role in diabetic nephropathy as shown by the successful use of 
advanced glycation inhibitors in diabetic rat and human studies (Wilkinson-Berka et al., 2002; 
Bolton et al., 2004). Damage induced by AGE occurs through mechanisms which include altering 
protein function (Zoellner et al., 2009), modification of extracellular matrix proteins (Wang et al., 
2011), and the activation of AGE-receptors associated with macrophages, endothelial and 
mesangial cells (Yan et al., 1994). Ligation of this receptor produces a ROS burst and activation of 
the transcription factor NF-κB, mesangial matrix expansion and glomerulosclerosis (Yan et al., 
1994; Reiniger et al., 2010; Tang et al., 2011). 
 
1.2.8 Measuring oxidative stress 
Oxidative damage may be defined as bimolecular damage caused by the direct attack of reactive 
species during oxidative stress (Halliwell and Whiteman, 2004). Reactive species can be measured 
directly, for example, by electron spin resonance (ESR) or various trapping methods, or indirectly 
by examining end products of their reaction with biomolecules. Assays for oxidative stress or 
antioxidant status, and some biomarkers, are shown in Appendix A. Oxidative stress biomarkers are 
progressively increased with increasing stages of CKD (Dounousi et al., 2006) and decreased 
following renal transplantation, compared to ESKD patients (Simmons et al., 2005). The positive 
correlation between oxidative stress levels and CKD progression is difficult to interpret given the 
various oxidative stress outcomes as well the influence of any overlying disorders such as diabetes 
and CVD. Several of the oxidative stress biomarkers that have likely pathological significance in 
CKD are discussed below. 
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1.2.8.1 The isoprostanes 
Most oxidative stress biomarkers detect levels of specific end-products from free radical damage. 
The isoprostanes are considered the best available biomarkers of lipid peroxidation and have been 
investigated extensively in the study of CKD (Kim et al., 2004; Simmons et al., 2005; Dounousi et 
al., 2006; Karamouzis et al., 2008). Studies have focused primarily on F2-isoprostanes, specifically 
8-isoprostanes (8-epi-prostaglandin F2-alpha/8-epi-PGF2a) which are formed by non-enzymatic 
peroxidation of arachidonyl lipids only after exogenous antioxidants have been exhausted. F2-
isoprostanes are best detected using mass spectroscopy, and techniques have been established to 
detect levels in urine and plasma in humans (Calabrese et al., 2007). However, F2-isoprostanes have 
been criticised since they are rapidly metabolised, thereby falsely elevating the plasma isoprostane 
levels. Morrow and colleagues (1998) demonstrated that O2 concentrations may also influence F2-
isoprostane levels. F2-isoprostane levels may have low repeatability because of discrepancies in 
levels detected from the same person at different times of the same day (Kanabrocki et al., 2002), 
and from day to day (Helmersson and Basu, 2001). Importantly, F2-isoprostanes, like all end-
product biomarkers, are a measure of whole body oxidative stress rather than that which occurs at a 
specific location, such as the kidney. Nevertheless, the use of isoprostanes has identified that levels 
of oxidative stress rise early in the progression of CKD (Oberg et al., 2004) and relate to kidney 
function (Dounousi et al., 2006). 
 
1.2.8.2 Malondialdehyde 
Malondialdehyde (MDA) is another end-product generated by lipid peroxidation and has been used 
to demonstrate increased oxidative stress during CKD (Atamer et al., 2008; Terrier-Lenglet et al., 
2011). Unlike F2-isoprostanes, MDA has the ability to react further and possibly cause protein and 
DNA adducts, thus levels of MDA should be interpreted with caution. MDA, along with other lipid 
peroxidation products such as 4-hydroxyalkenals, is a thiobarbituric acid reactive substance 
(TBARS) and earlier investigations into oxidative stress commonly used this as an assay technique 
(Stratta et al., 1994). Most TBARS in human body fluids are unrelated to lipid peroxidation, due to 
their non-specific and artifactual formation (Knight et al., 1988; Liu et al., 1997; Halliwell and 
Whiteman, 2004), and simple TBARS assays from early studies should be discounted as a reliable 
measure of oxidative stress because of this artifactual elevation. High performance liquid 
chromatography (HPLC) extraction of MDA from plasma, with subsequent quantification, is now 
considered a reliable method for oxidative stress determination (Marsh et al., 2006; Johnson et al., 
2007). Improved methods derivatise MDA with 2,4-dinitrophenylhydrazine, which forms specific 
hydrazones for MDA that can be separated by HPLC and quantified using methyl-MDA as an 
internal standard (Sim et al., 2003). The use of N-methyl-2-phenylindole to determine MDA content 
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alone, or with 4-hydroxyalkenals, is an alternate and simple method for quantifying lipid 
peroxidation (Gerard-Monnier et al., 1998). Urinary MDA evaluation in patients with impaired 
kidney function can be difficult to interpret. Renal clearance of MDA possibly provides an adaptive 
mechanism to prevent lipid peroxidation accumulating within kidney tubular cells, yet renal 
clearance of MDA would be impaired in these patients (Nath et al., 1990). 
 
1.2.8.3 Advanced oxidation protein products 
Advanced oxidation protein products (AOPP) accumulate in the serum of CKD patients, especially 
those with uraemia and diabetes (Witko-Sarsat et al., 1996; Mezzano et al., 2001). This 
accumulation contributes to the pathogenesis of CKD (Li et al., 2007). AOPP are primarily derived 
from serum albumin following hypochlorous acid (HOCl) free radical attack (Witko-Sarsat et al., 
1996; Capeillere-Blandin et al., 2004; Piwowar, 2010). In vivo studies have demonstrated enhanced 
inflammation and reduced kidney function with high serum levels of AOPP (Witko-Sarsat et al., 
1998; Li et al., 2007). AOPP as a marker of oxidative stress has yet to show a strong correlation 
with other more reliable markers of oxidative stress, such as F2-isoprostanes, but it does provide a 
valuable indicator of oxidation-mediated protein damage. The prevalence of 
albuminuria/proteinuria in CKD and its impact on AOPP has not yet been investigated.   
 
1.2.8.4 Protein carbonyls 
Protein carbonyl assays quantify the carbonyl groups associated with oxidant-damaged proteins. It 
is important to note that protein carbonyls are not specific for oxidative stress since they also 
measure glycated proteins and bound aldehydes (Halliwell and Whiteman, 2004). An increase in 
protein carbonyls has been demonstrated in CKD patients in stages 3-5, yet no correlation was 
found between protein carbonyl levels and GFR (Oberg et al., 2004). In addition, diabetic 
nephropathy patients have greater levels of protein carbonyls in plasma and lymphocytes compared 
to healthy control (Calabrese et al., 2007). 
 
1.2.8.5 Electron spin resonance and spin traps 
Because free radicals have extremely short half-lives (Cadenas and Davies, 2000), ESR or electron 
paramagnetic resonance (EPR) provides a means to properly determine the contribution of free 
radical generation in the kidneys, and subsequent systemic oxidative stress. This method consists of 
using a spin trap (nitrone) to react with the initial free radical, which forms a less reactive free 
radical adduct (nitroxide) that can be observed and quantified using EPR spectroscopy (Swartz et 
al., 2007). Different spin traps are used to trap specific free radicals. Commonly used spin traps 
include α-phenyl-N-tert-butylnitrone and 5,5-dimethyl-pyrroline N-oxide. These have been shown 
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to detect hydroxyl and carbon-centred radicals in the kidney after ischemia-reperfusion injury 
(Kadkhodaee et al., 1996). More recently, 5-diisopropoxyphosphoryl-5-methyl-1-pyrroline-N-oxide 
was used to trap O2
•-
 adducts formed in isolated mitochondria from the skeletal muscle of mice 
(Bhattacharya et al., 2011). Spin trapping and EPR present some practical limitations, especially in 
humans, where they must demonstrate a safe and efficacious effect, and are costly, thereby limiting 
their clinical use. 
 
1.2.8.6 γ-Glutamyl-transpeptidase 
Recently, γ-glutamyl transpeptidase (GGT) was suggested as a biomarker of CKD onset through a 
mechanism of oxidative stress (Lee et al., 2004). Extracellular GGT is required to metabolize 
extracellular-reduced glutathione, allowing for the intracellular synthesis of glutathione by addition 
of specific amino acids (Lash, 2009). Serum antioxidant levels were found to have an inverse 
relationship to serum GGT, indicating a redox-regulating role (Lim et al., 2004). The relationship 
between plasma and extracellular GGT is not fully defined, but it does appear that serum GGT 
presents a favourable biomarker of oxidative stress. It is stable, quick and inexpensive to test, and 
provides an indication of whole body oxidative stress compared to specific oxidative damage to 
lipids, DNA or proteins. 
 
 
1.2.9 Visualising metabolic changes in the kidney 
With the advancement of technologies over the past decade, visualising metabolic changes in real 
time in the kidney has become possible. Given that metabolism, especially mitochondrial 
metabolism, is intimately related to ROS production, dynamic visual changes can be representative 
of altered cellular redox control. Intravital multiphoton microscopy (MPM) is such a technology 
that allows direct visualisation of metabolic changes and associated structural and functional 
changes, in real time, in many biological tissues including the kidney. The principles of MPM and 
its use in experimental nephrology have been published as part of this thesis (Small et al., 2014) and 
will form part of the introduction to the relevant research chapter (Chapter 5). This segment gives a 
brief overview of MPM, specifically for kidney disease research. 
 
The primary source of endogenous fluorescence in the majority of biological tissue is 
NAD(P)H/NAD+ (Zipfel et al., 2003), which only fluoresces in its reduced form (NADH). NADH 
is a vital substrate for Complex I of the mitochondrial ETC required for oxidative phosphorylation, 
and its fluorescence has been used for a long time as an indicator of cellular metabolic state 
(Chance et al., 1962; Mironov and Richter, 2001). Therefore alterations to this endogenous 
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fluorescence, and indirectly, NADH, indicate intracellular metabolic changes. The combination of 
NADH and NADPH will be referred to as NAD(P)H, since NADPH is detected by MPM on the 
same wavelength and therefore cannot be excluded. However, NADPH is considered to contribute 
minimally. Elegant experiments by Balaban and Mandel (1988) using isolated rabbit proximal 
tubule demonstrated that the metabolic rate and NAD(P)H redox state of epithelial cells is highly 
sensitive to the metabolic substrate available. In particular, NAD(P)H fluorescence and oxygen 
consumption increase in a linear fashion with the addition of a variety of metabolic substrates. 
Furthermore, anoxia results in the maximal increase in NAD(P)H fluorescence due to lack of 
reducing equivalents for NAD(P)H, and “backing up” of the electron transport chain causing an 
increase in the NAD(P)H/NAD+ ratio. 
 
The principles of MPM allow greater compliancy for use in biological tissue, allowing intravital 
imaging over extended periods of time with minimal photodamage. A robust method to detect 
changes in NAD(P)H metabolism is to use fluorescence lifetime imaging microscopy (FLIM) in 
combination with MPM. The fluorescence lifetime of a fluorophore is the mean time a fluorophore 
remains in an excited state before emitting a photon (fluorescence) and returning to the initial 
ground state. The fluorescence lifetime of a fluorophore, either endogenous or synthetic, depends on 
the type of molecule, its conformation, and the way the molecule interacts with the surrounding 
microenvironment (Becker, 2012). FLIM constructs a spatial distribution map of fluorescence 
lifetimes of a sample imaged by confocal, multiphoton, endoscopic or wide-field microscopy (Elson 
et al., 2004). Importantly, FLIM microscopy can be used to measure molecular environmental 
parameters, the metabolic state of cells and tissues via endogenous autofluorescence, drug 
distribution and interactions, and protein-interactions by fluorescence resonance energy transfer 
(FRET). 
 
Intravital MPM can provide detailed information regarding kidney tissue oxygenation and 
mitochondrial redox state that often precede pathophysiological change. This information, coupled 
with classical oxidative stress assessments, and histopathological techniques, enables the 
determination of the spatial and temporal relationship of oxidative stress in the kidney. 
 
1.2.10 Combating CKD by targeting oxidative stress 
A major goal of therapy in patients with CKD is to slow, or halt, the progression to ESKD. Early 
detection of CKD is essential. Low-grade damage of the kidney, resulting in partial loss of 
functioning nephrons and/or glomeruli, activates an adaptive injury response within the remaining 
healthy kidney to compensate for this loss. Angiotensin II has been shown in vivo and in vitro to 
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induce pro-inflammatory and fibrogenic pathways (Sun et al., 2000). Therefore, inhibiting the 
RAAS should be an effective way to slow the progression of CKD to ESKD and also slow the 
development of associated CVD (Masajtis-Zagajewska and Nowicki, 2009; Hoogwerf, 2010). 
Established CKD therapies, therefore, rely primarily on the pharmacologic blockage of the RAAS 
with angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers. Despite 
the positive impacts of RAAS inhibition, decline of GFR continues and serum creatinine continues 
to be elevated (Brenner et al., 2001; Lewis et al., 2001). There is a great need for novel treatments 
and interventions. Increasing experimental evidence points to inflammation and oxidative stress as 
potentially rewarding targets. 
 
Although the use of anti-oxidant therapies in the prophylactic treatment and amelioration of CKD 
has had limited success clinically, oxidant dysregulation occurs with age and it is therefore 
conceivable that a supply of antioxidants will restore the balance and the essential role of oxidants 
as signalling molecules. Some modifiable pathways and antioxidant treatments are summarised in 
Fig. 1.5, and selected antioxidants are described here. 
 
1.2.10.1 N-acetyl cysteine 
N-acetyl cysteine (NAC) acts as an essential precursor to many endogenous antioxidants involved 
in the decomposition of peroxides (Zafarullah et al., 2003). NAC attenuates oxidative stress from 
various underlying causes, by replenishing intracellular glutathione stores. Glutathione is 
synthesized in the body by three amino acids by the catalysing intracellular enzymes gamma-
glutamylcysteine synthetase and glutathione synthetase. L-glutamic acid and glycine are two 
precursors of glutathione that are biologically and readily available. 
 
However, the limiting precursor to glutathione biosynthesis and the third amino acid, L-cysteine, is 
not readily available in a human diet. Although the primary basis for NAC supplementation is to 
replenish cellular cysteine levels to maintain intracellular glutathione and thus redox control, the 
sulfhydryl-thiol group of L-cysteine is also able to exert direct antioxidant effects by scavenging 
free radicals, and NAC may also exert its protective effects against 2,3,5-tris(glutathion-S-yl)-
hydroquinone toxicity. This was demonstrated in isolated renal tubular epithelial cells, in part by the 
activation of extracellular signal regulated protein kinase (ERK) 1/2 (Zhang et al., 2011). The 
cysteine residue of NAC also has a theoretical ability to change the intracellular redox environment 
by affecting intracellular signalling, promoting a reduced intracellular environment rather than an 
oxidised one (Diers et al., 2013). 
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Figure 1.5: Cellular sites of reducing oxidative stress by oxidant modifying compounds 
Inflammation, lipid peroxidation, and reactive oxygen species (ROS) from mitochondrial and 
cytoplasmic sources produce a harmful state of oxidative stress. Vitamin E incorporates into the 
phospholipid bilayer halting lipid peroxidation chain reactions. ω-3 fatty acids displace arachidonic 
acid in cell membrane and thus reduce arachidonic-derived ROS, but also significantly reduce 
inflammation and subsequent fibrosis. The cysteine residue of N-acetyl-cysteine (NAC) is a 
precursor for glutathione (GSH) synthesis, and the thiol group is able to scavenge ROS. Allopurinol 
inhibits xanthine oxidase derived ROS and the damaging effects of uraemia. Coenzyme Q10 (CoQ10) 
enhances the efficiency of electron transport in the mitochondria thereby reducing mitochondrial 
derived ROS and is also able to directly scavenge ROS. Mitochondrial-targeted antioxidants 
accumulate in the mitochondria, reducing mitochondrial derived ROS. 
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The results of NAC supplementation in kidney disease have been variable and largely depend on 
the type and cause of kidney injury and also the timing of treatment. In cultured human PTE cells, 
NAC reduced lipid peroxidation and maintained the mitochondrial membrane potential, thereby 
preventing apoptosis following H2O2 administration (Ye et al., 2010). Endothelial dysfunction 
caused by uremic toxins, such as indoxyl sulphate, induced ROS-dependent expression of the pro-
inflammatory and pro-oxidant NF-κB, which was ameliorated by NAC pre-treatment (Tumur et al., 
2010). 
 
Although NAC had no significant effect on markers of oxidative stress and inflammation in rats 
following unilateral ureteral obstruction (Pat et al., 2005), it reduced kidney MDA levels in a 
diabetic mouse model (Ribeiro et al., 2011). The treatment of CKD patients with NAC with the aim 
of improving renal function and preventing ESKD has been largely disappointing, with no evidence 
of reduction in proteinuria (Renke et al., 2008; Moist et al., 2010). NAC seems to exert the greatest 
antioxidant and anti-inflammatory properties when used against the greatest injury, such as in 
ESKD patients receiving either haemodialysis or peritoneal dialysis. In those cases, NAC reduced 
serum 8-isoprostane and the inflammatory cytokine IL-6 (Hsu et al., 2010; Nascimento et al., 
2010). In a randomised, double-blind, placebo controlled study where 10 non-diabetic ESKD 
patients on maintenance haemodialysis received 1200 mg NAC daily for 7 days, fibroblast growth 
factor (FGF)-19 increased, which is associated with normalisation of insulin and C-peptide 
signalling (Li et al., 2013). 
 
1.2.10.2 Vitamin E 
Vitamin E, or α-tocopherol (αTOC), is a lipid-soluble antioxidant that incorporates into the plasma 
membrane of cells, thereby scavenging free radicals, mainly the peroxyl radical, and thus halting 
lipid peroxidation chain reactions (Serbinova et al., 1991). A benefit of αTOC is its ability to restore 
its antioxidant capacity from its oxidized form following free radical scavenging, and incorporate 
back into the plasma membrane. Vitamin C (ascorbic acid) is able to directly reduce αTOC (Kagan 
et al., 1990; Kagan et al., 1992; Fujisawa et al., 2006), and intracellular glutathione and lipoic acid 
can restore αTOC indirectly by restoring vitamin C (Guo and Packer, 2000). This is a prime 
example of a cellular antioxidant network prone to dysregulation. Administration of αTOC to 
kidney PTE cells decreased cisplatin-induced ROS and increased cell viability (Schaaf et al., 2002). 
The beneficial effects of αTOC are not limited to its antioxidant properties and, recently, attention 
has focused on the ability of vitamin E to promote oxygenation of the blood, and also to affect 
endogenous cell signalling functions that promote cell protection (Sen et al., 2000).  
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Vitamin E foodstuffs primarily consist of α-tocotreinol, an isoform of αTOC which has higher 
antioxidant efficacy in biological membranes. Despite this, the uptake and distribution of α-
tocotreinol is far less than αTOC. Therefore, the basis of vitamin E supplementation is to enhance 
αTOC levels in cell plasma membranes to prevent lipid peroxidation and resultant oxidative stress. 
One drawback of αTOC is that it takes several days of pre-treatment to exhibit antioxidant effects 
(Machlin and Gabriel, 1982). Trolox (±-6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid), 
is an analogue of αTOC that has shown far better free radical scavenging properties owing to its 
water-solubility (Lucio et al., 2009). Therefore, the majority of in vivo studies using trolox have 
found beneficial effects in acute cases of renal injury, such as ischemia-reperfusion, due to rapid 
solubility and increased potency (Eum and Lee, 2004; Wongmekiat et al., 2007). A combination 
supplement containing both αTOC and trolox may offer greater efficacy due to the fast-acting 
activities of trolox combined with the sustained scavenging actions of αTOC. However, studies 
investigating the antioxidant effects of trolox in humans remain sparse due to its highly reactive 
nature. 
 
Patients with CKD stage 4 display the largest decrease in serum αTOC levels, following a 
progressive decline from stage 1, indicating an increased need for αTOC in the CKD population 
(Karamouzis et al., 2008). Interestingly, within the same cohort of patients, a positive correlation of 
endogenous serum αTOC levels and GFR was found (Karamouzis et al., 2008). The majority of 
studies evaluating αTOC supplementation has largely focused on the ESKD dialysis populations 
compared to healthy controls. They report a reduced risk of CVD, decreased oxidative stress and 
increase in erythrocyte antioxidants SOD, GPX and CAT (Boaz et al., 2000; Islam et al., 2000; 
Giray et al., 2003).  
 
The use of αTOC in CKD patients is not without controversy. Recently, a placebo-controlled, 
double blind clinical trial in haemodialysis patients over 12-months receiving mixed tocopherols 
(666 IU/d) plus α-lipoic acid (600 mg/d) did not significantly alter markers of oxidative stress, 
inflammation, nor alter mortality and hospitalization rates (Himmelfarb et al., 2014). Miller and 
colleagues (2005) concluded that high-dose (≥400 IU/day) vitamin E supplementation may increase 
all-cause mortality which may be due to αTOC displacing gamma-(γ)-tocopherol and delta-(δ)-
tocopherol in the body (Huang and Appel, 2003). However, this study was highly criticized owing 
to bias in data analysis and numerous methodological flaws (Baggott, 2005; Blatt and Pryor, 2005; 
Carter, 2005; DeZee et al., 2005; Hemila, 2005; Krishnan et al., 2005; Lim et al., 2005; Marras et 
al., 2005; Meydani et al., 2005; Possolo, 2005).  
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1.2.10.3 Omega-3 poly-unsaturated fatty-acids 
Inflammation and fibrosis are causes, as well as consequences, of oxidative stress (Dendooven et 
al., 2011; Irita et al., 2011). Direct targeting of inflammatory and fibrotic pathways with more 
specific modifying compounds presents a way to indirectly decrease oxidative stress in CKD. Long 
chain omega(ω)-3 polyunsaturated fatty-acids, including docosahexanoic acid (DHA) and 
eicosapentanoic acid (EPA), have been investigated in a large range of in vitro and in vivo kidney 
models and found to possess anti-inflammatory properties. Recently, ω-3 fatty acid treatment of 
peripheral blood mononuclear cells from pre-dialysis CKD patients reduced the inflammatory 
markers, IL-6, IL-1β, TNF-α and C-reactive protein to levels observed in healthy subjects (Shing et 
al., 2011). Although the beneficial effects of EPA/DHA are attributed to their anti-inflammatory 
properties, they are also known to enhance endogenous antioxidant defence systems, such as γ-
glutamyl-cysteinyl ligase and glutathione reductase (Arab et al., 2006). DHA and EPA incorporate 
into the phospholipid bilayer of cells where they displace arachidonic acid. Arachidonic acid can 
generate ROS through the cycloxygenase-2 and xanthine oxidase inflammatory pathways. 
DHA/EPA administration to renal epithelial cells and macrophages suppresses this pro-oxidant 
pathway (Kim and Chung, 2007).  Furthermore, chemoattractants derived from EPA are less potent 
that those derived from arachidonic acid (Sperling et al., 1993; Mayer et al., 2003). Recently, in 
vitro studies determined that EPA and DHA attenuated TNF-α-stimulated MCP-1 gene expression 
by interacting with ERK and NF-κB in rat mesangial cells (Diaz Encarnacion et al., 2011). Earlier 
evidence had shown that EPA and DHA inhibit NF-κB expression by stimulating PPARs in human 
kidney-2 (HK-2) cells in vitro (Li et al., 2005). In vivo studies have now confirmed an improvement 
in kidney function and structure using EPA and DHA supplementation. There was a reduction in 
oxidative stress, inflammation and tubulointerstitial fibrosis through the reversal of inflammatory 
and oxidant pathways (An et al., 2009; Peake et al., 2011). Fish oil ω-3 polyunsaturated fatty acids 
may also provide a means to directly decrease kidney disease through improving kidney structure, 
as well as indirectly by decreasing inflammation and oxidative stress. Clinical studies have found 
fish oil treatment modulates lipid levels (Harris, 1997; Bouzidi et al., 2010), and has antithrombotic 
(Woodman et al., 2002; Cohen et al., 2011) and antihypertensive effects due to vascular and 
endothelial actions (Matsumoto et al., 2009).   
 
1.2.10.4 Allopurinol 
Uric acid is the hepatic end-product of purine metabolism in humans, synthesised by the enzyme 
xanthine oxidase which catalyses the oxidation of hypoxanthine to xanthine and finally to uric acid. 
Uric acid is a nitrogenous waste product which may also possess antioxidant activity (Miller and 
RiceEvans, 1996). However, uric acid at toxic levels has been implicated in the progression of 
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CKD. Increased serum uric acid levels (hyperuricaemia) may arise from increased purine 
metabolism, increasing age and decreased renal excretion, and have harmful systemic effects. 
Hyperuricaemia is associated with an increased risk for developing CKD and enhances its 
progression. A 20.6 % prevalence of hyperuricaemia was found in a cross-sectional study of 18,020 
CKD patients (Shan et al., 2010), and a positive correlation was found between serum uric acid and 
serum creatinine with impaired renal function (Chen et al., 2009). Retention of uremic toxins 
promotes inflammation, and oxidative stress, by priming polymorphonuclear lymphocytes, 
activating IL-1β and IL-8 (Martinon et al., 2006) and stimulating the innate immune response 
through CD8+ cells (Sakamaki et al., 2008). Additionally, uric acid synthesis can promote oxidative 
stress directly through the activities of xanthine oxidase, which produce NO
•
, and ROS such as 
NADPH (Sanchez-Lozada et al., 2008). Allopurinol treatment aims is to inhibit xanthine oxidase to 
decrease serum uric acid and its associated toxic effects. 
 
Allopurinol and its metabolite, oxypurinol, act as competitive substrates for xanthine oxidase. They 
enhance urinary urate excretion and block uric acid reabsorption by urate transporters in the 
proximal tubule, thereby facilitating enhanced uric acid excretion (Sanders et al., 1997; El-Sheikh et 
al., 2008; Riegersperger et al., 2011). Allopurinol treatment of diabetic mice attenuated 
hyperuricaemia, albuminuria, and tubulointerstitial injury (Kosugi et al., 2009). Allopurinol may 
also have antioxidant activities in addition to its enzyme inhibitory activities, by scavenging OH
•
 as 
well as chlorine dioxide and HOCl (Das et al., 1987; Moorhouse et al., 1987). Although later in 
vivo studies revealed that rat serum, obtained after oral administration of allopurinol, did not contain 
allopurinol levels sufficient to scavenge free radicals (Klein et al., 1996), inhibition of xanthine 
oxidase-dependent production of NO
•
 and ROS provides allopurinol an indirect mechanism for 
decreasing oxidative stress in hyperuricaemic CKD patients. Interventional studies of use of 
allopurinol in renal disease have shown improved uric acid levels, GFR, cardiovascular outcomes 
and delayed renal disease progression. A prospective randomised trial of 113 patients with GFR 
<60 ml/min/1.73m
3
 given allopurinol 100 mg/d for 2 years found an increase in GFR of 1.31 
ml/min/1.73m
3
 compared to the controls which decreased, and a 71 % decreased risk of CVD 
(Goicoechea et al., 2010). Kanbay and colleagues (2007) found that allopurinol at 300 mg/d over 3 
months improved GFR, uric acid and C-reactive protein levels but had no change on proteinuria. 
Allopurinol given to ESKD patients on haemodialysis reduced the risk of CVD by decreasing 
serum low density lipoproteins, triglycerides and uric acid (Shelmadine et al., 2009). Large, long-
term interventional studies investigating kidney function in the CKD population are needed to fully 
determine if allopurinol is nephroprotective via anti-oxidant mechanisms. 
 
34 
 
1.2.10.5 Coenzyme Q10 
The kidneys contain the highest endogenous levels of CoQ9 and CoQ10 compared to all other organs 
(Lass et al., 1999; Lass and Sohal, 2000). This is likely due to the reliance of the kidney on aerobic 
metabolism, and the high density of mitochondria in the epithelial cells of the nephron. Endogenous 
CoQ10 levels must be maintained to ensure mitochondrial health, and this forms the rationale for 
CoQ10 therapy. CoQ10 is a fundamental lipid-soluble component of all cell membranes including 
those enclosing subcellular compartments. The physiological roles of CoQ10 act mostly within the 
mitochondria where it has three well-characterised functions: (1) the transfer of electrons from 
Complexes I and II to Complex III along the ETC of the inner mitochondrial membrane and 
subsequent membrane polarisation and ATP generation (Merker et al., 2007; Ohnishi et al., 2008); 
(2) the pro-oxidant generation of O2
•-
 and H2O2 (James et al., 2004; Linnane et al., 2007a); and (3) 
the anti-oxidant quenching of free radicals (Nohl et al., 1999). The continual oxidation-reduction 
cycle, and existence of CoQ10 in three different redox states, explains its actions as an important 
cellular redox modulator through its pro-oxidant and antioxidant actions. The fully oxidised form of 
CoQ10, or ubiquinone, is able to accept electrons, primarily from NADH, to become fully reduced 
(ubiquinol - CoQ10-H2). The reduced form of CoQ10 is able to give up electrons, thereby scavenging 
free radicals. The intermediate of ubiquinone and ubiquinol is the univalently-reduced 
ubisemiquinone (CoQ10-H
+
) which acts as a pro-oxidant to form O2
•-
 and, subsequently, H2O2. 
 
The major antioxidant role of CoQ10 is in preventing lipid peroxidation directly, and by interactions 
with αTOC (Frei et al., 1990). Ubiquinol is able to donate a hydrogen atom and thus quench 
peroxyl radicals, preventing lipid peroxidation chain reactions. CoQ10 and αTOC co-operate as 
antioxidants through the actions of CoQ10-H2 restoring α-tocopheroxyl back to αTOC (Kagan et al., 
1990; Stoyanovsky et al., 1995). However, the reactivity of αTOCs with peroxyl radicals far 
exceeds that of ubiquinols with peroxyl radicals, suggesting that, in vivo, ubiquinols do not act as 
antioxidants but regenerate the antioxidant properties of αTOCs (Lass and Sohal, 1998). This is in 
accordance with in vivo studies investigating the effects of CoQ10 supplementation which have 
primarily found a limited antioxidant capacity. The role of CoQ10 as a pro-oxidant in all biological 
membranes including the Golgi, endosome/lysosome systems, as well as mitochondria has led to 
much criticism regarding the claimed antioxidant power of CoQ10 supplementation in humans 
(Linnane et al., 2007a). Nonetheless, many in vitro studies demonstrate antioxidant properties of 
CoQ10 in single cells. The benefits of CoQ10 supplementation in humans is attributed to its ability to 
maintain efficient mitochondrial energy metabolism and thus prevent mitochondrial dysfunction, 
rather than act as a direct cellular antioxidant. CoQ10 supplementation in vivo reduced protein 
oxidation in skeletal muscle of rats but had no effect on mitochondrial H2O2 production in the 
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kidney (Kwong et al., 2002). However, Ishikawa and colleagues (2011) demonstrated a decrease in 
kidney O2
•-
 levels in hemi-nephrectomised rats on a CoQ10 supplemented diet, and increased renal 
function, compared to rats on a control diet. There is a general lack of human studies investigating 
CoQ10 therapy for the treatment and/or prevention of CKD. CoQ10 levels decrease with age, but 
there are no studies measuring endogenous CoQ10 levels in CKD patients and this could prove vital 
in the identification of any population where CoQ10 therapy may have beneficial outcomes. 
 
1.2.10.6 Mitochondrial-targeted antioxidants 
Mitochondrial-targeted compounds have created much interest for their application in reducing 
oxidative stress, due to the well-defined role of the mitochondria as the major cellular source of 
ROS. One of the most tested is the mitochondrial-targeted derivative of endogenous CoQ10, termed 
MitoQ (mitoquinone mesylate). The approach of this compound and those alike, such as 
mitochondrial-targeted vitamin E (MitoVit E), consists of covalently attaching a lipophilic cation to 
an alkyltriphenylphosphonium allowing rapid accumulation into the mitochondria driven by the 
large negative value of the mitochondrial membrane potential. Most evidence supporting the use of 
MitoQ as a nephroprotective agent lies in in vivo experimental models. MitoQ has been shown to 
accumulate in the kidneys, comparable to levels that protect cells in culture, and has been safely 
administered long-term to mice (Graham et al., 2009; Rodriguez-Cuenca et al., 2010). 
Administration of MitoQ in a rat model of diabetic nephropathy decreased mesangial expansion and 
tubulointerstitial fibrosis, thereby improving renal function (Chacko et al., 2010). Human trials have 
shown that MitoQ can decrease biomarkers of liver inflammation in hepatitis C patients (Gane et 
al., 2010). However, a larger scale double-blind, placebo-controlled study found that MitoQ did not 
slow the progression of untreated Parkinson’s disease, a disease associated with mitochondrial 
oxidative stress (Snow et al., 2010). The effect may be tissue specific, and early intervention with 
MitoQ in CKD patients could prove fruitful given that oxidative stress is evident early in CKD 
progression (stages 1-3). 
  
1.2.10.7 Targeting the Nrf2 pathway 
Bardoxolone methyl (2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid/CDDO-Me) demonstrated 
a high level of promise to the nephrology community for halting the early progressive decline of 
GFR in type 2 diabetic patients (Pergola et al., 2011a; Pergola et al., 2011b). Bardoxolone methyl is 
a triterpenoid derived from natural plant products and is a potent activator of the Nrf2 pathway 
(Eskiocak et al., 2010; Nagaraj et al., 2010; Honda et al., 2011). However, initial hopes were 
doused following the termination of a subsequent large-scale, randomised, placebo controlled trial 
in type 2 diabetes-stage 4 CKD patients, due to a higher rate of cardiovascular events and failure to 
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reduce the risk of ESKD or death from cardiovascular causes (de et al., 2013). The apparent failure 
of bardoxolone methyl was criticised largely due to a lack of scientific rigor in pre-clinical models, 
and rush to proceed with the large phase III trial despite strong evidence of serious adverse events 
in earlier phase II trials (Tayek and Kalantar-Zadeh, 2013). Prior to publication of the results of the 
phase IIa trial (BEAM) in stage 3b-4 CKD patients with type 2 diabetes, no publications existed 
using in vivo animal models examining renal or cardiovascular parameters following bardoxolone 
administration. All published data, prior to the BEAM results, principally examined the anti-
tumorigenic characteristics of bardoxolone methyl in mouse studies (Liby et al., 2007; Ling et al., 
2007; Gao et al., 2008; Liby et al., 2008; Liby et al., 2009; Auletta et al., 2010; Li et al., 2010; Liby 
et al., 2010; Nagaraj et al., 2010; Saha et al., 2010). Wu et al (2011) demonstrated, at 
approximately the same time as the BEAM trial results were published, that bardoxolone 
administration attenuated ischaemia-reperfusion induced AKI in a mouse model, that was 
associated with increased Nrf2, PPARγ, and HO-1 mRNA levels. A subsequent in vivo model 
demonstrated deleterious effects of bardoxolone methyl and its analogs in diabetic nephropathy 
(Zoja et al., 2013). Despite this, rodent models examining kidney parameters continually showed 
efficacy of bardoxolone methyl and triterpenoid analogs (Reisman et al., 2012; Chin et al., 2013; 
Ding et al., 2013), giving reason to continue research into targeting the Nrf2 pathway. As 
previously mentioned, the Keap1-Nrf2 pathway is a highly conserved, ubiquitous response not only 
to stress, but also responsible for constitutive expression of genes regulated by ARE during basal 
conditions. Considering the superior potency of bardoxolone methyl to upregulate Nrf2-ARE-
dependent genes (Walsh et al., 2014), it comes as little surprise that deleterious outcomes result 
from its constant activation. Therefore, modulating Nrf2 activation requires a greater understanding 
of basal Nrf2 regulation, the exact role of the Keap1-Nrf2 interaction, and how Nrf2 regulation is 
altered in metabolically unstable disease populations such as CKD. 
 
 
1.2.11 Exercise and lifestyle modification in CKD 
The “magic bullet” approach to reduce oxidative stress is increasingly being recognised as unlikely 
given the vast complexity and interactions that incorporate oxidative stress. Exercise and lifestyle 
modification improve general health and the burden of disease (Sattelmair et al., 2011; Belardinelli 
et al., 2012; Ezzati and Riboli, 2013; Wang et al., 2013). Regular physical activity alone reduces 
biomarkers of oxidative stress and increases endogenous antioxidants via a stress induced hormetic 
response. Nevertheless, convincing, practical and realistic implementation of exercise and lifestyle 
interventions to large populations of people, let alone chronic disease populations, is an enormous 
challenge. A greater understanding of the natural ability of the body to invoke a systemic protective 
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response is needed to determine whether these processes can be harnessed for the benefit of the 
chronic disease population such as CKD. 
 
There is a variety of biochemical, cellular, and systemic adaptations that occur in response to 
exercise that are intimately linked to redox control (Baar, 2014; Marton et al., 2014). ROS increase 
during and following exercise (Davies et al., 1982; Alessio and Goldfarb, 1988; Radak et al., 2001). 
This is a paradox given that exercise decreases the incidence of oxidative stress-related diseases, 
and is a further example of beneficial ROS signalling that is the result of exercise-induced 
adaptation. The site of increased ROS production is difficult to identify and is assumed to be from 
mitochondria, given that exercise causes an increase in oxygen consumption. However, as Gomez-
Cabrera et al (2008) describe, actively-respiring mitochondria that produce ATP from ADP, with a 
high electron flow from O2, produce one tenth of the ROS that are produced from resting state 
mitochondria (2 %) (Chance et al., 1979). Therefore, mitochondria as a source of increased ROS 
production in exercise should be reconsidered. Potential extracellular sources of exercise-induced 
ROS may occur given that the response to exercise is systemic and has been suggested to arise from 
xanthine oxidase activity (Hellsten et al., 1988; Pattwell et al., 2004). This is further supported from 
studies using allopurinol to prevent oxidation of glutathione and lipid peroxidation following 
exhaustive exercise (Vina et al., 2000). NADPH oxidases and phospholipase-A2-dependent 
processes have also been shown to contribute (Nethery et al., 1999; Frasier et al., 2013; Sakellariou 
et al., 2014). The importance of exercise-induced ROS signalling was highlighted in a recent study 
investigating the effects of a combination of vitamin C (1000 mg/day) and vitamin E (400 IU/day) 
on insulin sensitivity and ROS-sensitive transcriptional regulators (Ristow et al., 2009). The 
antioxidant combination prevented increased insulin sensitivity and upregulation of PPARγ, PGC-
1α and PGC-1β following physical exercise (Ristow et al., 2009). Similar findings were found in a 
rat model demonstrating a failure of training-induced mitochondrial biogenesis following oral 
administration of vitamin C (Gomez-Cabrera et al., 2008). However, a recent study demonstrated 
no differences in the exercise-induced adaptations of GLUT4, SOD 1/2, PGC-1α and mitochondrial 
biogenesis of vitamin C and E supplementation in a rat model (Higashida et al., 2011).  
 
There is strong evidence showing that skeletal muscle contraction induces antioxidant adaptation to 
chronic exercise training. Of the known antioxidant responses, SOD activity (primarily MnSOD) 
and GPX, have been demonstrated as the most consistent, by increasing in an exercise-dependent 
manner (Alessio and Goldfarb, 1988; Lawler et al., 1993; Leeuwenburgh et al., 1994; Powers et al., 
1994; Budiono et al., 2012). The skeletal muscle adaptation to exercise is clearly the most 
pronounced and most well-studied. However, this raises a question: is the systemic response to 
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exercise a consequence of all cells responding to exercise the same way as skeletal muscle? This is 
interesting considering that changes to antioxidant/oxidative stress biomarkers have been 
demonstrated in various other organs such as brain, kidney, heart and liver, and all appear to have a 
similar protective response despite reacting differently to changes in oxygen supply during exercise 
(Radak et al., 1996; Navarro et al., 2004; Radak et al., 2004; Iemitsu et al., 2006; Radak et al., 
2008). This suggests that an extracellular source of cytoprotective signalling may account for such a 
systemic response to exercise. 
 
Mitochondrial biogenesis is a consistent adaptation to exercise, and seems to contribute to the 
majority of gained benefits to systemic redox control (Baar et al., 2002; Koltai et al., 2012; Marton 
et al., 2014). Mitochondrial biogenesis is presumed to occur due to increased reliance on aerobic 
metabolism, and is initiated by increased ROS signalling (Kang et al., 2009). Metabolic regulation 
of PGC-1α is central not only to exercise-dependent mitochondrial biogenesis, but also upregulation 
of antioxidant enzymes and cytoprotective responses via coactivation of Nrf2 and upregulation of 
SOD1/2, GPX, CAT and HO-1 (Kim and Vaziri, 2010; Wu et al., 2011). The activity of PGC-1α is 
highly susceptible to changes in metabolism and is therefore regulated in many ways in response to 
exercise. PGC-1α phosphorylation is known to increase translocation to the nucleus and its ability 
to bind transcription factors for mitochondrial biogenesis (Puigserver et al., 2001). Furthermore, 
deacetylation by specific deacetylases increases nuclear translocation and cofactor recruitment 
(Rodgers et al., 2005). Sirt1 is a NAD+-dependent deacetylase and has been shown to deacetylate 
PGC-1α. Metabolic alterations, such as exercise, increase Sirt1 activity since lactate levels rise in 
skeletal muscle and change the redox state by increasing NAD+ and the ratio of NAD+/NADH (Li 
et al., 2009). A Sirt1 knock-out mouse exercise model surprisingly demonstrated unaltered PGC-1α 
acetylation and mitochondrial biogenesis compared to wild type animals (Philp et al., 2011), yet 
demonstrated a reduction in an acetyltransferase of PGC-1α (general control of amino-acid 
synthesis 5 – GCN5), demonstrating a Sirt1-independent mitochondrial biogenesis pathway. 
 
Increasing numbers of mitochondria allow lower levels of respiratory activity for the same degree 
of ATP production. The previously mentioned elusive site of exercise-dependent increased in ROS 
signalling could be explained by resting state respiring mitochondria in increased number due to the 
exercise-induced adaptation of mitochondrial biogenesis. However, this explanation would only 
account for the sustained increase in antioxidant/cytoprotective proteins and enzymes following 
mitochondrial biogenesis, occurring following repeated sustained exercise, and not responsible for 
the initiation of exercise-induced ROS signalling. 
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The benefits gained from physical activity depend on intensity, duration, and initial health of the 
individual. Continued research into the optimal intensity and duration for an individual to induce 
the greatest health benefits must be continued and harnessed. However, as a substantial body of 
evidence demonstrates (Sattelmair et al., 2011; Belardinelli et al., 2012; Ezzati and Riboli, 2013; 
Wang et al., 2013), as does common sense, any exercise is better than none (Bharakhada et al., 
2012). There is still a lack of evidence regarding the association between exercise, oxidative stress, 
and CKD. 
 
 
1.3 HYPOTHESIS AND AIMS 
 
CKD is a common and serious problem that adversely affects human health, limits longevity, and 
increases costs to healthcare systems worldwide. Its increasing incidence cannot be fully explained 
by traditional risk factors. Oxidative stress is prevalent in CKD patients and is considered to be an 
important pathogenic mechanism. Oxidative stress develops from an imbalance between free radical 
production often increased through dysfunctional mitochondria and reduced anti-oxidant defences. 
Perturbations in cellular oxidant handling influence downstream cellular signalling and, in the 
kidney, promote renal cell apoptosis and senescence, decreased regenerative ability of cells, and 
fibrosis.  
 
The overall hypotheses tested in this thesis were that: (1) oxidative stress impacts adversely on 
cellular bioenergetics in the kidney and leads to loss of functioning kidney tissue in chronic kidney 
pathologies; and (2) modulation of oxidative stress will minimise the development and progression 
of injury to kidney cells.  
 
The aims of this thesis were to: 
1. Use an in vitro model of kidney injury from oxidative stress to determine how the failure of 
balance between oxidative stress and oxidant control in PTE cells causes kidney cell injury, and 
then to determine whether exogenous antioxidants can prevent and restore renal cell bioenergetics 
and reduce cell injury (Chapters 3 and 4); 
2. Use an in vivo model of oxidative stress-induced kidney injury, with molecular and metabolic 
imaging, to measure potential oxidative stress biomarkers in association with changes in kidney 
structure and function, and to determine whether treatment with an antioxidant modulates kidney 
disease pathology (Chapters 5 and 6); 
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3. Explore the links between increasing oxidative stress and development of CKD in patients who 
are undergoing significant lifestyle change in conjunction with standard nephrology care, and to 
determine if biomarkers of oxidative stress correlate with clinical markers of renal function in CKD 
patients (Chapter 7). 
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CHAPTER 2 
 
Materials and Methods 
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This Chapter presents the general materials and methods for this thesis. More specific details are 
given in the original research Chapters (Chapters 3-7) for methods specific to those Chapters. 
 
2.1 MATERIALS 
 
All chemicals were of high purity and, unless otherwise indicated, were obtained from Sigma-
Aldrich (St. Louis, MO, USA). HK-2 cells were obtained from the American Type Culture 
Collection (ATCC) (Rockville, MA, USA), unless otherwise indicated. All plasticware for tissue 
culture was either Nunc brand (In Vitro Technologies, Noble Park North, Australia) or Corning 
Plastic (Sigma-Aldrich; St. Louis, MO, USA). Fetal bovine serum (FBS) was from Gibco 
(Invitrogen/Life Technologies Pty Ltd, Mt. Waverley, Australia). Antibiotics for tissue culture were 
obtained from BioWhittaker (Edward Keller Australia, Silverwater, Australia). Growth media were 
obtained from Invitrogen Pty Ltd (Life Technologies Pty Ltd, Mt. Waverley, Australia). The protein 
assay kit was from Pierce Pty Ltd (Quantum Scientific, Murarrie, Australia). The ApopTag® 
Peroxidase In Situ Apoptosis Detection Kit was supplied by Serologicals Corporation (Millipore 
Pty Ltd, North Ryde, Australia). Primary antibodies, their dilutions and suppliers are listed in 
sections on Western Immunoblots and immunohistochemistry (IHC). All secondary antibodies were 
from Zymed Laboratories (Invitrogen/Life Technologies, Mt. Waverley, Australia) and dilutions are 
listed in relevant chapter sections. The polyvinylidene difluoride (PVDF) membrane for Western 
immunoblots was from PerkinElmer (Thermo Fisher Scientific, Scoresby, Australia). Mice were 
purchased from the Translational Research Institute (TRI) Biological Research Facility breeding 
house (Woolloongabba, Australia). Powdered food for the mouse diet was from Specialty Feeds 
(Glen Forrest, Australia) and was donated from the laboratories of Professor Lindsay Brown 
(School of Health, Nursing and Midwifery, University of Southern Queensland, Toowoomba, 
Australia). 
 
2.2 CELL CULTURE 
 
HK-2 cells are adult human kidney PTE cells that have been transfected with human papilloma 
virus (HPV 16) E6/E7 genes, and are therefore immortalised. They were selected because they are 
highly representative of freshly isolated PTE cells based on histochemical, immune, cytochemical, 
and functional characteristics (Ryan et al., 1994). Freshly isolated human tubular epithelial cells 
have disadvantages owing to a limited availability of human sources and inherent patient variability 
of culture isolates, time-consuming and difficult isolation techniques, and limited ability of the cells 
for multiple passaging without inherent senescence (Vesey et al., 2009). 
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2.2.1 Cell culture 
HK-2 cells were maintained routinely in 25 cm
2 
or 75 cm
2 
cell culture flasks containing Dulbecco’s 
modified Eagle’s medium (DMEM)/Ham’s F12 containing 10% FBS with penicillin (1000 U/mL) 
and streptomycin (1000 U/mL). This will be termed “normal growth medium” in this thesis. Cells 
were grown in a humidified atmosphere of 95% air and 5% carbon dioxide (CO2) at 37˚C in a tissue 
culture incubator. Frozen stocks of cultures were stored in liquid nitrogen at -196 ˚C. Stocks were 
checked routinely for mycoplasma contamination and were always found to be uncontaminated. 
 
2.2.2 Sub-culturing techniques 
Cultures were passaged every 3-5 days when flasks were 90-100% confluent. HK-2 cells are 
adherent and were trypsinised using either 2.5% trypsin/versene solution or 2.5% 
trypsin/ethylenediaminetetraacetic acid (EDTA) at 37 ˚C until cells detached from the tissue culture 
flasks. Cell suspensions were transferred to a sterile 5 or 10 mL tube and centrifuged at 1000-1200 
revolutions per minute (rpm) for 5 min to pellet the cells. Cell pellets were resuspended in 5-10 mL 
of normal growth medium and transferred to sterile 25 cm
2
 or 75 cm
2
 tissue culture flasks 
containing 5-10 mL of growth medium. Aseptic technique was used, and normal growth medium 
was often filtered using a 0.2 µm syringe-adaptable filter. Following centrifugation and re-
suspension, cells were also either plated directly into 24-well multi-well culture plates containing 
sterile glass coverslips (12 mm diameter; Lomb Scientific, Taren Point, NSW, Australia) for 
microscopy, or plated into 6-well multi-well tissue culture plates or 100 mm tissue culture dishes 
for protein extraction, or 96-well plates for the MTT assay (section 2.2.5) or the fluorimetry assay 
(Section 2.2.6). Petri dishes routinely contained a coverslip that was fixed and stained for histology. 
Cells were grown for 24-48 h prior to treatment or until 80-90 % confluent. Phosphate buffered 
saline (PBS) was routinely used to wash cells. 
 
2.2.3 Frozen stocks of cell lines 
Frozen stocks of the cell lines were prepared periodically. Trypsinised cells were centrifuged, the 
supernatant discarded, and the cells were re-suspended in 1 mL of normal growth medium with 10 
% dimethyl sulphoxide (DMSO). Resuspended cells were transferred to labelled cryogenic tubes 
and frozen at -80 ºC in an insulated isopropanol-filled freezing container (Nalgene, Thermo Fisher 
Scientific, Scoresby, Australia; Cat. no. 5100-0001) which regulated the freezing rate. Frozen cells 
were then relocated to liquid nitrogen for long-term storage. 
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2.2.4 Cell treatments 
Specific cell treatments are described in relevant chapters. H2O2 cell treatment was common 
throughout in vitro studies and is therefore described here. A 5% H2O2 solution was prepared from 
a 30 % H2O2 stock solution by diluting 1:6. A 1 mM solution was prepared by adding 10.2 µL of the 
dilution to 15 mL normal growth medium. A serial dilution was prepared according to Table 2.1. 
 
Table 2.1: H2O2 serial dilution 
H2O2 Concentration Volume of 1mM H2O2 Volume of Media 
1 mM 5 mL 0 mL 
0.8 mM 4 mL 1 mL 
0.6 mM 3 mL 2 mL 
0.4 mM 2 mL 3 mL 
0.2 mM 1 mL 4 mL 
0 mM (Control) 0 mL 5 mL 
 
In preparation for treatment, cells were grown to 80-90 % confluence in appropriate culture vessels, 
as described in Section 2.2.2. Cells were washed X 1 with sterile PBS or culture media before the 
addition of treatments. Volumes added and incubation times are stated within specific treatment 
methods in relevant Chapters, and varied depending on the culture vessel and treatment used. For 
experiments involving co-treatments, chemicals were prepared at double the concentration and then 
combined at a 1:1 ratio to obtain the required concentration within the cell culture medium. All cell 
culture treatment studies included appropriate controls including an untreated culture. Vehicle 
controls were included where necessary. Concentration of vehicle controls was always less than 1 
% in the treatments and, in general, caused no change from normal growth media. 
 
2.2.5 Cell viability assay 
Cell viability was measured using the assay based on the reduction 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT) (Sigma, Missouri, USA). Following cell treatments in 96-
well plates, 100 µL of MTT solution prepared in serum-free growth medium (0.5 mg/mL) were 
added to wells and incubated for 90 min at 37 ˚C. Culture medium was removed and formazan 
crystals were dissolved in 200 µL DMSO. Absorbance was measured in a microplate reader at 570 
nm with background collection at 690 nm. 
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2.2.6 Cell fluorimetry assays 
Dihydroethidium (DHE) was used as a marker of ROS production in HK-2 cells since the oxidation 
of hydroethidine to ethidium is mediated by superoxide production. JC-1 was used to assess 
changes to the mitochondrial membrane potential since JC-1 fluoresces red when internalised into 
healthy polarised mitochondria, and green when it is in the cytoplasm unable to be taken into 
mitochondria with a depolarised membrane potential. HK-2 cells were seeded into black, clear-
bottom 96-well plates, incubated overnight, and subjected to treatments. Conditioned media were 
removed, cells were washed, and either 5 µM DHE or 3 µM JC-1 in serum-free DMEM Ham’s F12 
medium were added and incubated for 30 min. Cells were washed X2 in Hank’s Buffered Solution 
(HBS) before fluorimetry was read. Fluorescence was read on a Synergy Mx multi-mode microplate 
reader (BioTek, Winooski, VT) with DHE excited at 535 nm, JC-1 (red) at 525 nm, JC-1 (green) at 
490 nm, and emission detected at 610 nm (DHE), 590 nm (JC-1-red), and 530 nm (JC-1-green). 
Emitted fluorescence values were normalised to protein concentration determined by the Pierce 
bicinchoninic acid (BCA) protein assay (Pierce Chemical Co., Rockford, Illinois, USA) (Section 
2.5.2), which was performed using protein extracted from the black 96-well plate and transferred to 
a clear 96-well plate. 
 
2.2.7 ATP luminescence assay 
ATP production was measured using a luciferase-based luminescence assay (Promega, Sydney, 
Australia). Cells were seeded into white opaque 96-well plates and treated as previously described. 
Chemiluminescent reagent was added and cell lysis induced prior to measuring luminescence at an 
integration time of 0.5 sec using a Titertek-Berthold Luminometer (Titertek-Berthold Detection 
Systems, Pforzheim, Germany). 
 
2.2.8 Malondialdehyde assay for lipid peroxidation 
A colorimetric assay (Bioxytech LPO-586 Assay, OxisResearch Products, Percipio Biosciences 
Inc., USA) for lipid peroxidation was conducted as a measure of oxidative stress in treated HK-2 
cells. The assay measures malondialdehyde (MDA) content. MDA is generated from 
polyunsaturated fatty acid peroxides following lipid peroxidation. The shift in absorbance is based 
on the reaction of N-methyl-2-phenylindole with MDA which produces a stable chromophore. 
Absorbance is then read in triplicate at 620 nm using an ELISA plate reader. Protein extraction was 
performed in a similar method to that used for Western immunoblotting, with addition of 0.5 M 
butylated hydroxytoluene (BHT) to prevent any further oxidation of cells during protein extraction 
and sample preparation, in accordance with the manufacturer’s guidelines. Cells treated with 1 mM 
H2O2 were used in addition to treatments, as a positive control representing high oxidative stress. 
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Protein was analysed according to the supplier’s instructions 
(www.oxisresearch.com/pub/PDF/inserts/75820605.pdf). Protein concentration was determined by 
a BCA protein assay (Section 2.5.2) and spectroscopy was carried out at 540 nm. MDA absorbance 
values were then normalised according to the protein concentration of each cell homogenate. 
 
2.2.9 Total antioxidant capacity assay 
The OxiSelect
TM
 TAC Assay Kit (Cell Biolabs, Inc., Jomar Bioscience Pty Ltd., Welland, 
Australia) was used to determine the total antioxidant capacity (TAC) by measuring the reduction of 
the copper ion coupled to a chromogenic reagent, measured at 490 nm. Uric acid was used as a 
standard. The kit was used according to the manufacturer’s protocol. Treated and control cultures 
were washed X3 in PBS for 5 min before being lysed in PBS by sonification. Cell debris was 
removed by centrifugation at 10000 g for 10 min at 4 ºC. Protein concentration was determined by 
the BCA assay (Section 2.5.2) and spectroscopy performed at 540 nm so that 100 µg of protein was 
analysed for each treatment.  
 
2.3 CELL CULTURE MICROSCOPY 
 
2.3.1 Fixation 
Cell culture growth medium was discarded from control and treated cells on coverslips, followed by 
washing X 1 with PBS, pH 7.4. Cells were then fixed in 4% paraformaldehyde (PF) (Appendix B) 
for 30 min at room temperature (RT) or overnight at 4 °C. Cells were washed twice in PBS then 
either stained immediately or stored in PBS at 4 °C. For immunocytochemistry microscopy, cells on 
coverslips were fixed in 100 % methanol at -20 °C for 5 min prior to PBS washes.  
 
2.3.2 Haematoxylin and eosin (H&E) staining of cell culture 
Following fixation, PBS was discarded and cells were permeabilized with 0.2 % Triton X-100 in 
PBS for 10 min. Mayer’s haematoxylin stain was filtered (0.22 μm) onto coverslips for 
approximately 10 min. The haematoxylin was removed and cells “blued” in normal tap water for 2 
X 2 min, then with a “blueing” agent of 0.2 % (w/v) aqueous sodium carbonate for a further 5 min 
to intensify the stain. Cells were dehydrated in a series of ethanol solutions (70 %, 95 %, 100 %) for 
5 min each. The final 100 % ethanol solution was removed prior to adding eosin solution for 5 min. 
This was followed by 2 X 2 min washes in 100 % ethanol. Cells were transferred into a glass dish 
by small tweezers where they were cleared in xylene for 5 min. Coverslips were mounted onto 
slides using Depex mounting medium. Adequate time was allowed for the mounting medium to dry 
prior to light microscopy, or digital scanning. 
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2.3.3 Cytological assessment of apoptosis 
H&E stained coverslip-cultures were viewed using light microscopy or Aperio Image Scope digital 
histology software. The morphological features of apoptosis (Kerr et al., 1995; Gobe, 2009) that 
were used were: (i) shrunken eosinophilic cells with condensed, marginated nuclear chromatin and 
intact cell membrane; (ii) discrete apoptotic bodies compromising large, dense, pyknotic nuclear 
fragments usually surrounded by a narrow eosinophilic cytoplasmic rim; and (iii) clusters of small 
apoptotic bodies (assessed as a single apoptotic occurrence) (Fig 2.1). Cells with nuclear features of 
apoptosis not showing the characteristics of secondary necrosis (swollen cytoplasm), known to 
occur in cell culture were also counted as apoptosis. Apoptosis was counted in at least 10 
microscopic fields at x200 per coverslip culture and a minimum of 1000 cells was counted. Counts 
of apoptosis were calculated as a percentage of total cells (normal plus apoptotic) per field. 
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Figure 2.1: H&E-stained HK-2 cells undergoing apoptosis, mitosis and senescence 
Apoptosis was identified by shrunken eosinophilic cells with condensed, marginated nuclear 
chromatin and intact cell membrane (A.), discrete apoptotic bodies compromising large, dense, 
pyknotic nuclear fragments usually surrounded by a narrow eosinophilic cytoplasmic rim (B.), and 
clusters of small apoptotic bodies assessed as a single apoptotic occurrence (C.). Mitosis was 
identified by the formation of mitotic spindles occurring during metaphase and remaining visible in 
anaphase (D.), and cells in the later stages of mitosis, telophase (E.) or undergoing cytokinesis (F.). 
Morphological senescence was identified as large cells, at least 3-4 times the diameter of non-
senescing cells (G.), often appearing with multiple and bi-lobed nuclei per senescent cell (H. and I.). 
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2.3.4 Cytological assessment of mitosis or cell senescence 
The morphological characteristics used to distinguish mitosis were: (i) formation of mitotic spindles 
occurring during metaphase and remaining visible in anaphase; or (ii) cells in the later stages of 
mitosis, telophase or undergoing cytokinesis. Cell senescence was assessed initially by the presence 
of large cells, at least 3-4 times the diameter of non-senescing cells (Figure 2.1). 
 
2.3.5 Cell culture immunohistochemistry (IHC) 
After fixation of coverslip cultures and washing in PBS, cells were permeabilized with 0.2 % 
Triton-X100 in PBS for 10 min, then non-specific binding of peroxidase or antibody was blocked 
with 0.1 % sodium azide in 0.3 % H2O2 in Tris-buffered saline (TBS) for 10 min, followed by 4 % 
blotto in TBS for 20 min. The primary antibody was diluted in 1 % bovine serum albumin (BSA) 
prepared in TBS was applied at 4 
o
C overnight. Negative controls were prepared without primary 
antibody, or with non-specific serum. The LSAB+ peroxidase kit (DAKO Australia Pty Ltd, 
Campbellfield, Australia) was used for application of the secondary antibody and for the 
Horseradish Peroxidase (HRP) reaction and diaminobenzidine 2-hydrochloride (DAB) chromogen 
reaction. Cells were lightly counterstained with haematoxylin, dehydrated in a series of ethanols, 
cleared in xylene then mounted in Depex. 
 
2.3.6 Cell culture immunofluorescence (IF) 
After fixation of coverslips cultures and washing in PBS, cells were permeabilised with 0.2 % 
Triton-X100 in PBS for 10 min, then non-specific antibody binding was blocked with 10 % bovine 
calf serum (BCS) in PBS solution for 30 min. A primary antibody solution (Table 2.2) diluted in the 
blocking solution was added for 2 h and room temperature. Coverslips were washed in PBS for a 
total time of 20 min at least 6 X. The appropriate diluted secondary antibody solution was applied 
and incubated for 30 min at room temperature before washing coverslips in PBS for a total time of 
20 min with at least 6 washes. Mount coverslips onto glass slides using aqueous mounting medium. 
 
2.3.7 MitoTracker Red CMXRos confocal microscopy 
MitoTracker Red CMXRos (Invitrogen Australia Pty Ltd, Mt Waverley, Australia) is a fluorescent 
dye that localises to mitochondria with a healthy mitochondrial membrane potential. The dye fades 
as mitochondria lose mitochondrial membrane potential. Cells were first washed in PBS then 
incubated, shielded from light, in 100 nM MitoTracker Red for 30 min. Cells were then washed X 2 
in PBS, fixed in 4 % PF for 30 min at 4 ºC, then washed X 3 in PBS before being mounted onto 
glass slides using Vectashield anti-fade aqueous mounting medium (Vecta Laboratories, Abacus 
ALS, East Brisbane, Australia) with 4',6-diamidino-2-phenylindole (DAPI) blue nuclear fluorescent 
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dye. Cells were observed at 579 nm using a Zeiss 510 Meta confocal fluorescence microscope with 
Zen 2008 software, with x63 oil objective to obtain photographs. To analyse the mean intensity of 
MitoTracker Red CMXRos fluorescence for each treatment, cells were visualised using a Nikon 
FN-S2N fluorescence microscope (x63 objective) with a Nikon DS-U2/L2 USB camera and NIS-
Elements microscopy software. This allowed the florescence intensity of a single cell to be 
determined and expressed as arbitrary units (AU). 5 representative fields for each treatment were 
captured, the fluorescence of each cell within that field was measured, and an overall mean intensity 
calculated. 
 
2.3.8 JC-1 confocal microscopy 
JC-1 is a cationic fluorophore that possesses a mitochondrial membrane potential-dependent 
accumulation in mitochondria. A decrease in red fluorescence and increase in green fluorescence 
indicates mitochondrial membrane depolarisation. Cells on coverslips were washed in PBS then 
incubated in 3 µM JC-1 in serum-free medium for 30 min. Cells were then exposed to 0.4 mM 
H2O2 (moderate oxidative stress) and 1 mM H2O2 (high oxidative stress) in serum-free media for 1 
h. Coverslips were washed in PBS then fixed in 4 % PF for 30 min at 4 ºC, washed X 3 in PBS then 
mounted onto glass slides using Vectashield mounting medium with DAPI. Cells were then 
visualised at 590 nm (red), 529 nm (green) and 460 nm (blue) using the laser scanning confocal 
florescence microscopy stated in Section 2.3.6 (x63 oil objective). For live cell imaging, 1 X 10
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cells/mL were seeded onto glass bottom dishes (MatTec Corporation, Loveland, USA) and allowed 
24 h to adhere. Cells were incubated in 3 µM JC-1 for 30 min. A representative field of cells was 
then visualised using a Zeiss 510 Meta confocal fluorescence microscope with Zen 2008 software, 
x63 objective, and a live-cell imaging chamber at 37
o
C and 5% CO2 in air, to assess fluorescence 
leaching or alteration of mitochondrial membrane potential because of exposure to the laser. H2O2 
treatment was added to the cells and the same field viewed over a total of 25 min. A timed series of 
photos was taken in consecutive 5 min intervals to investigate the shift from red (590 nm) to green 
(460 nm) fluorescence under oxidative stress. 
 
2.3.9 Transmission electron microscopy 
The transmission electron microscopy (TEM) preparation work and imaging was performed under 
the supervision and assistance of Drs Richard Webb, Robin Webb, and Kathryn Green at the Centre 
for Microscopy and Microanalysis, University of Queensland, St Lucia, Australia. 
 
For immuno-labelling of Bax, cell samples were taken from trypsinised suspensions following 
treatment, re-suspended in PBS, then re-suspended in 2 mL 3 % glutaraldehyde in Sorensen’s 
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buffer, pH 7.4, for 30 min. The fixed samples were spun down, resuspended in Sorensen’s buffer, 
and stored at 4 º C. Cells were post-fixed in osmium tetroxide in PBS then embedded in Epon resin. 
Semi-thin sections were cut, stained with toluidine blue and viewed under a light microscope to 
select areas for preparation of ultra-thin sections. Selected areas were cut onto copper grids using an 
ultramicrotome. Prior to labelling and at room temperature, grids were washed 3 X in PBS and 
blocked to prevent non-specific binding, for 15 min in 0.2 % BSA 0.2 % fish skin gelatin, 20 mM 
glycine in PBS. Bax primary antibody (Table 2.2) dilated 1:70 in blocking buffer was applied to 
grids for 30 min, then was washed 4 X in blocking buffer, before adding anti-rabbit-10nm-gold 
secondary antibody diluted 1:70 in blocking buffer for 30 min. Grids were washed 4 X in PBS, then 
4 X in water, before being counterstained with 4 % uranyl acetate in 2 % methylcellulose solution. 
Images were acquired using a Jeol 1010 TEM. For mitochondrial ultrastructure, cells were grown 
on sapphire disks in control and H2O2 treatment culture conditions. High-pressure freezing fixation 
was used for optimal preservation of structure prior to 4 % uranyl acetate and Reynolds lead citrate 
staining. 
 
2.4 HISTOLOGY AND IMMUNOHISTOCHEMISTRY 
 
IHC was performed on coverslip cell cultures or paraffin-embedded sections of mouse kidney. In 
general, antibodies used in the Western blotting process were used at a higher concentration for 
IHC. Antibody dilutions for IHC are listed in Table 2.2. This work was carried out at the Histology 
Facility, Queensland Institute for Medical Research by Mr Clay Winterford. 
 
2.4.1 Haematoxylin and eosin staining of mouse kidney 
H&E staining was routinely performed for all blocked tissue, prior to any staining for IHC, 
ApopTag or Masson’s Trichrome. 3-4 µm sections were cut from paraffin embedded mouse kidney, 
dewaxed in xylene and rehydrated in descending grades of alcohol. Sections were briefly washed in 
water before staining in Mayer’s haematoxylin for 5-10 min. Sections were washed in water for 2 
min before the nuclear stain was blued in Scott’s solution (potassium bicarbonate 2 g/mL, 
magnesium sulphate 20 g/mL in distilled water [dH2O]), and washed in water for 2 min. Sections 
were washed in 70 % alcohol before alcoholic eosin was added as a counter stain for 1-3 min. 
Absolute alcohol was used to dehydrate the sections before being cleared in xylene and mounted 
using Depex.  
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2.4.2 Masson’s Trichrome stain for collagen 
This method applies the principle that larger molecular-sized dyes can replace (differentiate) 
smaller sized dyes that are first applied. This applies only for structures it can penetrate, such as 
collagen, but not in those it cannot penetrate, such as muscle or fibrin. Phosphotungstic acid can be 
replaced by the larger molecular sized dye Aniline Blue, which results in collagen being stained. 3-
4 µm mouse kidney sections were dewaxed and rehydrated to PBS using standard protocol. 
Sections were treated in Bouin’s fluid for 1 h at 56 ºC to add intensity to the colour, then washed in 
running water for 5 min or until colourless. Celestine Blue Stain R was added for 5 min, then 
washed in running water, followed by Mayer’s haematoxylin for 5 min. Sections were again washed 
in running water before 0.5 % acetic alcohol was added for 30 sec to differentiate nuclei, and 
washed off with water. Sections were then covered with Biebrich Scarlet-Acid Fuchsin. Following 
15 min, 1-2 drops of dH2O were added and sections were covered with 5 % tungstophosphoric acid 
solution for 20 min. The solution was drained and aniline blue solution was added for 20 min before 
being washed in 1 % acetic acid for 3 min. Sections were dehydrated to absolute alcohol, cleared in 
xylene and mounted using Depex. 
 
2.4.3 ApopTag® peroxidase in situ apoptosis detection in mouse kidney 
This method labels apoptotic cells by modifying DNA fragments, utilizing terminal 
deoxynucleotidyl transferase (TdT) for detection of apoptotic cells by specific staining. TdT 
catalyses a template-independent addition of nucleotide triphosphates to the 3'-OH ends of double-
stranded or single-stranded DNA. DNA fragments which have been labeled with a digoxigenin-
nucleotide bind an anti-digoxigenin antibody that is conjugated to peroxidase. The bound 
peroxidase antibody, conjugated enzymatically, generates a permanent, intense, localized 
chromogenic stain, providing sensitive detection. Methods were followed according to the 
manufacturer’s protocol (Millipore, S7100, CA, USA). Briefly, 3-4 µm paraffin sections were 
dewaxed and rehydrated with PBS using standard protocol. Freshly diluted proteinase K (20 µg/mL 
in 0.05 M Tris-HCl, 0.01 M CaCl2 pH 8.0) was added to the section for 10 min at room temperature 
before being washed 2 X in PBS. The sections were decanted of excess buffer and the equilibration 
buffer was added directly onto the section for 10 min. The equilibration buffer was removed and the 
working strength TdT enzyme was applied for 1 h at 37 ºC. TdT enzyme was removed prior and the 
stop wash buffer was added before incubating for 10 min and washing X 3 in PBS. Anti-
digoxygenin conjugate was added underlying a plastic coverslip for 30 min at room temperature 
before being washed X 4 in PBS. Colour was developed in DAB with H2O2 as a substrate for 5 min. 
Sections were washing in running water for 5 min and then counterstained with Mayer’s 
haematoxylin for 2 min. 
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2.4.4 Mouse kidney IHC for proliferating cell nuclear antigen 
Table 2.2 gives primary and secondary antibody dilutions for all IHC and IF. Proliferating cell 
nuclear antigen (PCNA) was used to verify morphological identification of mitosis. PCNA 
identifies cycling cells but is an accepted measure of cell proliferation. Paraffin blocks of fixed 
mouse kidney (commonly four kidneys per slide in a tissue array) were sectioned onto Superfrost ® 
Plus slides (Menzel-Glasser, Braunschweig, Germany) at 3-4 µm thickness and air dried overnight 
at 37 ºC. Sections were dewaxed and rehydrated through descending graded alcohols to TBS, pH 
7.4 prior to the blocking of endogenous peroxidase activity by incubating the sections in 2.0 % 
H2O2 in TBS for 10 min. Sections were washed X 3 in TBS, pre-treated with 0.2 M hydrochloric 
acid (HCl) for 20 min at RT, and washed a further 3 X in TBS. Endogenous immunoglobulin was 
blocked by incubating the sections in Biocare Medical Mouse Block M (Metagene.com.au; cat. no. 
RBM961) + Jackson ImmunoResearch (East Brisbane, Australia) anti-mouse F(ab’)2 fragments 
diluted 1:50 for 60 min, then washing X 3 in TBS. Normal goat serum (10%) was added for 30 min 
to stop non-specific binding. Excess normal serum was decanted from the sections and the diluted 
primary antibody for PCNA (Table 2.2) was incubated 90 min at room temperature. Sections were 
washed X 3 in TBS prior to the addition of Biocare Medical Mach2 anti-mouse for 30 min at room 
temperature. Following another 3 washes in TBS, colour was developed in DAB with H2O2 as the 
substrate for 5 min. Sections were washed in gently running tap water for 5-10 min to remove 
excess chromogen. Mayer’s haematoxylin was added as a light counterstain before the sections 
were dehydrated through ascending graded alcohols, cleared in xylene, and mounted using Depex. 
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Table 2.2: Primary and secondary antibodies used for immunohistochemistry and 
immunofluorescence 
Primary 
Antibody 
Supplier Ab 
name 
Source Supplier Catalogue 
number 
Dilution 
8-OHdG 8-OhdG (K-20) Goat 
(polyclonal) 
Santa Cruz sc-130085 1:100 (IHC) 
β-Gal Β-Gal (14B7) Mouse 
(monoclonal) 
Cell 
Signaling 
2372 1:500 (IF) 
p62 SQSTM1 (D-3) Mouse 
(monoclonal) 
Santa Cruz sc-28359 1:500 (IF) 
PCNA PCNA Mouse 
(monoclonal) 
Vector 
Laboratories 
VP-P980 1:75 (IHC) 
p-PPARγ p-PPARγ (Ser 
112)-R 
Rabbit 
(polyclonal) 
Santa Cruz sc-28001-R 1:100 (IHC) 
PPARγ PPARγ (H-100) Rabbit 
(polyclonal) 
Santa Cruz sc-7196 1:100 (IHC) 
    
Secondary Antibody Supplier Catalogue 
number 
Dilution 
Goat Probe and Goat-on-Rodent HRP-
Polymer 
Biocare 
Medical 
GHP516 G, 
H, L 
1:300 
Goat Anti-Mouse-HRP (MACH 2 Mouse 
HRP-Polymer) 
Biocare 
Medical 
MHRP520 
G, H, L, MM 
1:300 
Goat Anti-Rabbit-HRP (MACH 2 Rabbit 
HRP-Polymer) 
Biocare 
Medical 
RHRP520 G, 
H, L, MM 
1:300 
Anti-Mouse Alexa-Fluor Green Molecular 
Probes 
A-11001 1:50 
Ab = antibody; Appropriate dilutions for both primary and secondary antibodies and names of 
suppliers are included for all proteins. 
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2.4.5 Mouse kidney IHC for 8-hydroxy-2’-deoxyguanosine 
8-hydroxy-2’-deoxyguanosine (8-OHdG) is an indicator of oxidative stress in cells. Paraffin blocks 
of mouse kidney in tissue arrays were sectioned onto Superfrost ® Plus slides (Menzel-Glasser, 
Braunschweig, Germany) at 3-4 µm thickness and air dried overnight at 37 ºC. Sections were 
dewaxed and rehydrated through descending graded alcohols to PBS, pH 7.4, prior to the blocking 
of endogenous peroxidase activity by incubating the sections in 1.0 % H2O2, 0.1 % sodium azide in 
PBS for 10 min. Sections were washed X 3 in PBS prior to adding freshly-diluted proteinase K (20 
µg/mL in 0.05 M Tris-HCl, 0.01 M CaCl2, pH 8.0) to the section for 10 min at room temperature. 
Sections were washed 3 X in PBS with the first wash containing 0.5 % Triton X-100. Normal 
donkey serum (10 %) was applied for 30 min. Excess normal serum was decanted from the sections 
and the diluted primary antibody for 8-OHdG (Table 2.2) was added for 1 h at RT. Sections were 
washed 3 X in PBS, with the first wash containing 0.5 % Triton X-100, before adding Biocare 
Medical Goat Probe for 15 min. Sections were washed 3 X in PBS prior Biocare Medical Goat 
Polymer HRP was added for 15 min, then washed 3 X in PBS. Colour was developed in DAB with 
H2O2 as the substrate for 5 min and the sections were washed in gently running tap water for 5-10 
min to remove excess chromogen. Sections were counterstained in Mayer’s haematoxylin, then 
dehydrated through ascending graded alcohols, cleared in xylene, and mounted using depex. 
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2.5 WESTERN IMMUNOBLOT 
 
All primary and secondary antibody dilutions for Western immunoblotting are in tables 2.3 and 2.4. 
 
2.5.1 Protein extraction 
Cell cultures for protein extraction were grown in 6-well tissue culture plates or 100 mm petri 
dishes. Each vessel routinely contained a coverslip that was fixed and stained with H&E to compare 
morphological changes with any changes in protein expression. Remaining cells were washed twice 
in ice-cold PBS then incubated on ice with radioimmuno precipitation assay (RIPA) cell lysis buffer 
(Appendix B) containing protease and phosphatase inhibitors (10 µg/mL leupeptin, 10 µg/mL 
aprotinin, 100 µg/mL phenylmethanesulphonyl fluoride, 1 mM sodium vanadate) for 5 min. Cells 
were scrapped to one side and transferred to a sterile 1.5 mL Eppendorf tube. To ensure complete 
lysis and disruption of cell membranes, cells underwent probed sonication twice for 5 sec each. Cell 
debris was removed by centrifugation at 13,000 rpm for 20 min at 4 ºC. Mouse kidney tissue for 
protein extraction was snap frozen in liquid nitrogen at time of harvest and stored at -80 ºC. Kidney 
tissue (approximately 0.1 g) was transferred to a 5 mL flat bottom specimen container and 
suspended in 1 mL RIPA lysis buffer and with the additives mentioned above. Tissue was 
homogenised with an electric motorised tissue homogeniser for 10 sec X 2. To ensure complete 
disruption of cell membranes, homogenates were probe-sonicated twice for 5 sec. Cell debris was 
removed by centrifugation at 13,000 rpm for 20 min at 4 ºC. Centrifugation was repeated for tissue 
homogenates owing to the large amount of cell debris. Protein concentration was determined by the 
BCA protein assay and spectroscopy. 
 
2.5.2 BCA protein assay 
The Pierce BCA Protein Assay Kit (Pierce Chemical Co cat. no. 23227) was used. The BCA 
Working Reagent (WR) was prepared by mixing 50 units of BCA Reagent A with 1 unit of BCA 
Reagent B. The total volume of WR required was calculated by (number of standards + number of 
unknowns) x (number of replicated) x (200 µL of WR per sample). The following microplate 
procedure was used: 20 µL of each standard replicate was pipetted into a microplate well. The 
working range of the standards was 20-2,000 µg/mL and the amount per well was 50, 37.5, 25, 
18.75, 12.5, 6.25, 3.125, 0.625, and 1 µg. Sample volumes of 2-5 µL were used depending upon the 
available lysate volume. 200 µL of the WR were added to each well. The plate was incubated at 37 
ºC for 30 min then removed from the incubator and allowed to cool to RT. Absorbance was read at 
562 nm using a Labsystems iEMS Reader MF (Thermo, Helsinki, Finland). GraphPad Prism 5 or 6 
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was used to generate a BCA standard curve and polynomial fourth order function to calculate each 
sample protein concentration. 
Table 2.3: Primary antibodies used in Western immunoblotting 
Primary 
Antibody 
Supplier 
Ab name 
Ab Source Supplier Catalogue 
Number 
Western 
dilution 
Bax Bax (P-19) Rabbit 
(polyclonal) 
Santa Cruz sc-526 1:1000 
Bcl-XL Bcl-XL Rabbit 
(polyclonal) 
Santa Cruz sc-7195 1:1000 
GAPDH GAPDH Rabbit 
(polyclonal) 
Sigma G9545 1:10000 
HO-1 HO-1 Rabbit 
(polyclonal) 
Abcam ab13243 1:1000 
Keap1 KEAP1 Rabbit 
(polyclonal) 
Aviva Systems 
Biology 
ARP38981_P050 1:1000 
LC3β MAP 
LC3β (N-
20) 
Goat 
(polyclonal) 
Santa Cruz sc-16755 1:1000 
Nrf2-α GABPA Rabbit 
(polyclonal) 
Aviva Systems 
Biology 
P100832_T100 1:1000 
Nrf2-β GABPB2 Rabbit 
(polyclonal) 
Aviva Systems 
Biology 
P100925_P050 1:1000 
p16 p16 Mouse 
(monoclonal) 
Santa Cruz sc-9968 1:1000 
p62 SQSTM1 
(D-3) 
Mouse 
(monoclonal) 
Santa Cruz sc-28359 1:1000 
p66
shc
 p66Shc Rabbit 
(polyclonal) 
Upstate 
Biotechnologies 
07-150 1:1000 
Park2 Park2 Rabbit 
(polyclonal) 
Aviva Systems 
Biology 
ARP43038_P050 1:1000 
PGC-1α PGC-1 
alpha 
Rabbit 
(polyclonal) 
Novas 
Biologicals 
NBP1-04676SS 1:1000 
PPARα PPARα 
(H-98) 
Rabbit 
(polyclonal) 
Santa Cruz sc-9000 1:500 
p-PPARγ p-PPARγ 
(Ser 112)-
R 
Rabbit 
(polyclonal) 
Santa Cruz sc-28001-R 1:100 
PPARγ PPARγ 
(H-100) 
Rabbit 
(polyclonal) 
Santa Cruz sc-7196 1:1000 
SOD-2 SOD2 Rabbit 
(polyclonal) 
Aviva Systems 
Biology 
ARP58529_P050 1:5000 
TGF-β1 TFG β1 
(V) 
Rabbit 
(polyclonal) 
Santa Cruz sc-146 1:1000 
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Table 2.4: Secondary antibodies used in Western immunoblotting 
Secondary Antibody Supplier Catalogue 
Number 
Western 
Dilution 
Goat Anti-Rabbit IgG (H+L) HRP 
conjugate 
Invitrogen G21234 1:2000 
Rabbit Anti-Mouse IgG (H+L) HRP 
 
Invitrogen 61-6420 1:2000 
Rabbit Anti-Goat IgG (H+L) HRP Invitrogen 81-1620 1:2000 
Ab = antibody; appropriate dilutions for both primary and secondary antibodies and suppliers are 
included for all proteins. Primary antibody refers to the protein of interest referred to within text, 
and the supplier antibody name refers to the technical name of the antibody specified within a 
datasheet, which is commonly a synonym. 
 
2.5.3 SDS-PAGE, Western immuno-transfer and protein visualisation 
Lysates were resolved using 10 % sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) with either 10 or 15 lanes per gel. Using protein extracts from cells and kidney 
homogenates, 20-50 µg of total protein were loaded onto each gel lane. Electrophoresis was at 30 
mA/gel until the band of protein was observed to reach the bottom of the gel. Protein was then 
transferred to a PVDF membrane using a Bio-Rad Mini Protean 3 unit (Bio-Rad Laboratories Pty 
Ltd, Gladesville, Australia). At this stage, PVDF membranes were stained using Ponceau Solution 
to visualise and confirm the protein transfer as well as check for even distribution of protein 
between lanes. If an error was visualised, the protocol was halted at this step. Non-specific binding 
of antibodies to the membrane was inhibited by incubation in 5 % skim milk powder in Tis buffered 
saline-Tween 20 (TBST) buffer (blotto) (Appendix B) for 1 h with continuous rocking. Primary 
antibodies were prepared in 1 % blotto solution and incubated overnight at 4 ºC on a continual 
rotator. Information on antibodies and their dilutions are presented in Table 2.2. Probed membranes 
were washed 3 X 5 min in TBST then incubated with the appropriate secondary antibody diluted in 
1 % blotto for 1 h at RT with continuous motion. Membranes were washed 3 X 5 min in TBST 
before having Supersignal West Pico chemiluminescent substrate (Pierce Chemical Co., Rockford, 
Illinois, USA; cat. no. 1859674 and 1859675) added after being placed in a developing cassette. 
Protein bands were detected using enhanced chemiluminescence (ECL) imaging onto X-ray film 
(Kodak X-Omat AR-5 or Fuji Rx XR Film) and scanned using a Canon Canoscan 8400F at 300 dpi. 
Scion Image software version Alpha 4.0.3.2 or ImageJ (1.46r, National Institutes of Health, USA) 
was used to quantify the density of the bands in arbitrary densitometry units (ADU). Even loading 
of lanes (protein loading control) was assessed using glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) immunoblots. These were also used to normalise densitometry from the same membrane 
following stripping of the probed antibody. Membrane stripping involved adding the probed 
membrane to stripping buffer (1 M Tris, 20% SDS, 14.3 M β-mercaptoethanol) at 50 ºC for 30 min. 
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2.6 IN VIVO STUDIES 
 
2.6.1 Animals 
Male C57Bl6 mice weighing 20-30 g were purchased from The University of Queensland 
Biological Resource Facility. Mice were housed at the University of Queensland Biological 
Resource Facility at the Translational Research Institute and Princess Alexandra Hospital campuses. 
Animals were housed with 12 h light - 12 h dark and unlimited access to food and water during 
normal conditions. Diet was regulated during NAC antioxidant therapy studies. 
 
2.6.2 Surgical procedure and ischaemia-reperfusion model 
For the ischaemia-reperfusion (IR) experiments, 20-30 g mice (4-6 weeks old) were anaesthetised 
using a ketamine/xylazine combination (10 mg/mL and 1 mg/mL, respectively) administered via 
intra-peritoneal injection at a dose of 10 μL/g body weight. Mice were shaved on the left and right 
flanks, placed on a heated pad (38 °C), moistened eye lubricant and gauze were placed over the 
eyes, and the kidney on the left side was exposed using a flank incision through the skin and the 
muscle layers. The renal artery was cleared of fat and a non-traumatic vascular microclamp was 
placed over the vessels for 20 min. Vessel occlusion was confirmed by darkening of the kidney. The 
kidney was placed within the body cavity and moistened gauze was placed over this skin incision. 
The mouse was turned to its right side, and the procedure repeated. The second skin incision was 
covered with moistened gauze. Following 20 min of left renal vessel occlusion, the microclamp was 
removed from the left side, and the animal turned to remove the microclamp from the right side 
(approximately 20 min occlusion). In each case, reflow to the kidney was confirmed by a return to 
normal colour of the kidney. For chronic injury in the kidney, the muscle and skin incisions were 
sutured with 4-0 silk, and mice were allowed to recover for 21 days. 21 days was selected for 
chronic injury from our previous research into IR-induced injury in rodents which show progression 
to chronic injury at 14 and 28 days (Gobe et al., 1990; Gobe et al., 2014). In addition, we calculated 
that 21 days in a mouse was equivalent in a human to 2 years. 
 
2.6.3 Intravital multiphoton microscopy of kidney ischaemia-reperfusion 
After anaesthesia was obtained, the animal was shaved on the left and right flank. Surgical 
procedure was carried out on a heating platform set to 38 °C. The left kidney was externalised by 
making a small incision on the left flank through the retroperitoneum. For intravital imaging during 
ischaemia (when the microclamp is on) and during initial reperfusion (when the microclamp is just 
released) only the left kidney was externalised to prevent major trauma to the mouse and excess 
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body temperature loss. Renal vessels were occluded (as described in Section 2.4.1) and the mouse 
was moved to the multiphoton microscope (MPM) stage making sure to place the kidney over the 
objective bathed in dH2O. A heated jacket was placed over the mouse to maintain the normal body 
temperature (heated jacket at 38 °C) and images of the ischaemic kidney were acquired over 20 min 
from when the microclamp was attached. Intravital imaging during initial reperfusion was 
performed by releasing the microclamp following the 20 min renal ischaemia period, then quickly 
replacing the mouse to the microscope stage with the reperfused kidney over the objective bathed in 
warm dH2O and covering with the heated jacket. Images were acquired over 40 min from when the 
clamp was removed. Both left and right kidneys from healthy control mice and 21-day IR mice 
were imaged by the same procedure, with clamping omitted at the time of MPM. 
 
2.6.4 Intravital mitochondrial function assessment 
Tetramethylrhodamine methyl ester (TMRM) was infused intravenously (iv) and visualised via 
MPM to determine mitochondrial health following 21-days post IR injury. TMRM is a cell-
permeant, cationic fluorophore that is readily sequestered by active mitochondria with a polarised 
membrane potential. TMRM is ideal for MPM since the excitation wavelength does not overlap 
with NADH endogenous fluorescence excitation that commonly occurs with other mitochondrial 
membrane potential-dependant fluorescent probes (Hall et al., 2013). Prior to infusion, mice were 
prepared as previously described (Section 2.4.2) and images were captured at 740 nm (NADH) 
(Figure 2.2) and 800 nm (TMRM) excitation to gain a matched background signal. 20 µL of a 5 
µg/mL TMRM solution prepared in 0.9% saline or PBS, was infused into the tail vein. This volume 
and concentration would result in 0.1 µg/mL plasma concentration of TMRM.  The kidneys were 
then immediately imaged with MPM. Z-stack images were acquired shortly after infusion at both 
740 nm and 800 nm excitation in at least three separate fields per kidney.  
 
2.6.5 Intravital MPM image acquisition and analysis 
Images were captured using a X20 objective on a Nikon Ti Eclipse - LaVision MPM (LaVision 
BioTec GmbH, Bielefeld, Germany) equipped with an ultrashort (85 fs pulse width) pulsed mode-
locked 80 MHz Titanium:Sapphire MaiTai laser (Spectra Physics, Mountain View, USA)  and 
ImSpector Pro software. The excitation wavelength was set to 740 nm for NADH fluorescence, 900 
nm for collagen (Figure 2.3) via second harmonic generation (SHG), and 800 nm for TMRM. For 
TMRM experiments, using only control and 21-day post IR injury mice, background readings were 
obtained at 740 nm and 800 nm excitation prior to TMRM infusion. Emitted light was collected 
using three photomultiplier tube filters: 447 nm – 460 nm (blue), 485 nm – 550 nm (green), 575 nm 
– 630 nm (red). The objective was placed in a field of view that visualised detailed tubular 
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structures and serial (30-50) penetrating slice images were acquired from the renal cortex to a depth 
of 50-70 μm. A minimum of three fields of view per kidney was obtained. The image analysis 
software Imaris x64 7.6.0 (Bitplane Scientific Software, Zurich, Switzerland) was used to adjust the 
minimum and maximum exposure settings consistently throughout all acquired images for 
standardised quantification of fluorescence intensity. ImageJ (1.46r, National Institutes of Health, 
USA) was used to obtain mean fluorescent intensity values for NADH and TMRM detected 
fluorescence. For each of the three fields captured per kidney, the epithelial layer of definitive 
continuous tubules were selected and measured for mean intensity. Eight tubules per z-slice image 
were measured from five selected z-slice images per z-stack. 
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Figure 2.2: 740 nm excitation MPM of intravital mouse kidney cortex 
Representative healthy control kidney from mouse exciting fluorescence at 740 nm and detecting 
emission in three channels: Blue (A.); 447 nm – 460 nm. Green (B.); 485 nm – 550 nm. Red (C.); 
575 nm – 630 nm (red). (D.) depicts a combined image from all three channels. Image was captured 
29 µm below renal capsule. 
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Figure 2.3: 900 nm excitation MPM of intravital mouse kidney capsule and cortex 
Representative healthy control kidney from mouse exciting fluorescence at 900 nm and detecting 
emission in three channels: Blue (A.); 447 nm – 460 nm. Green (B.); 485 nm – 550 nm. Red (C.); 
575 nm – 630 nm (red). (D.) depicts a combined image from all three channels. A-D images were 
captured 6.82 µm below outermost capsule which can be visualised in sequential slice images (E.). 
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2.6.6 Multiphoton fluorescence lifetime imaging microscopy 
Dr Washington Y Sanchez performed and provided expert assistance with kidney FLIM 
experiments. FLIM was performed on mouse kidney post-sacrifice. Kidneys were harvested after 
euthanasia of the mice, and placed on ice. A custom-made kidney section apparatus was used to 
slice 1 mm thick sections through the middle of a coronal section from the kidney. The section was 
placed on a glass microscopy slide with an overlying glass coverslip taped down for stabilisation 
(Fig 2.4). Three areas each from both cortex and medulla were captured for FLIM data per kidney. 
Time from death to first image capture was no more than 30 min. Images were captured using a 
DermaInspect system (JenLab GmbH, Jena, Germany) equipped with an ultrashort (85 fs pulse 
width) pulsed mode-locked 80 MHz Titanium:Sapphire MaiTai laser (Spectra Physics, 25 Mountain 
View, USA). The excitation wavelength was set to 740 nm for kidney autofluorescence with an 
emission signal range of 350 to 650 nm established through the use of a BG39 bandpass filter. 
Images were recorded with a 40 x objective. The laser power was set to 15 mW and the acquisition 
time for obtaining images was 13.4 s per frame. FLIM data were collected with a time-correlated 
single-photon counting (TCSPC) SPC-830 detector (Becker & Hickl GmbH, Berlin, Germany) 
integrated into the DermaInspect MPM system. The TCSPC module assembles a photon 
distribution of the scan area across the χ and ϒ coordinates taken from four photon counters, with 
only three used for this project. The model determines the time of arrival for each photon detected 
within the fluorescence decay. Fluorescence emission was spectrally resolved between three 
linearly-arranged photon counters through the use of three dichroic filters in the beam path, 
spectrally dividing the emission light into three channels for each photon counter: 350 to 450 nm 
(reduced nicotinamide adenine dinucleotide phosphate – NAD(P)H), 450 to 515 nm (NAD(P)H, 
flavin adenine dinucleotide phosphate – FAD), and 515 to 610 nm (FAD). Each FLIM image was 
collected at an exposure of 13.4 s and acquisition image size of 214 x 214 μm. 
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Figure 2.4: Mouse kidney section preparation for MPM FLIM microscopy 
A 1 mm thick coronal section of a freshly harvested mouse kidney was placed onto a glass 
microscopy slide. A glass coverslip was overlaid on the kidney slice and adhered to the slide by 
adhesive tape.  
 
2.6.7 FLIM data analysis 
FLIM data analysis was performed using SPCImage 4.8 (Becker and Hickl GmbH). FLIM data are 
composed of an array of pixels containing several time channels distributed across the fluorescence 
decay curve. The decay curve represents a sum of multiple exponentials, or components, as each 
pixel contains an overlay of fluorescence from several endogenous fluorophores at various 
conformations. A double-exponential decay model function was used. The fitted decay curve 
establishes two lifetimes: the short (τ1) and long (τ2) fluorescence decay lifetimes (ps) and with 
corresponding relative amplitude coefficients α1 and α2 (%), respectively. The lifetime of NAD(P)H 
is resolved as a two-component system with the short (~0.3-4 ns) and long (~2.3 ns) lifetime 
represented as the free and protein-bound conformations, respectively (Lakowicz et al., 1992; 
Niesner et al., 2004; Berezin and Achilefu, 2010). The free-to-bound ratio of NAD(P)H, 
represented by the ratio of the amplitude coefficients for the short and long lifetimes (i.e. α1/α2), is 
related to the NADH/NAD+ ratio and was used as an indicator for redox changes within the cell 
(Bird et al., 2005). 
 
2.7 CLINICAL STUDIES 
 
2.7.1 Study design 
This study was a substudy of an ongoing open-label randomised controlled trial, known as the 
LANDMARK-III trial (Longitudinal Assessment of Numerous Discrete Modifications of 
Atherosclerotic Risk Factors in Kidney Disease). LANDMARK-III is a 3-year study comparing the 
effect of a nurse practitioner-led model of care with standard nephrology care on cardiovascular risk 
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factors. Patients were screened at the Princess Alexandra Hospital Nephrology Department, 
Brisbane, Australia.  
 
2.7.2 Participants 
Patients were eligible for inclusion if they were aged 18-75 years, had moderate CKD (eGFR 25-60 
ml/min/1.73 m
2
), and had one or more uncontrolled yet modifiable cardiovascular risk factors that 
were: blood pressure (BP) exceeding target (>130/80 mmHg, or >120/75 mmHg for those with 
diabetes or proteinuria > 1 g/ 24 h), overweight (body mass index [BMI] >25 kg/m
2
), poor diabetic 
control (haemoglobin A1c [HbA1c] >7%), or hyperlipidaemia (low-density lipoprotein [LDL-C] 
<2.5 or <2.0 mmol/L in those with diabetes or existing coronary heart disease). Exclusion criteria 
were: intervention for, or symptomatic, coronary artery disease (within 3 months), current heart 
failure (according to New York Heart Association class III and IV) or significant valvular heart 
disease, pregnant or planning to become pregnant, previous kidney transplant, and life expectancy 
or anticipated time to dialysis or transplant <6 months. Participants provided written informed 
consent and the study complied with the Declaration of Helsinki. 
 
2.7.3 Patients groups 
2.7.3.1 Control group 
The control group received standard nephrology care, which included review by a nephrologist, 
recommended lifestyle modification but no specific information or education, and referral to an 
allied health professional on an ad hoc basis. 
 
2.7.3.2 Exercise and Lifestyle intervention group 
In addition to standard nephrology care, cardiovascular risk factor management was provided by a 
multidisciplinary clinic including a CKD nurse practitioner, dietician, exercise physiologist, 
diabetic educator, psychologist, and social worker to target risk factors to national guidelines 
(Johnson, 2007; NHF, 2010). The exercise-training component involved 150 min of moderate 
intensity exercise per week, with 8 weeks of training supervised by an accredited clinical exercise 
physiologist. Patients attended gym sessions two to three times per week. The sessions included a 
warm-up, 20-30 min of aerobic activity using a treadmill, stationary bike, or rowing ergometer, and 
whole body resistance training with machines and free weights. On completion of the gym-based 
training, patients began a home-based program and were provided a booklet depicting resistance 
exercise using Thera-Bands and a Swiss ball. Regular contact was maintained via telephone and 
Email. Participants were questioned on their ability to maintain the prescribed exercise and if they 
identified difficulty, they were encouraged to attend gym-based refresher visits. Patients performed 
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exercise at a moderate intensity, with perceived exertion of 11-13 on a 20-point Borg scale (include 
reference), and was tailored individually. Patients also underwent 4 weeks of group behaviour and 
lifestyle modification facilitated by a dietician and psychologist. The program focused on 
sustainable diet and behaviour change to assist with weight loss. The dietician therapy complied 
with the Evidence-Based Practice Guidelines for Nutritional Management of CKD for patients with 
eGFR between 25 and 60 mL/min/1.73 m
2
 (Ash et al., 2006). 
 
 
2.7.4 Sample collection and handling 
Venous blood (10 mL) samples were collected following an overnight fast using 
ethylenediaminetetraacetic acid (EDTA) vacucontainers (BD Diagnostics, NJ, USA). For oxidative 
stress analysis (isoprostanes, GPX, and TAC), samples were stored on ice before being centrifuged 
at 2000g at 4 ºC for 10 min. Plasma was separated and stored at -80 ˚C with BHT (10 µL of 100 
mM to each 1.5 mL Eppendorf tube) to prevent artifactual oxidation. Routine blood biochemistry 
and additional blood measures of lipids, haemoglobin, phosphate, creatinine, C-reactive protein 
(CRP), albumin, glucose and insulin were conducted using standard laboratory techniques by 
Queensland Health Pathology Service at the Princess Alexandra Hospital (Woolloongabba, 
Brisbane, Australia). The Modification of Diet in Renal Disease-175 formula (Levey et al., 2006) 
was used to estimate eGFR and insulin resistance was computed using the homeostatic model 
assessment of insulin resistance method (Matthews et al., 1985). 
 
2.7.5 F2-isoprostanes assay 
Dr David Briskey, in the laboratory of Prof Jeff Coombes (School of Human Movement Studies, 
University of Queensland), was responsible for performing all measurements for isoprostanes. 
Detailed methods outlining the development and troubleshooting of the method used to measure 
plasma F2-isoporostanes have been published (Briskey et al., 2014). Briefly, a liquid-liquid 
extraction method prior to determination of total isoprostanes using negative chemical ionization 
gas chromatography-tandem mass spectroscopy in plasma was used. F2-isoprostane extraction 
involved vortexing the plasma sample with the internal standard (8-iso-PGF2α-d4), methanolic 
sodium hydroxide (NaOH) for saponification and dH2O for 5 sec, then incubating in a water bath at 
42 ºC for 60 min before placing on ice for 10 min. Proteins were precipitated out of the solution by 
adjusting to pH 3 using 3 M HCl and vortexing for 5 sec. Neutral lipids were then removed by 
adding hexane, gently mixing on a circular mixer at 20-30 rpm for 10 min, centrifuging (3000 x g) 
for 10 min at RT, then removing the supernatant using a glass Pasteur pipette into a clean glass 
tube. Extracts were dried under nitrogen stream at 40 ºC until completely dry. Dry extracts were 
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then reconstituted in acetonitrile and vortexed for 5 sec before being transferred into silonized glass 
inserts where they were again dried under a nitrogen stream at 40 ºC prior to derivatization. 
Derivatization involved adding pentafluorobenzylbromide (10% in acetonitrile) and di-
isopropylethylamine (10% in acetonitrile) to the extract, vortexing for 5 sec, and incubating at RT 
for 30 min to allow the reaction to proceed. Extracts were then dried for 30 min under nitrogen gas 
before being mixed with anhydrous pyridine and bis-(trimethylsily)trifluoroacetamide and 
trimethylchlorosilane (99:1), vortexed for 5 sec and incubated for 20 min at 45 ºC. Anhydrous 
hexane was added to the extract prior to loading into an autosampler carrier vial. Gas 
chromatography-tandem mass spectroscopy (GC-MS) was used to analyse samples for total 
isoprostane concentration using a Varian 320 MS/MS, with Varian 450 gas chromatograph 
equipped with a CP8400 auto sampler. The Varian MS Workstation System control software 
version 6.9.2 (Varian, Agilent.com) was used to analyse the data. 1 µL of sample was introduced in 
splitless mode (entire sample) using a 10 µL Hamilton syringe. After 1 min the injector port was 
switched to a 1:20 split. A Varian FactorFour Capillary Column (VF5 MS 30 m x 0.25 mm ID, DF-
0.25) using helium as the carrier gas at a flow rate of 1.0 mL/min with the injector operated at 250 
ºC was used. The column oven was started at 160 ºC for 1 min before being increased by 20 ºC at 1 
min intervals to reach 300 ºC where it was held for 10 min. The total column oven run time is 18 
min with the isoprostane peak eluted at approximately 9-10 min. The mode was set to run in 
negative chemical ionization mode at 70 eV. The chemical ionisation gas and collision gas was 
argon run at an ion source pressure of 4.20 Torr and 2.00 mTorr, respectively. The mass 
spectrometer was operating at a transfer line temperature of 250 ºC, ion volume temperature of 200 
ºC, and collision energy of 17 V. The detector operated at 1700 V. The peak identification of 
isoprostanes within a sample was established by comparing the retention time and the fragmentation 
pattern of a standard and deuterated standard. The mass size and transition of isoprostanes and the 
respective deuterated standard were established at m/z 569.3/299.3 and 573.3/303.3 respectively. 
 
Final total isoprostane concentrations were calculated by producing a standard curve by injecting 
known amounts of F2-isoprostane (200, 400 and 800 pg/ml) and F2-isoprostanes-d4 (internal 
standard). Comparing the ratio of internal standard to isoprostanes in both the aqueous standards 
and biological samples allows for quantification of the total isoprostanes. Percentage recovery of 
the internal standard added to biological samples compared to the aqueous standards determined the 
efficiency of the of the extraction process. Internal standard addition to each biological sample 
allows for the variability in recovery of every sample to be accounted for. This assay was validated 
by determining the average coefficient of variance of over 1000 different samples analysed in 
duplicate over 12 months. Pooled samples from “sick” individuals (chronic disease patients who 
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have plasma samples that would otherwise be discarded, and typically have high isoprostanes 
levels) and young healthy individuals (typically have low isoprostanes), acted as high and low 
quality control (QC) samples, respectively. QC samples were extracted in conjunction with study 
samples at the time of assay. Accuracy was assessed by comparing plasma samples spiked with 
known amounts of isoprostanes, and analysed in duplicate on multiple occasions. F2-isoprostane 
concentrations were separately quantified in these samples, unspiked samples and aqueous 
standards (Briskey et al., 2014). 
 
2.7.6 Glutathione peroxidase assay 
GPX was measured from plasma using slightly modified published methods (Wheeler et al., 1990; 
Andersen et al., 1997). This assay is based on the oxidation of NADPH following the reduction of 
t-butyl hydroperoxide. The oxidation of NADPH to NADP+ is accompanied by a decrease in 
absorbance at 340 nm and the rate of this decrease is proportional to the GPX activity in the sample. 
An automated assay was performed using the COBAS MIRA system (Roche Diagnostics, 
Australia) following sample and reagent preparation. Briefly, each sample was incubated for 50 sec 
with the sample reagent consisting of 0.25 mM NADPH, 0.205 units/mg glutathione reductase, 1.01 
mM glutathione in Tris-HCl buffer (0.1 M Tris, 0.5 mM EDTA sodium salt, pH 7.55). The reaction 
was started by the addition of 0.13% aqueous t-butyl hydroperoxide and absorbance at 340 nm was 
recorded for 450 sec. High and low QC samples were run simultaneously with patient samples and 
acted as internal controls for accuracy and validity. The linear portions of the absorbance curves 
were identified between two time points and were kept consistent for all calculations to determine 
the difference in absorbance over time. Sample absorbance per minute was converted to GPX units 
(U) to incorporate total volume in the cuvette (225 µL) and the molar extinction coefficient of 
NADPH (6.22 x 10
3
 L.mol
-1
.cm
-1
). 
 
2.7.7 Total antioxidant capacity assay 
TAC of patient plasma was measured using a similar method to that described previously (Rice-
Evans and Miller, 1994). The principle of this assay is based on the inhibition of the absorbance of 
the radical cation, 2,2’-azinobis(3-ethylbenzothiazoline 6-sulfonate) (ABTS+) from any substance 
within plasma that possesses antioxidant properties. The ABTS
+ 
cation is formed by the interaction 
of ABTS with the ferrylmyoglobin radical species that is generated by the activation of 
metmyoglobin with H2O2. Antioxidant compounds suppress the absorbance of ABTS
+
 to an extent 
that is dependent on time and the antioxidant capacity within the serum. The assay was performed 
in conjunction with Trolox standards prepared in PBS (0 mM – 2.5 mM at 0.5 mM intervals). 
Briefly, samples and Trolox standards were added to a 150 µM ABTS and 2.5 µM metmyoglobin 
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solution in PBS prior to starting the reaction with the addition of 75 µM H2O2. Absorbance was 
measured at 734 nm prior to H2O2 addition and 6 min after. Trolox standards were plotted as 
concentration versus change in absorbance at 734 nm over 6 min. Sample absorbance change values 
were interpolated from the Trolox standard curve and expressed as the mM concentration of a 
Trolox solution having the antioxidant capacity equivalent to a 1 mM solution under investigation 
(mmol/L). 
 
2.8 STATISTICS 
 
Specific statistical analysis is outlined in the relevant research chapters. Briefly, for in vitro and 
mouse experiments, the measured parameters were expressed as mean ± SEM, and an independent 
samples t-test was utilised for comparison between two groups. A one way analysis of variance 
(ANOVA) was used for comparisons between more than two groups, and where relevant, a Tukey’s 
post-hoc comparison. A two-way ANOVA was utilised to test the interaction between two 
independent variables, and where relevant, a Bonferroni’s post-hoc comparison. 
 
Dr Anne Bernard from QFAB Biostatistics, Translational Research Institute, Brisbane, Australia 
advised on statistical analysis regarding human clinical measures. Full statistical methods are 
outline in Chapter 7. Briefly, data were tested for normality using Shapiro-Wilk tests, and 
appropriate tests were performed on data following log transformation (expressed as natural 
logarithm, Loge). Data were expressed as mean ± SD for normally distributed data, or median ± 
interquartile range for non-normally distributed data. 
 
Statistical significance was determined at p ≤ 0.05. 
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CHAPTER 3 
 
In Vitro Model of Kidney Damage and the Role 
of Oxidative Stress 
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This chapter examines the separate, and cumulative, effects of cellular processes common to kidney 
diseases, namely, oxidative stress, mitochondrial dysfunction and cell senescence. The contents of 
this chapter have been published (Small et al., 2012, Appendix A). Below is a modification of that 
publication consistent with the format of this thesis. 
 
3.1 INTRODUCTION 
 
CKD affects approximately 10-15 % of the adult population in industrialized countries and the 
incidence of CKD, and its associated end stage disease, is increasing. Although diabetes and 
hypertension are known causes of CKD, ageing alone causes gradual loss of kidney function 
independent of any other pathology (Inagami, 2011). Oxidative stress increases with ageing (Finkel 
and Holbrook, 2000), and has been described in the pathogenesis of diabetes (Singh et al., 2011) 
and hypertension (Carnicer et al., 2012). Oxidative stress, as a significant cause of CKD and the 
associated loss of functioning renal mass, is still debated. Mitochondria are increasingly recognised 
as key participants in renal cellular metabolism (Cuttle et al., 2001), including generation of energy 
in the form of ATP, regulation of calcium homeostasis (Vay et al., 2009), tissue O2 gradients, 
apoptosis (Madesh and Hajnoczky, 2001), and cell signalling (Soubannier and McBride, 2009). 
However, their contribution to CKD is largely unknown. 
 
The kidney is a highly metabolic organ that relies heavily on oxidative phosphorylation, accounting 
for approximately 10 % of whole body O2 consumption. Mitochondrial energy generates 95 % of 
required ATP for the kidney (Rieg and Vallon, 2009). The PTE cells, often most atrophic in CKD, 
contain many large active mitochondria (Hall et al., 2009). A decrease in mitochondrial efficiency 
and subsequent cell function could have a significant impact on CKD development and renal 
failure. Mitochondria are also a major cellular producer of ROS and are themselves targets of ROS-
mediated damage (St-Pierre et al., 2002). Along the respiratory chain complexes of the inner 
mitochondrial membrane, reduction in molecular O2 yields ROS mainly in the forms of O2
•
- and 
H2O2. Defining mitochondrial dysfunction in the highly-metabolic PTE cells may hold a key to 
explaining how oxidative stress contributes to the pathogenesis of kidney diseases like CKD. 
 
Cell senescence is commonly observed in CKD with increased levels of senescence-associated β-
gal and lipofuscin granules predominately in tubular cells (Melk, 2003), and to a lesser extent in 
glomerular mesangial cells (Jiao et al., 2012). Senescent kidney cells can die or persist in a 
damaged form, showing little function and an inability to proliferate (Stenvinkel and Larsson, 
2013). Persisting senescent cells can compromise the healthy functioning of the kidney and reduce 
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the ability of the ageing nephron to cope with disease stresses, since it is the tissue in its whole form 
that accounts for function rather than individual cells. Senescent cells have been shown to secrete 
multiple pro-inflammatory growth factors, cytokines and chemokines (Campisi and d'Adda, 2007) 
therefore promoting inflammation, but also presenting promising targets to inhibit the many co-
morbid conditions associated with inflammation in CKD. Oxidative stress itself can induce 
premature senescence in non-renal cells: in fibroblast cultures (Frippiat et al., 2001); and in retinal 
epithelium during macular degeneration (Glotin et al., 2008). Senescing cells undergo irreversible 
cell cycle arrest, mainly in G1 phase, have increased β-gal activity, and up-regulation of cyclin-
dependent kinase inhibitors, like p16
ink4a
 (Stein et al., 1999). Oxidative stress may cause premature 
senescence of kidney cells in CKD. However, the mechanisms underlying mitochondrial 
dysfunction and subsequent oxidative stress-induced premature senescence in the kidney remain 
largely undefined. We had previously demonstrated that protecting the mitochondria in renal PTE 
protects these cells from increasing apoptosis (Cuttle et al., 2001). The aim of the current study was, 
therefore, to use an in vitro model to investigate the separate and cumulative effects of oxidative 
stress, mitochondrial dysfunction and cell senescence in promoting loss of renal tubular epithelium. 
 
3.2 MATERIAL AND METHODS 
 
Complete methods are outlined in Chapter 2. Below is a brief summary of the experimental 
materials and methods used specifically for this chapter. 
 
3.2.1 Experimental design 
HK-2 cells were grown in normal culture conditions outlined in Chapter 2. Following H2O2, 
apigenin (API) and NAC dose response studies, they were grown to 80-90 % confluence then 
treated for 18 h with 0.4 mM H2O2 for oxidative stress, and 100 µM API to induce renal cell 
senescence (Ryu et al., 2006). DMSO as a vehicle control was <1 % in growth medium. NAC was 
used as an antioxidant as a pre- and co-treatment at 10 mM (N=3 replicates). 
 
3.2.2 Determination of ATP, oxidative stress and cytotoxicity 
ATP levels (luciferase-based bioluminescence assay, Promega, Sydney, Australia); lipid 
peroxidation with MDA (Bioxytech LPO-586 Assay, OxisResearch Products, Percipio Biosciences 
Inc., CA); and TAC (OxiSelect
TM
 TAC Assay Kit, Cell Biolabs, San Diego, CA) were measured 
according to the manufacturers’ protocols and with appropriate controls. As a measure of 
cytotoxicity, lactate dehydrogenase (LDH) was measured as a % of maximal LDH release from 
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cells treated with 5 mM H2O2 (Cytotoxicity Detection Kit
PLUS
, Roche Diagnostics, Castle Hill, 
Australia). 
 
3.2.3 Mitochondrial function 
MitoTracker Red CMXRos (Invitrogen Australia) localises to mitochondria with healthy membrane 
potential, and fades as mitochondria lose membrane potential. HK-2 cells were incubated 30 min 
with 100 nM MitoTracker Red before being fixed in 4 % PF and mounted for microscopy 
(Vectashield anti-fade, Vecta Laboratories, East Brisbane, Australia). DAPI was used to label 
nuclei. A Zeiss 510 Meta confocal fluorescence microscope with Zen 2008 software (X63 oil lens; 
579 nm) was used. Mean fluorescence intensity was analysed (Nikon FN-S2N fluorescence 
microscope, NIS Image software, X63 objective). 
 
JC-1 is a fluorophore that has mitochondrial membrane potential-dependent accumulation in 
mitochondria. Decrease in red and increase in green fluorescence indicates mitochondrial 
membrane depolarisation. JC-1 (3 µM) was applied 30 min preceding H2O2 exposure and then for 1 
h of 0.4 mM H2O2 or 1 mM H2O2 (as high oxidative stress control). Cells on coverslips were fixed 
(4 % PF) before being mounted on glass slides (Vectashield mounting medium with DAPI) and 
visualised at 590 nm (red), 529 nm (green) and 460 nm (blue) using confocal florescence 
microscopy (X 63 oil lens). For live cell imaging, HK-2 cells were seeded onto MatTek Corp 
(Ashland, MA) glass bottom dishes before JC-1 incubation. Cultures were placed in a live-cell 
imaging chamber (Zeiss Axiovert 200M Live Cell Imager) at 37 
o
C and 5 % CO2 in air. A 
representative field was then visualised using confocal microscopy to assess background laser-
induced fluorescence leaching. H2O2 treatment was then added to the cells and the same field 
photographed over 25 min at consecutive 5 min intervals. 
 
3.2.4 Light and fluorescence microscopy 
Cells were fixed in 4 % PF or 100 % ice-cold methanol for 30 min at 4 ºC for H&E staining or 
fluorescence microscopy, respectively. H&E stained cells were assessed using the Aperio 
ScanScope XT system (Aperio Technologies, Vista, CA) for % apoptosis, mitosis and cell 
senescence by counting cells with noted morphological characteristics (Chapter 2, Section 2.3.3 – 
2.3.4) in ten frames of cells (X 200 magnification; an approximate total of 800-1000 cells) for each 
treatment (Hughes and Gobe, 2007). The ApopTag® Peroxidase In Situ Apoptosis Detection Kit 
(Merck-Millipore Pty Ltd, Kilsyth, Victoria, Australia) was used for identifying and verifying 
apoptosis according to our published methods (Hughes and Gobe, 2007). Ki67 (Santa Cruz 
Biotechnology Inc, Santa Cruz, CA; 1:100) immunocytochemistry was used to assess proliferative 
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activity. Senescent cell morphology and SA-β-gal immunofluorescence (Cell Signalling 
Technologies, Danvers, USA; 1:500) for cell senescence were used in parallel. Senescent cells had 
reduced staining saturation (Chen and Ames, 1994) and were 3-4 times the diameter of control 
cells. 
 
3.2.5 Western immunoblotting for Bax, Bcl-XL and p16
Ink4a
 
Protein was extracted by lysing HK-2 cells in RIPA buffer and following an established protocol 
(Chapter 2, Section 2.5). Protein concentration was determined (Pierce BCA assay) and 40 µg of 
each protein separated (10 % SDS-polyacrylamide gel electrophoresis). Immunoblotting was 
performed against Bax (1:1000, Santa Cruz Biotechnology); Bcl-XL (1:1000, Zymed); GAPDH 
(1:1000; Sigma); and p16
Ink4a
 (1:100; gift from A/Prof. Brian Gabrielli) (Wang et al., 1996). HRP-
conjugated secondary antibodies were used. Protein bands were visualised using ECL. Scion Image 
software Alpha 4.0.3.2 was used for densitometry. GAPDH immunoblots were used to normalise 
densitometry. 
 
3.2.6 Immuno-transmission electron microscopy (Bax) 
TEM and immuno-gold labelling were used to assess subcellular localisation of Bax following 
H2O2 treatment. The protocol is outlined in Chapter 2, Section 2.3.8. 
 
3.2.7 Statistical analysis 
Values reported are means ± SEM. Data were analysed using ANOVA and Tukey’s post hoc 
analysis, two-way ANOVA and Bonferroni’s post hoc test, or student’s t-test where appropriate, 
with statistical significance at p<0.05. 
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3.3 RESULTS 
 
3.3.1 ATP, lipid peroxidation and total antioxidant capacity assays indicate oxidative stress 
with all treatments 
API and H2O2, alone or in combination, significantly increased MDA (p<0.05; Fig. 3.1A) indicating 
oxidative stress. API, alone or in combination with H2O2, significantly reduced TAC (p<0.05; Fig. 
3.1B), whereas H2O2 alone significantly increased TAC (p<0.05; Fig. 3.1B). Both API and H2O2 
resulted in loss of ATP; however both treatments were necessary for a significant ATP loss 
compared to untreated controls (Fig. 3.1C). 
 
 
3.3.2. Confocal fluorescence microscopy and live cell imaging indicate loss of mitochondrial 
function with all treatments 
MitoTracker Red fluorescence was significantly reduced following API and/or H2O2 exposure (Figs 
3.2A-E) (p<0.05). There was no additive effect when H2O2 was delivered with API. Live cell 
imaging captured the loss of mitochondrial membrane permeability in the kidney cells with 
oxidative stress (H2O2). Results of time lapse photography (Figs 3.2F-K) using JC-1 demonstrated 
healthy polarised mitochondrial membrane (red fluorescence) transitioning to green fluorescence 
and dysfunctional mitochondria. Fixed cells (JC1, Figs 3.2L-M) also showed mitochondrial 
depolarisation in response to oxidative stress. Concomitant apoptosis is indicated (arrow, Fig. 
3.2M).  
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Figure 3.1: Lipid peroxidation, total antioxidant capacity and ATP generation following 
oxidative stress and cell senescence 
In A, lipid peroxidation was measured by malondialdehyde (MDA) assay. Cells exposed to API, 
H2O2, or API+H2O2 had a significant increase in MDA compared to DMSO vehicle controls (*, 
p<0.05 compared to DMSO).  In B, total antioxidant capacity was measured by colorimetric assay.  
Cells exposed to API or API+H2O2 had a significant reduction in total antioxidant capacity 
compared to DMSO controls. H2O2 induced a small but significant increase in total antioxidant 
capacity (*, p<0.05 compared to DMSO; #, p<0.05 compared to untreated controls). In C, ATP 
generation was measured by luminescence assay. 1 mM H2O2 was used to demonstrate maximal 
ATP loss. Compared with untreated controls, H2O2 caused the greatest ATP loss (*, p<0.05 
compared to DMSO; #, p<0.05 compared to all). 
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Figure 3.2: Live and fixed cell imaging verified mitochondrial dysfunction with oxidative 
stress and cell senescence 
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(Legend for Fig 3.2) 
MitoTracker Red CMXRos confocal fluorescence microscopy is demonstrated in A-D and 
fluorimetry is presented graphically in E as arbitrary fluorescence units (AFU). Compared with 
control cultures (A), all treatments (B = API; C = H2O2, and D = API+H2O2) had decreased 
MitoTracker Red. In E, AFU were significantly decreased in all treatments (*, p<0.05 compared to 
untreated controls). Confocal fluorescence microscopy using live cell imaging and JC-1 labelling is 
indicated in F-H. F demonstrates the control cells, and G and H demonstrate mitochondrial 
membrane depolarisation over 20 min exposure to H2O2. There was a gradual decrease in red 
fluorescence (polarised mitochondria, ~590 nm) to predominantly green fluorescence (depolarised 
mitochondria, ~525 nm). Mitochondrial depolarisation was also demonstrated by JC-1 pre-
treatment, oxidative stress, then fixing the cells before confocal microscopy (I-K). Control cells (I) 
have red fluorescing mitochondria. J and K demonstrate the predominance of green fluorescence 
after exposure to H2O2, again demonstrating mitochondrial membrane depolarisation. Apoptosis is 
also seen in K (DAPI-stained nuclear condensation and fragmentation, arrow). 
 
 
3.3.3 Oxidative stress as a mechanism unifies outcomes of increased renal cell apoptosis, 
decreased mitosis and cell senescence 
Apoptosis was increased, and mitosis decreased, by all treatments. API in association with H2O2 
produced greatest effect (Fig. 3.3A; p<0.05). These results were supported by the cytotoxicity assay 
(Fig. 3.3B). Representative photomicrographs of morphological characteristics of apoptosis, mitosis 
and senescence are demonstrated in Fig. 3.3C-G. ApopTag labelling is demonstrated in Figs 3.3H-
L. Ki67 immunocytochemistry is demonstrated in Figs 3.3M-Q. Representative Western 
immunoblots of Bax and Bcl-XL (Fig. 3.4A) and densitometry (Fig. 3.4B) demonstrated increased 
Bax and decreased Bcl-XL, with a pro-apoptotic ratio of Bax:Bcl-XL increased, with all treatments. 
Using immuno-electron microscopy, oxidative stress alone resulted in enhanced translocation of 
Bax to mitochondria demonstrated in Figs 3.5 and 3.6. The greatest increase was observed with 
API+H2O2 (all p<0.05).  
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Figure 3.3: Increased apoptosis and decreased mitosis occur with oxidative stress and 
senescence 
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(Legend for Fig 3.3) 
Graph A demonstrates the mean ± SEM of % apoptosis and mitosis. Apoptosis increased 
significantly with all treatments compared with control or DMSO but was greater than the addition 
of counts for API and H2O2 in the API+H2O2 treatment, indicating a synergistic effect of the 
treatments (*, p<0.05 compared to control). Mitosis decreased in all treatments compared to control 
and DMSO (#, p<0.05 compared to control). Graph B represents the mean ± SEM of lactate 
dehydrogenase (as % maximal cytotoxicity of HK-2 cells exposed to 5 mM H2O2). API and 
API+H2O2 produced the greatest % cytotoxicity compared with untreated cells and DMSO controls 
(*, p<0.05 compared to untreated control). Representative histology is demonstrated in C-Q. (C, H, 
M = control; D, I, N = DMSO; E, J, O = API; F, K, P = H2O2; G, L Q = API+H2O2).The 
morphological characteristics of apoptosis (arrows), and mitosis (*) and senescence (#) are shown 
in H&E stained cells (C-G)  Verification of apoptosis with ApopTag (brown nuclei, arrows) is 
demonstrated in H-L. In M-Q, proliferative activity was identified using Ki67 
immunocytochemistry (positive nuclei as intense brown, *). 
 
 
 
 
 
 
Figure 3.4: Western immunoblot and densitometry for Bax and Bcl-XL expression 
Representative examples of Western immunoblots for pro-apoptotic Bax and anti-apoptotic Bcl-XL 
plus the GAPDH loading controls for those blots are demonstrated in A, and the relative 
densitometry is demonstrated in B. Blots and densitometry are labelled with control, DMSO 
vehicle, API, H2O2, or API+H2O2. All treatments resulted in increased Bax and decreased Bcl-XL. 
Densitometry (B) was normalised to GAPDH, calculated as a fold change of controls, and presented 
graphically as a ratio of Bax:Bcl-XL. The pro-apoptotic ratio of Bax:Bcl-XL increased with all 
treatments compared with DMSO with the greatest increase observed in the API+H2O2 treatment 
(*, p<0.05). 
  
82 
 
 
 
Figure 3.5: Pro-apoptotic Bax protein does not associate with mitochondria in healthy cells 
Untreated HK-2 cells were imaged using transmission electron microscopy following immuno-gold 
(10 nm – red circle) labelling of Bax. Both A. and B. reveal predominately cytoplasmic localisation 
of Bax surrounding structurally healthy mitochondria.  
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Figure 3.6: Pro-apoptotic Bax protein associates with mitochondria during conditions of 
oxidative stress 
H2O2 treated HK-2 cells were imaged using transmission electron microscopy following immuno-
gold (10 nm – red circle) labelling of Bax. A-C reveals mitochondrial localisation of Bax and the 
presence of swollen mitochondria with distorted cristae.  
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Percentage senescent cells and β-gal immunofluorescence are presented in Figs 3.7A and 3.7B, 
respectively. API and API+H2O2 produced significant morphological changes of senescence 
(p<0.001 compared to DMSO), but all treatments caused increased β-gal immunofluorescence 
(p<0.05 compared to DMSO). Examples of immunofluorescence demonstrated little β-gal in 
controls (Fig. 3.7C), versus extensive punctuate green cytoplasmic fluorescence in Fig. 3.7D (API 
treatment).  
 
Expression of the cell cycle regulator p16
Ink4a
 (Figs 3.8A-C) did not change with API or H2O2 
treatments at 2 h exposure. However, a significant increase was demonstrated following H2O2 at 18 
h. 
 
 
Figure 3.7: Induction of senescence in HK-2 cells 
Senescence was identified and quantified using morphology (enlarged cells with reduced staining 
saturation) in A, and using immunofluorescence of senescence-activated β-galactosidase (SA-β-gal) 
(B-D). API and API+H2O2 produced significant changes in senescence morphology (B; *, p<0.05 
compared with controls), however SA-β-gal (A) was significantly increased by all treatments (*, 
p<0.05 compared to DMSO; #, p<0.05 compared to untreated controls). In the examples in C and 
D, immunofluorescence for controls (C) had little labelling versus extensive punctuate green 
fluorescence in the cytoplasm of API-treated cells. DAPI-stained nuclei are blue.   
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Figure 3.8: Western immunoblot and densitometry for p16
Ink4a 
Examples are demonstrated of Western immunoblots for the cell cycle regulator p16
Ink4a
 at 2 h and 
18 h treatment, plus the GAPDH loading controls. Suberohydroxamic acid (SBHA) (indicated by + 
in blots) was used as a positive control for induction of p16
Ink4a
 expression. Blots and densitometry 
are labelled with control, DMSO vehicle, API, H2O2, or API+H2O2. p16
Ink4a
 expression did not 
change significantly at 2 h following all treatments, however at 18 h exposure to H2O2 there was 
significantly increased p16
Ink4a
 expression (***, p<0.05 compared to C). 
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3.3.4 The antioxidant NAC protects renal cells from oxidative stress and senescence 
NAC significantly modulated apoptosis for all treatments, restored the mitotic potential of H2O2 
treated cells, and decreased senescence morphology induced by API and H2O2 (p<0.05; Figs 3.9A-
C). 
 
 
Figure 3.9: The antioxidant NAC ameliorates effects of oxidative stress and senescence 
Percentage apoptosis (A), mitosis (B) and senescence (C) are shown. Cells were pre-treated with the 
antioxidant N-acetyl cysteine (NAC) (10 mM), or with vehicle control, for 2 h prior to the 
treatments. Significant changes are indicated by * (p<0.05). NAC significantly modulated apoptosis 
for all treatments, restored the mitotic potential of H2O2 treated cells, and decreased senescence 
induced by API+H2O2. 
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3.4 DISCUSSION 
 
Although oxidative stress and cell senescence may contribute to renal cell dysfunction and attrition 
in CKD, the involvement of the mitochondria and their health or dysfunction in the pathogenesis of 
CKD had not been well defined. This study used an in vitro kidney disease model with oxidative 
stress and cell senescence to investigate their involvement in kidney epithelial cell dysfunction, as a 
cell culture model of oxidative stress in CKD. The results have provided evidence that oxidative 
stress and cell senescence combine to cause most renal cell loss, as well as decrease the renal cell 
proliferative activity, and both involve mitochondrial destabilization.  
 
One of the unusual outcomes was that the flavonoid API, used successfully here and elsewhere 
(Ryu et al., 2006) to induce renal cell senescence, also caused increased lipid peroxidation 
(increased MDA), decreased TAC, and caused greatest mitochondrial dysfunction with or without 
concurrent H2O2. Lagao et al have recently reported, using mitochondria isolated from rat brain and 
heart, that API (10 μM) inhibited the activity of Complex I of the electron transport chain by 
affecting the binding of the coenzyme substrate (Lagoa et al., 2011). Increased reliance on Complex 
I to III electron transfer reduces the efficiency of oxidative phosphorylation, perhaps leading to 
mitochondrial dysfunction. These results and our own suggest that the oxidative stress produced by 
API may exhaust antioxidant stores. In our study, API did not alter the expression of the cell cycle 
regulator p16
ink4a
 after 2 h or 18 h indicating that API-induced kidney cell senescence may occur via 
p16
Ink4a
 independent mechanisms. The apparent lack of p16
ink4a
 activity may indicate a protective 
mechanism, thereby ceasing their progression to transcription. Transcriptional regulation by API 
may need to be investigated, such as was published by Liu and colleagues (Liu et al., 2005) for the 
inhibitory action of API on vascular endothelial growth factor and angiogenesis. 
 
Apoptosis and mitosis contribute in renal homeostasis by ensuring adequate cell numbers for 
healthy renal function. Loss of functioning renal cells (increased apoptosis), decreased mitosis and 
increased cell senescence reflect a decreased ability for the kidney to metabolise and repair in CKD 
(Vogetseder et al., 2008; Percy et al., 2009). All of these characteristics featured in the current 
experiments. API and H2O2 were pro-apoptotic, notably with a synergistic effect seen on renal cell 
apoptosis when the treatments were combined. The pro-apoptotic effect of API has been recorded 
previously, but mostly in investigations of cancer treatments, where it caused apoptosis in cervical 
and prostate cancer cell lines when trialled as a therapy against cancer growth (Zheng et al., 2005; 
Shukla and Gupta, 2006).  
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Apoptosis, as a result of oxidative damage, is well-recognised. In CKD, apoptosis may initially act 
as a cellular adaptive response to oxidative stress to eliminate dysfunctional cells. The outcome for 
the whole kidney, however, is likely to be renal atrophy with loss of renal function. The Bcl-2 
family proteins, including pro-apoptotic Bax and anti-apoptotic Bcl-XL, regulate the intrinsic, 
mitochondrial-dependent, pathway of apoptosis (Madesh and Hajnoczky, 2001; Chipuk et al., 
2010). Changes in the ratio of pro-apoptotic Bax to anti-apoptotic Bcl-XL following oxidative insult 
have been seen previously in renal epithelium (Cuttle et al., 2001; Ye et al., 2010). In the current 
experiments, there was a similar pro-apoptotic change with all treatments.  
 
NAC is a free radical scavenger that has been used successfully to reduce injury in a variety of 
nephrotoxic and ischemic experimental and clinical renal models, and has had some success in 
CKD patients (Alonso et al., 2004). When it was used concurrently with API and/or H2O2, it 
significantly reduced apoptosis and senescence and also restored the regenerative capacity of the 
kidney. However, antioxidant therapy is sometimes disappointing in models of CKD (Quiroz et al., 
2009) and it will be important to repeat these studies in the whole animal (Chapter 6). 
 
In conclusion, the cellular and biomolecular alterations in the kidney during CKD are undoubtedly 
very complex, but the present investigation provides evidence that oxidative stress and cell 
senescence together produce greatest renal cell loss and mitochondrial destabilisation. The 
antioxidant NAC attenuated many of the characteristics that likely contribute to CKD. A more 
targeted approach to antioxidant therapy in CKD may limit mitochondrial dysfunction, with 
improved outcome for CKD patients. The model may serve as a baseline to test the role of 
mitochondria after various putative causes of CKD, and to further analyse the benefits of 
antioxidants in ameliorating mitochondrial dysfunction in CKD. 
  
89 
 
 
 
 
CHAPTER 4 
 
The Role of PPARγ in Oxidative Stress-Induced 
Kidney Damage 
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Oxidative stress encompasses more than an imbalance between ROS and endogenous antioxidants. 
Oxidative stress also affects intracellular signalling pathways that are vital for normal cell function. 
Mitochondrial dysfunction was identified in Chapter 3 as a major contributor to oxidative stress-
induced injury to epithelial cells of the kidney. This chapter defines the role of a specific oxidant 
signalling regulatory mechanism, one regulated by PPARγ.  The study sought to (1) investigate the 
role of PPARγ in oxidative stress and mitochondrial destabilisation causing damage and loss of 
kidney PTE cells; and (2) to determine whether PPARγ modulation could protect kidney PTE cells 
from oxidative stress-induced damage by preserving mitochondrial function. The contents of this 
Chapter have been published (Small et al., 2014, Appendix A). The report in this chapter is a 
modification consistent with the format of this thesis. 
 
4.1 INTRODUCTION 
 
Alterations in the bioenergetic controls of kidney cells can lead to a failure in oxidant handling, 
leading to a state of oxidative stress in kidney disease. The causes are multiple, from high glucose 
of diabetes, to ischaemia-reperfusion, toxins and AKI, to the long-term effects of ageing and 
development of CKD. Kidney atrophy, often due to apoptosis of the PTE cells, is a common 
characteristic of these diseases and therefore presents a crucial target to preserve kidney health 
(Nath, 1992; Niizuma et al., 2011). Oxidative stress is a mediating factor in mitochondrial 
dysfunction and subsequent cell dysregulation and death during kidney disease (Granata et al., 
2009; Small et al., 2012; Xu et al., 2013). The importance of mitochondrial dysregulation comes 
from the large number of mitochondria in the PTE cells and their heavy reliance on oxidative 
phosphorylation for ATP-dependent active solute transport in the nephron (Hall et al., 2011). 
Identifying oxidant-handling pathways that are perturbed in the kidney during oxidative stress is 
necessary for development of reliable targeted therapies. 
 
PPARγ is a member of the highly conserved nuclear hormone receptor superfamily of ligand-
dependent transcription factors that play central roles in lipid metabolism, glucose homeostasis, cell 
proliferation and inflammation (Ahmadian et al., 2013). Ligand binding induces heterodimer 
formation with the retinoic acid receptor and complex binding to the peroxisome-proliferator 
response element within the promoter region of target genes (Guan et al., 2002). Phosphorylation 
may modulate the activity of PPARγ through activating multiple kinase signalling pathways, 
including ERK and AMPK. However, PPARγ phosphorylation does not always indicate activation 
of PPARγ (Hu et al., 1996; Zhang et al., 1996; Camp and Tafuri, 1997). Its altered expression may 
91 
 
also be important for overall outcome that largely depends on tissue type and mode of PPARγ 
modulation. 
 
The family of TZDs consists of potent pharmacological agonists of PPARγ, commonly used in the 
treatment of type 2 diabetes where it modulates insulin levels. The targeting of PPARγ, however, is 
not limited to diabetes. First, PPARγ mRNA expression is increased in kidney biopsies of CKD 
patients of diverse aetiologies (Lepenies et al., 2010) raising the possibility of mechanisms not 
dependent on insulin. Second, the TZD rosiglitazone attenuated kidney structural and functional 
damage in a mouse model of diabetes, yet no change was observed in glucose, insulin or lipid levels 
(Calkin et al., 2006). Finally, a reduction in proteinuria was achieved in patients with non-diabetic 
kidney disease of various aetiologies following 4 months of rosiglitazone treatment (Kincaid-Smith 
et al., 2008). A possible explanation for the diverse outcomes from PPARγ agonist success is that 
PPARγ also positively regulates mitochondrial biogenesis through the activation of the PGC-1α. 
Thus, PPARγ may influence mitochondrial function (Funk et al., 2010; Chiang et al., 2013). This is 
important given the vital role mitochondria play in regulating the intracellular redox environment 
(Zhan et al., 2013). Healthy mitochondrial function relies on the degradation of defective 
mitochondria via activation of selective autophagy pathways (mitophagy) and up-regulation of 
mitochondrial biogenesis pathways to restore a healthy pool of functioning mitochondria 
(Weinberg, 2011). PPARα, an alternate isoform of PPAR, also plays a role in mitochondrial 
biogenesis, but is more widely expressed in skeletal muscle and liver than the kidney (Guan and 
Breyer, 2001). 
 
Several molecular pathways may be involved for any influence of PPARγ on mitochondrial 
function. A major pathway for injury-induced mitochondrial degradation is the PINK1-Park2 
pathway. Park2 is an E3 ubiquitin ligase that translocates to mitochondria and mediates 
mitochondrial degradation (Narendra et al., 2008; Cai et al., 2012). The adaptor protein p62 
facilitates selective autophagy into the LC3β regulated machinery for lysosomal degradation 
(Bjorkoy et al., 2005; Geisler et al., 2010). p62 is not required for Park2 translocation to damaged 
mitochondria, but is essential for final autophagic clearance (Geisler et al., 2010). PGC-1α is a 
nuclear transcription factor shown to mediate almost all aspects of mitochondrial biogenesis and is 
therefore considered a master regulator of biogenesis (Hock and Kralli, 2009). Failure to restore 
mitochondrial homeostasis and function can lead to a progressive increase in ROS and ensuing 
oxidative stress. Therefore, PGC-1α activation presents a crucial target for mitochondrial 
preservation. Previous studies have demonstrated TZD induction of mitochondrial biogenesis 
(Hondares et al., 2006; Rasbach and Schnellmann, 2007). 
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This study sought to (1) investigate the role of PPARγ in oxidative stress and mitochondrial 
destabilisation in damage and loss of human kidney proximal tubular cells; and (2) determine 
whether PPARγ modulation can protect human kidney PTE cells from oxidative stress-induced 
damage by preserving mitochondrial function. 
 
4.2 METHODS AND MATERIALS 
 
Complete methods are outlined in Chapter 2. Below is a brief summary of the experimental 
materials and methods that are specific for this chapter. 
 
4.2.1 Experimental design 
HK-2 cells were grown in normal culture conditions outlined in Chapter 2. Cells were treated with 
H2O2 0.2 mM – 1.0 mM for 2 h and 18 h to induce oxidative stress. In some treatments, the PPARγ 
agonists troglitazone, rosiglitazone and pioglitazone were used as treatments for 2 h prior to and 
during H2O2 exposure. Troglitazone (#T2573) and pioglitazone (#E6910) were purchased from 
Sigma-Aldrich (Castle Hill, Australia); rosiglitazone (#71740) was purchased from Cayman 
Chemicals (Ann Arbor, USA). All were dissolved as stock solutions in DMSO and stored frozen as 
small aliquots. A DMSO vehicle control was always used for these experiments. 
 
4.2.2 Western immunoblot 
Western blots were performed from whole cell lysates dissociated in lysis buffer. Protein was 
separated by SDS-PAGE on 10 % acrylamide gel and electrophoretically transferred onto PVDF 
membrane. Membranes were blotted using antibodies against PPARγ, phosphorylated PPARγ (p-
PPARγ; phosphorylation site Ser112), PPARα, PGC-1α, Park2, p62, LC3β, and GAPDH for 
loading control (see Table 2.3 for dilutions and suppliers). Appropriate secondary antibodies (see 
Table 2.4 for dilutions and suppliers) were used and visualised with ECL and X-ray film. Scion 
software (Release Alpha 4.0.3.2) was used to quantify bands for densitometry that was normalised 
to GAPDH. 
 
4.2.3 Light and fluorescence microscopy 
Cells were grown on glass coverslips for treatments and fixed in 4 % PF. Immunofluorescence and 
cytochemistry were used to assess p62 cellular localisation. Apoptosis and mitosis were assessed 
using morphology (Gobe, 2009) following H&E staining and digital scanning using Aperio 
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ImageScope histology software. Results are expressed as a % apoptotic or mitotic cells per field of 
view. 
 
4.2.4 Oxidative stress and mitochondrial function 
Oxidative stress was determined and quantified using microfluorimetry detection of the oxidation of 
dihydroethidium (DHE) to ethidium. O2
•-
 selectively oxidises this reaction, and is an essential 
precursor to harmful cellular oxidants, such as OH• and ONOO
-
. Cells were cultured in black 96-
well plates and treated as previously described. The growth medium was then replaced with DHE-
supplemented normal growth media and incubated for 30 min. Fluorescence intensity was measured 
at 536 nm excitation and 610 nm emission (Synergy Mx Multi-Mode Microplate reader, BioTek, 
Winooski, VT). Fluorescence values were normalised to protein content for corresponding wells 
and expressed as DHE fluorescence per µg protein. JC-1 was used to assess the mitochondrial 
membrane potential and was quantified using the same technique. A decrease in red fluorescence 
(JC-1 aggregate uptake into healthy mitochondria) and increase in green fluorescence (JC-1 in 
cytoplasm) indicates mitochondrial membrane depolarisation. ATP production was measured using 
a luciferase-based luminescence assay (Promega, Sydney, Australia). Cells were seeded into white 
opaque 96-well plates and treated as previously described. Chemiluminescent reagent was added 
and cell lysis induced prior to measuring luminescence at an integration time of 0.5 sec using a 
Titertek-Berthold Luminometer (Titertek-Berthold Detection Systems, Pforzheim, Germany). 
 
4.2.5 Mitochondrial health 
MitoTracker Red CMXRos (Invitrogen
TM
, Mulgrave, Australia) and confocal fluorescence 
microscopy were used to determine mitochondrial density. MitoTracker localises to mitochondria 
with a healthy mitochondrial membrane potential. Cells were grown on glass coverslips and 
exposed MitoTracker Red CMXRos for 30 min following treatments as previously described. 
Coverslips were mounted following fixation in 4 % PF and DAPI staining. Cells were observed at 
x63 with a Zeiss 510 Meta confocal fluorescence microscope using Zen 2008 software. 
Transmission electron microscopy was used to visualise the ultrastructure of mitochondria, 
according to an established protocol outlined in Chapter 2, Section 2.3.8. 
 
4.2.6 Cell viability 
Cell viability was measured using the MTT assay. Absorbance was measured in a microplate reader 
at 570 nm with background collection at 690 nm. 
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4.2.7 Transmission electron microscopy 
TEM was used to assess mitochondrial ultrastructure. The protocol is outlined in Chapter 2, Section 
2.3.8. 
 
4.2.8 Statistical analysis 
Values reported are mean ± SEM. Data were analyzed using ANOVA and Tukey’s post hoc 
analysis, two-way ANOVA and Bonferroni’s post hoc test, or student’s t-test where appropriate. 
Significance was established at p < 0.05. 
 
4.3 RESULTS 
 
4.3.1 Oxidative stress decreased PPARγ expression and increased PPARγ serine 112 
(Ser112) phosphorylation  
HK-2 cells displayed a dose-dependent significant increase in apoptosis and dose-dependent 
decrease in mitosis following oxidative stress at both 2 h and 18 h (Fig 4.1A and B). This was 
associated with a decrease in PPARγ protein levels (Fig 4.2A; p<0.001 starting at 0.4 mM H2O2) 
and a dose-dependent increase in p-PPARγ levels (Fig 4.2A; p<0.001 starting at 0.4 mM H2O2) 
following 2 h exposure to H2O2. Following 18 h H2O2 exposure (Fig 2B), PPARγ and p-PPARγ 
returned to basal levels indicating that oxidative stress promotes phosphorylation of PPARγ as an 
early response. Conversely, PPARα expression decreased in a dose-dependent manner following 2 
h exposure to H2O2 (Fig 4.2A; p<0.05 starting at 0.4 mM H2O2) and returned to control levels 
following 18 h H2O2 exposure (Fig 4.2B). 
 
4.3.2 Oxidative stress induced mitochondrial dysfunction 
Mitochondrial function was significantly reduced following exposure to H2O2 for both 2 h and 18 h 
(Fig 4.3). 0.6 mM H2O2 significantly increased DHE fluorescence indicating enhanced levels of O2
•-
production and confirming an intracellular state of oxidative stress (Fig 4.3A; p<0.05). The 
mitochondrial membrane potential significantly decreased, indicated by a decrease in JC-1 red 
fluorescence intensity (Fig 4.3B; p<0.01 starting at 0.4 mM H2O2) and increase in JC-1 green 
fluorescence intensity (Fig 4.3C: p<0.01 starting at 0.4 mM H2O2). Confocal microscopy revealed 
that, compared with untreated HK-2 cells (Fig 4.3H), uptake of MitoTracker Red CMXRos 
fluorescence was impaired following H2O2 exposure at both 2 h (Fig 4.3I) and 18 h (Fig 4.3J). 
Mitochondrial ultrastructure (Figs 4.3D-G) revealed abundant elongated mitochondria with clear 
cristae in untreated HK-2 cells (Figs 4.3D and E), compared with Fig 3F (segmented and swollen 
mitochondria) and Fig 4.3G (cristae absent) following H2O2 exposure. These changes relate to a 
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significant dose-dependent decrease in ATP production by mitochondria following H2O2 exposure 
at both 2 h (Fig 4.4A; p<0.001 at 0.4 mM H2O2) and 18 h (Fig 4.4B; p<0.001 at 0.4 mM H2O2), 
indicating impaired oxidative phosphorylation. 
 
 
 
Figure 4.1: Oxidative stress promotes apoptosis and impairs mitosis in HK-2 cells 
HK-2 cells were exposed to H2O2 at concentrations ranging from 0.2 mM to 1.0 mM. % apoptosis 
significantly increased in a dose-dependent manner following H2O2 exposure at both 2 h and 18 h 
(A.). % mitosis significantly decreased in a dose-dependent manner following H2O2 exposure at 
both 2 h and 18 h (B.). Results are expressed as mean ± SEM (*** p<0.001, compared to 18 h 
Control; # p<0.05; ## p<0.01, compared to 2 h Control; bar, compared as indicated). 
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Figure 4.2: PPARγ and PPARα expression at 2 h and 18 h 
HK-2 cells were exposed to a range of H2O2 concentrations (0.2 mM – 1.0 mM) for 2 h and 18 h. 
Representative Western blots are supplied. There was a dose-dependent significant increase in 
PPARγ phosphorylation (p-PPARy) following 2 h H2O2 exposure (A.) that corresponded to a 
decrease in PPARγ expression. PPARα significantly increased in a dose-dependent manner 
following 2 h H2O2. 18 h H2O2 (B.) did not significantly alter PPARγ phosphorylation or PPARα 
expression. p-PPARγ and PPARγ were expressed as a ratio, and PPARα protein expression was 
normalised to GAPDH expression. Results are expressed as mean ± SEM (* p<0.05; ** p<0.01; 
***p<0.001, compared to Control). 
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Figure 4.3: Oxidative stress induces mitochondrial dysfunction 
HK-2 cells were exposed to a range of H2O2 concentrations (0.2 mM – 0.6 mM) for 2 h and 18 h. 
DHE and JC-1 fluorescence was quantified by fluorimetry at 18 h. DHE fluorescence significantly 
increased following 0.6 mM H2O2 exposure demonstrating ROS generation at 18 h (A.). JC-1 red 
fluorescence significantly decreased in a dose-dependent manner (B.) while increasing in green 
fluorescence (C.) indicating mitochondrial membrane depolarisation at 18 h. Transmission electron 
microscopy revealed elongated morphologically healthy mitochondria with cristae in untreated HK-
2 cells (D. and E.) and segmented, swollen mitochondria (F.) often with absent cristae (G.) in 0.6 
mM H2O2 treated HK-2 cells at 18 h (arrow heads). MitoTracker Red CMXRos uptake was 
visualised with confocal microscopy and shown to decline following both 2 h (I.) and 18 h (J.) of 0.6 
mM H2O2 exposure compared to untreated HK-2 cells (H.). Results are expressed as mean ± SEM (* 
p<0.05; ** p<0.01; ***p<0.001, compared to Control). 
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Figure 4.4: Oxidative stress impairs cellular ATP production 
HK-2 cells were exposed to a range of H2O2 concentrations (0.2 mM – 1.0 mM) for 2 h and 18 h. 
ATP assay was performed based on luminescence. ATP levels significantly decreased in a dose-
dependent manner following H2O2 exposure for both 2 h (A.) and 18 h (B.). Results are expressed as 
mean ± SEM (***p<0.001, compared to Control). 
 
4.3.3 Oxidative stress-induced PPARγ dysregulation impaired mitochondrial autophagy 
(mitophagy) and biogenesis 
Following oxidative stress and the initial insult affecting mitochondrial function (Figs 4.3 and 4.4), 
the cellular autophagy machinery needed for selective mitochondrial clearance was upregulated. 
These results are presented in Fig. 4.5. 2 h H2O2 exposure significantly increased Park2 expression 
(Fig 4.5A; p<0.01 at 0.4 mM H2O2) indicating effective tagging of defective/damaged mitochondria 
for autophagic clearance. Simultaneously, expression of the adapter protein p62 was significantly 
down-regulated (Fig 4.5B; p<0.05 at 0.4 mM H2O2), and a significant increase was seen in LC3β 
protein levels (Fig 4.5C; p<0.01 at 0.6 mM H2O2), demonstrating early selective autophagy of 
mitochondria (mitophagy). Park2 expression did not alter significantly following extended (18 h) 
H2O2 exposure (Fig 4.5D), yet there was a significant increase in p62 and LC3β protein levels, 
indicating impaired p62 degradation with intracellular accumulation. Altered p62 expression seen 
by Western immunoblot, and assumed intracellular accumulation, was verified using confocal 
microscopy (Figs 4.5G-I). There was a decrease in the PPARγ co-activator and mitochondrial 
biogenesis marker PGC-1α following 2 h H2O2 exposure (Fig 4.6A; p<0.05 at 0.4 mM H2O2) that 
corresponded with the changes in Park2, p62 and LC3β. The cumulative results demonstrate 
impaired PPARγ-dependent mitochondrial biogenesis. 
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Figure 4.5: Oxidative stress promotes selective mitochondrial autophagy (mitophagy) 
HK-2 cells were exposed to a range of H2O2 concentrations (0.2 mM – 1.0 mM) for 2 h and 18 h. 
Cells were lysed and Western blot analysis performed. Immunofluorescence of p62 was performed 
(anti-p62 is green fluorescence and nuclear DAPI is blue). Protein levels of Park2 (A.) and p62 (B.) 
significantly increased and decreased, respectively, in a dose-dependent manner, while LC3β (C.) 
significantly increased following 2 h H2O2 exposure. Park2 protein levels returned to control levels 
following 18 h H2O2 (D.), while p62 (E.) and LC3β (F.) expression significantly increased in a dose-
dependent manner. Immunofluorescence revealed decreased cytoplasmic localisation of p62 
following 2 h H2O2 (H.) compared to untreated HK-2 cells (G.), which increased following 18 h 
H2O2 (I.) to show a punctate perinuclear cytoplasmic pattern (white arrowhead). Protein expression 
was normalised to GAPDH expression. Results are expressed as mean ± SEM (* p<0.05; ** p<0.01; 
***p<0.001, compared to Control). 
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Figure 4.6: Oxidative stress impairs PGC-1α-dependent mitochondrial biogenesis that persists 
long-term 
HK-2 cells were exposed to a range of H2O2 concentrations (0.2 mM – 1.0 mM) for 2 h and 18 h. 
Cells were lysed and Western blot analysis performed. Protein levels of PGC-1α significantly 
decreased in a dose-dependent manner following both 2h (A.) and 18 h (B.) of H2O2 exposure. 
Protein expression was normalised to GAPDH expression. Results are expressed as mean ± SEM (* 
p<0.05; ** p<0.01; ***p<0.001, compared to Control). 
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4.3.4 PPARγ activation does not protect kidney proximal tubular cells from oxidative stress 
induced damage 
PPARγ expression and phosphorylation changes with selective PPARγ TZD agonists were tested to 
determine whether this protected cells from oxidative stress. The TZD agonists were delivered 2 h 
prior to H2O2 (0.6 mM) exposure and during the 2 h and 18 h H2O2 treatment periods. 
Concentrations of the TZD agonists (rosiglitazone and troglitazone at 10 µM; pioglitazone at 1 µM) 
were chosen from preliminary data (Appendix C) and were consistent with concentrations used in 
similar previous studies (Hondares et al., 2006; Fujisawa et al., 2009; Martin et al., 2012; Miglio et 
al., 2012; Chiang et al., 2013). Expression of p-PPARγ was calculated as a ratio of PPAR and then 
a fold change on control cells compared for each of the TZDs at 2 h (Figs 4.7A-C) and 18 h (Figs 
4.7G-I). H2O2 exposure alone caused a significant increase in Ser112 phosphorylation of PPARγ at 
both 2 h and 18 h (Figs 4.7A-C; p<0.05 and Figs 4.7G-I; p<0.001, respectively). This occurred in 
conjunction with a significant decrease in cell viability compared with control cells at 2 h and 18 h 
(Figs 4.7D-F; p<0.001 and Figs 4.7J-L; p<0.001, respectively). The cell viability was not improved 
above H2O2 levels when each of the PPARγ agonists was used in combination with H2O2 for 2 h 
(Figs 4.7D-F). Thus, these results demonstrate a lack of protection by TZDs against oxidative 
stress-induced loss of viability at a time when p-PPARγ:PPAR was significantly increased. 
Following extended exposure to PPARγ agonists and H2O2 (18 h), cell viability levels remained 
significantly low (Figs 4.7J-L; p<0.001), with the cell viability of the dual TZD and H2O2 treatment 
showing a further significant reduction with rosiglitazone and troglitazone (Figs 4.7J and K; 
p<0.05). Expression of p-PPARγ:PPARγ remained significantly increased at 18 h for rosiglitazone 
combined with H2O2 (Fig 4.7G; p<0.001), while the ratio returned to that observed in untreated 
controls following troglitazone co-treatment (Fig 4.7H) and lower than untreated controls with 
pioglitazone co-treatment (Fig 4.7I; p<0.01). Extended exposure of TZD agonists for 18 h prior to 
H2O2 exposure also demonstrated no protection to cell viability and significantly decreased cell 
viability when either TZD was used alone (Fig 4.7M-O; p<0.01). A representative TZD 
(troglitazone), used in combination with H2O2, was assessed for apoptosis and mitosis (Fig 4.8A-B). 
Pre-exposure to troglitazone did not prevent the significant increase in apoptosis caused by H2O2 
alone (Fig 4.8A; p<0.05). Using a high concentration of troglitazone (100 µM) significantly 
increased apoptosis alone or with H2O2 (Fig 4.8A; p<0.05). Similarly, troglitazone did not prevent 
reduced mitosis caused by H2O2 alone (Fig 4.8B; p<0.001). Using a high concentration of 
troglitazone (100 µM) significantly reduced mitosis alone or in combination with H2O2 (Fig 4.8B; 
p<0.001).  
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Figure 4.7: PPARγ activation does not protect HK-2 cells against oxidative stress induced 
injury 
HK-2 cells were exposed for 2 h (A. – L.) or 18 h (M. – N.) with either rosiglitazone (Rosi – 10 
µM), troglitazone (Trog – 10 µM) or pioglitazone (Piog – 1 µM) followed by 2 h and 18 h exposure 
to H2O2 (0.6 mM) in combination with Rosi, Trog or Piog. Western blot analysis and MTT assay 
were performed. At 2 h, H2O2 alone and in combination with Rosi significantly increased the fold 
difference in the p-PPARγ:PPARγ ratio compared with controls (A.). H2O2 and Trog treatment 
alone or in combination, significantly increased p-PPARγ:PPARγ (B.). H2O2 treatment alone or in 
combination with Piog significantly increased p-PPARγ:PPARγ (C.). Cell viability significantly 
decreased following H2O2 treatment alone and in combination with Rosi (D.), Trog (E.) or Piog (F.). 
At 18 h, H2O2 exposure alone and in combination with Rosi significantly increased p-
PPARγ:PPARγ, while Rosi treatment alone significantly decreased p-PPARγ:PPARγ (G.). H2O2 
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exposure alone significantly increased, while Trog treatment alone significantly decreased, p-
PPARγ:PPARγ (H.). H2O2 treatment alone significantly increased p-PPARγ:PPARγ, which was 
significantly decreased when H2O2 was used in combination with Piog (I.). Cell viability was 
significantly decreased following H2O2 exposure alone, and this was significantly enhanced when 
combined with Rosi (J.) or Trog (K.). Pioglitazone treatment in combination with H2O2 significantly 
decreased cell viability compared to Control (L.). Treatment with TZD for an extended period (18 h) 
prior to H2O2 co-treatment for 18 h significantly decreased cell viability alone or in combination 
with Rosi (M.), Trog (N.) or Piog (O.). Results expressed as mean ± SEM (* p<0.05; ** p<0.01; 
***p<0.001, compared to Control; # p<0.05, compared as indicated). 
 
 
 
 
Figure 4.8: The PPARγ agonist troglitazone does not protect against oxidative stress induced 
apoptosis or reduced mitosis 
HK-2 cells were exposed for 2 h with troglitazone (Trog – 10 µM or 100 µM) followed 18 h 
exposure to H2O2 (0.6 mM) in combination with Trog. Apoptosis and mitosis were quantified using 
morphology and H&E staining. H2O2 alone or in combination with Trog (both 10 µM and 100 µM) 
resulted in a significant increase in apoptosis. Trog (100 µM) was sufficient to significantly increase 
apoptosis alone. H2O2 alone or in combination with Trog (both 10 µM and 100 µM) resulted in a 
significant decrease in mitosis. Trog (100 µM) was sufficient to significantly decrease mitosis. 
Results expressed as mean ± SEM (* p<0.05; ***p<0.001, compared to Control). 
  
 
4.4 DISCUSSION 
 
Oxidative stress and mitochondrial dysfunction have been implicated in the pathogenesis of kidney 
disease of diverse causes, including diabetes and CKD, two diseases of increasing incidence 
(Dounousi et al., 2006; Gomes et al., 2009; Granata et al., 2009). However, the molecular 
mechanisms are still unclear. Here, oxidative stress-induced PPARγ alterations were associated 
with mitochondrial destabilisation and a failure to restore mitochondrial health due to defective 
activation of PPARγ-dependent biogenesis pathways. Furthermore, selective PPARγ activation 
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enhanced oxidative stress-mediated tubular cell damage that was associated with PPARγ Ser112 
phosphorylation. The results suggest that, despite positive benefits in other tissues, PPARγ 
activation may be detrimental to kidney PTE cells in the scenario of oxidative stress-induced injury. 
 
Our results demonstrate that PPARγ is present in kidney PTE cells and is responsive early in 
oxidative stress-induced injury. The associated increase in Ser112-phosphorylation of PPARγ (p-
PPARγ) was not beneficial to cellular outcome in these cells. The increase in the p-PPARγ:PPARγ 
ratio may be injurious to cells via development of mitochondrial dysfunction. However, at 18h 
exposure to oxidative stress, the p-PPARγ:PPARγ ratio was not elevated, perhaps demonstrating 
that early stress-induced PPARγ dysregulation stimulates a series of persistent negative cellular 
events, primarily targeting mitochondrial homeostasis.  
 
Oxidative stress-induced post-translational modifications to PPARγ, including phosphorylation, 
have had little study in kidney PTE cells. In adipocytes, mitogen-activated protein kinase-induced 
phosphorylation of PPARγ at Ser112 was linked to decreased transcriptional activity of PPARγ by 
inhibition of ligand binding and co-factor recruitment (Hu et al., 1996; Zhang et al., 1996; Camp 
and Tafuri, 1997). In addition, PPARγ phosphorylation at Ser87 by AMP kinase in Baby Hamster 
Kidney (BHK) cells repressed the transactivating function of the receptor (Leff, 2003). Our data, 
demonstrating a decrease in PPARγ transcriptional activity, along with a failure to upregulate PGC-
1α and mitochondrial biogenesis, at a time of increased Ser112 PPARγ phosphorylation in the 
human kidney PTE cells, agree with those reports. The decrease in total functional PPARγ is likely 
due to phosphorylation. Similar results have been shown in kidney mesangial cells exposed to a 
high glucose environment (Whiteside et al., 2009), a mechanism of kidney injury involving 
increased oxidative stress (Stanton, 2011; Shao et al., 2013). 
 
PTE cells of the kidney have a high density of mitochondria (Hall et al., 2009). It is likely, 
therefore, that the relationship between PPARγ and mitochondrial function will be especially 
important. Yang and colleagues have previously shown, in an in vivo rat model of ageing, that 
PPARγ activation attenuates age-related mitochondrial injury in the kidney by maintaining the 
integrity of the mitochondrial membrane potential (Yang et al., 2009). However, these results 
represent outcome from the heterogeneous renal cell population, and not specifically mitochondria 
from PTE cells. The majority of in vitro studies, that demonstrate protective actions of PPARγ, do 
so in glomerular cell types, namely podocytes and mesangial cells (Yang et al., 2006; Kanjanabuch 
et al., 2007; Miglio et al., 2012). Our results demonstrate oxidative stress-induced PTE cell 
mitochondrial dysfunction that is associated with a decreased p-PPARγ:PPARγ ratio. This alteration 
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is persistent, indicating that PPARγ induces negative downstream effects. We hypothesised that 
PPARγ phosphorylation induced disruptions to the mitochondrial homeostatic machinery, and was 
responsible for this persistent cumulative dysfunction. 
 
Autophagy is a highly conserved protective response to eliminate damaged cellular components. 
Mitochondrial homeostasis relies on the degradation of defective mitochondria and upregulation of 
mitochondrial biogenesis to restore a healthy pool of functioning mitochondria (Egan et al., 2011). 
Our results demonstrate significant perturbation to these pathways during oxidative stress. The 
induction of selective mitophagy mediated by the Park2-p62-LC3β pathway is evident following 
the initial (2 h) response to oxidative stress. However, long-term (18 h) oxidative stress facilitates 
significant impairments to this system, indicated by p62 aggregation. Park2 upregulation following 
2h oxidative stress demonstrates labelling and translocation of the E3-ligase, Parkin, to depolarised 
mitochondria and initiate poly-ubiquination to signal p62 binding (Geisler et al., 2010). p62 
degradation has been shown to be a consistent marker of selective autophagy due to its clearance 
within the autophagosome (Komatsu et al., 2010; Komatsu et al., 2012; Jiang et al., 2013; Wang et 
al., 2013), and our results further confirm this with enhanced LC3β expression. Mitophagy has 
received little study in the kidney, with Parkin-mediated mitophagy previously shown to be 
dependent upon p62 in HeLa and neuroblastoma cell lines (Geisler et al., 2010). Recently, Ishikawa 
and colleagues used rat AKI models to demonstrate that increased mitophagy in the kidney was 
highly influenced by ROS (Ishihara et al., 2013). The results of the present investigation show an 
increase in p62 following 18h oxidative stress, demonstrating impaired selective turnover and 
accumulation of p62. Previous studies have demonstrated liver injury is accompanied by the 
formation of p62-positive inclusions, and that the removal of p62 attenuated this injury (Komatsu et 
al., 2007). Impaired selective mitochondrial autophagy caused by persistent ROS production and 
ensuing oxidative damage results in p62 accumulation, which further contributes to cellular 
dysfunction. This result was compounded by the failure of PPARγ to activate PGC-1α to stimulate 
mitochondrial biogenesis and restore the cellular redox environment. This change would have 
provided a continuation of negatively-regulating intracellular signalling, with persistent oxidative 
stress and reduced mitochondrial-dependent ATP production. This demonstrates early, persistent, 
and indirect mitochondrial dysfunction resulting from a failure of PGC-1α activity following 
oxidative stress.  
 
PPARγ agonist treatment has previously been shown to protect against mitochondrial dysfunction in 
other cell types, including neuronal (Fuenzalida et al., 2007; Wu et al., 2009) and endothelial cells 
(Fujisawa et al., 2009). In the kidney, disparate results have been described previously and largely 
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depend on the cell type and cause of injury (Kanjanabuch et al., 2007; Whiteside et al., 2009; Wu et 
al., 2009). Important to note is that PPARγ Ser112 phosphorylation has been shown to modify 
PPARγ activity, rather than act as a marker of PPARγ activation. PPARγ agonists can inhibit 
obesity-linked Ser273 phosphorylation of PPARγ by cyclin-dependent kinase 5 in adipose tissue 
(Choi et al., 2010). Our results show an inability of rosiglitazone to inhibit PPARγ Ser112 
phosphorylation during oxidative stress, therefore preventing classical downstream actions of 
PPARγ, primarily the upregulation of PGC-1α and maintenance of mitochondrial homeostasis 
(Rasbach and Schnellmann, 2007; Hock and Kralli, 2009). This finding appears to be unique to 
kidney tubular cells. Of note is that PPARα is an alternate inducer of PGC-1α-dependent 
mitochondrial biogenesis (Portilla et al., 2002; Weinberg, 2011), and its downregulation in response 
to oxidative stress further impairs the restoration of mitochondrial homeostasis. The ability of 
rosiglitazone and troglitazone to decrease PTE cell viability following extended oxidative stress is a 
novel finding and may result from the inability to prevent PPARγ phosphorylation, not only at 
Ser112, but other sites of phosphorylation including Ser273 and Ser82 that were not studied here. 
 
In summary, our findings describe oxidative stress-induced PPARγ alterations and resulting 
mitochondrial destabilisation, and a failure to restore mitochondrial health due to defective 
activation of PPARγ-dependent biogenesis pathways. These changes may contribute to the 
pathogenesis of diverse kidney disease, including CKD. A novel finding is that activation of PPARγ 
by TZD enhances oxidative stress-mediated tubular cell damage that is associated with PPARγ 
Ser112 phosphorylation. This may account for tubular damage, and a lack of therapeutic benefit of 
TZD, seen in some human trials. 
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CHAPTER 5 
 
In Vivo Model of Oxidative Stress-Induced 
Kidney Injury 
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Chapters 3 and 4 investigated specific pathways that are perturbed and could contribute to oxidative 
stress in one important cell type in the kidney, the PTE cell. However, the renal microenvironment 
is a complex three-dimensional network of heterogeneous cell populations comprising glomeruli, 
tubules, interstitial space and vasculature. Alterations that occur in one cell are likely to have a 
stochastic effect not only on neighbouring structures, but on whole organ physiology. Therefore, an 
in vivo model of oxidative stress-induced kidney injury was used to investigate alterations identified 
in Chapters 3 and 4, as well as identify temporospatial changes in the kidney resulting from 
oxidative stress. 
 
5.1 INTRODUCTION 
 
The pathophysiology of CKD, of multiple causes, involves persistent, insidious, cycles of common 
disease processes including cell death, fibrosis, senescence and inflammation. However, an 
important concept in understanding the pathogenesis of CKD and its progression to ESKD is that 
this likely involves common processes that are independent of the original cause of CKD. Important 
characteristics of CKD progression, that are independent of its cause, include reductions in renal 
mass and nephron number, vascular insufficiency, cell cycle disruption and maladaptive repair 
mechanisms. Clinical AKI, and experimental studies using AKI models, also highlight these 
characteristics of injury, leading to the suggestion of common integrated clinical syndromes (Fig 
5.1) (Chawla and Kimmel, 2012). The early teaching that patients who survive an episode of AKI 
achieve full or nearly full recovery (Clarkson et al., 2008), has been surpassed by current evidence, 
from a diverse range of large population studies, demonstrating a significant risk for the progression 
to advanced stage CKD in patients that survive a single episode of AKI (Ishani et al., 2009; Chawla 
et al., 2011; Coca et al., 2012). 
 
As demonstrated in Chapters 3 and 4, mitochondrial alterations influence PTE cell outcome during 
oxidative stress. Oxidative stress, mitochondrial dynamics and metabolism have all been shown to 
play an intimate role in AKI, however the role of mitochondrial function during progressive renal 
pathologies, such as CKD and ESKD, has not yet received detailed investigation. 
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Figure 5.1: Acute kidney injury and chronic kidney disease as an integrated syndrome 
Acute kidney injury and chronic kidney disease has a bi-directional relationship that is modulated 
by some common pathological mechanisms such as reduced nephron number, vascular 
insufficiency, cell cycle disruption, and maladaptive repair. These mechanisms primarily contribute 
to common outcomes of this progression such as increased cardiovascular events, end stage kidney 
disease (ESKD), and increased morbidity and mortality. 
 
IR injury is a common cause of AKI. The kidney has minimal glycolytic capacity owing to an 
abundance of PTE cells, high activity, and reliance on oxidative phosphorylation for ATP synthesis, 
increasing the susceptibility to hypoxia (Basile et al., 2001). The dynamics of mitochondria during 
ischaemia and following reperfusion have been extensively studied and are shown to involve 
oxidative stress and overproduction of ROS (Hall et al., 2013). The current understanding of 
mitochondrial dynamics during ischaemic starvation is characterised by depletion in ATP, 
depolarisation of the mitochondrial membrane potential (MMP), disruption of the inner 
mitochondrial membrane (IMM) cristae that house the ETC, due to a loss of ATP-dependent actin 
polymerisation, and mitochondrial swelling due to a loss of osmotic regulation. Re-energising 
mitochondria is necessary for ATP recovery and cell survival following ischaemia. However, 
alterations to the ETC components of the IMM cristae lead to a defect in the functional capacity of 
mitochondria to produce ATP through oxidative phosphorylation. At the point of reperfusion, and 
the re-presentation of O2 to damaged components of the ETC, increased mitochondrial ROS 
production is thought to contribute significantly to the pathogenesis of kidney IR injury. Within the 
literature, there has been a broad classification of mitochondrial dysfunction following IR injury. 
The fate of the cell during reperfusion, either via cell death, senescence, impaired function or 
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complete restoration (reversible injury), appears to be determined by the ability of mitochondria to 
restore cell metabolism and redox control.  Mitochondrial dysfunction should not exclude the 
homeostasis of mitochondrial degradation and regeneration via biogenesis, as these also contribute 
significantly to the subsequent cell fate and function. Furthermore, the basis of our current 
understanding of mitochondrial biology in vivo during normal and diseased conditions is primarily 
based on the extrapolation of in vitro experimental evidence from isolated cells or organelles. There 
has been little investigation of the contribution of mitochondrial ROS in vivo, and their contribution 
to IR-induced AKI. 
 
The kidneys constitute less than 0.5 % of body mass but receive greater than 20 % of the total 
cardiac output which is filtered within the kidneys. Thus, the metabolism of the kidneys is vitally 
important for overall health. The supply and utilisation of metabolic substrates for oxidative 
phosphorylation, such as NADH and FAD, is necessary for mitochondrial and cellular function. 
NADH is a metabolic substrate for complex 1 of the mitochondrial ETC and exists primarily in two 
forms - oxidised NAD+ and reduced NADH. These two molecules are continually being cycled 
through a redox reaction and are, therefore, vital to maintaining a healthy intracellular redox 
environment. NADH is produced from the conversion of oxidised NAD+ in the citric acid cycle 
(Figure 5.2). The biosynthesis of NAD+ can occur either through de novo production from 
tryptophan or aspartic acid, or from the salvage of preformed compounds containing nicotinamide 
(nicotinic acid and nicotinamide) commonly obtained through the diet. An amount of NAD+ is 
phosphorylated by NAD+ kinase to form NADP+ that can go on to be reduced to form NADPH. 
NADP+ is similar to NAD+, however it plays a different role in metabolism. The reduced forms of 
the NADP+/NADPH and NAD+/NADH ratios (NADPH and NADH, respectively) are the major 
components. NADPH is primarily required as a reducing agent for cellular anabolic reactions such 
as lipid and nucleic acid synthesis and is considered to play little part in renal metabolism given its 
high energy requirements. FAD is another important metabolic substrate linked to mitochondrial 
regulation. FAD is a redox cofactor and can exist in two different forms depending on its state 
within a redox reaction – oxidised FAD and reduced FADH2. FADH2 is generated by the citric acid 
cycle and binds with complex II of the mitochondrial ETC that oxidises succinate to fumarate. Two 
hydrogen ions are left within the inner-mitochondrial membrane to contribute to the polarisation of 
the MMP.  
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Figure 5.2: Simplified schematic of integrated metabolism that occurs within mitochondria to 
produce ATP 
NADH is produced from the conversion of oxidised NAD+ in the citric acid cycle which then acts 
as a substrate for complex I of the mitochondrial electron transport chain for oxidative 
phosphorylation that drives the conversion of ADP to ATP. Perturbation to any point of this cycle 
can result in cell dysregulation due to a reduction in ATP production.  
 
As mentioned in Chapter 1, Section 1.2.9, the spectral properties of NAD+, NADH, FAD and 
FADH2 can indicate dynamic metabolic processes (the combination of NADH and NADPH will be 
refered to as NAD(P)H, since NADPH is detected by MPM on the same wavelength and therefore 
cannot be excluded. However, NADPH is considered to contribute minimally). Direct in vivo 
visualisation of metabolic substrates can be achieved through MPM and FLIM techniques. The 
basic principles of fluorescence apply to MPM imaging. Fluorescence occurs by the absorption of a 
photon by a fluorophore that brings an electron from the fluorophore to an excited state. The 
electron returning to its ground state causes the release of a photon (fluorescence emission photon), 
which is then efficiently detected (Coling and Kachar, 2001; Ghiran, 2011). The initial excitation 
photon is typically of a high energy. This is known as single-photon fluorescence. MPM 
fluorescence is based on the simultaneous absorption of two low-energy, near-infrared wavelength, 
photons by a fluorophore; hence the alternative name “two-photon fluorescence” (Figure 5.3). 
Three-photon excitation and second harmonic generation work on similar principles and can also be 
used to visualise fluorescent optical sections (Zipfel et al., 2003). Although the energy of either of 
these photons is too low to raise an electron to an excited state, it is the combination of the two 
energies that is sufficient to excite and thus release a fluorescence emission photon. This approach 
is far more compliant to biological tissue due to significantly reduced phototoxicity. A further 
advantage of using near-infrared wavelengths, instead of ultraviolet light, for fluorescence 
excitation is the reduction of scattering and increase in imaging penetration depth in the sample 
from approximately 20 µm to 500-600 µm. However, in the kidney, the maximal penetration depth 
is approximately 150 µm owing to substantial scattering of emission photons from the high 
refractory index and heterogeneity of kidney tissue (Young et al., 2011a; Young et al., 2011b). 
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Figure 5.3: Pictorial representation of one-photon and two-photon fluorescence 
Two-photon excitation occurs via simultaneous absorption of infrared laser pulses at a single point, 
compared to one-photon excitation which uses visible or ultraviolet light lasers that excite photons 
throughout the biological material, and thereby may casue phototoxicity. 
 
A useful application of FLIM in conjunction with MPM in the kidney is measuring the fluorescence 
lifetime of NAD(P)H. NAD(P)H lifetime measurements are widely used for metabolic and redox 
imaging in vitro and in vivo (Bird et al., 2005; Skala et al., 2007a; Skala et al., 2007b; Sanchez et 
al., 2010; Leite-Silva et al., 2013; Thorling et al., 2013). The lifetime of NAD(P)H is resolved as a 
two-component system with the short (α1) (~0.3-4 ns) and long (α2) (~2.3 ns) lifetime represented as 
the free and protein-bound conformations, respectively (Lakowicz et al., 1992; Niesner et al., 2004; 
Berezin and Achilefu, 2010). As previously mentioned, the oxidised form of NADH, NAD+, is not 
fluorescent and the ratio of NADH:NAD+ has been used previously as a measure of the redox state 
of the cell. Bird and colleagues demonstrated that the free-to-bound ratio of NAD(P)H, represented 
by the ratio of the amplitude coefficients for the short and long lifetimes (i.e. α1/α2), is related to the 
NADH/NAD+ ratio and can be used as an indicator for redox changes within the cell (Bird et al., 
2005). FAD is also examined routinely by FLIM for intracellular metabolic and redox states. While 
FAD can be found in a free and protein-bound conformation, the former has a significantly higher 
quantum yield with a lifetime of 2.91 ns (Berezin and Achilefu, 2010). In contrast to NAD(P)H, 
only the oxidised form of FAD is fluorescent and is used to measure changes in the redox state of 
the cell in combination with NADH (Chance et al., 1979). The fluorescence lifetimes of NAD(P)H 
and FAD are useful indicators of IR injury within the liver and kidney in vivo (Abulrob et al., 2007; 
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Thorling et al., 2011; Thorling et al., 2013). The fluorescence lifetime changes associated with 
necrosis and apoptosis have also been described and can be used to measure tissue responses to 
drug treatments and disease states within the kidney (Wang et al., 2008; Sanchez et al., 2010; Yu et 
al., 2011) 
 
There are many pathological mechanisms responsible for driving the progression of CKD. 
Structural defects give rise to reduced renal function and result in a viscious cycle of increased 
systemically-circulating toxins and a failure of compensatory and protective mechanisms. However, 
changes in cellular metabolism often underlie subsequent structural changes and perturbed cell 
signalling common to all pathogenic mechanisms. The aim of this chapter was to use in vivo MPM 
to visualise IR-induced tubular redox changes and tubulointerstitial damage in real-time and 
correlate these with histology and markers of oxidative stress. 
 
5.2 MATERIALS AND METHODS 
 
5.2.1 Animals and kidney ischaemia-reperfusion injury model 
Male 4-6 week old C57Bl6 mice were anaesthetised using a ketamine/xylazine combination (10 
mg/mL and 1 mg/mL, respectively) administered via intra-peritoneal injection at a dose of 10 μL/g 
body weight. Bilateral kidney IR injury was induced according to the protocol outlined in Chapter 
2, Section 2.6.2. Briefly, the left kidney was exposed via a flank incision and the renal artery was 
cleared of fat before a non-traumatic vascular microclamp was placed over the vessels. The left 
kidney was placed within the body cavity, the mouse turned to its right side, and the procedure 
repeated. The microclamps were removed following 20 min occlusion of left or right renal vessels. 
For chronic injury to the kidney, the muscle and skin incisions were sutured, and mice were allowed 
to recover for 21 days. From previous experiments (Gobe et al., 1990; Gobe et al., 2014), 
significant progression to CKD had been observed to occur by 21 days. For intravital MPM during 
IR injury, a modified protocol was performed (Section 5.2.2). All experiments were approved by 
the University of Queensland Animal Ethics Committee 2013 – AEC No: MED/053/12/CKDR. 
 
5.2.2 Intravital MPM of kidney ischaemia-reperfusion injury 
A detailed protocol is outlined in Chapter 2, Section 2.6.3. Briefly, mice were anaesthetised and the 
left kidney externalised by making a left flank incision. Renal vessels were occluded and the mouse 
was moved to the MPM stage. A heated jacket (38 ºC) was placed over the mouse to maintain 
normal body temperature and images of the ischaemic kidney were acquired over the 20 min period 
from when the clamp was attached. Intravital imaging during initial reperfusion was performed by 
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releasing the microclamp, then quickly replacing the mouse to the MPM stage. Images were 
acquired over a 40 min period from when the microclamp was removed. Both left and right kidneys 
from healthy control mice and 21-day IR mice were imaged by the same procedure, with clamping 
omitted at the time of MPM. Images were captured using a Nikon Ti Eclipse – LaVision MPM 
equipped with an ultrashort pulse mode locked 80 MHz Titanium:Sapphire MaiTai laser and 
ImSpector Pro software. The excitation wavelength was set to 740 nm for NAD(P)H fluorescence 
and 900 nm for collagen. Emitted light was collected using three photomultiplier tube filters: 447 
nm – 460 nm (blue), 485 nm – 550 nm (green), 575 nm – 630 nm (red). The objective was placed in 
a field of view that visualised detailed tubular structures and serial (30-50) penetrating slice images 
were acquired from the renal cortex to a depth of 50-70 μm. A minimum of three fields of view per 
kidney was obtained. Imaris x64 7.6.0 software was used to adjust the minimum and maximum 
exposure settings consistently throughout all acquired images for standardised quantification of 
fluorescence intensity. ImageJ was used to obtain mean fluorescence intensity values for NAD(P)H 
(green channel). For each of the three fields captured per kidney, the epithelial layer of definitive 
continuous tubules was selected and measured for mean intensity. Eight tubules per z-slice image 
were measured from five selected z-slice images per field. 
 
5.2.3 Fluorescence lifetime imaging microscopy 
FLIM was performed on mouse kidney slices immediately post-sacrifice in healthy control and 21-
day IR mice (2 kidneys for controls or 21-day IR, 3 fields of view per kidney). A detailed protocol 
is outlined in Chapter 2, Section 2.6.7. Briefly, kidneys were harvested after euthanasia of mice and 
placed on ice. A coronal kidney section was placed on a glass slide and overlayed with a glass 
coverslip. Time from death to first image capture was no more than 30 min. Images were captured 
using a DermaInspect system equipped with an ultrashort pulsed mode-locked 80 MHz 
Titanium:Sapphire MaiTai laser. The excitation wavelength was set to 740 nm for kidney 
endogenous fluorescence with emission signal range of 350 to 650 nm. FLIM data were collected 
with a time-correlated single-photon counting (TCSPC) SPC-830 detector integrated into the 
DermaInspect MPM system. Fluorescence emission was spectrally resolved between three linearly 
arranged photon counters through the use of three dichroic filters that divide the emission light into 
three channels for each photon counter: 350 to 450 nm (NAD(P)H), 450 to 515 nm (NAD(P)H and 
FAD), and 515 to 610 nm (FAD). FLIM data analysis was performed using SPCImage 4.8. 
 
5.2.4 Histology 
Following intravital MPM, kidneys were cut transverse to the length of the kidney at the equatorial 
plane, and half was fixed in 4 % formalin overnight, embedded in paraffin, and stained with H&E 
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according to the protocol outlined in Chapter 2, Section 2.4.1. Stained slides were scanned using 
Aperio ScanScope software software and visualised using ImageScope software.  
 
5.2.5 Western immunoblotting 
Following intravital MPM and euthanasia, the second half of the kidneys (after tissue collection for 
histology, see Section 5.2.4) was snap frozen in liquid nitrogen and stored at -80 ºC. Kidney tissue 
proteins were extracted and Western immunoblotting was performed for TGF-β1, SOD2, Keap1 
and Nrf2, as outlined in Chapter 2, Section 2.5. 
 
5.3 RESULTS 
 
5.3.1 Histopathology of renal ischaemia-reperfusion injury  
Figure 5.4 gives an overview of the kidney structure from controls (A), IR mice 20-40 min (early) 
after reperfusion (B), and IR mice 21 days after reperfusion (C). Kidneys from control mice had no 
abnormal structures. Kidneys from early IR mice showed evidence of cell swelling and eosinophilia 
especially in the outer stripe of the outer medulla (straight segment of the proximal tubule [S3] and 
thick ascending limb of the Loop of Henle), and cast formation along the nephron. The IR kidneys 
at 21 days showed diffuse areas of atrophy (intensely stained purple because of atrophic epithelial 
structures staining with haematoxylin in C) within the outer medulla but also radiating up into the 
cortex. 
 
Figure 5.5 demonstrates high power microscopy of the control and early IR kidneys. In A and B, 
normal kidney structure of the cortex (A) and medulla (B) is demonstrated. IR kidneys that had had 
20 min bilateral renal ischaemia and then were collected after the early reperfusion time, during 
which they had been viewed with MPM (20-40 min), are demonstrated in C and D. C shows 
minimal disruption of the cortex but some epithelial cell swelling and cast formation, in contrast 
with D, where there is clear evidence of epithelial cell swelling and eosinophilia in the proximal 
tubule straight segment and the thick ascending limb of the Loop of Henle. 
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Figure 5.4: Overview of the kidney structure for IR experiments 
Kidneys from controls (A), IR mice 20-40 min (early) after reperfusion (B), and IR mice 21 days 
after reperfusion (C) are demonstrated. The changes in B are subtle at this magnification but show 
general swelling around the outer stripe of the outer medulla, and debris in the lumens of the 
nephrons. In C areas of atrophy (intense stain) are clearly visible in the medulla, and radiating up 
into the renal cortex.  
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Figure 5.5: Early IR changes to kidney structure 
Control kidney cortex is demonstrated in (A.) and control kidney medulla is demonstrated in (B.). 
(C.) demonstrates early changes to the cortex at reperfusion. Cast material can be found in the 
lumen of tubules (arrow), disappearance of the brush border, and peritubular vascular expansion. 
(D.) demonstrates early changes to the medulla at reperfusion. Red blood cell accumulation is 
observed within thick straight tubules (arrow) and peritubular vascular expansion. 
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Figure 5.6 demonstrates higher power microscopy of the control and 21 day IR kidneys. In A, 
normal kidney structure of the cortex is demonstrated. Cortex was selected because this is the zone 
of the kidney that can be visualised by MPM. IR kidneys that had had 20 min bilateral renal 
ischaemia and then were collected after 21 days are demonstrated in B and C (cortex) and D 
(medulla). All show evidence of atrophy. Although the vicinity of the glomeruli to the renal casule 
should have allowed their visualisation using MPM, in only one instance was a glomerulus seen as 
a round, non-fluorescent area. Figure 5.7 demonstrates specific microscopic features of the cortex of 
21 day IR kidneys. Control kidney cortical structure is demonstrated in A. In B, a distinct 
subcapsular intensely-stained atrophic region is seen with relatively healthy tubules deeper in the 
cortex. C and D demonstrate some of the pathological characteristics of the atrophic cortical 
regions, with apoptosis (arrows) and a golden, probably lipofuscin, pigment indicated by asterisks. 
Lipofuscin pigment is an indicator of autophagy. 
 
5.3.2 Renal ischaemia-reperfusion injury promotes structural and metabolic changes that 
can be visualised by intravital multiphoton microscopy 
Intravital MPM (Excitation: 740 nm) allows clear visualisation of the renal cortical network in 
healthy control kidney from endogenous NAD(P)H fluorescence (Fig 5.8A-C). Cellular boundaries 
and tubular architecture was identifiable showing tubular lumen and interstitial space. During 20 
min ischaemia, tubular diameter increased causing a reduction in the interstitial space, luminal 
material was present (Fig 5.8D-F), and NAD(P)H fluorescence significantly increased (Fig 5.8J; 
p<0.01 compared to control). The greatest amount of tubular and cellular damage occurred at the 
early stages of reperfusion (5 to 40 min following the release of the microclamp). Tubular epithelial 
cell effacement and the formation of cast material, were well as the appearance of epithelial cell 
striations, are apparent at this time (Figure 5.8G-I). 
 
Chronic renal pathology was evident 21 days following IR when visualised with intravital MPM 
(Fig 5.9) with widespread areas of tubular atrophy containing highly fluorescent punctate regions 
most likely demonstrating enlarged lysosomes (Fig 5.9D-E). Within areas of observable atrophic 
pathology, were structurally-normal cortical tubules which contained a significantly higher 
NAD(P)H fluorescence compared to control kidneys (Fig 5.9G). Areas of observable pathology 
were highly variable as is demonstrated in Fig 5.9E. The endogenous fluorescence of the kidney 
cortex (collagen) was visualised at an excitation of 900 nm via second harmonic generation. This is 
clearly depicted by a 3D-reconstruction from Z-stack images co-detecting endogenous NAD(P)H 
fluorescence of tubules and collagen of the renal capsule (Fig 5.10A). The capsule appeared to 
thicken by 21 days after IR compared to control kidneys. This was consistent with histological 
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observations (Fig 5.6 and 5.7B). Collagen was not detected within the tubulointerstitial space via 
MPM (900 nm). 
 
 
 
 
Figure 5.6: 21 day IR pathology 
Control kidney cortex is demonstrated in A. B and C demonstrate areas of atrophy in the cortex of 
21 day IR kidneys. In both, there is thickening of the capsular membrane. In B, atrophic tubules 
intermix with relatively healthy tubules in the subcapsular region. In C, there is general subcapsular 
atrophy, and here the glomeruli are close enough to the renal capsule to allow visualisation with 
MPM. In D, the medulla of the IR kidneys showed evidence of previous acute injury that had 
healed and had developing fibrosis. These regions were too deep in the kidney to be seen by MPM. 
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Figure 5.7: High power microscopy 21 days post IR injury 
Control kidney cortical structure is demonstrated in A. In B, a distinct subcapsular intensely stained 
atrophic region is seen with relatively healthy tubules deeper in the cortex. C and D demonstrate 
some of the pathological characteristics of the atrophic cortical regions, with apoptosis (arrows) and 
a golden, probably lipofuscin, pigment indicated by asterisks.  
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Figure 5.8: Intravital MPM demonstrates metabolic and structural alterations during kidney 
IR injury 
Endogenous fluorescence of NAD(P)H excited at 740 nm in the healthy control kidney cortex 
clearly demonstrates the cortical tubular network with distal tubules, proximal tubules with 
associated brush border, and interstitial space (A.-C.). During 20 min ischaemia, tubular swelling 
and a reduction in interstitial space is evident (D.-F.) and is associated with a significant increase in 
tubular cell NAD(P)H endogenous fluorescence (J.). Tubular pathology is apparent during 
immediate reperfusion (G.-I.), demonstrated by epithelial cell striations (arrow head), tubular cell 
effacement and the formation of cast material (arrow) all of which indicating a loss of cell integrity, 
in some cases early cell death, but also perhaps repairable damage. Results expressed as mean ± 
SEM tubular epithelial cell fluorescence a 740 nm (** p<0.01 compared as indicated). Scale bar 
represents 50 µm.  
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Figure 5.9: Intravital MPM demonstrates metabolic and structural alterations in the 
chronically damaged kidney following IR injury 
Endogenous fluorescence of NAD(P)H excited at 740 nm in the healthy control kidney cortex 
clearly demonstrates the cortical tubular network with distal tubules, proximal tubules with 
associated brush border, and interstitial space (A.-C.). 21-days following IR injury (21d-IR) (D.-F.), 
there was widespread areas of tubular atrophy with highly fluorescent punctate regions most likely 
demonstrating enlarged lysosomes (arrow). Tubular structure was highly variable with structurally 
normal tubules appearing directly within areas of atrophy, which demonstrated a significantly 
greater NAD(P)H fluorescence signal (G.). Results expressed as mean ± SEM tubular epithelial cell 
fluorescence a 740 nm (*** p<0.001 compared as indicated). Scale bar represents 50 µm. 
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Figure 5.10: Three-dimensional reconstruction of kidney cortex using endogenous NAD(P)H 
and collagen fluorescence with MPM 
(A.) Healthy control kidney demonstrates a normal cortical tubular architecture underlying the renal 
capsule. Green – Ex: 740 nm; Blue – Ex: 900 nm. (B.-C.) 21-days post IR, tubular pathology is 
present demonstrated by areas of tubular atrophy. The kidney capsule can be visualised and was 
shown to be thicker. However no collagen was detected using MPM within areas of atrophic 
damage within the parenchyma of the cortex. 
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5.3.3 Ischaemia-reperfusion injury promotes long-term alterations to tubular cell 
metabolism in the kidney cortex 
Representative FLIM images of the τm (pseudocoloured according to the average weighted lifetime 
τm) are shown in Figure 5.11 across three spectral channels depicting NAD(P)H, NAD(P)H/FAD 
and FAD from control and 21d-IR kidney cortex. The results demonstrate that, in the first channel 
(Em 350-450 nm; NAD(P)H), there is a change in the τm demonstrated by a shift from blue to green 
pseudocolour of NAD(P)H in 21d-IR kidneys compared to control (Fig 5.11A and B). This 
indicates an increase in the τm of NAD(P)H (Fig 5.11D). This observation is also demonstrated in 
the histogram data by a right shift of the 21d-IR kidneys compared to control (Fig 5.11C). Channel 
2, which detects both NAD(P)H and FAD, demonstrated a significant increase in the τm of 
NAD(P)H/FAD following 21d-IR compared to the control kidney (Fig 5.11E, F and H). This was 
further demonstrated with a right shift of the 21d-IR NAD(P)H/FAD lifetime compared to control 
(Fig 5.11G). Isolating the spectral properties of FAD in channel 3 demonstrated no significant 
differences between control and 21d-IR kidneys (Fig 5.11I-L), suggesting that major differences in 
channel 2 are primarily due to τm changes to NAD(P)H. 
 
5.3.4 Ischaemia-reperfusion injury promotes chronic impairments to redox signalling in the 
kidney 
Oxidative stress-responsive proteins were shown to be significantly altered following early acute 
injury to the kidney and at 21 days post IR (Fig 5.12). Nrf2 is a transcription factor responsible for 
the expression of vital cytoprotective genes, and was shown to be significantly upregulated early 
after initial reperfusion and significantly decreased following long-term injury compared to control 
(Fig 5.12A-B; *** p<0.001). The intracellular inhibitor of Nrf2, Keap1, and the mitochondrial 
antioxidant protein, SOD2, decreased significantly following 21d-IR (Fig 5.12C; *** p<0.001 and 
Fig 5.12D; * p<0.05). The pro-fibrotic cytokine TGF-β1 significantly decreased following early 
reperfusion but was significantly increased following 21d-IR compared to control kidneys (Fig 
5.12E; p<0.01). 
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Figure 5.11: Fluorescence lifetime imaging microscopy  
FLIM suggests alterations in the average weighted fluorescence lifetime (τm) in the kidney cortex 
following 21-days post IR. Kidneys were imaged immediately post-sacrifice to allow medulla and 
cortex to be seen. FLIM data were measured within three spectral ranges using excitation at 740 nm 
(pseudo colour range is indicated in the parenthesis below images): 350-450 nm, 450-515 nm, and 
515-620 nm to capture NAD(P)H, NAD(P)H/FAD, and FAD respectively. Representative images 
are shown in (A, B, E, F, I and J). Histograms (C, G and K) represent the average pixel intensity for 
each τm lifetime and the corresponding average τm lifetimes from the three spectral channels are 
graphed (D, H and L). The τm of NAD(P)H and NAD(P)H/FAD significantly increased 21d-IR 
compared to control and no change in τm was observed in FAD alone. Results represent mean ± 
SEM (N = 2 kidneys and three fields per view per kidney. ** p<0.01 as indicated). 
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Figure 5.12: IR-injury promotes chronic impairments to redox signalling in the kidney 
Protein was extracted from whole kidneys after intravital MPM at early reperfusion (IR) and 21-
days post IR (21d-IR) and probed via Western blotting. Representative Western immunoblots for 
Nrf2, Keap1, SOD2 and TGF-β1 are shown in (A.). Following early reperfusion there was a 
significant increase in Nrf2 protein expression that was significantly decreased compared to healthy 
kidneys at 21d-IR (B.). Keap1 (C.) and SOD2 (D.) significantly decreased at 21d-IR and while 
TGF-β1 increased. Protein expression was normalised to GAPDH protein expression. Results are 
expressed as mean ± SEM (* p<0.05; ** p<0.01; *** p<0.001 compared as indicated). 
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5.4 DISCUSSION 
 
The progression to advanced stage CKD following AKI may be modulated by common 
pathological mechanisms, such as reduced nephron number, vascular insufficiency, cell cycle 
disruption and maladaptive repair (Chawla and Kimmel, 2012; Coca et al., 2012). The underlying 
mechanisms behind these common modulators of injury remain to be defined. Here, oxidative stress 
and metabolic alterations within PTE cells of the kidney (renal cortex) are presented as common 
contributors to the initiation and progression of chronic alterations in the kidney following IR-
induced AKI. Furthermore, to our knowledge, we are the first to apply intravital MPM to visualise 
chronic alterations in the kidney following IR-induced AKI. 
 
Our results demonstrate significant structural and metabolic changes during renal ischaemia and 
during early reperfusion in the tubulointerstitial region of the kidney cortex. Tubular epithelial cell 
swelling causing a reduction in interstitial space was observed during ischaemia. Cell swelling is a 
common observation during hypoxic conditions within many cell types (Heiss, 2012), and in 
tubular epithelial cells of the renal cortex is due to osmotic dysregulation by disturbed sodium 
potassium (Na
+
/K
+
) ATPase function (Molitoris et al., 1992; Coux et al., 2009). Decreased ATP-
dependent cellular functions are further demonstrated by our observed increase in endogenous 
NAD(P)H fluorescence since NADH is a substrate for complex I of the ETC. Decreased O2 supply 
coupled with the minimal glycolytic capacity of tubular epithelial cells cause underutilisation of 
NADH to be oxidised into NAD+ (non-fluorescent by MPM) by complex I of the ETC. This 
“backing up” of NADH results in increased endogenous fluorescence. The results are consistent 
with intravital MPM results from rats with AKI after IR injury (Hall et al., 2013), and similar 
findings have been demonstrated in brain with microregional hypoxia (Polesskaya et al., 2012) and 
in assays of NADH in isolated renal tubule preparations after various short-chain fatty acid, 
carboxylic acid, and amino acid treatments (Balaban and Mandel, 1988). Interestingly, early studies 
investigating renal IR-induced injury have demonstrated that the occlusion of small vessels caused 
by tubular swelling can contribute to the pathology of ensuing reperfusion injury (Obermuller et al., 
1997). Furthermore, loss of osmotic regulation due to ATP depletion has similar effects on 
mitochondria, inducing swelling and disappearance of the IMM (Kaasik et al., 2007). ROS 
generation and the peroxidation of cardiolipan during ischaemia have been suggested to result in 
IMM disruption (Lesnefsky et al., 2009; Wiswedel et al., 2010).  
 
An important component of the IMM is the ETC for effective ATP production via oxidative 
phosphorylation. It has been well documented that the majority of IR-induced injury occurs at the 
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point of reperfusion (Plotnikov et al., 2007; Lejay et al., 2014). Intravital MPM at early reperfusion 
enabled the visualisation of dynamic tubular pathological changes, including epithelial cell 
effacement, cast formation, and cellular striations, all of which indicate loss of cell integrity, in 
some cases early cell death, but also perhaps repairable damage. Increased mitochondrial ROS 
production is thought to be the major pathological process when O2 is re-presented to damaged 
components of the ETC of the IMM, as seen in reperfusion. Depleted ATP also causes significant 
impairment to ATP-dependent actin polymerisation (Atkinson et al., 2004) causing cytoskeletal 
changes in tubular epithelial cells and resulting in the breakdown of the brush border, cell-cell 
contact, disruption of barrier function and cell detachment (Sharfuddin and Molitoris, 2011). 
Mitochondrial permeability transition due to cristae disruption can also result in the release of Cyt C 
from the IMM and the initiation of apoptosis (Madesh and Hajnoczky, 2001; Halestrap, 2010). Our 
results demonstrate histological tubular epithelial cell apoptosis in kidney sections collected 
following early reperfusion. Apoptosis and acute tubular necrosis are common pathological 
mechanisms after kidney IR injury resulting in reduced kidney function (Heyman et al., 2011). 
 
Increased ROS generation has previously been shown to upregulate important genes responsible for 
cytoprotection (Kensler et al., 2007; Fourquet et al., 2010; Shelton et al., 2013). Our results 
demonstrate that the kidney responds well to the initial acute injury, at the time of early reperfusion, 
indicated by the upregulation of Nrf2 following IR-induced ROS generation. Downstream targets of 
Nrf2 include HO-1, PPARγ, and GPX responsible for neutralisation of increased ROS and 
maintenance to the intracellular redox environment (Wu et al., 2011; Sadi et al., 2014). 
Interestingly, the intracellular inhibitor of Nrf2, Keap1, did not change significantly at the 
corresponding time point, indicating that the dissociation of Keap1 from Nrf2, as the mechanism of 
inhibiting  Nrf2, rather than decreased Keap1 protein levels, which is consistent with other findings 
(Kim et al., 2014). 
 
The early acute phase response to IR-injury was followed by dampened regulation of cytoprotective 
defences promoting an oxidative stress environment. Decreased levels of Nrf2 were observed 
following 21-days post IR-injury indicating a failure of antioxidant responses and promotion of 
ROS. Impaired Nrf2-Keap1 signalling has been previously demonstrated in CKD rodent models in 
association with decreased renal function and increased tubulointerstitial damage (Kim and Vaziri, 
2010; Aminzadeh et al., 2013). Similar results were seen with neurodegenerative disease (Jin et al., 
2013) and age-related macular degeneration (Sachdeva et al., 2014). Furthermore, the 
mitochondrial endogenous antioxidant SOD2, decreased during chronic injury implicating 
mitochondrial dysfunction and the promotion of mitochondrial-derived ROS production. ROS have 
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been previously shown to promote TGF-β1 activation of tubulointerstitial myofibroblasts, aiding in 
their proliferation and the deposition of collagen (Bondi et al., 2010). However, detection of 
collagen using MPM (second harmonic generation/SHG) detected fluorescence of the kidney 
capsule but did not detect collagen within the tubulointerstitial region of the cortex. Pena and 
colleagues (2005) have demonstrated high optical activity by SHG from type I collagen, which is 
the predominate collagen type throughout the body including the kidney capsule (Di et al., 2002), 
compared to type IV collagen that has little or no SHG optical activity and mainly constitutes basil 
lamina (Yurchenco and Schittny, 1990). This is primarily due to the fibrillar and nonfibrillar nature 
of collagen type I and type IV respectively, and highlights that SHG microscopy is sensitive to the 
organisation of collagen molecules in the tissue rather than the collagen type (Pena et al., 2005). 
The results in the present study suggested a thickening of the kidney capsule 21d-IR compared to 
the healthy kidney capsule which was confirmed following standard histological morphology. The 
dysregulation of Nrf2, Keap1, SOD2 and TGF-β1 implicate redox alterations within the chronically 
damaged kidney. These findings are also consistent with, and likely result from, observable 
alterations to tubular epithelial metabolism in the chronically damaged kidney. 
 
Significant impairment to cortical tubular epithelial cell structure and metabolism was observed 21-
days following IR-induced injury. Widespread yet focal areas of tubulointerstitial atrophy and the 
presence of structurally-normal tubules adjacent to atrophic tubules were observed, suggesting 
cross-talk was possible between sites of persistent and chronic damage, and the normal-looking 
tubules. Increased endogenous NAD(P)H fluorescence within structurally-normal tubules located 
within areas of atrophy suggest impaired NADH metabolism and mitochondrial function due to 
reduced O2 delivery. Traditionally, it is the outer stripe of the outer medulla that is damaged acutely 
in IR-induced AKI. MPM did not allow its visualisation, due to a restriction of depth of excitation 
approximately 70 µm beneath the kidney capsule (Small et al., 2014). It is well documented that the 
outer stripe of the outer medulla is highly susceptible not only to ischaemic insult, but also toxic 
insult (Yamamoto et al., 1984a, b). This region of the kidney has the greatest oxygen concentration, 
mainly due to constitutive S3 segments of the proximal tubule that contain a high density of 
mitochondria (Venkatachalam et al., 1978). Nevertheless, the renal cortex accounts for 80 % of 
oxygen in the kidney, which is mainly accounted for by the remainder of the proximal tubule, 
making it an important site to consider. Depth restriction remains a challenge to intravital MPM 
preventing an accurate comparison between medullary and cortical dynamics in response to AKI 
and ensuing chronic pathology. Different approached to this limitation are explored in Chapter 6. 
However, MPM provided novel data on the participation of cortical regions to IR injury of the 
kidney. 
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Tubular atrophy and subsequent whole organ atrophy are primarily due to increased levels of 
apoptosis respective to levels of mitosis (Gobe and Axelsen, 1987; Gobe et al., 1990). Continuing 
apoptosis in preserved tubules would occur due to the inflammatory infiltrate and a developing 
hypoxic environment due to vascular insufficiency. In vivo MPM investigations of brain have 
demonstrated increased endogenous NAD(P)H fluorescence when tissue oxygen levels are less than 
10 mmHg (Polesskaya et al., 2012). Low O2 levels reduce the activity of the mitochondrial complex 
I and the conversion of NADH to NAD+, resulting in increased fluorescence detection. Reduced 
nephron number due to tubular atrophy likely induces a compensatory function in remaining tubules 
and subsequent increase in ATP demand. Hypoxia causes mitochondrial dysfunction within these 
functional remaining tubules which reduces ATP synthesis, further enhancing ATP demand, and 
producing a vicious cycle of metabolic insufficiency. Cell death via apoptosis or autophagy 
resulting in perturbed tubular function is the ultimate result. An alternate theory may argue that the 
compensatory nature of these functional remaining tubules results in a greater density of 
mitochondria. This would produce higher basal levels of NADH. However, greater levels of O2 
supply would be needed to maintain NADH turnover and oxidative phosphorylation, which is 
highly unlikely given that vascular insufficiency is a hallmark of all chronic kidney pathologies and 
was observed histologically in the present study. 
 
Our preliminary observations investigating the fluorescence lifetime changes of NAD(P)H and 
FAD suggest impaired NAD(P)H dynamics in the chronically-damaged kidney following AKI. We 
identified an increase in the τm observed in both the 350-450 and 450-515 nm spectral channels, 
both of which encompass NAD(P)H endogenous fluorescence (Yu et al., 2012). A lack of any 
change in the 515-620 spectral channel, which predominately isolates FAD endogenous 
fluorescence, supports the conclusion that NAD(P)H is responsible for the τm changes detected in 
the 450-515 nm spectral channel. Interestingly, previous studies have demonstrated that increased 
τm of NAD(P)H is associated with ischaemic necrosis and apoptosis in skin and cancer cell lines 
(Wang et al., 2008; Sanchez et al., 2010). Both of these processes are associated with oxidative 
damage which may alter the protein recruitment of NAD(P)H and result in an increased lifetime 
fluorescence that we observe. However, further investigations are required to identify the changes 
associated with protein binding in NAD(P)H in chronically-damaged kidneys following IR-injury, 
such as the redox ratio which provides an expression of free and bound NAD(P)H (Skala et al., 
2007a). FLIM was performed on kidney slice preparations immediately after kidney collection, 
compared to MPM which was performed intravitally. Nonetheless, the validity of lifetime changes 
is supported by the obvious preservation of the tissue within the time until first image. In addition, 
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the comparative nature between two different samples (control and 21d-IR), rather than dynamic 
changes due to experimental intervention to the same tissue, also supports data validity. It has been 
described previously that ex-vivo skin maintains NAD(P)H autofluorescence when kept at 4 ºC for 7 
days despite the possibility of post-death changes, such as autolysis. The kidney is likely to have a 
shorter half-life of endogenous fluorescence given the high reliance on aerobic metabolism, 
although there are no previous studies that have investigated this. 
 
In summary, this study strongly suggests that NAD(P)H alterations influence oxidative stress in IR-
induced AKI and future development of progressive CKD. The early stages of IR damage in the 
kidney were characterised by significantly increased NAD(P)H endogenous fluorescence. At 
reperfusion, structural damage in the tubulointerstitial regions of the cortex occurred rapidly. By 
21d-IR, there was focal tubular atrophy and significantly increased NAD(P)H fluorescence in 
functional remaining tubules. Compared with control kidneys, molecular analysis demonstrated 
increased Nrf2 expression at reperfusion but decreased at 21d-IR. Mitochondrial SOD2 decreased. 
In conclusion, mitochondrial dysfunction is persistent in functional remaining tubules of the 
chronically-damaged kidney following AKI. The results present oxidative stress and mitochondrial 
preservation as crucial in vivo targets following AKI to prevent progression to CKD. 
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CHAPTER 6 
 
Targeting Oxidative Stress in Kidney Disease 
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Chapters 3 to 5 have demonstrated that intracellular oxidative stress and impairments to cellular 
metabolism are major contributing factors to kidney dysfunction and the progression to chronic 
damage. The known contribution of oxidative stress due to mitochondrial dysfunction suggests that 
targeting excess ROS production will attenuate progressive kidney injury. In Chapter 3, in vitro 
evidence suggested that use of an exogenous antioxidant could benefit oxidative stress-induced 
kidney injury, including by reducing apoptosis. Targeting anti-oxidant defence mechanisms against 
oxidative stress is a broad area of research that has attracted many different approaches. The aims of 
Chapter 6 were (1) to use an in vitro model of oxidative stress-induced kidney injury to determine 
which antioxidant/s best prevented cell damage, and (2) to then translate these benefits into an in 
vivo model of chronic kidney injury following AKI after IR-induced injury. 
 
6.1 INTRODUCTION 
 
Progression of chronic diseases, including chronic kidney diseases, is driven by numerous 
deleterious and converging physiological processes, regardless of the cause. Targeting the 
progressive nature of disease is increasingly difficult and further exaggerated by advanced stage 
disease. Oxidative stress is a cellular process that contributes to the myriad of pathological events 
attributed to progressive kidney disease including fibrosis, apoptosis, senescence, vascular 
insufficiency and maladaptive repair. As suggested from findings in Chapter 5, metabolic 
alterations within the kidney are intimately linked to oxidative stress, mitochondrial dysfunction, 
and the promotion of ROS generation. This presents oxidative stress and ROS as underlying 
common contributors, and targets to reduce the pathological consequences and progression of CKD. 
 
That antioxidant therapy is successful in reducing AKI has been demonstrated best in contrast-
induced nephropathy (Hsu et al., 2012; Kongkham et al., 2013), renal IR-injury (Seguro et al., 
2012; Peerapanyasut et al., 2014), and acute toxin nephropathies (Parra et al., 2003; Kadkhodaee et 
al., 2007). Targeting oxidative stress in progressive kidney diseases, such as CKD, with the use of 
exogenous antioxidant compounds has produced ambivalent findings primarily due to the use of 
small patient populations and suboptimal study quality. The outcomes have been of insufficient 
power to confirm any benefit. A recent meta-analysis of 10 studies assessing antioxidant therapy in 
haemodialysis, transplant recipients and non-dialysis CKD patients found that antioxidant therapy 
significantly reduced the development of ESKD, but showed no clear benefit on cardiovascular and 
all-cause death or major cardiovascular events in CKD patients (Jun et al., 2012). Pre-clinical in 
vivo models commonly demonstrate beneficial results of antioxidant interventions, primarily in AKI 
models. Considering that AKI is commonly followed by insidious maladaptive and progressive 
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kidney pathology with asymptomatic kidney functional decline (Kang et al., 2002; Lafrance and 
Miller, 2010), the apparent benefit of antioxidant therapy to reduce the onset of CKD is less clear. 
Recently, Himmelfarb et al. (2014) conducted a well-powered trial investigating whether mixed 
tocopherols and α-lipoic acid would alter oxidative stress and inflammation biomarkers in 
maintenance haemodialysis patients, and found no detectable change compared to placebo controls. 
These data highlight the need for more basic research into oxidative stress to design appropriate 
targets. 
 
Chapter 1 Section 1.2.9 provided detailed information about the mechanism of action of selected 
antioxidants and reviewed their current use for CKD (Small et al., 2012). Briefly, NAC acts as an 
essential precursor to many endogenous antioxidants involved in the decomposition of peroxides 
(Zafarullah et al., 2003; Zhang et al., 2011), as well as replenishing intracellular glutathione stores. 
In addition, the sulfhydryl-thiol group of L-cysteine is able to exert direct antioxidant effects by 
scavenging free radicals. NAC seems to exert the greatest antioxidant and anti-inflammatory 
properties when used against the greatest injury, such as in ESKD patients receiving either 
haemodialysis or peritoneal dialysis. In those cases, NAC reduced serum F2-isoprostanes and the 
inflammatory cytokine IL-6 (Hsu et al., 2010; Nascimento et al., 2010). In a randomised, double-
blind, placebo-controlled study where 10 non-diabetic ESKD patients on maintenance 
haemodialysis received 1200 mg NAC daily for 7 days, pro-fibrotic FGF-19 was decreased (Li et 
al., 2013). αTOC is a lipid-soluble antioxidant that incorporates into the plasma membrane of cells 
scavenging free radicals and preventing lipid peroxidation (Serbinova et al., 1991). Despite this, 
αTOC as a therapeutic agent remains controversial owing to trials demonstrating increased risk of 
prostate cancer and all cause-mortality with its use. CoQ10 is another fundamental component of the 
lipid membrane that acts primarily within mitochondria for electron transfer, membrane polarisation 
and ATP generation, and is a popular compound as an antioxidant therapy. There is a general lack 
of human studies investigating CoQ10 therapy for the treatment and/or prevention of CKD despite 
positive pre-clinical models. CoQ10 levels decrease with age, but there are no studies measuring 
endogenous CoQ10 levels in CKD patients and this could prove vital in the identification of 
populations where CoQ10 therapy may have beneficial outcomes. 
 
Oxidative stress incorporates the disruption of vital intracellular signalling networks that are redox 
sensitive. Nrf2-Keap1 dynamics during an oxidative stress environment and developing renal 
pathologies have gained increased attention as a result of the thwarted BEACON trial (de et al., 
2013). The results, where Nrf2 was targeted with bardoxolone methyl, suggest that altering such up-
stream, highly conserved targets can have negative systemic consequences (Tayek and Kalantar-
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Zadeh, 2013). Furthermore, as demonstrated in Chapter 4 (Small et al., 2014), oxidative stress-
induced alterations to PPARγ can disrupt important PPARγ-dependent processes such as 
mitochondrial homeostasis and mitophagy in PTE cells. It is not known whether these effects occur 
during AKI and CKD. 
 
This chapter aimed to determine whether targeting oxidative stress could improve mitochondrial 
dysfunction and metabolic alterations following AKI and during any subsequent progression to 
CKD. 
 
6.2 MATERIALS AND METHODS 
 
6.2.1 Materials 
Powdered mouse food (normal feed) from Specialty Feeds (Glenn Forrest, WA) was a gift from 
Prof. Lindsay Brown (Southern Cross University, Lismore, Australia). NAC (catalogue number 
A7250), αTOC (catalogue number T3251) and Trolox (Tlx – catalogue number 238813) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Coenzyme-Q10 was a gift from A/Prof. Luis 
Vitetta and Medlab (Alexandria, NSW). 
 
6.2.2 Cell culture model 
Dose-response experiments were performed on HK-2 cells for each chosen antioxidant to obtain the 
highest concentration that did not significantly damage the cultures. This was assessed by 
measuring cell death (mainly, morphological features of apoptosis) or mitosis (morphological 
assessment described in Chapter 2 Sections 2.3.2 – 4). Concentrations were as follows; NAC – 
0.01, 0.1, 1.0, 10, 20 mM; αTOC – 0.1, 0.5, 1.0 mg/ml; Tlx – 1.0, 1.5, 2.0 mM; CoQ10 – 0.01, 0.1, 
1.0, 10 μM;. Stock concentrations were prepared using DMSO for Tlx and NAC and ethanol 
(EtOH) for αTOC and CoQ10. The final working concentration of the vehicle never exceeded 1 % in 
culture and an appropriate vehicle-control was used throughout all experiments. Oxidative stress 
was induced using 0.6 mM H2O2 exposed to HK-2 cells over 18 h. This induced a significant 
increase in apoptosis and decrease in mitosis and, after dose-response studies, was therefore chosen 
as the treatment concentration for co-treatment studies with antioxidants. For co-treatment studies, 
HK-2 cells were exposed to the selected antioxidant alone for 2 h prior to co-administration of 0.6 
mM H2O2 and the antioxidant for 18 h. Appropriate controls were always used. 
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6.2.3 In vivo mouse model 
4-6 week old male C57Bl6 were housed in temperature controlled boxes with a 12 h light – 12 h 
dark cycle. Mice were fed a normal powdered food diet or a normal powdered food diet with the 
addition of 5 % NAC since this oral dosage has previously been shown to be beneficial (Malins et 
al., 2002). The average 30 g male C57Bl6 mouse consumes 4.5 g of dry food daily (Bachmanov et 
al., 2002). Mice were an average weight of 25 g with no mouse weighing greater than 30 g. 
Therefore each mouse (individually housed) was allotted 4.5g of food each day. Mice consumed 
either the normal powdered food or powdered food with 5% NAC (NAC diet). They did not 
consume the full amount provided within a 24 h period, by observation. However, there was no 
difference in the residue food amounts for control or NAC-fed mice, indicating they consumed 
equivalent food amounts. Mice were fed the diets one week prior to kidney IR surgery, and for 21-
days following kidney IR. Intravital MPM and kidney collection occurred following initial kidney 
IR injury and at 21-days post IR. (N = 4 – 6 animals per group). All experiments were approved by 
the University of Queensland Animal Ethics Committee 2013 – AEC No: MED/053/12/CKDR. 
 
6.2.4 Western immunoblotting 
Protein expression levels were determined for p-PPARγ, PPARγ, Keap1, Nrf2, SOD2, HO-1 and 
TGF-β1 from whole kidney protein extracts, using methods described in Chapter 2 Section 2.5. 
GAPDH was used as a loading control and densitometry was used to semi-quantitate protein 
expression. 
 
6.2.5 Mouse kidney histology and immunohistochemistry 
Kidneys were collected from control mice, those at early reperfusion, and at 21-days following IR 
surgery. H&E, Masson’s Trichrome stain, in situ enzymatic ApopTag, and IHC for PCNA, 8-
OHdG, p-PPARγ, PPARγ were performed according to protocols detailed in Chapter 2 Section 2.4. 
Morphometry was performed using ImageScope following digital scanning of slides using the 
Aperio ScanScope XT slide scanning system (Aperio Technologies Inc., Vista, California, USA) at 
x20 magnification. Entire kidney sections were analysed and separated into cortex and medulla. 
Algorithms selected for quantification were as follows:  IHC Nuclear v1, Version 1 for ApopTag 
and PCNA staining, with strong positive (+3) and positive (+2) included into mean values; Positive 
Pixel Count v9, Version 9.1 for 8-OHdG staining, with strong positive (+3) only included into mean 
values; and Masson’s Trichrome stain using the Positive Pixel Count v9, Version 9.1 algorithm, 
with Total Negative Pixels included into mean values since blue is detected as negative staining. 
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6.2.6 Intravital MPM of kidney IR injury 
The same protocol was used as described in Chapter 5 and is detailed in Chapter 2, Section 2.6. The 
mitochondrial membrane potential dependent dye TMRM was infused intravenously and imaged 
with intravital MPM to assess mitochondrial dynamics in the chronically-damaged kidney. These 
methods are outlined in Chapter 2, Section 2.6.4.  
 
6.2.7 Fluorescence lifetime imaging microscopy 
The same protocol was used as described in Chapter 5 and is detailed in Chapter 2, Sections 2.6.7 
and 2.6.8. As an extension to FLIM data described in Chapter 5, more replicates were performed (N 
= two animals per group, both kidneys were analysed, N = 4), as well as differentiating the medulla 
from the cortex. Areas of focal fibrotic change were analysed. 
 
6.3 RESULTS 
 
6.3.1 In vitro models support NAC as a superior antioxidant to prevent oxidative stress-
induced kidney injury 
Apart from 1 mg/ml, αTOC significantly increased apoptosis in a dose-dependent manner compared 
to untreated and vehicle control HK-2 cells (Fig 6.1A); p<0.001). 1.0 mg/ml also had no detrimental 
effect on mitosis in controls (Fig 6.1B). 1.0 mg/ml αTOC was then applied as an antioxidant in 
combination with H2O2. 2 h pre-treatment with 1.0 mg/ml αTOC prior to and during 18 h H2O2 did 
not attenuate H2O2-induced apoptosis (Fig 6.1C) or reduced mitosis (Fig 6.1D). A non-significant 
trend of increased apoptosis when αTOC was used in conjunction with H2O2, compared to H2O2 
treatment alone, suggests αTOC could promote apoptosis (Fig 6.1C). Tlx (water soluble αTOC) 
significantly increased apoptosis when used at 2 mM (Fig 6.2A; p<0.001), but none of the lesser 
concentrations had detrimental effects. No treatment concentrations had any significant effect on 
mitosis (Fig 6.2B). 1 mM Tlx was selected as the treatment concentration and was therefore applied 
in combination with H2O2. 1 mM Tlx pre-treatment for 2 h, and during 18 h H2O2 exposure, did not 
attenuate H2O2-induced apoptosis (Fig 6.2C) or decreased mitosis (Fig 6.2D). CoQ10 did not alter 
levels of apoptosis (Fig 6.3A) or mitosis (Fig 6.3B) at concentrations ranging from 0.001 to 10 µM. 
The highest soluble CoQ10 concentration (10 µM) was chosen to be used in combination with H2O2. 
2 h exposure of 10 µM CoQ10 prior to and during 18 h H2O2 exposure did not attenuate H2O2-
induced apoptosis (Fig 6.3C) or reduced mitosis (Fig 6.4D). In the NAC dose response tests, only 
20 mM significantly increased apoptosis in HK-2 cells compared to untreated and vehicle control 
cultures (Fig 6.4A; p<0.001). There was no significant alteration in mitosis (Fig 6.4B). 10 mM 
NAC did not significantly alter apoptosis or mitosis and was therefore chosen to use in combination 
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with H2O2. 2h exposure to NAC prior to and during 18h H2O2 exposure significantly reduced H2O2-
induced apoptosis (Fig 6.4C; p<0.001) but did not improve the H2O2-induced reduction in mitosis 
(Fig 6.4D). The DMSO vehicle significantly reduced H2O2-induced apoptosis (Fig 6.4C; p<0.05). 
 
 
 
 
Figure 6.1: The antioxidant αTOC promotes oxidative stress induced apoptosis 
After dose-response studies as described in text, HK-2 cells were exposed to 0.1 mg/ml αTOC 2 h 
prior to and during 18 h H2O2 treatment. The combination of αTOC and H2O2 induced a significant 
increase in apoptosis similar to that observed in cells treated with H2O2 alone (C.). The combination 
of αTOC and H2O2 induced a significant decrease in mitosis similar to that observed in cells treated 
with H2O2 alone (D.). Within the graphs the ethanol vehicle is indicated by EtOH. Results are 
expressed as means ± SE (** p<0.01; *** p<0.001 compared to untreated control). 
  
139 
 
 
 
 
 
 
 
 
 
 
Figure 6.2: The antioxidant Tlx does not protect against oxidative stress induced apoptosis or 
reducted mitosis 
In the dose response tests, Trolox (Tlx) significantly increased apoptosis at a concentration of 2 mM 
(A.) Tlx did not affect levels of mitosis (B.). HK-2 cells were exposed to 1 mM Tlx 2 h prior to and 
during 18 h H2O2 treatment. In a scenario of oxidative stress (0.6 mM H2O2), Tlx did not decrease 
the significant increase in % apoptosis induced by H2O2 alone. (C.). Tlx also did not improve the 
low levels of mitosis induced by H2O2 alone (D.). Within the graphs the dimethyl sulfoxide vehicle 
is indicated by DMSO. Results are expressed as mean ± SE (*** p<0.001 compared to untreated 
control). 
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Figure 6.3: The antioxidant CoQ10 does not protect against oxidative stress induced apoptosis 
or reduction in mitosis 
CoQ10 at concentrations of 0.01 – 10 µM did not alter levels of apoptosis (A.) or mitosis (B.). HK-2 
cells were exposed to 10 µM CoQ10 2 h prior to and during 18 h H2O2 treatment. CoQ10 had no 
significant effect on levels of apoptosis induced by H2O2 alone (C.). Similarly, CoQ10 did not 
improve the reduced levels of apoptosis induced by H2O2 alone (D.). Within the graphs the ethanol 
vehicle is indicated by EtOH. Results are expressed as mean ± SE (*** p<0.001 compared to 
untreated controls). 
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Figure 6.4: The antioxidant NAC attenuates oxidative stress induced apoptosis and a 
reduction in mitosis 
In the dose response tests, NAC significantly increased apoptosis only at a concentration of 20 mM 
(A.). There was no significant effect at 0.01 – 10 mM compared to untreated controls (A.). NAC did 
not significantly alter levels of mitosis (B.). HK-2 cells were exposed to 10 mM NAC 2 h prior to 
and during 18 h H2O2 treatment. Oxidative stress significantly increased apoptosis. NAC 
significantly decreased oxidative stress-induced apoptosis (C.). Note that DMSO also significantly 
improved outcome in H2O2-induced apoptosis. The addition of NAC significantly improved 
outcome in the H2O2-induced reduction in mitosis (D.). Within the graphs the dimethyl sulfoxide 
vehicle is indicated by DMSO. Results are expressed as mean ± SEM (* p<0.05; ** p<0.01; *** 
p<0.001 compared to untreated control, and as indicated). 
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6.3.2 Progression of chronic kidney pathology following acute kidney injury is enhanced by 
the antioxidant NAC  
The progression of fibrosis was evident at 21d-IR by significantly increased interstitial collagen 
deposition, detected by Masson’s Trichrome staining, within the interstitial spaces at 21d-IR 
compared to control kidneys from mice fed a normal diet (Fig 6.5A, C and G; p<0.05) and mice fed 
a normal diet + 5% NAC (NAC diet; Fig 6.5D, F and G; p<0.001). Tubular damage at early 
reperfusion (IR), regardless of diet, is evident by the presence of cell debris within tubules (Fig 
6.5B and E). PCNA IHC demonstrates significantly increased proliferation of cells within the 
interstitium, likely to be myofibroblasts, at 21d-IR compared to control kidneys from mice fed a 
normal diet (Fig 6.5H, J and K; p<0.01) and mice fed the NAC diet (Fig 6.5 L, N and K; p<0.001). 
The interstitial cell PCNA labelling was further enhanced in the kidneys of mice fed the NAC diet 
(Fig 6.5K; p<0.001). TGF-β1 protein expression from whole kidney extracts was significantly 
increased in mice fed the NAC diet compared to mice fed a normal diet (Fig 6.5O and P; p<0.05) 
and remained significantly increased at 21d-IR regardless of diet compared to control mice on a 
normal diet (Fig 6.5O and P; p<0.01). Apoptosis was significantly increased within tubular 
epithelial cells at IR in mice fed a normal diet (Fig 6.7A, B and G; p<0.05). Apoptosis was 
attenuated in mice fed the NAC diet (Fig 6.7D, E and G; p<0.05) at this acute time. Apoptosis 
remained significantly increased at 21d-IR regardless of diet compared to control kidneys (Fig 
6.7A, C and G; p<0.05. Fig 6.7D, F and G; p<0.001) and was significantly enhanced in mice fed the 
NAC diet (Fig 6.7C, F and G; p<0.001 compared to 21d-IR normal diet). Representative images 
demonstrating kidney capsule thickening at 21d-IR compared to control, acquired by intravital 
MPM and second harmonic generation of fibrillar collagen, are shown in Fig 6.6A and B. Fibrillar 
collagen appears to penetrate the cortex overlying sites of tubular atrophy. 
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Figure 6.5: Progression to fibrosis following AKI is enhanced by the antioxidant NAC 
Masson’s Trichrome staining and morphometry (A.-G.) demonstrate increased interstitial collagen 
deposition 21-days following IR injury (21d-IR) compared to healthy controls and early reperfusion 
(IR) for both normal diet (A.-C.) and normal diet + 5% NAC (NAC diet; D.-F.). Proliferation 
detected by proliferating cell nuclear antibody (PCNA) and quantified by morphometry (H.-N.) 
increased within the interstitium of the cortex 21d-IR for both normal diet (H.-J. and K.) and the 
NAC diet (K.-N.). The NAC diet enhanced interstitial cell proliferation for 21d-IR compared to 
mice on a normal diet (K.). Transforming growth factor-beta-1 (TGF-β1) from whole kidney 
protein extracts, detected by western immunoblotting (O.) and quantified by densitometry (P.), 
increased in mice on a normal diet for 21d-IR compared to control. The NAC diet increased TGF-
β1 expression compared to mice on a normal diet in control kidneys (P.). Results expressed as mean 
± SE (* p<0.05; ** p<0.01: *** p<0.001 compared as indicated). Scale bar represents 50 µm. 
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Figure 6.6: Kidney capsule thickening in the chronically damaged kidney detected by MPM 
Z-stack reconstruction and section view of the mouse kidney acquired with intravital MPM is 
demonstrated. Green shows NAD(P)H endogenous fluorescence excited at 740 nm depicting the 
renal cortical tubular network. Blue shows fibrillar collagen endogenous fluorescence excited at 900 
nm depicting type 1 collagen of the renal capsule. A thin and uniform renal capsule composed of 
collagen can be visualised in the healthy control kidney with 900 nm excitation (A.). At 21-days 
following IR injury (21d-IR; normal diet), the renal capsule was noticeably thicker in regions 
overlying areas of cortical tubular atrophy (B.).   
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Figure 6.7: NAC prevents apoptosis following AKI and enhances apoptosis during chronic 
kidney pathology 
The enzymatic in situ stain ApopTag labels apoptotic cells and bodies (A.-E.). Labelling was 
quantified with morphometry (G.). Apoptosis significantly increased in tubular epithelial cells at 
early reperfusion (IR) (B.) and 21-days following kidney IR-injury (21d-IR) (C.) in mice on a 
normal diet. The 5% NAC dietprevented tubular cell apoptosis at IR (E.) but significantly enhanced 
apoptosis at 21d-IR (F.) compared to mice on a normal diet. Results expressed as mean ± SE (* 
p<0.05; ** p<0.01: *** p<0.001 compared as indicated). Scale bar represents 50 µm. 
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6.3.3 NAC enhances chronic oxidative damage in progressive kidney pathology by altering 
endogenous antioxidant responses 
The oxidative damage marker 8-OHdG was weakly positive in the tubular epithelium of control 
kidneys regardless of the type of diet (Fig 6.8A and D). Distal tubular epithelium possessed stronger 
8-OHdG positivity than proximal tubular epithelium (Fig 6.8A and D). There was no significant 
increase in 8-OHdG immediately after reperfusion (IR) regardless of the diet (Fig 6.8B and E). 
However, at 21d-IR, there was a significant increase in 8-OHdG that was further enhanced by the 
NAC diet (Fig 6.8C, F and G; p<0.001). 
 
Nrf2 protein expression from whole kidneys significantly increased at IR in mice on a normal diet 
demonstrating a cytoprotective response (Fig 6.8H; p<0.05). This did not occur in mice on the NAC 
diet. An non-significant increase was observed in Nrf2 expression in 21d-IR mice on the NAC diet 
compared to control (Fig 6.8H; p<0.0587). Keap1 protein expression did not alter significantly (Fig 
6.8I). 
 
Western immunoblotting detected HO-1 protein expression at approximately 32-34 kDa plus a 
lighter HO-1 protein (HO-1Truncated) consistent with C-terminal truncation (Lin et al., 2007b) (Fig 
6.8J representative western blot). HO-1 protein expression significantly increased at 21d-IR 
compared to control kidneys regardless of diet (Fig 6.8J; p<0.01 and p<0.001 compared to 
respective control kidneys). Mice on the NAC diet had significantly higher HO-1 expression at IR 
compared to mice on a normal diet (Fig 6.8J; p<0.05). 
 
SOD2 protein expression significantly decreased at 21d-IR compared to control kidneys regardless 
of diet (Fig 6.8K; p<0.05 and p<0.05 compared to respective controls). NAC diet significantly 
reduced SOD2 compared with normal diet at 21d-IR (Fig 6.8K; p<0.05). 
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Figure 6.8: NAC enhances oxidative damage in the chronically damaged kidney following 
AKI 
8-OHdG IHC (A.-F.) and morphometry (G.) demonstrate increased oxidative damage 21-days 
following IR injury (21d-IR) for mice on a normal diet and mice with the addition of 5 % NAC 
(NAC diet), compared to control kidneys (G.). NAC diet significantly enhanced 8-OHdG positivity 
at 21d-IR compared to mice on a normal diet (C., F., and G.). Nuclear factor like-2 (Nrf2) protein 
expression increased in mice on a normal diet at early reperfusion (IR), and an increase trend was 
observed at 21d-IR in mice on the NAC diet (H.). No changes were observed in Kelch-like ECH-
associated protein 1 (Keap1) protein expression (I.). Heme-oxygenase-1 (HO-1) protein expression 
increased at 21d-IR in mice on a normal diet and on the NAC diet compared to control kidneys (J.). 
Apart from the normal 32-34kDa band, a band for truncated HO-1 was detected (J. – representative 
Western blot). Superoxide dismutase-2 (SOD2) decreased at 21d-IR in mice on a normal diet 
compared to controls. SOD2 was further decreased in mice on the NAC diet (K.). Results expressed 
as mean ± SE (* p<0.05; ** p<0.01: *** p<0.001 compared as indicated). Scale bar represents 50 
µm. 
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6.3.4 Serine 112 phosphorylation of PPARγ-1 is associated with chronic kidney pathology 
following acute kidney injury in vivo 
Localisation of PPARγ and p-PPARγ protein was investigated using IHC in kidney sections from 
the MPM animals, comparing mice on a normal diet (Fig 6.9A-F) and the NAC diet (Fig 6.9G-L). 
PPARγ expression was low and localised to the brush border of proximal tubular epithelial cells in 
the cortex of control kidneys regardless of diet (Fig 6.9A and G). p-PPARγ expression was 
localised to nuclei of tubular epithelial cells in the cortex regardless of diet (Fig 6.9D and J). At IR, 
PPARγ expression was lost from the brush border and appeared within punctate regions of tubular 
epithelial cells and glomerular cells (Fig 6.9B and H) whilst p-PPARγ nuclear expression was 
maintained in tubular epithelial cells (Fig 6.9E and K) regardless of diet. Brush border localisation 
of PPARγ was low in atrophic tubules at 21d-IR regardless of diet (Fig 6.9C and I), but localised to 
interstitial cells in mice fed the NAC diet (Fig 6.9I). Nuclear labelling of p-PPARγ within tubular 
epithelial cells appeared greater in atrophic areas at 21d-IR regardless of diet (Fig6.9F and L). 
Western immunoblotting identified protein expression of both PPARγ-1 and PPARγ-2 isoforms. 
Only phosphorylation (ser112) of PPARγ-1 (p-PPARγ-1) was seen (Fig 6.9M). PPARγ-2 protein 
expression significantly increased at IR compared to respective control kidneys regardless of diet 
(Fig 6.9N; p<0.05 and p<0.01 compared to control normal diet and the NAC diet, respectively), 
whereas PPARγ-1 expression did not alter (Fig 6.9O). Mice on a normal diet had significantly 
lower PPARγ-1 protein expression at 21d-IR compared to mice on the NAC diet (Fig 6.9O; 
p<0.05). The p-PPARγ-1 to PPARγ-1 ratio significantly increased at 21d-IR in kidneys of mice on 
both types of diet compared to control mice (Fig 6.9P; p<0.01 and p<0.05 for mice on a normal diet 
and the NAC diet, respectively). 
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Figure 6.9: Ser112 phosphorylation of PPARγ is associated with chronic kidney pathology 
following AKI 
PPARγ and p-PPARγ protein localisation was examined by IHC, comparing mice on a normal diet 
(A.-F.) and normal diet + 5% NAC (NAC diet; G.-L.) in control kidneys, early reperfusion (IR) and 
21-days following IR-injury (21d-IR). Control kidneys regardless of the type of diet demonstrated 
cytoplasmic and brush-border localisation of PPARγ within proximal tubular cells (A. and G.) and 
nuclear localisation of p-PPARγ (D. and J.). Punctate regions within tubular cells positive for 
PPARγ were apparent at IR regardless of the type of diet (B. and H.) and no change was observed 
in p-PPARγ localisation (E. and K.). 21d-IR PPARγ expression was localised primarily to the 
interstitium (C. and I) which matched nuclear localisation of p-PPARγ (F. and L.). Western blotting 
of whole kidney extracts for PPARγ protein expression detected PPARγ-1 and PPARγ-2 isoforms. 
Only phosphorylation of PPARγ-1 was detected (p-PPARγ-1) (M.). Densitometry demonstrated 
increased PPARγ-2 expression at IR in mice regardless of diet (N.) and decreased PPARγ-1 
expression at 21d-IR in mice on a normal diet compared to mice on the NAC diet (O.). The p-
PPARγ-1:PPARγ-1 ratio was significantly increased at 21d-IR in the kidneys on mice on a normal 
diet compared to control kidneys (P.). Results are expressed as mean ± SE (* p<0.05; ** p<0.01: 
*** p<0.001 compared as indicated). Scale bar represents 50 µm. 
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6.3.5 Metabolic alterations in the kidney cortex underlie the progression of chronic kidney 
pathology following AKI that is not prevented by the antioxidant NAC 
Intravital MPM at 740 nm excitation demonstrated no observable differences in the renal cortical 
tubular network structure or mean NAD(P)H fluorescence between mice on a normal diet and on 
the NAC diet (Fig 6.10A, E and I). During 20 min of kidney ischaemia, tubular epithelial cell 
swelling was associated with a significant increase in mean NAD(P)H fluorescence, regardless of 
diet (Fig 6.10B, F and I; p<0.001 compared to respective controls), and a reduction in interstitial 
space that occurred with both diet regimens. Tubular and cellular damage was observed at the early 
stages of reperfusion (IR; 5 to 40 min follow end of ischaemia), and this was indicated by epithelial 
cell striations, cell effacement and the formation of cast material in kidneys of mice on either diet. 
NAD(P)H fluorescence returned to control levels (Fig 6.10C, G and I). The mean NAD(P)H 
fluorescence within tubular epithelial cells was significantly lower in mice on normal diet compared 
to the NAC diet (Fig 6.10I; p<0.05). Chronic kidney pathology (tubular atrophy, interstitial 
expansion) was apparent at 21d-IR. The areas of tubular atrophy contained highly fluorescent 
punctate regions, perhaps indicating enlarged lysosomes (Fig 6.10D and H). Remnant tubules 
possessed significantly higher NAD(P)H endogenous fluorescence compared to controls. This was 
enhanced in mice on the NAC diet (Fig 6.10D, H and I; p<0.001 compared to respective controls. 
P<0.05 compared to 21d-IR normal diet). 
 
Intravital MPM has restricted depth in the kidney, hindering analysis, and so kidney slice 
preparations were imaged immediately after animal euthanasia, by MPM coupled with FLIM. This 
allowed visualisation of the cortex and medulla (Fig 6.11 and 6.12), and each zone of the kidney 
was then compared. Figure 6.11A demonstrates FLIM images (pseudocoloured according to 
averaged weighted lifetime τm) across three spectral channels that detect NAD(P)H, 
NAD(P)H/FAD, and FAD, from kidneys cortex from control or 21d-IR mice, whether on an NAC 
diet or not. The data demonstrate that, in all spectral channels, there was a decrease in τm between 
control kidney cortex and 21d-IR regardless of diet, indicated by a change from green to blue within 
representative images. This observation was also seen in τm lifetime histograms by a left-shift in 
21d-IR τm peaks compared to control τm peaks, regardless of diet (Fig 6.11B-D). The average τm 
significantly decreased at 21d-IR in mice on a normal diet for NAD(P)H (Fig 6.11E; p<0.01), 
NAD(P)H/FAD (Fig 6.11F; p<0.001), and FAD (6.11G; p<0.001), and in mice on the NAC diet for 
NAD(P)H (Fig 6.11E; p<0.01 compared to control normal diet), NAD(P)H/FAD (Fig 6.11F; 
p<0.01), and FAD (6.11G; p<0.001). 21d-IR mice on a normal diet had a significantly lower FAD 
average τm compared to mice on a NAC diet at 21d-IR (Fig 6.11G; p<0.001). 
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Figure 6.10: Intravital MPM demonstrates metabolic and structural alterations in chronic 
kidney pathology following kidney IR-injury that it not attenuated by NAC 
Endogenous fluorescence of NAD(P)H, excited at 740 nm, in healthy control kidney cortex 
demonstrates the cortical tubular network with distal tubules, proximal tubules with associated 
brush border, and interstitial space that was unaltered in mice fed 5% NAC (NAC diet; A. and E.). 
During 20 min ischaemia, tubular swelling and a reduction in interstitial space was evident in both 
normal diet (B.) and the NAC diet (F.) and was associated with a significant increase in tubular cell 
NAD(P)H endogenous fluorescence (I.). Epithelial cell detachment and cast material formation 
(arrow) was evident at early reperfusion in both normal diet (C.) and the NAC diet (G.). 21-days 
following IR injury (21d-IR) there was widespread tubular atrophy with highly fluorescent punctate 
regions perhaps demonstrating enlarged lysosomes (arrowhead). Tubular structure was highly 
variable with structurally normal tubules appearing within areas of atrophy, perhaps allowing 
crosstalk between these tubules. There was a significantly greater NAD(P)H fluorescence signal in 
the normal-looking tubules for both normal diet (D. and I.) and the NAC diet (H. and I.). Results are 
expressed as mean ± SE tubular epithelial cell fluorescence a 740 nm (* p<0.05; ** p<0.01: *** 
p<0.001 compared as indicated). Scale bar represents 50 µm. 
  
152 
 
 
 
Figure 6.11: Fluorescence lifetime imaging microscopy in the cortex of the chronically 
damaged mouse kidney following NAC therapy 
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(Legend for Fig 6.11) 
Representative average weighted fluorescence lifetime (τm) images of control and 21-day following 
IR-injury (21d-IR) in the cortex of the kidney from mice on a normal diet, or a normal diet + 5% 
NAC (NAC diet) are shown in (A.). Fluorescence lifetime data were measured within three spectral 
ranges (pseudocolour range from blue-red indicated in colour bar): 350 to 450 (750 to 1500 ps) to 
capture NAD(P)H, 450 to 515 (1000 to 1750 ps) to capture NAD(P)H/FAD, and 515 to 620 nm 
(500 to 1750 ps) to capture FAD. τm lifetime histograms, representing the average pixel intensity for 
each τm lifetime, are shown (B.-D.). The corresponding average τm lifetimes from the three spectral 
channels are charted for control and 21d-IR kidney cortex from mice with or without NAC (E.-G.). 
τm lifetime histograms demonstrate a decreased pixel intensity for 21d-IR kidneys in the cortex 
regardless of diet and within all three spectral channels (B.-D.). An observable left-shift is apparent 
in 21d-IR kidney cortex compared to control kidneys, which is more pronounced in mice on a 
normal diet (B.-D.). The τm detected in all three spectral channels was significantly decreased in the 
cortex of 21d-IR kidneys compared to respective control kidneys, regardless of diet (E.-G.), and this 
was enhanced for FAD in mice on a normal diet (G.). Results are expressed as mean ± SE (* 
p<0.05; ** p<0.01: *** p<0.001 compared as indicated). Scale bar represents 30 µm. 
 
 
Figure 6.12A demonstrates FLIM images of the kidney medulla in control and 21d-IR mice on the 
NAC diet or not, across the same three spectral channels as 6.11A. The data demonstrate alterations 
to the τm within all spectral channels in the medulla at 21d-IR compared to controls, especially in 
mice on the NAC diet (Fig 6.12A). These changes are not apparent in τm histogram data (Fig 6.12B-
D), yet are confirmed when τm is averaged (Fig 6.12E-G). The average τm significantly decreased at 
21d-IR in mice on the NAC diet for NAD(P)H (Fig 6.12E; p<0.01), NAD(P)H/FAD (Fig 6.12F: 
p<0.01), and FAD (Fig 6.12; p<0.01) compared to mice on an NAC diet that did not undergo 21d-
IR. Mice on a normal diet at 21d-IR had a significantly decreased average τm within the 
NAD(P)H/FAD spectral range compared to control mice (Fig 6.12F; p<0.05).  
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Figure 6.12: Fluorescence lifetime imaging microscopy in the medulla of the chronically 
damaged mouse kidney following NAC therapy 
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(Legend for Fig 6.12) 
Representative average weighted fluorescence lifetime (τm) images of control and 21-day following 
IR-injury (21d-IR) in the medulla of the kidney from mice on a normal diet, or a normal diet + 5% 
NAC (NAC diet) are shown in (A.). Fluorescence lifetime data were measured within three spectral 
ranges (pseudocolour range from blue-red indicated in colour bar): 350 to 450 (750 to 1500 ps) to 
capture NAD(P)H, 450 to 515 (1000 to 1750 ps) to capture NAD(P)H/FAD, and 515 to 620 nm 
(500 to 1750 ps) to capture FAD. τm lifetime histograms, representing the average pixel intensity for 
each τm lifetime, are shown in (B.-D.). The corresponding average τm lifetimes from the three 
spectral channels are charted for control and 21d-IR kidney medulla from mice with or without 
NAC (E.-G.). τm lifetime histograms demonstrate high pixel intensity for control kidney medulla in 
mice on an NAC diet, and low pixel intensity for 21d-IR kidney medulla regardless of diet, within 
all three spectral channels (B.-D.). The τm detected in the NAD(P)H and FAD channels (E. and G., 
respectively) was significantly decreased in the medulla of 21d-IR kidneys compared to control 
kidneys in mice on the NAC diet. The NAD(P)H/FAD channel detected a decreased τm in the 
medulla of the 21d-IR kidney regardless of diet (F.). Results are expressed as mean ± SE (* p<0.05; 
** p<0.01 compared as indicated). Scale bar represents 30 µm. 
 
 
6.3.6 Mitochondrial dysfunction within remnant cortical tubules indicates a site of persistent 
oxidative stress 
τm changes in NAD(P)H of the chronically damaged kidney were further investigated since NADH 
is a vital metabolic substrate for complex 1 of the ETC within mitochondria. Figure 6.13 A and D 
show representative redox FLIM images of the kidney cortex and medulla, respectively, that are 
pseudocoloured according to the ratio of free (α1) to bound (α2) NAD(P)H (redox ratio). The redox 
ratio appears higher in the cortex of 21d-IR kidneys regardless of diet (red) compared to control 
kidneys regardless of diet (green) (Fig 6.13A). The relationship is also observed in the medulla (Fig 
6.13D). This observation is also seen in the α1/α2 histograms which show a right-shift at 21d-IR, 
regardless of diet, primarily within a secondary peak in both the cortex (Fig 6.13B) and medulla 
(Fig 6.13E). The average redox ratio significantly increased in the cortex at 21d-IR regardless of 
diet (Fig 6.13C; p<0.001 compared to respective controls). Mice on the NAC diet had a 
significantly increased redox ratio in the medulla, that did not occur in mice on a normal diet (Fig 
6.13F; p<0.001). This indicates an increase in free NAD(P)H or decrease in bound NAD(P)H in the 
cortex of the chronically-damaged kidneys. This change was also present in the renal medulla of 
mice on the NAC diet. 
 
To further investigate apparent mitochondrial dysfunction in the cortex of the chronically-damaged 
kidney in vivo, the mitochondrial membrane potential-dependent dye TMRM, was infused into mice 
and imaged with intravital MPM (Fig 6.14). Three representative images demonstrate uptake of 
TMRM into tubules of the cortex in healthy kidney (Fig 6.14A-C), which is impaired in tubules of 
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21d-IR kidneys (Fig 6.14D-F) demonstrating mitochondrial dysfunction. TMRM quantification per 
tubular epithelium was shown to be significantly decreased at 21d-IR compared to control (Fig 
6.14G; p<0.001). TMRM and NAD(P)H co-localisation to the basolateral region of tubular 
epithelium in control mice confirmed mitochondrial accumulation (Fig 6.14H-J), which was 
disrupted at 21d-IR (Fig 6.14K-M). 
 
Z-stack 3D reconstructions of healthy control regions of the cortex following TMRM infusion 
demonstrated NAD(P)H and TMRM fluorescence and accumulation within normal tubular 
epithelial cells (Fig 6.15A-C). Three representative areas of atrophic regions within the cortex at 
21d-IR demonstrated remnant, structurally-normal tubules that retained NAD(P)H endogenous 
fluorescence yet displayed impaired TMRM uptake and ensuing mitochondrial dysfunction (Fig 
6.15D-F). 
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Figure 6.13: Changes in the redox ratio (α1/α2) in the chronically damaged mouse kidney 
following NAC therapy 
 Representative redox images of control and 21-days following IR-injury (21d-IR) kidney cortex 
(A.) and medulla (D.) from mice on a normal diet, or on a normal diet + 5% NAC (NAC diet), 
depict changes in the free (α1) to bound (α2) NAD(P)H ratio. Fluorescence lifetime data were 
measured in the 350 to 340 nm spectral channel to capture NAD(P)H and pseudocoloured according 
to the α1/α2 range 0 to 5 (blue to red). Redox ratio histograms, representing the average pixel 
intensity for each redox ratio value, are shown in (B.) and (E.) for the cortex and medulla, 
respectively. The corresponding average redox ratios are charted for the control and 21d-IR kidneys 
for cortex (C.) and medulla (F.). The pixel intensity for the average redox ratio was noticeably 
decreased in 21d-Ir kidneys regardless of diet in both the cortex (B.) and medulla (E.). The redox 
ratio was increased in the cortex of 21d-IR kidneys compared to controls regardless of diet (C.). 
Mice on the NAC diet had increased redox ratio in the medulla of the kidney at 21d-IR compared to 
control mice (F.). The NAC diet decreased the redox ratio in the healthy control kidney (F.). Results 
are expressed as mean ± SE (* p<0.05; *** p<0.001 compared as indicated). Scale bar represents 30 
µm.  
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Figure 6.14: In vivo imaging reveals impaired mitochondrial function within tubular epithelial 
cells of the kidney cortex 21-days following ischaemia-reperfusion injury 
The mitochondrial membrane potential-dependent fluorophore tetramethylrhodamine methyl ester 
(TMRM) was infused into mice and imaged with intravital MPM at excitation 800 nm 
(pseudocoloured red). Three representative images of the healthy control kidney revealed 
accumulation of TMRM into tubular epithelial cells (A.-C.). Accumulation of TMRM into tubular 
epithelial cells of the cortex 21-days following IR-injury (21d-IR) was noticeably reduced in three 
representative images (D.-F.). TMRM fluorescence quantification per tubule demonstrated a 
significant decrease in TMRM accumulation compared to control (G.). The co-localisation of 
TMRM (H.) and NAD(P)H (excitation at 740 nm) (I.) to the basolateral region of tubular epithelial 
cells (J.) confirmed mitochondrial accumulation. Basolateral localisation of TMRM and NAD(P)H 
fluorescence was disrupted at 21d-IR with the formation of punctate vesicles, perhaps enlarged 
lysosomes, strongly detected at both excitations (K.-M.). Results are expressed as mean ± SE (*** 
p<0.001 compared to control). Scale bar represents 50 µm (A.-F.) and 15 µm (H.-M.). 
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Figure 6.15: Remnant tubules in the kidney cortex 21-days post ischaemia-reperfusion injury 
are a site of persistent mitochondrial dysfunction 
Three representative fields (z-stack 3-dimensional reconstructions) of the healthy control kidney 
(A.-C.) depict green NAD(P)H autofluorescence (excitation 740 nm) and red TMRM fluorescence 
(excitation 800 nm) accumulation within normal tubular epithelial cells. Three representative z-
stack 3D reconstructions 21-days following IR-injury (21d-IR) (D.-F.), demonstrate the appearance 
of remnant, structurally-normal tubules within areas of tubular atrophy, that have low TMRM 
accumulation yet retain NAD(P)H fluorescence (arrow heads). 
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6.4 DISCUSSION 
 
Despite numerous reported positive benefits of antioxidant therapy against AKI, targeting oxidative 
stress in chronic progressive kidney disease has yielded limited and often disappointing results in 
patient cohorts (Jun et al., 2012; Himmelfarb et al., 2014). The results of the present study further 
support the use of a known general antioxidant (NAC) to target systemic oxidative stress to reduce 
early IR-induced AKI. However, we provide new evidence that the ensuing progression to chronic 
kidney pathology can be enhanced by antioxidant therapy by eliminating redox-sensitive 
endogenous cytoprotective signalling. Furthermore, we provide a description of metabolic 
alterations in the chronically-injured kidney that are specific to mitochondrial dysfunction and have 
only previously been described in models of acute injury. 
 
In vitro experiments demonstrated a superior benefit of the antioxidant NAC to reduce oxidative 
stress-induced apoptosis of kidney PTE cells, compared to other commonly-used antioxidant 
therapies vitamin E (αTOC and Tlx) and CoQ10. NAC is consistently a successful antioxidant 
therapy in cell culture models of oxidant-induced injury (Zhong et al., 2009; Ye et al., 2010; Zhang 
et al., 2011). This may be due to the potency of the sulfhydryl-thiol group of L-cysteine directly 
scavenging ROS, in such a confined system as cell culture. The results showing a lack of benefit 
conferred by vitamin-E derivatives, αTOC and Tlx, contribute to a growing body of evidence that 
implicates vitamin-E with negative outcomes (Miller et al., 2005; Klein et al., 2011), including a 
study demonstrating its pro-apoptotic actions (Jia et al., 2010). CoQ10 also did not alter oxidative 
stress-induced apoptosis. The major contributing factor in cell culture is the low solubility of 
CoQ10, owing to a long isoprenyl side chain, which would limit its ability to enter the cell and the 
mitochondria, where the majority of beneficial actions would be exerted (Sohal et al., 2006). The 
bioavailability of CoQ10 in vivo also remains a challenge (Bhagavan and Chopra, 2006). Tubular 
cell apoptosis remains a common contributing factor to AKI and CKD pathogenesis (Gobe et al., 
2014). Therefore the ability of NAC to attenuate oxidative stress-induced pathological processes in 
vitro was investigated in vivo. 
  
A diet of 5% NAC for one week attenuated tubular epithelial cell apoptosis in the kidney cortex at 
the time of early IR-induced injury, demonstrating acute protection. These findings are consistent 
with human clinical trials investigating NAC pre-treatment against AKI, including contrast-induced 
nephropathy (Kay et al., 2003), and cardiovascular bypass surgeries (Santana-Santos et al., 2014). 
IR injury of the kidney primarily occurs at the time of reperfusion. At this time, re-presentation of 
oxygen to components of the mitochondrial ETC membrane complexes, previously damaged from a 
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failure of ATP-dependent actin polymerisation during ischaemia, subsequently causes ROS 
production (Atkinson et al., 2004; Plotnikov et al., 2007). This mechanism is supported by 
visualising NAD(P)H dynamics during IR-induced injury with intravital MPM. Increased 
NAD(P)H fluorescence demonstrates a failure of ETC complex 1 to convert NAD+, in both normal 
and NAC-treated mice. The apparent decrease in NAD(P)H fluorescence in NAC-treated mice, 
compared to normal diet, may represent efficient ETC complex 1 activity at reperfusion due to 
NAC detoxification of ROS and subsequent improvement in mitochondrial membrane damage 
(Brunet et al., 1995).  
 
Nrf2-Keap1 dynamics during an oxidative stress environment promote the upregulation of 
cytoprotective enzymes and proteins to protect against cell damage (Kensler et al., 2007). 
Interestingly, Nrf2 upregulation at the time of early reperfusion was prevented in mice on an NAC 
diet. Nrf2 nuclear translocation and binding to the ARB sequence is regulated through increased 
intracellular ROS signalling forming a highly conserved cytoprotective response (Zhang and 
Hannink, 2003; Sekhar et al., 2010). Recent studies demonstrate that Nrf2 dissociation from Keap1, 
a substrate adapter for the ubiquitin E3 ligase complex, occurs by ROS modification of the Keap1 
cysteine 288 residue (Kim et al., 2014). NAC, as a general cellular antioxidant, has the ability to 
eliminate intracellular ROS, and thereby eliminate ROS signalling that is dependent on cysteine 
modification, such as cysteine 288 of Keap1. This would result in maintained binding of Keap1 to 
Nrf2, subsequent degradation, and failure to upregulate cytoprotective responses through ARB 
binding. Furthermore, the cysteine residue of NAC forms a competitive antagonist type mechanism 
for ROS-dependent Nrf2 activation. The anti-apoptotic effect of NAC early after reperfusion can be 
attributed to immediate ROS detoxification and protection of the intrinsic mitochondrial apoptotic 
pathway (Higuchi et al., 1998). This is supported by the in vitro experiments in the present study, 
which represent a more acute model of ROS-induced kidney cell apoptosis. However, an underlying 
disruption to kidney cell redox control is apparent during the ensuing progression of disease 
following AKI. The ability of NAC to prevent a highly conserved cytoprotective response to IR, in 
kidney cells with disrupted redox control, becomes apparent during the progression of disease 
following AKI. 
 
Maladaptive repair is a defining characteristic of the progression to CKD from AKI (Bonventre and 
Yang, 2011; Yang et al., 2011). The underlying mechanisms driving maladaptive repair following 
AKI are poorly understood, yet are associated with cell cycle arrest (Yang et al., 2010), interstitial 
proliferation and fibrosis (Chen et al., 2011), and enhanced cell death (Gobe et al., 2014). Our 
findings demonstrate that a perturbed redox environment due to prolonged NAC therapy can 
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promote fibrosis and the secretion of pro-fibrotic TGF-β1, and these changes may enhance other 
characteristics of maladaptive repair, such as increased apoptosis of tubular epithelial cells in the 
cortex. In the current study, increased PCNA labelling was found in cells within the interstitial areas 
at 21d-IR, consistent with increased myofibroblast or macrophage/monocyte proliferation (Forbes 
et al., 2000). Myofibroblasts and macrophages are known to secrete fibrogenic factors like TGF-β1 
(Okada et al., 2005). This process, combined with increased apoptosis of tubular epithelial cells, 
demonstrates disrupted repair mechanisms that result in chronic kidney pathology. It is important to 
note that some PCNA-positive cells were found within the tubular epithelium, indicating an attempt 
to repair via epithelial cell repopulation to preserve a functional tubule. This repair mechanism has 
gained recent attention and indicates the importance of remnant tubules within areas of focal 
fibrotic change (Kusaba et al., 2014), as observed in the present study. 
 
Kidney function was not measured in the current investigation and this may be seen as a criticism. 
However, we would expect the greatest degree of functional impairment to occur at 1-4 days post 
reperfusion (Vesey et al., 2004; Johnson et al., 2006), and to then return to normal levels at 3 weeks 
post-IR. This is also representative of functional decline and re-establishment in human AKI. 
Reduced kidney function at 21d-IR in the present study was not expected since substantial areas of 
functional kidney parenchyma were observed histologically thereby allowing compensation to 
occur. In addition, the aim of this study was to understand the underlying alterations to kidney cell 
metabolism and redox control, using the novel methods of MPM and FLIM.  
 
Our description of the ability of NAC to enhance fibrosis is novel, and is in contrast to previous 
studies reporting the antifibrotic actions of NAC within isolated pro-fibrotic hepatic stellate cells 
(Meurer et al., 2005), and fibroblasts (Kopp et al., 2006). However, these studies were carried out 
in vitro and highlight the superior antioxidant mechanisms of NAC in the cell culture environment, 
as was noted here earlier. Borkham-Kamphorst et al. (2005) demonstrated that phosphorylation of 
PDGF, ERK or protein kinase B could not be inhibited despite high NAC administration to hepatic 
stellate cells in vitro. Therefore PDGF-dependent activation of ERK in renal myofibroblasts, and 
their subsequent proliferation and collagen synthesis, may play an important role in vivo in response 
to NAC following AKI-induced progressive fibrosis. In support of NAC-induced TGF-β1 
expression in vivo, an hepatic bile-duct ligation mouse model of liver fibrosis analysed TGF-β1 
expression in livers of mice given NAC orally. Sham surgery mice with NAC had increased TGF-
β1 expression, compared to sham mice on a normal diet, however, the increase was, unfortunately, 
not analysed for significance (Galicia-Moreno et al., 2012). Recent evidence suggests that TGF-β1 
can suppress Nrf2 activation (Ryoo et al., 2014). This is interesting given that, in our study, TGF-β1 
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levels were high in NAC-treated control kidneys and may suggest that NAC-induced TGF-β1 
expression inhibits Nrf2 activation at a time of early reperfusion, rather than NAC saturation of 
ROS and the prevention of Keap1 cysteine 288 modification, as previously suggested. Nevertheless, 
the work by Ryoo et al (2014) supports our findings that NAC dampens the Nrf2-dependent 
cytoprotective response following kidney IR injury. The mechanism by which NAC induces TGF-
β1 in the kidney requires further investigation, yet is likely to involve alterations to the redox 
environment, that include a pro-oxidant role. There have been studies that suggest harmful effects 
of NAC in various clinical settings (Peake et al., 1996; Childs et al., 2001; Spapen et al., 2005; 
Laisalmi-Kokki et al., 2009), including a randomised placebo-controlled study showing a trend for 
increased mortality in multisystem organ failure (Molnar et al., 1999). This highlights the 
importance of basic research into the mechanisms of NAC within the kidney, especially in 
progressive kidney disease. 
 
Oxidative stress incorporates alterations in normal cell redox networks, which are vital for 
physiological cell function. Long-term alterations following IR-induced injury lead to increased 
HO-1 expression. HO-1 is the inducible HO isoform responsible for the degradation of heme in 
tissues, and the induction of HO-1 is recognized as a protective response against virtually any 
insult, including AKI (Chen et al., 2005; Bolisetty et al., 2010; Stec et al., 2012). We report 
unchanging HO-1 expression at immediate (30-40 min) reperfusion. Zager et al. (2012) 
demonstrated that peak HO-1 expression in the kidney occured at 4 h following reperfusion, thus 
observable increases in HO-1 at 30-40 min may not occur. Despite genetic knock in/out mouse 
models confirming a protective relationship, physiological HO-1 induction in response to IR injury 
does not prevent overall damage (Mayer et al., 2003; Bolisetty et al., 2010; Kezic et al., 2013). 
Thus, many researchers use HO-1 expression as a marker of oxidative stress, rather than an 
indicator of a full cytoprotective response. We demonstrate an increase in HO-1 expression at 21d-
IR that is associated with maladaptive repair and fibrosis. Within the tissue milieu, HO-1 induction 
is likely responding to an oxidative stress environment indicated by enhanced 8-OHdG detection, 
and so is likely to be an attempt to promote antioxidant and cytoprotective benefit. The detection of 
an HO-1 isoform of lower kDa size to the normal HO-1 indicates protease-mediated truncation of 
HO-1 at the C-terminal domain (Yoshida et al., 1991). The functional relevance of this truncation 
has been explored by Lin and colleagues and shown to aid nuclear-cytoplasmic HO-1 shuttling and 
altered binding of transcription factors involved in oxidative stress, thereby affording protection 
against H2O2 (Lin et al., 2007a). We noted an observable decrease in HO-1Truncated at 21d-IR 
compared to healthy controls, regardless of diet, suggesting that truncated HO-1 may be more 
functionally-relevant in a chronic oxidative stress environment in the kidney. Alternatively, the 
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truncation of HO-1 by oxidative stress may prevent its translocation to the nucleus. This 
functionality appears relevant in the murine kidney, however only the un-truncated isoform was 
detected in human PTE cells with and without oxidative challenge (our data, not shown). 
 
We have previously demonstrated (Chapter 4) that oxidative stress induces PPARγ alterations and 
mitochondrial destabilisation within isolated PTE cells (Small et al., 2014). The results presented in 
the current Chapter support the association between increased PPARγ ser112 phosphorylation and a 
failure to induce cytoprotective responses during an oxidative stress environment in the kidney. 
However, the cell types involved, and responsive PPARγ isoforms, are more diverse following 
kidney IR-induced injury. The heavier PPARγ-2 isoform was detected from whole kidney protein 
extracts and was found to be especially responsive during early IR compared to PPARγ-1. This 
indicates that the punctate regions within PTE cells seen via IHC are more likely to be attributable 
to PPARγ-2. This is in contrast to our in vitro studies detecting only PPARγ-1 from isolated PTE 
cells, and may indicate species differences, or PPARγ-2-mediated responses within glomerular cell 
types that were detected by IHC (Zhu et al., 2011; Miglio et al., 2012). PPARγ-1 and PPARγ-2 
regulate similar genes, yet PPARγ-2 is the dominant isoform expressed in adipose tissue of rodents 
(Chawla et al., 1994; Tontonoz et al., 1994). 
 
PPARγ is an important regulator of PGC-1α and subsequent mitochondrial biogenesis (Rasbach and 
Schnellmann, 2007; Hock and Kralli, 2009). Furthermore, at 21d-IR total PPARγ-1 and PPARγ-2 
remained relatively unaltered compared to control, yet ser112 phosphorylation of PPARγ-1 
increased and was primarily localised to nuclei of atrophic tubules within regions of fibrotic change. 
These findings are consistent with decreased cell and mitochondrial function due to PPARγ-1 
phosphorylation within PTE cells when oxidative stress is involved in the damage, and further 
contributes to a cycle of oxidative stress and tissue damage, progressing fibrotic change. These 
differential expression profiles of PPARγ-1 and PPARγ-2 may suggest different and unique 
mechanisms of the two isoforms in response to injury in the kidney, whereby PPARγ-2 plays an 
early adaptive and protective role against injury, whereas PPARγ-1 is primarily influenced by post-
translational phosphorylation long-term. Targeting PPARγ with TZD agonists has proved beneficial 
in rodent models of kidney IR-induced injury (Yang et al., 2009; Miglio et al., 2012). Interactions 
resulting from therapeutic PPARγ activation on tubular epithelial cells preventing the ensuing 
phosphorylation may prove beneficial in preserving renal function. Important to note is a relative 
lack of effect of an NAC diet on PPARγ responses following kidney injury, besides maintaining 
total PPARγ-1 expression at 21d-IR. PPARγ plays a vital role in fatty acid oxidation and 
metabolism, which suggests that the influence of NAC cannot alter these processes. 
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The metabolic coenzymes NAD(P)H and FAD are the primary electron donor and acceptor, 
respectively, in oxidative phosphorylation. The results in this Chapter present the first 
demonstration of differences in the redox and metabolic state of kidney tubular epithelial cells 
between healthy and IR-induced chronic damage. Using FLIM, the main metabolic changes were 
observed in the cortex, rather than medulla, of the chronically-damaged kidney. This is consistent 
with a high O2 tension in the cortex (Epstein et al., 1994), and an unexpected result because the 
medulla, particularly the outer stripe of the outer medulla, is thought to be the main site of injury in 
the IR-injured kidney (Bonventre and Yang, 2011). Using MPM for observations of changes in 
metabolism presented technical limitations on measuring changes in the outer stripe of the outer 
medulla, where the severity of ischaemic AKI is most pronounced. However, within the cortex, a 
decrease in τm was observed in all spectral channels that encompass NAD(P)H and FAD 
endogenous fluorescence. This result indicates that the cortex is also a critical site of metabolic 
dysfunction in IR-induced kidney injury. Decreased NAD(P)H τm has been observed previously in 
photo-damaged skin compared to solar-protected skin (Sanchez et al., 2013), and in hepatocytes 
following IR injury at 4 h (Thorling et al., 2013),  and is attributed to metabolic damage, namely 
oxidative damage due to ROS generation. NAD(P)H may be recruited by proteins related to 
oxidative repair, causing the lifetime changes we observe. Contrasting differences have been 
observed in NAD(P)H τm changes due to IR-induced necrosis and apoptosis, that are associated with 
increases in NAD(P)H τm (Skala et al., 2007; Wang et al., 2008; Sanchez et al., 2010). Despite these 
processes also involving oxidative stress, they represent a more acute response to injury that may 
result in alternative NAD(P)H protein recruitment compared to that observed in chronic injury, 
which contributes to a persistent and underlying metabolic dysfunction.  
 
Using FLIM, the protein-binding interactions of NAD(P)H were investigated further, with the ratio 
of free to bound NAD(P)H (α1/α2) found to increase. Considering that all values are greater than 1, 
an increased ratio demonstrates either an increase in free NAD(P)H or decrease in protein-bound 
NAD(P)H. NAD(P)H binding primarily occurs on the mitochondrial membrane (complex I). 
Therefore, a decreased redox ratio indicates impaired mitochondrial function, and is consistent with 
intravital MPM data, describing complex I-deficient backing up of NAD+ at 21d-IR. Similar 
NAD(P)H binding dynamics were not observed in the medulla, except under NAC conditions, 
indicating that long-term NAC therapy contributes to metabolic dysfunction, that is usually 
preserved in the medulla following IR-induced injury. Conesa et al. (2001) have previously 
demonstrated that NAC can enhance renal medullary perfusion, suggesting that increased O2 
presentation to deficient mitochondria can potentiate metabolic impairments long-term. Further 
studies are required to identify the specific protein binding associations of NAD(P)H in the cortex 
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of the chronically-damaged kidney. Decreased FAD τm likely demonstrates decreased protein-
bound FAD to the succinate dehydrogenase enzyme complex of complex II of the ETC and, in 
addition, decreased free FAD due to decreased complex II utilisation and re-presentation of FAD to 
the citric acid cycle. Both explanations underlie impaired metabolism and/or mitochondrial 
dysfunction within tubular epithelial cells of the cortex. The results, showing that NAC diet 
significantly enhanced the observed decrease in FAD at 21d-IR, further contribute to the evidence 
within this chapter, that altering the cellular redox environment in the kidney through exogenous 
means, can worsen outcome after injury, perhaps by functional metabolic impairments. 
 
The intimate relationship between mitochondria and metabolism in the kidney has been previously 
recognised. In the present study, growing evidence of mitochondrial dysfunction and subsequent 
metabolic impairment in the chronically-damaged kidney has been presented, including reduced 
SOD2 expression and an increased redox ratio. Furthermore, 8-OHdG, which was used to assess 
oxidative damage, revealed predominant cytoplasmic localisation that is consistent with 
mitochondrial DNA damage (Tan et al., 2013). Mitochondrial DNA is more susceptible than 
nuclear DNA to increased oxidative damage and mutations because of a lack of histone protection 
and limited capacity of DNA repair systems (Lum and Roebuck, 2001; Stadtman and Levine, 
2003). This indicates oxidative stress-induced mutations to mitochondrial DNA could contribute to 
mitochondrial destabilisation in IR-induced chronic kidney damage, and thus increase impaired 
tubular metabolism. Of particular importance is the presence of remnant tubules within areas of 
focal fibrotic change in the kidney cortex, that display reduced mitochondrial function indicated by 
impaired TMRM uptake. This has important implications for mitochondrial-targeted therapies that 
rely on mitochondrial membrane potential differences to accumulate within mitochondria to exert 
beneficial effects. The current lipophilic triphenylphosphonium cation, MitoQ, is reliant on this 
process and this may explain the lack of effect in clinical trials of MitoQ as a disease modifying 
therapy for Parkinson’s disease (Snow et al., 2010). More so, the apparent structural normality of 
these tubules that remain in such damaged areas is at odds with their measured dysfunction in 
metabolism. Crosstalk between the atrophic tubules and these structurally-normal tubules may 
explain subsequent disease progression and this is worthy of future investigation. Mitochondrial 
dysfunction is a common driver of ROS generation (Che et al., 2014), as well as causing a reduction 
in ATP-dependent processes. The stimulus for sustained mitochondrial dysfunction during chronic 
progression is most likely explained by chronic tubular hypoxia caused by peritubular capillary loss 
(Basile et al., 2001). Persistent ROS generation, and cell cycle arrest and secretion of fibrogenic 
factors which has been recently demonstrated (Yang et al., 2010; Canaud and Bonventre, 2014), 
may contribute to stimulating focal progressive and chronic change to decrease kidney function. An 
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alternative explanation may be that terminally-differentiated PTE can re-express apparent stem-cell 
markers during injury-induced de-differentiation and repair, to repopulate epithelial cells following 
AKI (Kusaba et al., 2014). Remnant tubules may represent these sub-populations of cells. 
 
In summary, our study presents data that suggest metabolic dysfunction of tubular epithelial cells, 
resulting from AKI, at least in part underlies the progression of CKD. The antioxidant NAC did not 
reduce oxidative damage and significantly altered the cellular redox environment to promote 
metabolic and mitochondrial dysfunction. The results of this study do not support the use on long-
term general antioxidant therapy, such as with NAC, in chronic kidney pathologies. We believe that 
NAC saturates vital ROS-dependent intracellular signalling networks, thereby preventing conserved 
cytoprotective responses. The results do, however, present mitochondrial preservation, and a 
reduction of excess mitochondrial-derived ROS, as therapeutic targets. The contribution of 
oxidative stress to AKI and future CKD is an important process within the cellular milieu of the 
kidney, which requires specific and target therapies rather than a general approach. 
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CHAPTER 7 
 
Oxidative Stress Biomarkers in  
Chronic Kidney Disease 
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Chapters 3-6 have investigated the role of oxidative stress in cell culture and animal models. 
However, oxidative stress is also being given consideration as a cause of disease progression in 
CKD patients. Chapter 7 examines biomarkers of oxidative stress in stage 3-4 CKD patients to 
understand the relationship of these factors on the progression of the disease. 
 
7.1 INTRODUCTION 
 
Systemic biomarkers of oxidative stress have been associated with the progression of CKD (Witko-
Sarsat et al., 1996; Dounousi et al., 2006; Karamouzis et al., 2008; Kuchta et al., 2011). 
Furthermore, biomarkers of oxidative stress have been shown to decrease following renal 
intervention therapies, such as kidney transplantation (Simmons et al., 2005; Vostalova et al., 
2012). However, as is demonstrated in numerous chronic disease patient clinical trials, not 
necessarily in CKD, reducing oxidative stress through dietary antioxidant compounds has yielded 
little benefit to disease progression (Bjelakovic et al., 2012; Jun et al., 2012). The complexity and 
heterogeneity of a typical CKD patient population, with associated co-morbidities and poor lifestyle 
habits, highlights the importance of identifying and characterising alterations to the systemic redox 
environment during CKD, to employ appropriate therapies to target oxidative stress in this 
population. 
 
CVD is the leading cause of morbidity and mortality in the CKD population, with patients more 
likely to die from CVD than progress to ESKD (Go et al., 2004). Oxidative stress has been 
implicated as common modulator linking CKD and CVD (Cachofeiro et al., 2008; Rubattu et al., 
2013). This association and increased risk is compounded by common co-morbidities of CKD and 
lifestyle diseases, including obesity, Type 2 diabetes and hypertension (Jha et al., 2013). 
Conventional pharmacological strategies targeting CVD and co-morbidities are only partially 
effective in reducing the progression of CKD (Brenner et al., 2001; Lewis et al., 2001). The variety 
of contributing factors to CVD risk within CKD suggests a comprehensive strategy to modify 
disease progression. This was demonstrated in a recent comprehensive trial targeting modifiable 
CVD and lifestyle risk factors in moderate (stage 3 and 4) CKD patients through exercise training 
and lifestyle intervention, which resulted in significant improvements in cardiorespiratory fitness, 
body composition and diastolic function (Howden et al., 2013). Improvements in cardiovascular 
function are attributed to systemic adaptation of physical exercise. However, the influence of 
physical exercise on metabolism and systemic redox homeostasis has been suggested to underlie the 
proven benefits on health and the burden of disease (Radak et al., 2008; Radak et al., 2013). 
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Systemic adaptations to regular physical exercise include decreased ROS production (Radak et al., 
2004) and increased activity of antioxidant enzymes (Alessio and Goldfarb, 1988; Radak et al., 
2001), which favour a reduction in oxidative stress. Mitochondrial biogenesis is a consistent 
adaptation to regular physical exercise that plays a central role in correcting redox homeostasis 
(Marton et al., 2014). Initial increases in ROS as a result of physical exercise have been 
demonstrated to promote cellular adaptations to exercise via vital ROS-dependent intracellular 
signalling promoting cytoprotection (Gounder et al., 2012; Muthusamy et al., 2012). This ability of 
the body to adapt to challenges of physical stress demonstrates a highly conserved physiological 
adaptation to promote health over time. Harnessing these adaptations in the CKD population is a 
promising mechanism to what already is a disrupted metabolic environment. 
 
Measuring a dynamic process such as oxidative stress is difficult, and primarily relies on the 
quantification of specific end-products from free radical damage. F2-isoporstanes (IsoP) are 
considered stable and one of the better available measures (Tucker et al., 2013). IsoPs are end-
products of non-enzymatic peroxidation of arachidonyl lipids and have been studied extensively in 
the relationship between oxidative stress and CKD (Roberts and Morrow, 2002; Dounousi et al., 
2006; Karamouzis et al., 2008). A change in endogenous antioxidant levels can influence the 
overall development of oxidative damage and should, therefore, be considered in assessments of 
systemic oxidative stress (Calderon-Salinas et al., 2011; Sedighi et al., 2014). Identifying site 
specific changes in ROS generation in vivo is difficult to assess, however, considering that oxidative 
stress likely influences overall disease progress, systemic markers need to be considered. 
 
The primary aim of this study was to investigate the effect of exercise training and lifestyle 
intervention on systemic biomarkers of oxidative stress in stage 3-4 CKD patients, over a 12-month 
period. The secondary aim was to determine any association between oxidative stress biomarkers 
and changes in clinical parameters. 
 
 
7.2 MATERIALS AND METHODS 
 
Many people were involved in many aspects of this study. These include Dr Erin Howden and 
Kassia Weston from the Centre for Research Excellence, Physical Activity and Health, The 
University of Queensland; and the renal research and data management team at the Nephrology 
Department, Princess Alexandra Hospital, Brisbane Australia. Dr Anne Bernard from QFAB 
provided statistical support. A/Prof Nicole Isbel is the LANDMARK III-trial leader. 
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7.2.1 Study design 
This study was a sub-study of an ongoing open-label randomised controlled trial, known as the 
LANDMARK-III trial (Longitudinal Assessment of Numerous Discrete Modifications of the 
Atherosclerotic Risk Factors in Kidney Disease). LANDMARK-III is a 3-year study comparing the 
effect of a nurse practitioner-led model of care with standard nephrologic care on cardiovascular 
risk factors. Patients were screened at the Princess Alexandra Hospital Nephrology Department. 
 
7.2.2 Participants 
The study received approval from the Princess Alexandra Human Research Ethics Committee 
(HREC 2007/190) and University of Queensland Medical Research Ethics Committee (MREC 
2008000184), and was registered at www.anzctr.org.au (Registration Number ANZCTR 
12608000337370). Patients were eligible for inclusion if they were aged 18-75 years, had moderate 
CKD (stages 3 and 4; estimated GFR [eGFR] 25-60 ml/min per 1.73 m
2
), and had one or more 
uncontrolled yet modifiable cardiovascular risk factors that were: blood pressure (BP) exceeding 
target (>130/80 mmHg, or >120/75 mmHg for those with diabetes or proteinuria > 1 g/ 24 h); 
overweight (body mass index [BMI] >25 kg/m
2
); poor diabetic control (haemoglobin A1c [HbA1c] 
>7%); or hyperlipidaemia (low-density lipoprotein [LDL-C] <2.5 or <2.0 mmol/L in those with 
diabetes or existing coronary heart disease). Exclusion criteria were: intervention for, or 
symptomatic, coronary artery disease (within 3 months); current heart failure (according to New 
York Heart Association class III and IV) or significant valvular heart disease; pregnant or planning 
to become pregnant; previous kidney transplant; and life expectancy or anticipated time to dialysis 
or transplant <6 months. Participants provided written informed consent and the study complied 
with the Declaration of Helsinki.  
 
7.2.3 Outcomes 
The primary outcomes of this sub-study were change in (∆) systemic oxidative stress over 12 
months, as measured by (IsoP, GPX and TAC). Secondary outcome was ∆ kidney function over 12 
months, as measured by eGFR. 
 
7.2.4 Patient groups 
7.2.4.1 Control group 
The control group received standard nephrology care, which included review by a nephrologist, 
recommended lifestyle modification but no specific information or education, and referral to an 
allied health professional on an ad hoc basis.  
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7.2.4.2 Exercise training and lifestyle modification group 
In addition to standard nephrologic care, cardiovascular risk factor management was provided by a 
multidisciplinary clinic, including a CKD nurse practitioner, dietician, exercise physiologist, 
diabetic educator, psychologist, and social worker to target risk factors to national guidelines 
(Johnson, 2007; NHF, 2010). The exercise-training component involved 150 min of moderate 
intensity exercise per week, with 8 weeks of training supervised by an accredited clinical exercise 
physiologist. Patients attended gym sessions two to three times per week. The sessions included a 
warm-up, 20-30 min of aerobic activity using a treadmill, stationary bike, or rowing ergometer, and 
whole body resistance training with machines and free weights. On completion of the gym-based 
training, patients began a home-based program and were provided a booklet depicting resistance 
exercise using Thera-Bands and a Swiss ball. Regular contact was maintained via telephone and 
email. Participants were questioned on their ability to maintain the prescribed exercise and, if they 
identified difficulty, they were encouraged to attend gym-based refresher visits. Patients performed 
exercise at a moderate intensity, with perceived exertion of 11-13 on a 20-point Borg scale (Borg, 
1982), and which was tailored individually. Patients also underwent 4 weeks of group behaviour 
and lifestyle modification facilitated by a dietician and psychologist. The program focused on 
sustainable diet and behaviour change to assist with weight loss. The dietician therapy complied 
with the Evidence-Based Practice Guidelines for Nutritional Management of CKD for patients with 
eGFR between 25 and 60 ml/min per 1.73 m
2
 (Ash et al., 2006). 
 
7.2.5 Outcome measures 
7.2.5.1 Oxidative stress biomarkers 
Full details of oxidative stress assays are described in Chapter 2 Sections 2.7.5-7. Briefly, IsoP was 
determined via negative chemical ionization gas chromatography-tandem mass spectroscopy from 
plasma (Briskey et al., 2014). GPX was measured via a spectrophotometric assay based on the 
oxidation of NADPH to NADP+. TAC was measured via a spectrophotometric assay based on the 
inhibition of the absorbance of the radical cation ABTS
+
. 
 
7.2.5.2 Laboratory assessment 
Venous blood and spot urine samples were collected from all patients following an overnight fast. 
Kidney function was determined as the eGFR using the Modified Diet in Renal Disease formula 
based on the isotype dilution mass spectroscopy standardized creatinine assay (MDRD175) (Levey et 
al., 1999). Blood urea, haemoglobin (Hb), HbA1c, homeostasis model assessment (HOMA), high 
density lipoprotein (HDL), low density lipoprotein (LDL), cholesterol and triglycerides were 
measured using standard automated laboratory techniques by Queensland Health Pathology. 
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Demographic data relating to co-morbidities and medication use was collected from patient 
histories. 
 
7.2.6 Statistical analysis 
Data were checked for normality using the Shapiro-Wilk test. Data that were not normally 
distributed were log transformed (as an expression of the natural logarithm Loge.). Data that 
remained non-normally distributed after log transformation underwent non-parametric statistical 
tests to prevent assumptions of normality. Results are expressed as mean ± SD for normally 
distributed data, median (interquartile range) for non-normally distributed data, or total number (n) 
percentage (%) for categorical data. Baseline characteristics and change scores over 12-months (∆ 
12-mo) were compared between groups using independent t-tests for normally distributed data, and 
Mann-Whitney U tests for non-normally distributed data. The full set of patient samples was 
separated into different batches to be assayed (for IsoP, GPX and TAC) on different days. Therefore 
a possible batch effect was tested using a one-way analysis of variance (ANOVA) comparing the 
differences between means of different batches. To investigate the effect of exercise training and 
lifestyle intervention on IsoP, GPX and TAC in stage 3-4 CKD patients, a linear mixed model was 
performed to test the main effect of patient group (standard care or lifestyle intervention), time 
(baseline or 12-mo), and the interaction between them. Patient group, time point, and their 
interaction were defined as fixed-effects for the model, whilst patient identification number was 
defined as a random effect to account for repeated measures. Batch number was defined as a 
random effect to adjust for a possible batch effect. Pearson’s product-moment correlations and 
spearman’s correlations were performed between changes in oxidative stress measures and other 
secondary measures. Data were analysed using standard commercially available statistical software 
(SPSS version 22, Chicago, IL). Statistical significance was defined as p≤0.05. 
 
7.3 RESULTS 
 
7.3.1 Patient characteristics 
The effects of the exercise and lifestyle intervention on health and fitness outcomes have been 
previously reported (Howden et al., 2013), with an 11 % improvement in maximal oxygen 
consumption (VO2 max), 20 % improvement in diastolic tissue velocity (e’), and decreased body 
mass index (BMI). The baseline characteristics of this patient group are summarised in Table 7.1 
and there were no significant group differences at baseline. Men comprised the majority of each 
group and mean BMI of each patient group was within the obese range. The prevalence of co-
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morbidities was high with 96 % and 69 % of patients having hypertension or hyperlipidaemia, 
respectively. All patients were taking at least one medication. 
 
7.3.2 Changes in oxidative stress biomarkers 
Table 7.2 presents the results of Shapiro-Wilk tests for normal distribution on oxidative stress 
biomarkers (IsoP, GPX and TAC) and eGFR after log transformation. All data were log 
transformed prior to Shapiro-Wilk tests for normality. All data were normally distributed except for 
baseline eGFR (p=0.033), ∆12-mo eGFR (p<0.0001), and GPX ∆12-mo (p=0.014). 
 
There was no statistically significant difference (p>0.05; independent samples t-test) between 
patient groups at baseline for each of the oxidative stress biomarkers (IsoP, GPX and TAC). There 
was a noticeable large range of variation in oxidative stress biomarkers which is indicated in the 
reported SD values. A significant batch effect was identified using a one-way analysis of variance 
(ANOVA) on batch data for IsoP (p<0.01) and GPX (p<0.0005), and a Kuskal-Wallis Test for TAC 
(p<0.0005). Batch means were also found to follow the trend of the quality control sample measures 
at the time of each batch. Therefore, the batches were taken into account as random effects in the 
linear mixed model to adjust the results for this effect 
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Table 7.1: Baseline Demographics 
 
Standard Care 
(n=64) 
Lifestyle Intervention 
(n=72) 
Women 30 (40) 29 (41) 
Age (yr) 58.8±11.9 61.1±9.3 
Height (cm) 168.6±9.9 168.6±8.9 
Weight (kg) 94±20 95.8±22.7 
BMI (kg/m
2
) 33±6 33.6±7.1 
Clinical Markers     
     eGFR (ml/min per 1.73 m
2
) 38.8±8.5 40.6±8.9 
     Urea (mmol/L) 11.1±3.9 10.3±3.9 
     Hb (g/L) 131.7±16.4 132.1±13.8 
     HbA1c (%) 6.3±1.5 6.6±1.4 
     HOMA 9.9±21.9 9.3±14.1 
     HDL (mmol/L) 1.2±0.6 1.1±0.3 
     LDL (mmol/L) 2.6±0.8 2.3±0.9 
     Cholesterol (mmol/L) 4.4±0.9 4.5±1.2 
     Triglycerides (mmol/L) 1.6±0.9 2.2±2 
Risk Factors     
     Diabetes 32 (43) 28 (40) 
     Hyperlipidaemia 47 (63) 47 (67) 
     Myocardial Infarction 11 (15) 14 (20) 
     Heart Failure 3 (4) 2 (3) 
     Peripheral vascular disease 17 (23) 8 (11) 
     Hypertension 70 (95) 61 (87) 
     Stent 9 (12) 8 (11) 
     Coronary artery bypass graft 7 (9) 5 (7) 
Medications     
     ACEi 34 (45) 35 (50) 
     β-Blocker 23 (31) 31 (44) 
     Thiazide 13 (17) 16 (23) 
     Statin 47 (63) 42 (60) 
     Insulin 15 (20) 16 (23) 
     Allopurinol 9 (12) 13 (19) 
Values are mean ± SD, or number (%) for categorical variables. Abbreviations: BMI, body mass 
index; eGFR, estimated glomerular filtration rate; HbA1c, Haemoglobin A1c; HOMA, homeostatic 
model assessment; Hb, Haemoglobin; HDL, high density lipoprotein; LDL, low density 
lipoprotein. 
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Table 7.2: Normal or non-normal distribution of baseline and change in oxidative stress 
biomarkers  
 Standard Care Group Lifestyle Intervention Group 
 Baseline ∆12-month Baseline ∆12-month 
IsoP 0.659 0.185 0.337 0.084 
GPX 0.351 0.348 0.055 0.014* 
TAC 0.958 0.487 0.395 0.686 
eGFR 0.033* 0.257 0.281 <0.0001* 
* p value from Shapiro-Wilk test of normality distribution. p < 0.05 rejects the null 
hypothesis of normal distribution 
 
 
There was no statistically significant difference in mean IsoP ∆ 12-mo (p=0.88) between patients 
undergoing standard care (35.2±117.8 pg/mL) and patients undergoing the lifestyle intervention 
(26.9±146.6 pg/mL) demonstrated in Figure 7.1A and Table 7.3. A linear mixed model found no 
interaction between patient group and time on IsoP levels (Table 7.4; p=0.893). Patients identified 
as having high IsoP at baseline (defined as > 250 pg/mL at baseline) had a mean decrease in IsoP 
following standard care (-38.1±81.6 pg/mL), and this was more pronounced in patients undergoing 
lifestyle intervention (-106.2±157.8 pg/mL). However, differences in mean ∆ 12-mo IsoP between 
groups in patients with high IsoP was not statistically significant (p=0.064). The observed power of 
this relationship was 16 %. This is demonstrated in Figures 7.1B and C, and Table 7.3. 
 
177 
 
 
Figure 7.1: Changes in plasma isoprostanes over 12-months following exercise and lifestyle 
intervention 
Values are mean ± SD of normally distributed data following log transformation – Log [IsoP 
(pg/mL)]. All CKD patient IsoP measures at baseline and over 12-months (A.) and CKD patient 
subgroups that had high (> 250 pg/mL) IsoP at baseline demonstrating no significant differences 
(B.). Repeated measures comparison demonstrates individual subject changes in IsoP over 12-
months in patients receiving standard care or undergoing a lifestyle intervention (C.). 
 
 
Table 7.3: Baseline and changes in plasma isoprostanes measures 
  Standard Care Group Lifestyle Intervention Group 
p value* 
  Baseline ∆ 12-month Baseline ∆ 12-month 
IsoP (pg/mL) 192.0±80.3 35.2±117.8 187.0±115.4 26.9±146.6 0.88 
High IsoP 
(pg/mL) 
319.8±53.1 -38.1±81.6 373.3±132.1 -106.2±157.8 0.064 
Values are mean ± SD for plasma isoprostanes (IsoP) measurements (pg/mL). Patients 
identified with >250 pg/mL IsoP at baseline have been allocated a subgroup (High Iso). *p 
value indicates parametric unpaired t-test performed on ∆ 12-month log transformed IsoP data. 
 
 
178 
 
Table 7.4: Linear mixed model testing the effect of time and patient group of plasma 
isoprostanes 
 F df1 df2 p value 
Corrected Model 0.696 3 226 0.555 
Time-Point 
(Baseline and 12-month) 
1.476 1 226 0.226 
Patient Group 
(Standard care and lifestyle 
intervention) 
0.525 1 226 0.469 
Interaction 
(between time-point and patient 
group) 
0.018 1 226 0.893 
Linear mixed model incorporated the time-point, patient group, and the interaction between 
time-point and patient group as the main effects on plasma IsoP. Subject trial number to 
account for repeated measures, and sample batch data to account for the known batch effect 
were incorporated as random effects into the model. F, F-statistic of F distribution; df1, 
degrees of freedom of effect; df2, degrees of freedom of error; p Value, significant effect at ≤ 
0.05. Linear mixed model was performed on log transformed IsoP data 
 
There was no statistically significant difference in mean GPX ∆ 12-mo (p=0.87) between patients 
undergoing standard care (5.0±4.1 U/L) and patients undergoing the lifestyle intervention (5.3±6.0 
U/L), as demonstrated in Figure 7.2A and Table 7.5. Table 7.6 demonstrates the results of the 
linear-mixed model performed on the data. The main effect of time (12 months) was a significant 
effect on GPX activity in patients, regardless of whether they were receiving standard care or 
lifestyle intervention (95% CI, -0.3 to -0.1, t(-6.1)=-0.2, p<0.0001; Fig 7.2B). Yet there is no 
statistically significant interaction between patient group and time on GPX levels (p=0.787). 
 
 
Figure 7.2: Changes in plasma glutathione peroxidase activity over 12-months following 
exercise and lifestyle intervention 
Values are mean ± SD following log transformation – Log [GPX (U/L)] (A.). The main effect of 
time was a significant interaction on GPX activity which is identified in Table 7.5. 
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Table 7.5: Baseline and changes in plasma glutathione peroxidase activity 
 Standard Care Group Lifestyle Intervention Group 
p value* 
 Baseline ∆ 12-month Baseline ∆ 12-month 
GPX (U/L) 24.3±4 5.0±4.1 24.7±4.3 5.3±6.0 0.87 
Values are mean ± SD for plasma glutathione peroxidase (GPX) activity (U/L). *p value 
indicates non-parametric Mann-Whitney U Test performed on ∆ 12-month log transformed 
GPX data. 
 
 
Table 7.6: Linear mixed model testing effect of time and patient group on plasma glutathione 
peroxidase activity 
 F df1 df2 p value 
Corrected Model 17.8 3 220 <0.0001* 
Time-Point 
(Baseline and 12-month) 
52.9 1 220 <0.0001* 
Patient Group 
(Standard care and lifestyle intervention) 
0.173 1 220 0.678 
Interaction 
(between time-point and patient group) 
0.073 1 220 0.787 
 
   95% confidence interval  
Coefficient Std. E t Lower Upper p value 
Intercept 3.383 0.028 122.521 3.33 3.438 <0.0001* 
Time-Point -0.202 0.033 -6.069 -0.268 -0.137 <0.0001* 
Patient Group 0.005 0.032 0.167 -0.057 0.068 0.867 
Interaction 0.010 0.037 0.271 -0.063 0.083 0.787 
Linear mixed model incorporated the time-point, patient group, and the interaction between time-
point and patient group as the main effects on plasma GPX. Subject trial number to account for 
repeated measures, and sample batch data to account for the known batch effect were incorporated 
as random effects into the model. F, F-statistic of F distribution; df1, degrees of freedom of effect; 
df2, degrees of freedom of error; t, t-statistic; p Value, significant effect at ≤ 0.05. Linear mixed 
model performed on log transformed GPX data. 
 
There was no statistically significant difference in mean TAC ∆ 12-mo (p=0.56) between patients 
undergoing standard care (-0.03±0.1 mmol/L) and patients undergoing the lifestyle intervention (-
0.05±0.2 mmol/L), as demonstrated in Figure 7.3 and Table 7.7. A linear mixed model found no 
interaction between patient group and time on TAC levels (Table 7.8; p=0.926). 
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Figure 7.3: Changes in plasma total antioxidant capacity over 12-months following exercise 
and lifestyle intervention 
Values are mean ± SD of normally distributed data following log transformation – Log [TAC 
(mmol/L)]. 
 
Table 7.7: Baseline and changes in plasma total antioxidant capacity measures 
  Standard Care Group Lifestyle Intervention Group 
p value* 
  Baseline ∆ 12-month Baseline ∆ 12-month 
TAC (mmol/L) 1.8±0.2 -0.03±0.1 1.7±0.2 -0.05±0.2 0.56 
Values are mean ± SD for plasma total antioxidant capacity (TAC) measurements (mmol/L). 
*p value indicates parametric unpaired t-test performed on ∆ 12-month log transformed TAC 
data. 
 
Table 7.8: Linear mixed model testing effect of time and patient group of plasma total 
antioxidant activity 
 F df1 df2 p value 
Corrected Model 1.155 3 221 0.328 
Time-Point 
(Baseline and 12-month) 
3.300 1 221 0.071 
Patient Group 
(Standard care and lifestyle intervention) 
0.145 1 221 0.703 
Interaction 
(between time-point and patient group) 
0.009 1 221 0.926 
Linear mixed model incorporated the time-point, patient group, and the interaction between time-
point and patient group as the main effects on plasma TAC. Subject trial number to account for 
repeated measures, and sample batch data to account for the known batch effect were incorporated 
as random effects into the model. F, F-statistic of F distribution; df1, degrees of freedom of effect; 
df2, degrees of freedom of error; p Value, significant effect at ≤ 0.05. Linear mixed model 
performed on log transformed TAC data 
 
181 
 
Figure 7.4 and Table 7.9 demonstrate that there was no statistically significant difference in mean 
eGFR ∆ 12-mo (p=0.33) between patients undergoing standard care (-0.2±7.8 mL/min/1.73m2) and 
patients undergoing the lifestyle intervention (-1.6±6.7 mL/min/1.73m
2
). 
 
 
Figure 7.4: Changes in estimated glomerular filtration rate over 12-months following exercise 
and lifestyle intervention 
Values are mean ± SD of data following log transformation – Log [eGFR (mL/min per 1.73 m2)] 
 
Table 7.9: Baseline and changes in estimated glomerular filtration rate 
  Standard Care Group Lifestyle Intervention Group 
p value* 
  Baseline ∆ 12-month Baseline ∆ 12-month 
eGFR 
(mL/min/1.73m
2
) 
40.6±8.9 -0.2±7.8 38.8±8.5 -1.6±6.7 0.33 
Values are mean ± SD for plasma estimated glomerular filtration rate (mL/min/1.73 m
2
). *p 
value indicates non-parametric Mann-Whitney U Test performed on ∆ 12-month log 
transformed eGFR data. 
 
7.3.3 Clinical correlations to changes in oxidative stress biomarkers 
Table 7.10 outlines clinical parameters that were associated with oxidative stress biomarkers 
regardless of patient allocation at baseline. There was a small positive correlation between IsoP and 
BMI (rs=0.209, p=0.020), HDL (rs=0.274, p=0.002), total cholesterol (rs=0.333, p<0.001), and total 
triglycerides (rs=0.272, p=0.002) at baseline. There was a small negative correlation between IsoP 
and Hb (rs=-0.176, 0.048). There was a small positive correlation between GPX and eGFR 
(rs=0.235, p=0.008), HbA1c (rs=0.190, p=0.035), and HDL (rs=0.193, p=0.033) at baseline. There 
was a small negative correlation between TAC and eGFR (rs=-0.192, p=0.030) and a small positive 
correlation between TAC and Hb (rs=0.220, p=0.012) at baseline. 
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Table 7.11 outlines clinical parameters that were associated with oxidative stress biomarkers at 
baseline in standard care and lifestyle intervention patient groups. There was a moderate positive 
correlation between IsoP and total cholesterol (rs=0.434, p<0.001), IsoP and total triglycerides 
(rs=0.344, p=0.008), and a small positive correlation between GPX and HbA1c (rs=0.292, p=0.023) 
at baseline in the standard care group. In the lifestyle intervention group there was a small positive 
correlation between TAC and BMI (rs=0.253, p=0.042), TAC and weight (rs=0.261, p=0.036), and 
IsoP and HDL (rs=0.373, p=0.003) at baseline.  
 
Table 7.12 outlines changes in clinical parameters that were associated with changes in oxidative 
stress biomarkers in standard care and lifestyle intervention groups. There was a moderate positive 
correlation between change in IsoP and change in HDL (rs=0.317, p=0.044), and a moderate 
negative correlation between change in TAC and change in total triglycerides (rs=-0.305, p=0.039) 
over 12-months in the standard care group. In the lifestyle intervention group there was a small 
negative correlation between change in TAC and change in eGFR (rs=-0.291, p=0.042) over 12-
months. 
 
Table 7.13 demonstrates selected categorical patient characteristics, co-morbidities and medications 
that were associated to changes in oxidative stress biomarkers in standard care and lifestyle 
intervention groups. Patients with hypertension receiving standard care had a statistically significant 
greater increase in GPX over 12-months, compared to patients without hypertension receiving 
standard care (5.3±3.8 U/L and 0.8±5.4 U/L respectively; p=0.011). Females had a statistically 
significant greater increase in GPX over 12-months compared to males (6.9±5.9 U/L and 4.3±6.0 
U/L respectively; p=0.029) in the lifestyle intervention. Patients in the lifestyle intervention who did 
not have hypertension had a statistically significant greater increase in GPX over 12-months, 
compared to patients who had hypertension (11.4±5.3 U/L and 4.9±5.9 U/L, respectively; p=0.032). 
Patients taking a thiazide diuretic had a statistically significant greater increase in GPX over 12-
months compared to patients who were not on such medication within the standard care group 
(7.1±3.9 U/L and 4.1±3.9 U/L, respectively; p=0.025) and in the lifestyle intervention group 
(8.1±5.4 U/L and 4.4±6.06 U/L, respectively; p=0.039). Patients on insulin therapy had a more 
pronounced decrease in TAC over 12-months compared to patients not on insulin therapy (-0.2±0.2 
mmol/L and -0.01±0.2 mmol/L, respectively; p=0.018) within the intervention group. There was no 
significant influence of peripheral vascular disease, or allopurinol or ACEi medication use, on 
changes in biomarkers of oxidative stress over 12-months in patients receiving standard care or 
undergoing lifestyle modification. 
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Table 7.10: Correlation analysis between clinical parameters and oxidative stress 
biomarkers at baseline in all patients 
 
 Baseline 
 IsoP (pg/mL)  GPX (U/L)  TAC (mmol/L) 
Baseline  rs p  rs p  rs p 
Kidney Function          
eGFR (ml/min/1.73m
2
)  -0.007 0.942  0.235** 0.008  -0.192* 0.030 
Urea (mmol/L)  0.046 0.611  0.065 0.467  0.060 0.503 
Body Parameters          
BMI (kg/m
2
)  0.209* 0.020  -0.147 0.106  0.064 0.479 
Weight (kg)  0.095 0.295  -0.135 0.136  0.101 0.260 
Glycaemic Control          
HbA1c (%)  0.034 0.707  0.190* 0.035  -0.049 0.589 
HOMA (mmol/L)  0.136 0.134  0.033 0.719  0.109 0.226 
Blood Profile          
Hb (g/L)  -0.176* 0.048  -0.043 0.636  0.220* 0.012 
HDL (mmol/L)  0.274** 0.002  0.193* 0.033  0.067 0.456 
LDL (mmol/L)  0.129 0.168  0.094 0.318  0.054 0.564 
Cholesterol (mmol/L)  0.333** <0.001  0.092 0.311  -0.026 0.775 
Triglycerides(mmol/L)  0.272** 0.002  -0.148 0.101  0.053 0.556 
Spearman’s correlation was performed on continuous clinical parameters and oxidative 
stress biomarkers to obtain a coefficient (rs) and p value of the relationship. * p<0.05; 
**p<0.01. Shaded boxes indicate Pearson’s correlation that was performed to confirm 
significant relationship on normally distributed data. All analysis was performed on log 
transformation data. Abbreviations: IsoP, isoprostanes; GPX, glutathione peroxidase; 
TAC, total antioxidant capacity eGFR, estimated glomerular filtration rate; BMI, body 
mass index; HbA1c, Haemoglobin A1c; HOMA, homeostatic model assessment; Hb, 
Haemoglobin; HDL, high density lipoprotein; LDL, low density lipoprotein. 
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Table 7.11: Correlation analysis between clinical parameters and oxidative stress biomarkers at baseline in patients randomised to 
standard care or lifestyle intervention. 
 
 Standard Care (Baseline)  Lifestyle Intervention (Baseline) 
 IsoP (pg/mL)  GPX (U/L)  TAC (mmol/L)  IsoP (pg/mL)  GPX (U/L)  TAC (mmol/L) 
Baseline  rs p  rs p  rs p  rs p  rs p  rs p 
Kidney Function                   
eGFR (ml/min/1.73m
2
)  0.002 0.985  0.242 0.061  -0.178 0.166  -0.027 0.832  0.242 0.052  -0.202 0.104 
Urea (mmol/L)  0.100 0.444  0.112 0.391  0.119 0.357  0.040 0.751  0.024 0.847  -0.014 0.913 
Body Parameters                   
BMI (kg/m
2
)  0.195 0.139  -0.136 0.303  -0.141 0.284  0.241 0.055  -0.149 0.241  0.253 0.042* 
Weight (kg)  0.123 0.353  -0.149 0.261  -0.064 0.627  0.066 0.606  -0.125 0.325  0.261 0.036* 
Glycaemic Control                   
HbA1c (%)  0.056 0.671  0.292 0.023*  -0.050 0.702  0.006 0.964  0.091 0.478  -0.054 0.669 
HOMA (mmol/L)  0.114 0.390  0.060 0.651  0.012 0.926  0.156 0.220  0.024 0.853  0.203 0.105 
Blood Profile                   
Hb (g/L)  -0.180 0.166  -0.195 0.133  0.211 0.100  -0.180 0.150  0.095 0.478  0.242 0.051 
HDL (mmol/L)  0.179 0.184  0.239 0.070  0.006 0.926  0.373 0.003**  0.139 0.274  0.107 0.395 
LDL (mmol/L)  0.214 0.132  0.160 0.263  -0.099 0.490  0.068 0.590  0.067 0.596  0.183 0.144 
Cholesterol (mmol/L)  0.434 0.001**  0.014 0.915  -0.155 0.238  0.236 0.058  0.160 0.202  0.101 0.421 
Triglycerides(mmol/L)  0.344 0.008**  -0.156 0.239  -0.119 0.364  0.207 0.097  -0.152 0.227  0.236 0.056 
Spearman’s correlation was performed on continuous clinical parameters and oxidative stress biomarkers to obtain a coefficient (rs) and p 
value of the relationship. * p<0.05; **p<0.01. Shaded boxes indicate Pearson’s correlation that was performed to confirm significant 
relationship on normally distributed data. All analysis was performed on log transformation data. Abbreviations: IsoP, isoprostanes; GPX, 
glutathione peroxidase; TAC, total antioxidant capacity eGFR, estimated glomerular filtration rate; BMI, body mass index; HbA1c, 
Haemoglobin A1c; HOMA, homeostatic model assessment; Hb, Haemoglobin; HDL, high density lipoprotein; LDL, low density lipoprotein. 
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Table 7.12: Correlation analysis between clinical parameters and oxidative stress biomarkers over 12-months in patients undergoing 
standard care or lifestyle intervention. 
 
 Standard Care (∆ 12-Months)  Lifestyle Intervention (∆ 12-Months) 
 IsoP (pg/mL)  GPX (U/L)  TAC (mmol/L)  IsoP (pg/mL)  GPX (U/L)  TAC (mmol/L) 
∆ 12-Months  rs p  rs p  rs p  rs p  rs p  rs p 
Kidney Function                   
eGFR (ml/min/1.73m
2
)  0.075 0.637  0.104 0.492  -0.001 0.994  0.257 0.088  0.081 0.586  -0.291 0.042* 
Urea (mmol/L)  0.006 0.969  -0.074 0.623  0.133 0.374  -0.015 0.923  -0.104 0.481  0.275 0.055 
Body Parameters                   
BMI (kg/m
2
)  0.110 0.489  0.076 0.613  -0.191 0.197  -0.046 0.764  -0.003 0.983  0.095 0.515 
Weight (kg)  0.107 0.498  0.083 0.582  -0.184 0.217  -0.014 0.927  0.015 0.922  0.108 0.460 
Glycaemic Control                   
HbA1c (%)  0.192 0.229  0.192 0.205  0.003 0.983  0.071 0.651  0.029 0.847  -0.135 0.366 
HOMA (mmol/L)  0.097 0.563  -0.157 0.322  0.218 0.161  -0.089 0.591  -0.052 0.727  0.114 0.440 
Blood Profile                   
Hb (g/L)  0.092 0.560  -0.116 0.444  0.170 0.253  0.083 0.586  -0.008 0.956  -0.105 0.478 
HDL (mmol/L)  0.317 0.044*  0.269 0.074  -0.016 0.915  0.087 0.569  0.121 0.412  0.010 0.948 
LDL (mmol/L)  -0.040 0.814  0.137 0.393  -0.046 0.774  0.082 0.591  0.111 0.459  -0.181 0.217 
Cholesterol (mmol/L)  0.139 0.387  0.152 0.320  -0.122 0.420  -0.139 0.361  -0.146 0.323  0.147 0.312 
Triglycerides(mmol/L)  0.293 0.063  0.002 0.991  -0.305 0.039*  0.077 0.616  -0.195 0.185  0.080 0.584 
Spearman’s correlation was performed on continuous clinical parameters and oxidative stress biomarkers to obtain a coefficient (rs) and p 
value of the relationship. * denotes p<0.05. Shaded boxes indicate Pearson’s correlation that was performed to confirm significant relationship 
on normally distributed data. All analysis was performed on log transformation data. Abbreviations: IsoP, isoprostanes; GPX, glutathione 
peroxidase; TAC, total antioxidant capacity eGFR, estimated glomerular filtration rate; BMI, body mass index; HbA1c, Haemoglobin A1c; 
HOMA, homeostatic model assessment; Hb, Haemoglobin; HDL, high density lipoprotein; LDL, low density lipoprotein. 
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Table 7.13: Influence of categorical patient characteristics on changes in oxidative stress biomarkers in patients undergoing standard care or lifestyle 
intervention 
 Standard Care (∆ 12-Month)  Lifestyle Intervention (∆ 12-Month) 
 IsoP (pg/mL)  GPX (U/L)  TAC (mmol/L)  IsoP (pg/mL)  GPX (U/L)  TAC (mmol/L) 
 Mean p  Mean p  Mean p  Mean p  Mean p  Mean p 
Gender                  
Male 13.7±71.7 
0.233 
 4.8±3.5 
0.881 
 -0.02±0.1 
0.506 
 22.9±151.9 
0.196^ 
 4.3±6.0 0.029
*^ 
 -0.02±0.2 
0.128 
Female 64.7±158.7  5.1±4.8  -0.05±0.2  32.8±141.9  6.9±5.9  -0.10±0.2 
Diabetes                  
Yes 26.3±123.8 0.215
^ 
 6.4±3.2 
0.044 
 -0.06±0.2 0.321
^ 
 -9.33±143.5 
0.059 
 4.5±6.5 0.511
^ 
 -0.09±0.2 
0.236 
No 41.8±115.2  3.7±4.4  -0.01±0.1  55.6±145.0  6.1±.6  -0.02±0.2 
Hypertension                  
Yes 34.0±116.3 
0.482 
 5.3±3.8 0.011
* 
 -0.04±0.1 
0.051 
 20.1±149.5 
0.141 
 4.9±5.9 0.032
*^ 
 -0.07±0.2 
0.092 
No 47.6±151.7  0.8±5.4  0.1±0.01  108.2±74.2  11.4±5.3  0.1±0.3 
PVD                  
Yes -29.0±57.6 
0.069 
 3.9±3.0 
0.471 
 -0.1±0.3 
0.264 
 20.4±113.2 
0.922 
 2.6±5.4 0.061
^ 
 -0.1±0.2 
0.378 
No 45.1±121.9  5.1±4.3  -0.02±0.1  29.0±156.5  6.1±6.1  -0.04±0.21 
Allopurinol                  
Yes 84.9±144.7 
0.055 
 6.2±4.5 0.622
^ 
 -0.03±0.2 
0.940 
 117.5±233.3 
0.091^ 
 6.7±8.1 0.872
^ 
 -0.1±0.2 
0.194 
No 21.1±107.1  4.6±4.0  -0.03±0.1  9.6±124.4  5.1±5.7  -0.03±0.2 
ACEi                  
Yes 20.4±125.8 
0.085 
 5.05±3.4 
0.774 
 -0.03±0.2 
0.972 
 5.0±182.1 
0.263^ 
 5.3±4.6 
0.487 
 -0.04±0.2 
0.715 
No 53.7±107.1  4.8±5.1  -0.03±0.1  48.8±106.8  5.4±7.3  -0.06±0.2 
Thiazide                  
Yes 16.9±105.4 
0.809 
 7.1±3.9 0.025
*^ 
 -0.04±0.1 
0.776 
 30.6±99.8 
0.583 
 8.1±5.4 0.039
*^ 
 -0.1±0.2 
0.345 
No 42.7±123.3  4.1±3.9  -0.03±0.1  25.7±163.1  4.4±6.06  -0.03±0.2 
Insulin                  
Yes 57.4±143.3 
0.655 
 7.2±3.9 
0.102 
 -0.1±0.2 
0.261 
 -17.7±150.4 
0.487 
 5.6±7.9 
0.895 
 -0.2±0.2 0.018
* No 28.9±111.1  4.2±4.0  -0.01±0.1  39. 4±148.6  5.3±5.5  -0.01±0.2 
Mean or median oxidative stress ∆ 12-month values between each patient characteristic (categorical) were compared by a unpaired t-test for normally distributed data 
or a Mann-Whitney U test for non-normally distributed data denoted by (^). * denotes p < 0.05 and is highlighted by shaded boxes. All tests were performed on log 
transformed data. Abbreviations: IsoP, isoprostanes; GPX, glutathione peroxidase; TAC, total antioxidant capacity; PVD, peripheral vascular disease; ACEi, 
angiotensin converting enzyme inhibitor. 
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7.4 DISCUSSION 
The influence of metabolism and systemic redox homeostasis may underlie the proven benefits of 
physical exercise and lifestyle modification in general health and the burden of disease. This study 
sought to understand the role of exercise and lifestyle modification on systemic biomarkers of 
oxidative stress in the progression of moderate CKD. Improvements in cardiorespiratory fitness, 
body composition, and diastolic function of exercise and lifestyle intervention have been previously 
demonstrated within a smaller cohort of these patients (Howden et al., 2013). We demonstrated that 
changes in systemic biomarkers of oxidative stress over 12-months in stage 3-4 CKD patients 
undergoing an exercise and lifestyle intervention were not different from patients receiving standard 
nephrology care. Secondly, changes in systemic biomarkers of oxidative stress were highly variable 
and associated with many clinical parameters within these moderate CKD patients. 
 
Previous studies have demonstrated changes in systemic oxidative stress biomarkers in response to 
exercise and lifestyle intervention despite disease (Alessio and Goldfarb, 1988; Radak et al., 2001). 
However, the majority of studies investigating exercise and lifestyle interventions within chronic 
disease populations commonly report improvements in functional parameters of disease, yet rarely 
report changes to oxidative stress biomarkers or mechanisms underlying the benefit (Wang et al., 
2013). In the haemodialysis CKD population, 4 months of intradialytic exercise training reduced 
plasma TBARS that was associated with a reduction in epicardial fat thickness (Wilund et al., 
2010). Chronic heart failure patients undergoing 6-month exercise therapy have been shown to 
increase skeletal muscle GPX and CAT while reducing lipid peroxidation (Linke et al., 2005), 
whereas coronary artery disease patients, who demonstrate improved endothelial dysfunction, do so 
independent of changes in oxidative stress markers (Luk et al., 2012). This variability of oxidative 
stress responses to different types of exercise, for different periods of time, and within different 
disease populations, highlights the complexities of adaptations to exercise. We would expect to 
observe significant differences in oxidative stress biomarkers, especially in the patient group 
randomised to the intervention, considering the noted impact exercise can have on the systemic 
redox environment. Failure to do so could indicate a resistance to exercise-induced redox 
adaptations within a uraemic CKD state, or alternately, the beneficial physical adaptations to 
exercise do not involve changes in oxidative stress in the CKD population. The latter is unlikely 
considering that patients, identified as having high systemic oxidative stress (> 250 pg/mL IsoP) at 
baseline, appeared to have an enhanced reduction in IsoP following 12-month of exercise and 
lifestyle intervention compared to patients receiving standard care. However, the power of this 
comparison is 16 %, indicating that there is an 84 % chance that this is a type 2 statistical error. A 
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sample size of 250 patients is necessary to achieve power of 95 % of this comparison to confirm a 
relationship. This finding suggests patients with high IsoPs may benefit from therapies aimed at 
reducing oxidative stress. A similar concept exists for vitamin D therapy, whereby vitamin D-
deficient CKD patients were more responsive than those who are not (Marckmann et al., 2012; 
Petchey et al., 2013). Future work that follows these “responders” may demonstrate associated 
improvements in physiological function and burden of disease with sustain exercise and lifestyle 
modification. 
 
GPX activity was highly responsive over the course of the trial. GPX activity over 12-months 
significantly increased in CKD patients, regardless of the intervention therapy, as well as being 
associated with various co-morbidities and medication use in this population. GPX is an 
intracellular endogenous antioxidant responsible for the scavenging of ROS, as well as a crucial 
regulator of intracellular glutathione homeostasis, which in itself is vital for maintaining the cellular 
redox environment (Raha et al., 2000; Godoy et al., 2011). Previous studies have demonstrated 
dampened GPX activity with decreased kidney function (eGFR) in mild-moderate CKD patients 
(El-Far et al., 2005; Crawford et al., 2011), which is consistent with the baseline data we report. 
Increased GPX activity over 12 months may indicate a greater ability to counter ROS and ensuing 
oxidative stress. However, this effect is not due to exercise and lifestyle modification in the current 
study. CKD is characteristically progressive, regardless of exercise or lifestyle habits. Increased 
GPX may indicate, more so, an increase in ROS and therefore increased adaptive ability to reduced 
ROS through GPX activity, which is demonstrated in unchanging levels of IsoP. Furthermore, 
eGFR levels did not change significantly within both patient groups, which may suggest that 
maintenance of kidney function is dependent on increased GPX activity. This is interesting 
considering that PTE cells are the main source of plasma GPX activity (Avissar et al., 1994). 
 
A high degree of variability in systemic oxidative stress biomarkers is evident, regarding cross-
sectional differences, as well as change, over 12 months. This high degree of variation questions the 
reliability of plasma IsoP, GPX and TAC as valid biomarkers of systemic oxidative stress. IsoPs are 
generated from arachidonic acid through cyclooxygenase-independent pathways following free 
radical damage, and are considered a reliable marker primarily because they are stable (Roberts and 
Morrow, 2002). Despite IsoP being chemically stable and reliably assayed, the biological variation 
of IsoP remains uncharacterised and appears to be large, as our results suggest. There have been 
claims that IsoP levels vary with time of day, and from day to day, within samples taken from the 
same subjects at different times (Helmersson and Basu, 2001; Kanabrocki et al., 2002). This is 
relevant considering that oxidative stress is a highly dynamic process that can change significantly 
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as a result of minor influences such as O2 supply and metabolism (Tribble and Jones, 1990; 
Stincone et al., 2014; Zorov et al., 2014). Therefore it is essential that systemic biomarkers of 
oxidative stress take biological factors of variation into account (Strobel et al., 2011). Within the 
current CKD population, this was difficult given complexity of co-morbid disorders, many of which 
have previously shown a relationship to oxidative stress, including peripheral vascular disease 
(Roller et al., 2001), hypertension (Velayutham et al., 2013), obesity (Matsuda and Shimomura, 
2013), as well as medication use, such as allopurinol (Vina et al., 2000) and ACEi/ARB (Nakamura 
et al., 2013). Measuring oxidative stress systemically is an area of research that requires further 
characterisation considering the extensive use of oxidative stress biomarkers in clinical oxidative 
stress studies. This also supports site-specific measurements of oxidative stress rather than systemic 
assessments. An alternative means to gauge responses in oxidative stress would be to assess a 
functional reserve, whereby subjects would undergo a stress test, such as exercise, and oxidative 
stress markers would be analysed from plasma pre- and post-stress. The capacity to respond to this 
oxidative challenge, through changes in the activity of antioxidant enzymes and end-products of 
oxidative damage, may provide a more relevant assessment of oxidative stress and impart some 
control over complex patient variables. However, variability has still been shown following these 
measures (Mullins et al., 2013). A kidney biopsy would provide a “gold” standard in kidney-
specific changes in oxidative stress in this CKD population, however, this is unrealistic considering 
its invasive nature. Alternatively, a skeletal muscle biopsy that is less invasive may provide more 
relevant information, especially since skeletal muscle is known to be highly responsive to exercise 
therapy and oxidative stress (Radak et al., 2013). 
 
Plasma IsoPs in both patient groups correlated significantly with changes in blood lipid profiles. 
This is primarily because IsoP is a primary measure of lipid peroxidation. Specifically, HDL is the 
major lipoprotein carrier for IsoP (Proudfoot et al., 2009) and is more susceptible to oxidation than 
LDL (Raveh et al., 2000; Nagyova et al., 2001), which is consistent with the observed positive 
correlation with IsoP in the standard care patient group over 12 months. Blood lipids may present a 
biological influence on plasma IsoP concentration, and therefore may need to be considered for the 
interpretation of oxidative stress. 
 
Kidney function, measured by eGFR, did not change significantly over time or with respect to the 
intervention. Dramatic differences between changes in eGFR of both patient groups are unlikely 
over 12 months, even in the standard care group. Stage 3-4 CKD indicates existing kidney damage. 
Tubulointerstitial fibrosis has the strongest correlation to impaired kidney function (Rodriguez-
Iturbe et al., 2005), and represents irreversible kidney damage that most interventions would fail to 
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improve. However, improvements in eGFR, within the exercise and lifestyle intervention groups, 
may be off-set by increases in serum creatinine due to increased physical activity or lean body 
mass. eGFR was calculated using the serum creatinine-based MDRD formula (Levey et al., 1999). 
Creatinine is a breakdown product of creatinine phosphate in muscle and is produced at a constant 
rate that is freely excreted by the kidneys during resting conditions. Baxmann et al. (2008) 
demonstrated that healthy individuals with moderate/intense physical activity have higher serum 
and urinary creatinine compared to sedentary individuals. Furthermore, creatinine clearance 
(measured by urine and serum creatinine) can return to resting levels 1 h after stopping physical 
exercise, however serum creatinine remains elevated (Poortmans et al., 2013). Whether these 
changes apply to patients with established CKD remains unknown, however the biological 
possibility does exist. A recent in-depth review of GFR estimation noted increased accuracy of 
eGFR formulas that incorporate serum cystatin C (Levey et al., 2014), namely, the 2012 CKD-EPI 
creatinine-cystatin C equation (Inker et al., 2012). Cystatin C is a cysteine protease inhibitor that is 
produced by all nucleated cells and enters the blood, where it is freely filtered then reabsorbed and 
catabolized by tubules without re-entering the blood (Curhan, 2005). Therefore, it is unlikely 
physical activity would interfere with eGFR determination, and would be interesting to pursue in 
the current population. 
 
There were relevant limitations to the present study. These include the open label design increasing 
the chance of observer and performance biases, the relatively short duration, and small sample size 
increasing the likelihood of type 2 statistical errors. The observed results may not be generalizable 
to other centres considering that this is a single centre study design. Proteinuria, as a marker of 
kidney damage, was not evaluated and therefore no association can be made between oxidative 
stress biomarkers and kidney damage in moderate CKD patients. Notably, there is a lack of 
consistent, robust associations of oxidative stress markers with clinical variables raising doubts 
about validity and possibility of type 1 statistical error.  
 
In summary, this study has demonstrated that exercise training and lifestyle intervention in patients 
with stage 3-4 CKD does not produce changes in systemic biomarkers of oxidative stress. GPX 
activity is responsive to the progression of CKD independent of exercise and lifestyle changes. 
CKD patients identified with high systemic levels of oxidative stress are more responsive to 
exercise and lifestyle interventions, and may present an ideal population to treat with oxidative 
stress-targeted therapies. However, the accurate assessment of oxidative stress and/or alterations to 
the body’s redox state is difficult, owing to vast biological variation and the dynamic nature of 
oxidative stress that is enhanced markedly in the CKD population. Future research into exercise and 
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lifestyle interventions longer than 12 months, and the association of oxidative stress biomarkers to 
the noted improvements in physical fitness, may prove more informative. One positive outcome of 
the study is that patients, randomised to undergo exercise and lifestyle intervention, now possess 
additional physical fitness, support, and knowledge, to improve general health and potentially 
reduce their disease burden, regardless of a known underlying mechanism. 
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CHAPTER 8 
 
Conclusions and Future Directions 
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8.1 OVERVIEW 
 
CKD is a common and serious problem to human health that is characterised by progressive failure 
of kidney function and structural damage. The pathophysiological mechanisms common to the 
progressive changes in kidney function and structure form a complex network of overlapping, 
cyclical, yet distinct processes: tubular epithelial cell death by apoptosis or autophagic cell death, 
and cell cycle arrest; intra-renal capillary loss causing parenchymal hypoxia; activation and 
proliferation of tubulointerstitial fibroblasts causing fibrosis;, and maladaptive repair. These 
combine to promote nephron loss. The resultant impact on the kidney is a sustained progression of 
CKD, eventually to ESKD. 
 
Oxidative stress has been associated with the progression of CKD, as well as each cellular and 
molecular pathological mechanism common to CKD including apoptosis, senescence and fibrosis 
(Dounousi et al., 2006; Percy et al., 2009). Despite this, antioxidant trials continue to demonstrate a 
lack of benefit in preventing CKD progression (Bjelakovic et al., 2012; Jun et al., 2012). This 
paradox highlights the need to better understand and define oxidative stress. ROS have a tightly 
regulated role as effectors of intracellular signalling pathways, by the activation of downstream 
targets for the maintenance of healthy tissue functionality. Mitochondrial function is central to cell 
metabolism, ROS production, and oxidative stress. Mitochondrial dysfunction is both a contributor 
and target of oxidative stress in the kidney. 
 
The hypotheses tested in this thesis were that: (1) oxidative stress impacts adversely on cellular 
bioenergetics in the kidney and leads to loss of functioning kidney tissue in chronic kidney 
pathologies; and (2) modulation of oxidative stress will minimise the development and progression 
of kidney cell injury. The aims were to: (1) determine how oxidative stress in PTE cells causes cell 
injury and to then determine whether exogenous antioxidants can prevent or reduce renal cell injury 
in vitro; (2) use molecular and metabolic imaging with an established model of oxidative stress-
induced kidney injury and progression, to measure oxidative stress processes in association with 
structure and function, and to then determine whether antioxidant therapy modulated kidney disease 
pathology in vivo; and (3) explore the association of systemic biomarkers of oxidative stress in 
CKD patients undergoing standard nephrology care in addition to exercise therapy and lifestyle 
changes, and to determine if oxidative stress correlates to clinical markers of renal function. 
 
The hypotheses were partially upheld. Oxidative stress does impact adversely on cellular 
bioenergetics in the kidney and leads to loss of functioning kidney tissue in chronic kidney 
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pathologies. However, a general antioxidant therapy does not minimise the development and 
progression of kidney cell injury. Rather, in the results presented here, kidney cell injury and 
progression of chronic kidney pathology could be enhanced by antioxidant therapy. 
 
8.2 DISCUSSION OF MAJOR RESULTS 
 
8.2.1 Oxidative stress involves more than an imbalance of oxidants and antioxidants 
Oxidative stress was first defined by Sies in 1985 as “a disturbance in the pro-oxidant-antioxidant 
balance in favour of the former” (Sies, 1985; Sies and Cadenas, 1985). This thesis demonstrates that 
this definition is far too simple, and that vital intracellular signalling related to overall cell 
functionality is disrupted during oxidative stress in the kidney. These alterations account for the 
primary pathological consequences that result in whole organ dysfunction and failure. 
 
In PTE cells, oxidative stress combined with senescence to induce the greatest renal cell loss and 
mitochondrial destabilisation. Senescent PTE cells further promoted oxidative stress and therefore 
mitochondrial dysfunction. PPARγ signalling is a specific intracellular pathway disrupted during, 
and contributing to, oxidative stress in PTE cells of the kidney. Oxidative stress induced-PPARγ 
Ser112 phosphorylation of PTE cells resulted in mitochondrial destabilisation, and a failure to 
restore mitochondrial health due to defective activation of PPARγ-dependent biogenesis pathways. 
This mechanism was conserved in vivo following AKI and future development of chronic kidney 
pathology. 
 
The role of ROS and endogenous antioxidants still has a pathological significance. However, the 
biological role of ROS in physiology is one that is highly conserved and of great importance, 
especially within highly metabolic tissue, such as the kidney. This is supported in this thesis, 
demonstrating enhanced chronic kidney pathology with antioxidant therapy. Correcting these 
imbalances is difficult given the dynamic and reactive nature of ROS. Therefore more focus should 
be aimed at correcting oxidative stress-induced altered cellular signalling, rather than simply ROS 
levels. 
 
8.2.2 Mitochondrial preservation and restoration is vital 
The ancestral origins of mitochondria highlight the importance of them for life. Countless studies 
have implicated mitochondrial dysfunction in a diverse range of diseases. This thesis has 
demonstrated the key role of mitochondria in the cellular redox environment, and its dysregulation, 
which often precedes pathological change in the kidney. 
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In vitro experiments demonstrated mitochondrial dysfunction during oxidative stress contributing to 
senescence and apoptosis in PTE cells. Mitochondrial homeostasis, indicated by specific mitophagy 
and biogenesis pathways, was significantly impaired following oxidative stress-induced alterations 
to PPARγ signalling, causing PTE cell death. Intravital imaging demonstrated conserved 
mitochondrial dysfunction in the tubular epithelium in vivo, and this was associated with altered 
metabolic substrate utilisation that triggered persistent mitochondrial dysfunction and oxidative 
stress in the chronically damaged kidney. SOD2 decreased and cytoplasmic localisation of 8-OHdG 
in tubular epithelial cells implicated mitochondrial damage as an event that preceded tubular cell 
death, senescence and atrophy. Remnant tubules within areas of focal fibrotic change displayed 
consistently impaired metabolism and mitochondrial health, and they were identified as a site of 
persistent ROS production. 
 
It is important to note the differences of kidney damage in humans versus animal models when 
assessing mitochondrial dynamics. A recent detailed study of human kidney clamp ischaemia 
during partial nephrectomy surgery highlighted these differences. Biopsies were taken prior to 
clamping, at the end of clamping, and after 5 min reperfusion. Findings demonstrated less severe 
structural damage of PTE cells and rapid resolution of mitochondrial swelling, suggesting that 
human kidneys can safely tolerate 30-60 min of controlled ischaemia with only minor structural 
changes and transient yet mild acute functional loss at 24 h post IR (Parekh et al., 2013). 
 
8.2.3 General cell antioxidants can enhance progressive kidney pathology 
Antioxidant therapy for CKD continues to show inconclusive results despite oxidative stress 
continually being associated to CKD progression. This thesis demonstrated that targeting oxidative 
stress using a general cell antioxidant, NAC, promoted the progression of chronic kidney pathology 
following AKI. NAC was the only antioxidant that showed benefit in vitro. NAC has also been used 
in human trials for preventing hospital acquired AKI (Kay et al., 2003; Santana-Santos et al., 2014). 
 
Treatment of PTE cells in vitro with NAC during oxidative stress inhibited oxidative stress-induced 
apoptosis, senescence and restored the proliferative capacity of PTE cells. In vivo, the protective 
effects of NAC were maintained in the early response to IR-induced AKI, however proved 
deleterious long-term. NAC promoted chronic kidney pathology by altering the cellular redox 
environment, thereby promoting metabolic and mitochondrial dysfunction, and preventing 
conserved cytoprotective redox-signalling, such as Nrf2 activation. TGF-β1 protein expression 
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increased in mice on an NAC diet, and this was thought to enhance the progression of chronic 
injury in the kidney. 
 
This general failure of non-specific antioxidant therapy supports the evidence that non-
mitochondrial ROS have important physiological signalling roles in the kidney, especially 
following AKI. Therefore mitochondrial-derived ROS in the kidney present a crucial target. This is 
discussed in the ensuing paragraphs. More importantly, the lack of translation of in vitro antioxidant 
benefit to in vivo benefit in the kidney, highlights the need for careful interpretation of in vitro 
antioxidant studies. The results also highlight the susceptibility of kidney metabolism to alterations 
in the cellular redox environment. 
 
8.2.4 Oxidative stress is an important cellular mechanism of kidney injury 
The association of oxidative stress to CKD progression relies on the measurement of systemic end-
products of oxidative damage. It is has been shown previously that end-products of oxidative 
damage vary significantly in different tissues within the same organism (Abarikwu, 2014; Guillot et 
al., 2014). This thesis demonstrated dynamic alterations to cellular processes during oxidative 
stress-induced damage to cells of the kidney, yet no association was seen of systemic biomarkers of 
oxidative stress in association with the progression of CKD in human patients. 
 
However, this does not exclude oxidative stress as a major contributor to kidney disease. Rather, it 
questions the methods and times of measurement of systemic oxidative stress in human disease 
populations. For example, IsoP is a measure of lipid peroxidation. Lipid peroxidation is an end-
product of a single pathway of oxidative damage, and does not account for many cell-specific 
changes that occur as a result of oxidative stress, such as impaired PPARγ signalling, mitochondrial 
dysfunction, or Nrf2 activation. Accurate oxidative stress assessments in the CKD population 
remain a challenge given the high degree of biological variation, and multiple assays should always 
be incorporated. 
 
8.3 FUTURE DIRECTIONS 
 
Future directions of this thesis have been outlined in the discussion of results chapters. Major future 
directions are discussed here. 
 
It is clear that targeting oxidative stress by preserving and restoring mitochondrial health may offer 
a better approach to prevent or slow the progression of CKD. The development of mitochondrial-
197 
 
specific antioxidants has already made progress, however experimental evidence has largely 
occurred in models of AKI. More research is needed to determine the long-term use of 
mitochondrial-targeted therapies to prevent progression to chronic kidney pathology after AKI. An 
in vivo model similar to that used in this thesis may provide this information. It remains unknown 
whether eliminating mitochondrial-derived ROS would have a similar affect to that of general cell 
antioxidants in enhancing chronic kidney pathology long-term, as was demonstrated in this thesis. 
In the case of chronic kidney pathologies where mitochondrial dysfunction (specifically, a 
depolarised mitochondrial membrane potential) is already established, promise lies with 
mitochondrial-targeted antioxidants whose mechanism of action is not dependent on a positive 
charge. One such agent, Szeto-Schiller (SS)-31 peptide, has been shown to exert effects mediated, 
in part, by its interaction with cardiolipan and inhibition of Cyt C mediation of peroxidation on the 
IMM (Birk et al., 2013). However, this has only been shown in IR-induced AKI and it remains to 
be determined if these beneficial effects are preserved long-term. 
 
We have demonstrated chronic metabolic alterations within remnant tubules in focal fibrotic areas 
of the cortex in the chronically damaged kidney. Future work is needed to characterise these 
populations of cells and their role in either repair after injury, or their potential pathogenic role as a 
site for progressive damage. It is possible that these populations of cells stem from the 
dedifferentiation and proliferation of damaged PTE cells, rather than remnant tubules more resistant 
to damage. Sub-populations of these fully-differentiated PTE cells that can dedifferentiate have 
been previously demonstrated by cell lineage tracing in models of AKI (Kusaba et al., 2014). 
However, considering that these populations of cells display impaired mitochondrial function and 
metabolic profiles following chronic damage, they present a promising target to restore the cellular 
bioenergetics and proliferative capacity. 
 
Intravital MPM has provided valuable insights into the kidney over the past decade. Nevertheless, 
much more can be discovered using this technology. Intravital MPM has the potential to increase 
our understanding of mitochondrial biology in vivo which at present is limited and based primarily 
on extrapolation from in vitro experiments from isolated cells and organelles. We simply do not 
know the extent of ROS generation from mitochondria in vivo. The infusion of specific ROS 
detectors, and imaging with MPM during AKI and CKD animal models, will increase this 
knowledge. Real-time cell signalling interactions of oxidative stress-responsive proteins, such as 
PPARγ and Nrf2, could be investigated using genetic mouse models of conditional proximal tubule 
expression of fluorescent tags, coupled with MPM. Advances in imaging technology are currently 
restricted by the depths within the kidney cortex, but new developments will improve this 
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technology. Human in vivo MPM is a promising advance, however at present this is also limited to 
the cortex via endoscopic utilisation. Intravascular studies with a flexible microscope objective are 
still not possible due to the large size of the microscope objective compared with renal luminal 
vasculature. 
 
8.4 SUMMARY 
 
This thesis presents oxidative stress as a common and unifying concept of pathophysiological 
change in chronic kidney pathology at a cellular level. Oxidative stress actively promotes cell death 
and cell cycle arrest in PTE cells whilst enhancing the secretion of pro-fibrotic factors to increase 
tubulointerstitial fibrosis. Targeted approaches are required to correct oxidative stress and prevent 
its diverse range of damaging pathophysiological consequences. The difficulty of finding useful 
targeted therapies for CKD is that we still do not fully understand the complexity of the cellular, 
physiological, and systemic responses of the kidney to oxidative stress. Progress is being made on 
multiple fronts. However, we continue to be humbled by this insidious disease whose morbidity and 
mortality rates remain at epidemic proportions. 
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SUMMARY AT A GLANCE
Oxidative stress is an important
mechanism of injury in chronic kidney
disease. Potential pathways of oxidative
stress mediating kidney injury are
discussed.
ABSTRACT:nep_1572 311..321
Chronic kidney disease (CKD) is a common and serious problem that
adversely affects human health, limits longevity and increases costs to
health-care systems worldwide. Its increasing incidence cannot be fully
explained by traditional risk factors. Oxidative stress is prevalent in CKD
patients and is considered to be an important pathogenic mechanism. Oxi-
dative stress develops from an imbalance between free radical production
often increased through dysfunctional mitochondria formed with increas-
ing age, type 2 diabetes mellitus, inflammation, and reduced anti-oxidant
defences. Perturbations in cellular oxidant handling influence downstream
cellular signalling and, in the kidney, promote renal cell apoptosis and
senescence, decreased regenerative ability of cells, and fibrosis. These factors
have a stochastic deleterious effect on kidney function. The majority of
studies investigating anti-oxidant treatments in CKD patients show a reduc-
tion in oxidative stress and many show improved renal function. Despite
heterogeneity in the oxidative stress levels in the CKD population, there has
been little effort to measure patient oxidative stress levels before the use of
any anti-oxidants therapies to optimize outcome. This review describes the
development of oxidative stress, how it can be measured, the involvement
of mitochondrial dysfunction and the molecular pathways that are altered,
the role of oxidative stress in CKD pathogenesis and an update on the
amelioration of CKD using anti-oxidant therapies.
One of the key functions of the kidneys is to filter waste
products that build up in the blood. Renal failure determines
that waste products are not removed completely or suffi-
ciently. This can occur quickly (acute renal failure, or acute
kidney injury) often as the result of ischaemia, toxins or
mechanical trauma. More often, however, the development
of renal failure is gradual and insidious, with resultant
chronic kidney disease (CKD). It is often many years before
noticeable loss of renal function occurs. People with CKD
have a high risk of death from stroke or heart attack, and
CKD may also progress to total and permanent renal failure
(end-stage renal disease). Dialysis or transplantation is then
necessary, with loss of quality of life, decreased individual life
expectancy and increased costs to health-care systems. This
review article focuses mainly on patients developing CKD.
Chronic kidney disease has increasing incidence and
prevalence in developed and developing nations. The
kidneys show the greatest age-associated chronic pathology
compared with brain, liver and heart,1 and one in six adults
over 25 years of age has some degree of CKD,2 with inci-
dence increasing with age. A study of almost 20 000 ethnic
Chinese men and women greater than 20 years of age dem-
onstrated that changes in renal function could predict
longevity.3 The structural characteristics of CKD include
increased tubular atrophy, interstitial fibrosis, glomeruloscle-
rosis, renal vasculopathy and reduced renal regenerative
capability. These characteristics may be caused, at least in
part, by the gradual loss of renal energy through develop-
ment of mitochondrial dysfunction and resultant, increasing,
oxidative stress.
OXIDATIVE STRESS AND NORMAL KIDNEY
METABOLISM
Oxidative stress may be defined as a disturbance in regular
cellular and molecular function caused by an imbalance
between production of reactive species and the natural anti-
oxidant ability of our cells. Reactive oxygen species (ROS)
and reactive nitrogen species often act together to create a
state of oxidative stress. ROS are arguably the most
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important of the free radicals in biological systems. A list of
the common reactive species is found in Table 1. The main
ROS are superoxide (O2-), the hydroxyl radical (OH-) and
hydrogen peroxide (H2O2). Examples of the endogenous and
exogenous sources of reactive species are listed in Table 2.
Estimated levels of ROS within mitochondria are 5- to
10-fold higher than other cytosolic and nuclear compart-
ments.4 Other contributing sites of ROS generation include
the endoplasmic reticulum, peroxisomes and lysosomes. One
to three per cent of inspired molecular oxygen is converted
to O2-, which is the most common of the ROS and a powerful
precursor of H2O2.5 Although cellular H2O2 is stable, it has the
potential to interact with a variety of substrates to cause
damage, especially in the presence of the reduced metal ion
Fe2+. This leads to H2O2 to break down and form the most
reactive and damaging of the ROS, OH-. In healthy cells, the
production of the potentially harmful H2O2 is countered by
the catalysing actions of mitochondrial or cytosolic catalase
(CAT) or thiol peroxidases into H2O and O2. Figure 1 dem-
onstrates pathways to, and natural anti-oxidant neutraliza-
tion of, common ROS.
Given that ROS are likely to be highly damaging molecules
to cells, why have the mitochondria not evolved more effi-
cient systems that limit mitochondrial oxidants? One pos-
sible answer is that ROS have an essential role in oxidant
metabolism where they are involved in highly conserved
basic physiological processes as effectors of downstream
pathways. Thus, to some, oxidative stress theories of disease
pathogenesis must be intrinsically flawed.6 Nonetheless, ROS
are damaging molecules. Even when they are produced
during normal respiration, they could cause cumulative
damage that would eventually lead to loss of cell and tissue
function and, ultimately, disease. Their production is known
to increase, over natural anti-oxidant levels, during progres-
sive disease and during ageing.4
The kidney is highly energetic and therefore relies heavily
on aerobic metabolism for the production of ATP by oxida-
tive phosphorylation. The reduction of molecular O2 along
the electron transport chain (ETC) within mitochondria is
vital for renal cellular function, yet potentially devastating
long-term. The ETC consists of five multi-enzyme complexes
responsible for maintaining mitochondrial membrane
potential and ATP generation. Each of these complexes pre-
sents a site of ROS generation; however, complexes I and III
have been identified as primary sites of O2- generation.7
Complex I, also known as nicotinamide adenine dinucle-
otide (NADH) dehydrogenase, or NADH-CoenzymeQ
(NADH-CoQ) reductase, facilitates the transfer of electrons
between NADH and CoQ10 (sometimes known as
ubiquinone). Defects in oxidative phosphorylation may be
due to the use of substrates in the respiratory chain, such as
the reduced NADH and NADH oxidase, and not due to alter-
ations in the proteins of the respiratory complexes. Thus, it
is likely that altered respiratory complexes and substrates
lead to an inefficiency of electron transport, and subsequent
increased ROS, decreased ATP and a loss of the mitochon-
drial membrane potential. Oxidatively damaged proteins of
the mitochondrial complexes increase with age in mice.8 In
CKD patients (stages 2–3) and haemodialysis patients,
impaired mitochondrial respiration was recorded.9 In this
latter report, Granata and colleagues used a combined strat-
egy based on high throughput genome-based microarray
and classical molecular methodologies, to investigate the
mechanisms underlying alterations in cell metabolism in
CKD patients. In particular, oxidative phosphorylation
system components were analysed. The results demon-
strated clear deregulation of the mitochondrial respiratory
machinery in CKD patients, closely associated with
enhanced oxidative stress. These results may help explain
other reports on CKD patients that indicate a subnormal
energy metabolism in this population.
NATURAL DEFENCES: ENDOGENOUS
ANTI-OXIDANTS
The production of ROS is usually in balance with the avail-
ability and cellular localization of anti-oxidant enzymes and
thiols, such as superoxide dismutase (SOD), CAT, glutathione
peroxidase (Gpx) and glutathione (GSH) (Fig. 2). GSH syn-
thesis is dependent on ATP but the maintenance of its reduc-
ing power is dependent on NADPH and the pentose
phosphate pathway.10 In vivo studies have found accumu-
lated oxidative damage occurs from decreased levels of these
endogenous anti-oxidants rather than increased ROS pro-
Table 1 Common physiological reactive species
Free radicals† Non-radical‡
Reactive oxygen
species
Superoxide (O2-) Hydrogen peroxide (H2O2)
Hydroxyl (OH-) Organic peroxides (R-OOH)
e.g. lipid peroxides
Peroxyl (R-O-) Hypochlorous acid (HOCl)
Reactive nitrogen
species
Nitric oxide (NO) Peroxynitrite (ONOO-)
Nitrogen dioxide (NO2)
†A free radical is deﬁned as any molecule that has an unpaired electron in its
outer shell. ‡A non-radical does not contain unpaired electrons but is either an
oxidizing agent or is easily converted to a free radical.
Table 2 Endogenous and exogenous sources of reactive species
Endogenous factors Exogenous factors
Mitochondrial oxidative phosphorylation Environmental pollutants and
toxins
Xanthine oxidase, NADPH oxidase Cigarette smoke
Inﬂammatory cells Hypoxia
Endosome/lysosome degradation Hyperoxia
Angiotensin II Radiation (sunlight, UV radiation)
Fibroblasts Infectious microbes
Endoplasmic reticulum High calorie diet
Peroxisomes Glucotoxicity
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duction.11 However, adequate levels of both are likely to be
vital for normal cell function. Mitochondria possess their
own pool of anti-oxidants such as mitochondrial manganese-
SOD (Mn-SOD) to counteract their generation of ROS.
Mn-SOD or copper/zinc-SOD (Cu/Zn-SOD) converts O2- to
H2O2, which is then decomposed to H2O and O2 by CAT and
Gpx. Cu/Zn-SOD has been implicated in stabilizing O2-
within other cellular compartments, especially peroxisomes,
and must be considered in maintenance of the redox state of
the whole cell. Limited anti-oxidant actions of Cu/Zn-SOD
may also occur within the inter-membrane space of the
mitochondria.
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Fig. 1 Cellular sites of free radical generation
and interactions. Mitochondria produce high
levels of the superoxide anion (O2-•) as a
by-product of oxidative phosphorylation. This is
converted to the stable hydrogen peroxide
(H2O2) by manganese superoxide dismutase
(MnSOD). Protein assemblage by the endoplas-
mic reticulum and fatty acid breakdown by per-
oxisomes also account for O2-• generation,
whereby conversion to H2O2 occurs due to
copper/zinc superoxide dismutase (Cu/ZnSOD).
Catalase (CAT) and glutathione peroxidase (Gpx)
are able to neutralize H2O2 into water (H2O) and
oxygen (O2). However, in the presence of high
amounts of H2O2, heavy metals (Fe+3 or Cu+2) can
generate the highly reactive hydroxyl anion
(OH•). Nitric oxide (NO•) and O2-• have the ability
to form the highly reactive nitrogen species,
peroxynitrite (ONOO-), which in the presence of
carbon dioxide (CO2) forms nitrogen dioxide
(NO2) and the reactive carbonyl species, the car-
boxyl anion (CO3-•).
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Fig. 2 Cellular sites of reducing oxidative stress
by oxidant modifying compounds. Inﬂamma-
tion, lipid peroxidation and reactive oxygen
species (ROS) from mitochondrial, cytoplasmic
and extracellular sources contribute to oxida-
tive stress. Vitamin E incorporates into the
phospholipid bilayer of the cell membrane
halting lipid peroxidation chain reactions. w-3
fatty acids displace arachidonic acid in the
cell membrane and thus reduce arachidonic-
derived ROS, but also signiﬁcantly reduce
inﬂammation and subsequent ﬁbrosis. The cys-
teine residue of N-acetyl-cysteine (NAC) is a pre-
cursor for glutathione (GSH) synthesis, and the
thiol group is able to scavenge ROS directly.
Allopurinol inhibits xanthine oxidase derived
ROS and the damaging effects of uraemia.
Coenzyme Q10 (CoQ10) enhances the efﬁciency
of electron transport in the mitochondria,
thereby reducing mitochondrial derived ROS,
and is also able to directly scavenge ROS.
Mitochondrial (mito)-targeted anti-oxidants
accumulate in the mitochondria, reducing
mitochondrial-derived ROS.
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Among the various endogenous defences against ROS,
glutathione homeostasis is critical for a cellular redox envi-
ronment. Glutathione-linked enzymatic defences include
Gpx, glutathione-S-transferase (GST), glutaredoxins (Grx),
thioredoxins (Trx) and peroxiredoxins (Prx). Many of these
proteins are known to interact with each other, forming
networks that may be prone to dysfunction. Mitochondrial-
specific isoforms of these proteins also exist,12 and these may
be more critical for cell survival compared with their cyto-
solic counterparts. Mitochondrial dysfunction, resulting in
depleted ATP synthesis, has the potential to reduce the redox
control of glutathione because the rate of glutathione syn-
thesis is ATP-dependent. In the kidney, intracellular synthe-
sis of glutathione from amino acid derivatives (glycine,
glutamate and cysteine) accounts for the majority of cellular
glutathione compared with, for example, the uptake of
extracellular glutathione from the basolateral membrane in
epithelial tubular cells of the renal nephron.13 This charac-
teristic may account for different segments of the nephron
being differentially susceptible to the same insult, as proxi-
mal tubular epithelial cells lack the ability to synthesize glu-
tathione, compared with other segments of the nephron,
which have that ability.14
DYSFUNCTIONAL MITOCHONDRIA AND
OXIDATIVE STRESS
Mitochondrial biogenesis and degradation (mitophagy)
usually occur in balance within healthy cells, and their
imbalance may be a major contributor to oxidative stress
and cellular metabolic decline. Mitophagy is carried out by
autophagy, a process that was originally thought to be a
non-selective cell regulatory mechanism for the degrada-
tion of dysfunctional organelles within the cellular lyso-
some system. More recently, the discovery of the
autophagy (Atg) genes has uncovered a highly selective
process for removal of damaged mitochondria.15 In particu-
lar, the mitochondrial transmembrane receptor gene Atg32
directs autophagosome formation. This response is
enhanced by a decrease in ATP production due to dysfunc-
tional mitochondria, and is regulated by the intracellular
energy sensor, adenosine monophosphate-activated protein
kinase.16 Should ATP reach critical levels through removal
of too many dysfunctional mitochondria, autophagic cell
death will be induced. Increasing mitochondrial biogenesis
is an attractive target to reduce cellular metabolic injury.
However, increasing the number of mitochondria could
possibly worsen or induce tissue hypoxia due to increased
oxygen consumption.
Oxidative stress also induces apoptosis,17 a process central
to functional tissue loss in CKD.18 Oxidative stress-induced
mitochondrial dysfunction and ROS generation may cause
suppression of phosphorylation of the anti-apoptotic B-cell
lymphoma-2 (Bcl-2) protein and loss of mitochondrial
membrane potential. The intrinsic, mitochondrial-driven,
pathway to apoptosis is of particular importance to age-
related CKD.19 Opening of the mitochondrial permeability
transition pore releases the pro-apoptotic factor cytochrome
C (CytC). CytC is bound to the inner mitochondrial mem-
brane by an association with the anionic phospholipid, car-
diolipan. Increased ROS result in dissociation of CytC from
cardiolipan, and increased amounts of CytC in the cytosol.
Pro-apoptotic proteases, known as caspases, also play essen-
tial roles in apoptosis. Cytoplasmic CytC forms an apopto-
some with apoptotic peptidase activating factor-1 and
caspase-9, leading to cleavage and activation of caspase-9
and caspase-3, and the structural changes of apoptosis. The
translocation of the Bcl-2 family proteins, especially pro-
apoptotic Bax (Bcl-2-associated x protein) and Bak (Bcl-2
antagonist killer), to the mitochondria of kidney cells is the
precursor to opening of the mitochondrial permeability
transition pore, release of CytC and resultant apoptosis.20
These proteins can interact with the outer mitochondrial
membrane, causing its permeabilization. Endogenous anti-
apoptotic Bcl-XL (the Bcl-X long isoform) also translocates
from the cytoplasm to the mitochondrial membrane, and is
known to protect renal distal tubular epithelium against oxi-
dative stress.17
OXIDATIVE STRESS IN CKD
During the pathogenesis of CKD, perturbations in cellular
oxidant handling influence downstream cell signalling and,
in the kidney, promote renal cell apoptosis and senescence,
decreased regenerative ability of cells and fibrosis. The path-
ways are tightly controlled, with transcription often deter-
mined by specific transcription factors, and post-translational
modifications that include phosphorylation, methylation,
acetylation, ubiquitination and O-GlcNAylation to regulate
outcomes. Several of these genes, which are regulated by
oxidative stress and may act in the development of CKD, are
reviewed in the following paragraph.
The Forkhead (FoxO) proteins are a family of transcription
factors that play a critical role in the regulation of genes
in ageing. They comprise FoxO1 to FoxO4 and FoxO6;
however, FoxO1 has most association with CKD. FoxO1 has
increased levels of phosphorylation in the kidneys of elderly
overweight people with type 2 diabetes and CKD21 and old
hypertensive rats with CKD.1 FoxOs induce apoptosis mainly
by upregulation of pro-apoptotic genes such as Bax,22 yet
they can also detoxify harmful cellular oxidants like O2- and
H2O2 and protect cells.23 Their exact role in oxidative stress-
induced CKD needs further investigation. Nuclear factor-
kappa B (NF-kB) comprises a family of rapid-acting nuclear
transcription factors that transcriptionally regulate a wide
variety of genes involved in inflammation, immunity, apop-
tosis, cell proliferation and differentiation. In oxidative
stress-induced kidney disease, NF-kB is activated by ROS and
initiates signalling pathways involved in renal fibrosis.24 It
has been implicated in the transcriptional activation of the
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cell cycle inhibitor p21,25 linking this transcriptional regula-
tor with renal cell senescence. The adapter protein p66shc is a
mediator of mitochondrial dysfunction.26 An isoform of the
ShcA protein, p66shc antagonizes the cell proliferative actions
of two other isoforms, p46shc and p52shc. Oxidative stress
induces the phosphorylation of serine 36 of p66shc before its
translocation into the mitochondria. Here, it translates oxi-
dative stress into Ca2+-mediated mitochondrial damage and
subsequent apoptosis.27 Although the role of p66shc has been
noted in glomerulopathies and diabetes,28 and its differential
expression has been demonstrated in ageing kidneys,1 the
functional significance of p66shc in the pathogenesis of CKD
needs further investigation.
Uremic toxins may also be a source of oxidative stress in
CKD patients. Uric acid is the hepatic end-product of purine
metabolism in humans. It is synthesized by xanthine oxi-
doreductase, which catalyses the oxidation of hypoxanthine
to xanthine and xanthine to uric acid. Resulting hyperuri-
caemia is associated with an increased risk for developing
CKD and enhances its progression.29 In addition, retention of
uremic toxins promotes inflammation, and therefore oxida-
tive stress, by priming polymorphonuclear lymphocytes,
activating IL-1b and IL-830 and stimulating the innate
immune response through CD8+ cells.31 Uric acid synthesis
can also promote oxidative stress directly through the activ-
ity of xanthine oxidoreductase. This enzyme is synthesized as
xanthine dehydrogenase, which can be converted to xan-
thine oxidase by calcium-dependant proteolysis32 or modifi-
cation of cysteine residues.33 In doing so, the enzyme loses its
capacity to bind NADH by alterations in its catalytic site and,
instead, transfers electrons to O2, thereby generating O2-.34
However, the role of uric acid in many conditions associated
with oxidative stress is not clear and there are experimental
and clinical data showing that uric acid also has a role in vivo
as an anti-oxidant.35
MEASURING OXIDATIVE STRESS
Free radicals have extremely short half-lives, so that in most
cases oxidative stress is measured by specific end-products of
the process. Reactive species can be measured directly by
electron paramagnetic resonance or various spin trapping
methods, but these methods present some practical limita-
tions, especially in humans. At present, they are costly, and
their safety and efficacy have not been proven. Oxidative
stress biomarkers are available, and it is their use that has
indicated a positive correlation between increasing oxidative
stress with increasing stages of CKD.36 Assays for oxidative
stress or anti-oxidant status and some of the popular biom-
arkers are shown in Table 3, which also indicates whether
the end-product can be measured in urine, serum, tissue, cell
culture or other biological products. Common and reliable
assays for oxidative stress in CKD in humans are discussed
specifically.
Isoprostanes
As with most oxidative stress biomarkers, the isoprostanes
detect levels of specific end-products from free radical
damage. They are considered by some researchers to be the
best available biomarker of lipid peroxidation and have been
investigated in the pathogenesis of CKD.36–38 Studies have
focused primarily on F2-isoprostanes, which are formed
by non-enzymatic peroxidation of arachidonyl lipids.
Specifically, 8-isoprostane (8-epi-PGF2a) is measured.
F2-isoprostanes are best detected using mass spectroscopy,
and urine and plasma are typically used.39 One of their limi-
tations as a biomarker of oxidative stress is that they are
rapidly metabolized and, as a result, any increase in plasma
isoprostane concentration may be due not only to their
increased formation from lipid peroxidation, but also to a
slower metabolism.40,41 Measurements of F2-isoprostanes
also have relatively low reproducibility, for example, in the
one healthy patient on a defined diet and exercise regimen,
carried out at the same time of day on subsequent days.42 A
final, important, consideration is that the F2-isoprostanes,
like all end-product biomarkers, are a measure of whole-
body oxidative stress rather than oxidative stress localized
only to the kidney. Nevertheless, the use of isoprostanes has
delivered important information on increased oxidative
stress and related loss of kidney function,36 early in the
progression of CKD.38
Malondialdehyde
Malondialdehyde (MDA) is another end-product generated
by lipid peroxidation and has been used to demon-
strate increased oxidative stress during CKD.43 Unlike
F2-isoprostanes, MDA has the ability to react further and
possibly cause protein and DNA adducts, thus levels of
MDA should be interpreted with caution. MDA, along
with other lipid peroxidation products such as
4-hydroxyalkenals, is a thiobarbituric acid reactive sub-
stance (TBARS). Earlier investigations into oxidative stress
commonly assayed TBARS; however, simple TBARS assays
are unreliable measures of oxidative stress because most
TBARS in human body fluids are formed non-specifically
and artefactually, and are not specifically related to lipid
peroxidation.44 High-performance liquid chromatography
extraction of MDA from plasma, with subsequent quanti-
fication, is considered a reliable measure of oxidative
stress.45 Improved methods derivatize MDA with 2,4-
dinitrophenylhydrazine, which forms specific hydrazones
for MDA that can be separated by high-performance liquid
chromatography and quantified using methyl-MDA as an
internal standard.46 Urinary MDA as a measure of impaired
kidney function in patients can be difficult to interpret
given that renal clearance of MDA possibly provides an
adaptive mechanism to prevent lipid peroxidation accumu-
lating within kidney tubular cells.47
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Other common assays or biomarkers of oxidative
stress in CKD patients
Advanced oxidation protein products (AOPP) accumulate in
the serum of CKD patients, especially those with uraemia
and diabetes,48 contributing to the pathogenesis of CKD.49
AOPP are primarily derived from serum albumin following
hypochlorous acid free radical attack50 and they provide a
valuable indicator of oxidation-mediated protein damage.
The prevalence of albuminuria/proteinuria in CKD and its
impact on AOPP has not yet been investigated. Protein car-
bonyl assays quantify the carbonyl groups associated with
oxidant-damaged proteins. Protein carbonyls are not specific
for oxidative stress as they also measure glycated proteins
and bound aldehydes.51 An increase in protein carbonyls was
demonstrated in CKD patients in stages 3–5, yet no correla-
tion was found between protein carbonyl levels and
decreased GFR.38 The pathogenesis of type 2 diabetes
includes oxidative stress as a mechanism.52 Protein carbonyls
are increased in plasma and lymphocytes of diabetes patients
compared with healthy control.39 g-Glutamyl transpeptidase
(GGT) has been trialled as a biomarker of CKD onset through
the mechanism of oxidative stress. Extracellular GGT is
required to metabolize extracellular-reduced glutathione,
allowing for the intracellular synthesis of glutathione. Serum
anti-oxidant levels had an inverse relationship to serum
GGT, indicating a redox-regulating role.53 The relationship
between plasma and extracellular GGT is not fully defined,
but it does appear that serum GGT presents a favourable
biomarker of oxidative stress. It is stable, quick and inexpen-
sive to test, and provides an indication of whole-body oxi-
dative stress compared with specific oxidative damage to
lipids, DNA or proteins. In an excellent review of measures of
oxidative stress, Halliwell and colleagues discuss more
broadly the different measures of oxidative stress, including
reasons leading to poor correspondence between markers,
like the rapid metabolism of isoprostanes compared with the
slower metabolism of oxidized proteins.51
COMBATING CKD BY TARGETING
OXIDATIVE STRESS
Two major goals for controlling development of CKD are
early detection and slowing progression to end-stage renal
Table 3 Markers and assays of oxidative stress
Marker type or method Samples
Blood Urine Tissue Culture Other
Lipid peroxidation
F2-isoprostanes ✓ ✓ ✓ ✓
Malondialdehyde ✓ ✓ ✓ ✓
Thiobarbituric acid reactive substances ✓ ✓ ✓ ✓
Aldehydes Breath
Lipid hydroperoxides ✓ ✓ ✓
Protein oxidation or nitration
Protein carbonyls ✓ ✓ ✓ ✓
3-nitrotyrosine ✓ ✓ ✓ ✓
Advanced glycation end-products ✓ ✓ ✓ ✓ Skin
Advanced oxidation protein products ✓ ✓ ✓
Kidney injury molecule-1 (KIM-1) ✓ ✓ ✓
Oxidized low-density lipoproteins ✓ ✓ ✓
Reactive oxygen species
Intracellular ROS (ﬂuorescence) ✓
Hydrogen peroxide ✓ ✓ ✓ ✓ Breath
Electron spin resonance for ROS ✓ ✓
DNA or RNA damage
8-hydroxy deoxyguanosine (8-OHdG) ✓ ✓ ✓ ✓
Double strand breaks (ApopTag) ✓ ✓
Comet assay for general DNA damage ✓ ✓
Anti-oxidants
Catalase ✓ ✓ ✓
Glutathione ✓ ✓ ✓ ✓
Reduced-oxidized glutathione (GSH : GSSH) ✓ ✓ ✓
Glutathione peroxidase ✓ ✓ ✓ ✓
Superoxide dismutase (Mn-SOD and Cu/Zn-SOD) ✓ ✓ ✓ ✓
Oxygen radical anti-oxidant capacity (ORAC) ✓ ✓ ✓ Food samples
Hydroxyl radical anti-oxidant capacity (HORAC) ✓ ✓ ✓ Food samples
Ferric reducing ability of plasma (FRAP) ✓
Total anti-oxidant capacity (TAC) ✓ ✓ ✓ ✓ Food samples
DM Small et al.
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disease. Using oxidative stress biomarkers in a panel of biom-
arkers of processes known to impact on CKD development
may allow early detection. Slowing its development is
more problematic. Traditionally, inhibition of the renin-
angiotensin-aldosterone system has been used to slow the
progression of CKD,54 with established therapies relying
on pharmacologic blockade of the renin-angiotensin-
aldosterone system with angiotensin-converting enzyme
inhibitors and angiotensin II receptor blockers. However,
decline of GFR and elevated serum creatinine have contin-
ued in treated patients,55,56 and the need for novel treatments
and interventions continues. Although the prophylactic use
of anti-oxidant therapies in the treatment and amelioration
of CKD is still in dispute, oxidant dysregulation occurs with
age and age is one of the greatest risk factors for CKD. Some
modifiable pathways and anti-oxidant treatments are sum-
marized in Figure 2. There are many anti-oxidants that
might be mentioned here, but we have selected some that
have some demonstrated benefits in CKD.
Vitamin E
Vitamin E comprises a family of eight different lipid-soluble
tocopherols and tocotrienols that scavenge free radicals by
incorporating into the plasma membrane of cells, thus
halting lipid peroxidation chain reactions.57 Vitamin E food-
stuffs primarily consist of a-tocotrienol, which has a higher
anti-oxidant efficacy; however, a-tocopherol has higher bio-
availability in vivo than the other seven compounds and so
the focus has been on its usage. The basis of vitamin E
supplementation is to enhance a-tocopherol levels in cell
plasma membranes to prevent lipid peroxidation and result-
ant oxidative stress. Vitamin E is often delivered with
vitamin C in an attempt to boost the anti-oxidant efficacy, as
vitamin C has been shown to assist in recycling vitamin E.
One drawback of a-tocopherol is that it takes several days of
pretreatment to exhibit anti-oxidant effects.58 Trolox (1-6-
hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid), is
an analogue of a-tocopherol that has shown far better free
radical scavenging properties owing to its water solubility.
The majority of in vivo studies using Trolox have reported
beneficial effects in acute cases of renal injury such as
ischaemia reperfusion, due to rapid solubility and increased
potency.59 A combination supplement containing both
a-tocopherol and Trolox may offer greater efficacy due to the
fast-acting activities of Trolox combined with the sustained
scavenging actions of a-tocopherol.
Patients with progressive CKD display the largest decrease
in serum a-tocopherol levels, indicating an increased need
for a-tocopherol in the CKD population.37 Supplementation
of a-tocopherol in an end-stage kidney disease dialysis popu-
lation reduced the risk of associated cardiovascular disease,
decreased oxidative stress and increased erythrocyte anti-
oxidants SOD, Gpx and CAT.60 However, in a meta-analysis
by Miller and colleagues,61 based on the combination of
several studies, an increase in all-cause mortality was found
with high-dose vitamin E (400 IU/day) in patients with
chronic diseases.62 Furthermore, the SELECT trial demon-
strated that dietary supplementation with vitamin E signifi-
cantly increased the risk of prostate cancer among healthy
men.63 Future trials should determine the cause of these risks
as well as focus on g- and d-tocopherol supplementation.
Omega-3 polyunsaturated fatty acids
Although considered more an anti-inflammatory64 than anti-
oxidant treatment, long chain omega(w)-3 polyunsaturated
fatty acids, including docosahexanoic acid and eicosapen-
tanoic acid, have been investigated in a large range of in vitro
and in vivo CKDmodels. They were found to enhance endog-
enous anti-oxidant defence systems such as g-glutamyl-
cysteinyl ligase and glutathione reductase.65 In models of
progressive renal fibrosis, kidney function and structure
were improved using eicosapentanoic acid and docosahex-
anoic acid supplementation, with reduced oxidative stress,
inflammation and tubulointerstitial fibrosis.66 Use of w-3
polyunsaturated fatty acids in human CKD patients is under
multicentre trials and the anti-oxidant status of the patients
will, hopefully, be recorded in these trials.
N-acetyl cysteine
N-acetyl cysteine (NAC) is an essential precursor to many
endogenous anti-oxidants involved in the decomposition of
peroxides. It attenuates oxidative stress from various under-
lying causes by replenishing intracellular glutathione stores.
The limiting precursor to glutathione biosynthesis is
L-cysteine. This amino acid is not readily available in the
human diet and this was the primary basis for NAC supple-
mentation – to replenish cysteine levels. However, the
sulfhydryl-thiol group of L-cysteine is also able to exert direct
anti-oxidant effects by scavenging free radicals. The results of
NAC supplementation in kidney disease have been variable.
NAC pretreatment reduced endothelial dysfunction caused
by uremic toxins by reducing ROS-dependent expression of
NF-kB.67 NAC reduced kidney MDA levels in a mouse model
of diabetic nephropathy.68 The treatment of CKD patients
with NAC has been largely disappointing,69 but in end-stage
kidney disease patients receiving either haemodialysis or
peritoneal dialysis, NAC reduced serum 8-isoprostane and
the inflammatory cytokine IL-6.70,71
Allopurinol
Allopurinol and its metabolite, oxypurinol, are xanthine oxi-
doreductase inhibitors that lower serum uric acid levels.
Treatment with allopurinol blocks uric acid reabsorption by
urate transporters in the proximal tubule, facilitating
enhanced uric acid excretion.72 Allopurinol has a protective
effect in diseases involving oxidative stress in their pathogen-
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esis. Allopurinol treatment of diabetic mice attenuated hype-
ruricaemia, albuminuria, and tubulo-interstitial injury.73
Several studies in human CKD patients have shown the
benefit of treatment with allopurinol. For example, Kao et al.
reported that allopurinol ameliorated endothelial dysfunc-
tion and prevented increased left ventricular mass in patients
with CKD,74 and Siu et al. reported that allopurinol slowed
progression of CKD through its ability to lower serum uric
acid levels.75
Coenzyme Q10 and mitochondrial-targeted
anti-oxidants
The kidneys contain the highest endogenous levels of CoQ9
and CoQ10 compared with all other organs.76 This is likely
due to the reliance of the kidney on aerobic metabolism and
high density of mitochondria. It is imperative that endog-
enous CoQ10 levels are maintained to ensure mitochondrial
health, and this forms the rationale for CoQ10 therapy. CoQ10
has three well-characterized functions: (i) the transfer of
electrons from complexes I and II to complex III along the
ETC of the inner mitochondrial membrane and subsequent
membrane polarization and ATP generation;77 (ii) the pro-
oxidant generation of O2- and H2O2;78 and (iii) the anti-
oxidant quenching of free radicals.79 The major direct anti-
oxidant role of CoQ10 is prevention of lipid peroxidation,
and it also acts indirectly through its interactions with
a-tocopherol.80 Although results regarding its benefit are
disparate, Ishikawa and colleagues81 demonstrated a
decrease in kidney O2- levels and improved renal function in
hemi-nephrectomized rats on a CoQ10 supplemented diet.
There is a general lack of human studies investigating CoQ10
therapy for the treatment and/or prevention of CKD, but
CoQ10 levels decrease with age
82 and identification of patients
with low CoQ10 levels may allow for targeted therapy with
beneficial outcome.
Mitochondrial-targeted compounds have created much
interest for their application in reducing oxidative stress. One
of the most tested is the mitochondrial-targeted derivative of
endogenous CoQ10, termed MitoQ (mitoquinone mesylate).
This compound and those alike, such as mitochondrial-
targeted vitamin E (MitoVitE), are prepared by covalently
attaching a lipophilic cation to an alkyltriphenylphospho-
nium, allowing rapid accumulation into the mitochondria
driven by the large negative value of the mitochondrial
membrane potential. Administration of MitoQ in a rat model
of diabetic nephropathy decreased mesangial expansion and
tubulointerstitial fibrosis, thereby improving renal func-
tion.83 Human trials have shown that MitoQ can decrease
biomarkers of liver inflammation in hepatitis C patients.84
However, a larger scale, double-blinded, placebo-controlled
study found that MitoQ did not slow the progression of
untreated Parkinson’s disease, a disease associated with
mitochondrial oxidative stress.85 The effect may be tissue
specific, and early intervention with MitoQ in CKD patients
could prove fruitful given that oxidative stress is evident
early in CKD progression (stages 1–3).
SUMMARY
The transcriptional networks that maintain oxidant balance
in the mature kidney provide promising entry points for
future therapeutic interventions, including for CKD. The use
of anti-oxidants targeted to specific pathways that are altered
in CKD may prove beneficial, but it is likely that several
anti-oxidants will be needed as a multi-drug therapy to
target oxidant modifying pathways during the development
of CKD. These include lipid peroxidation, which can be
improved by a-tocopherol; glutathione redox regulation,
which can be restored by NAC; uremic toxins, which can be
reduced by allopurinol; inflammation, which can be attenu-
ated by w-3 polyunsaturated fatty acids; and finally, mito-
chondrial dysfunction, which may be improved by CoQ10.
Mosca and colleagues86 found that healthy individuals taking
a combination of a-tocopherol, a-lipoic acid, CoQ10, car-
nitines and selenomethionine increased plasma anti-oxidant
status, decreased lymphocyte apoptosis and decreased
mitochondrial-derived ROS. In the CKD population, identi-
fication of patients who would benefit from anti-oxidant
therapy is first needed, and then a multifaceted anti-oxidant
approach may be necessary for successful treatment of CKD.
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oxidant N-acetyl-cysteine (NAC) were investigated.  Results: 
H 2 O 2 and API, separately, increased oxidative stress and mi-
tochondrial dysfunction, apoptosis and cell senescence. Al-
though API caused cell senescence, it also induced oxidative 
stress at levels similar to H 2 O 2 treatment alone, indicating 
that senescence and oxidative stress may be intrinsically 
linked. When H 2 O 2 and API were delivered concurrently, 
their detrimental effects on renal cell loss were compound-
ed. The antioxidant NAC attenuated apoptosis and senes-
cence, and restored regenerative potential to the kidney. 
 Conclusion: Oxidative stress and cell senescence both cause 
mitochondrial destabilization and cell loss and contribute to 
the development of the cellular characteristics of CKD. 
 Copyright © 2013 S. Karger AG, Basel 
 Introduction 
 Chronic kidney disease (CKD) affects approximately 
10–15% of the adult population in industrialised coun-
tries. The incidence of CKD and its associated end-stage 
disease are increasing. Although diabetes and hyperten-
sion are known causes of CKD, aging alone causes a grad-
ual loss of kidney function independent of any other pa-
thology  [1] . Oxidative stress increases with aging  [2] , and 
 Key Words 
 Chronic kidney disease · Cell senescence · Oxidative stress · 
Apoptosis · Mitochondria 
 Abstract 
 Background: 
The incidence and cost of chronic kidney disease (CKD) are 
increasing. Renal tubular epithelial cell dysfunction and at-
trition, involving increased apoptosis and cell senescence, 
are central to the pathogenesis of CKD. The aim here was to 
use an in vitro model to investigate the separate and cumu-
lative effects of oxidative stress, mitochondrial dysfunction 
and cell senescence in promoting loss of renal mass.  Meth-
ods: Human kidney tubular epithelial cells (HK2) were treat-
ed with moderate hydrogen peroxide (H 2 O 2 ) for oxidative 
stress, with or without cell cycle inhibition (apigenin, API) for 
cell senescence. Adenosine triphosphate (ATP) and oxida-
tive stress were measured by ATP assay, lipid peroxidation, 
total antioxidant capacity, mitochondrial function with con-
focal microscopy, MitoTracker Red CMXRos and live cell im-
aging with JC-1. In parallel, cell death and injury (i.e. apopto-
sis and Bax/Bcl-X L expression, lactate dehydrogenase), cell 
senescence (SA-β-galactosidase) and renal regenerative 
ability (cell proliferation), and their modulation with the anti-
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it has been described in the pathogenesis of diabetes  [3] 
and hypertension  [4] . Nonetheless, oxidative stress as a 
significant cause of CKD and the associated loss of func-
tioning renal mass are still being debated. Mitochondria 
are increasingly being recognised as key participants in 
renal cellular metabolism  [5] including the generation of 
energy in the form of adenosine triphosphate (ATP) and 
the regulation of calcium homeostasis  [6] , tissue O 2 gra-
dients, apoptosis  [7] and cell signalling  [8] . However, 
their contribution to CKD is largely unknown.
 The kidney is a highly metabolic organ that relies heav-
ily on oxidative phosphorylation, accounting for approx-
imately 10% of the O 2 consumption of the whole body. 
Mitochondrial energy generates 95% of required ATP for 
the kidney  [9] . The proximal tubular epithelial cells, most 
often atrophic in CKD, contain many large active mito-
chondria  [10] . A decrease in mitochondrial efficiency and 
subsequent cell function could have a significant impact 
on CKD development and renal failure. Mitochondria are 
also a major cellular producer of reactive oxygen species 
(ROS) and are themselves targets of ROS-mediated dam-
age  [11] . Along the respiratory chain complexes of the 
inner mitochondrial membrane, reduction in molecular 
O 2 yields ROS mainly in the forms of the superoxide an-
ion (O 2– · ) and hydrogen peroxide (H 2 O 2 ). Defining mito-
chondrial dysfunction in the highly metabolic proximal 
tubular epithelium may hold a key to explaining how ox-
idative stress contributes to the pathogenesis of diseases 
like CKD.
 Cell senescence is commonly observed in CKD with 
increased levels of senescence-associated β-galactosidase 
(SA-β-gal) and lipofuscin granules predominately in tu-
bular cells  [12] , and to a lesser extent in glomerular me-
sangial cells  [13] . Senescent kidney cells can die or persist 
in a damaged form, showing little function and an inabil-
ity to proliferate  [14] . Persisting senescent cells can com-
promise the healthy functioning of the kidney and reduce 
the ability of the aging nephron to cope with disease stress-
es, since it is the tissue in its whole form that accounts for 
function rather than the individual cells. Senescent cells 
have been shown to secrete multiple pro-inflammatory 
growth factors, cytokines and chemokines  [15]  and there-
fore promote inflammation, and also present promising 
targets to inhibit the many co-morbid conditions associ-
ated with inflammation in CKD. Oxidative stress itself can 
induce premature senescence in non-renal cells: in fibro-
blast cultures  [16] and in retinal epithelium during macu-
lar degeneration  [17] . Senescing cells undergo irreversible 
cell cycle arrest, mainly in the G1 phase, have
increased SA-β-gal activity and up-regulation of cyclin-
dependent kinase inhibitors, like p16 ink4a  [18] . Oxidative 
stress may cause premature senescence of kidney cells in 
CKD. However, the mechanisms underlying mitochon-
drial dysfunction and subsequent oxidative stress-induced 
premature senescence in the kidney remain largely unde-
fined. We demonstrated previously that protecting the 
mitochondria in renal proximal tubular epithelium pro-
tects these cells from increasing apoptosis  [5] . The aim of 
this study was, therefore, to use an in vitro model to inves-
tigate the separate and cumulative effects of oxidative 
stress, mitochondrial dysfunction and cell senescence in 
promoting loss of renal tubular epithelium.
 Material and Methods 
 Experimental Design 
 The human renal proximal tubular epithelial cell line HK2 
(ATCC, Rockville, Mass., USA) was cultured in Dulbecco’s modi-
fied Eagle’s medium/Ham’s F12 containing 10% fetal bovine se-
rum and antibiotics using published methods  [5] . After dose-re-
sponse studies (unpublished data), they were grown to 80–90% 
confluence and then treated for 18–24 h with 0.4 m M H 2 O 2 for 
oxidative stress, and 100 μ M apigenin (API) to induce renal cell 
senescence  [19] . DMSO as a vehicle control was <1% in growth 
medium). N-acetyl-cysteine (NAC), a general renal cell antioxi-
dant  [20] , was used at 10 m M (n = 3 replicates).
 Determination of ATP, Oxidative Stress and Cytotoxicity 
 ATP levels (luciferase-based bioluminescence assay, Promega, 
Sydney, N.S.W., Australia), lipid peroxidation with malondialde-
hyde (MDA) (Bioxytech LPO-586 Assay, OxisResearch Products, 
Percipio Biosciences Inc., Calif., USA) and total antioxidant capac-
ity (TAC; OxiSelect TM TAC assay kit, Cell Biolabs, San Diego, Cal-
if., USA) was measured according to the manufacturers’ protocols 
and with appropriate controls. Lactate dehydrogenase was mea-
sured as a % of its maximal release from cells treated with 5 m M 
H 2 O 2 (Cytotoxicity Detection Kit PLUS , Roche Diagnostics, Castle 
Hill, N.S.W., Australia).
 Mitochondrial Function 
 MitoTracker Red CMXRos (Invitrogen Australia) localises to 
mitochondria with healthy membrane potential, and fades as mi-
tochondria lose membrane potential. HK2 cells were incubated for 
30 min with 100 n M MitoTracker Red before being fixed (4% para-
formaldehyde) and mounted for microscopy (Vectashield anti-
fade, Vecta Laboratories, East Brisbane, Qld., Australia). DAPI 
(4′,6-diamidino-2-phenylindole) was used to label nuclei. A Zeiss 
510 Meta confocal fluorescence microscope with Zen 2008 soft-
ware (×63 oil lens; 579 nm) was used. Mean fluorescence intensity 
was analysed (Nikon FN-S2N fluorescence microscope, NIS Image 
software, ×63 objective).
 JC-1 is a fluorophore that has mitochondrial membrane poten-
tial-dependent accumulation in mitochondria. A decrease in red 
fluorescence and an increase in green fluorescence indicate mito-
chondrial membrane depolarisation. JC-1 (3 μ M ) was applied 30 
min preceding H 2 O 2 exposure and then for 1 h of 0.4 or 1 m M H 2 O 2 
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(as high oxidative stress as control) treatments. Cells were fixed 
(4% paraformaldehyde) before being mounted (Vectashield 
mounting medium with DAPI) and visualised at 590 nm (red), 529 
nm (green) and 460 nm (blue) using confocal florescence micros-
copy (×63 oil lens). For live-cell imaging, HK2 cells were seeded 
onto MatTek Corp (Ashland, Mass., USA) glass bottom dishes be-
fore JC-1 incubation. Cultures were placed in a live-cell imaging 
chamber at 37  °  C and 5% CO 2 in air. A representative field was then 
visualised to assess background laser-induced fluorescence leach-
ing. H 2 O 2 treatment was then added to the cells and the same field 
photographed over 25 min at consecutive 5-min intervals.
 Light and Fluorescence Microscopy 
 Cells were fixed in 4% buffered paraformaldehyde or 100% ice-
cold methanol for 30 min at 4  °  C for haematoxylin and eosin (HE) 
staining or fluorescence microscopy. HE-stained cells were as-
sessed using the Aperio ScanScope XT system (Aperio Technolo-
gies, Vista, Calif., USA) for % apoptosis, mitosis and cell senes-
cence by counting ten frames of cells (×200) for each treatment 
 [21] . The ApopTag ® peroxidase in situ  apoptosis detection kit 
(Merck-Millipore Pty Ltd, Kilsyth, Vic., Australia) was used for 
identifying apoptosis according to our published methods  [21] . 
Ki67 (Santa Cruz Biotechnology Inc., Santa Cruz, Calif., USA;
1: 100) immunocytochemistry was used to assess proliferative ac-
tivity. Senescent cell morphology and SA-β-gal immunofluores-
cence (Cell Signalling Technologies, Danvers, Mass., USA; 1: 500) 
for cell senescence were used in parallel. Senescent cells had re-
duced staining saturation  [22] and were 3–4 times the diameter of 
control cells.
 Western Immunoblotting for Bax, Bcl-X L and p16 Ink4a 
 Protein was extracted by lysing HK2 cells in RIPA buffer ac-
cording to our published protocols  [5, 20] . Protein concentration 
was determined (Pierce BCA assay) and 40 μg of each protein sep-
arated (10% SDS-polyacrylamide gel electrophoresis). Immuno-
blotting was performed against Bax (1: 1,000, Santa Cruz Biotech-
nology), Bcl-X L (1: 1,000, Zymed), GAPDH (1: 1,000; Sigma) and 
p16 Ink4a (1: 100;  [23] ). HRP-conjugated secondary antibodies were 
used. Protein bands were visualised using enhanced chemilumines-
cence. Scion Image software Alpha 4.0.3.2 was used for densitom-
etry. GAPDH immunoblots were used to normalise densitometry.
 Statistical Analysis 
 Values reported are mean ± SEM. Data were analysed using 
one-way analysis of variance (ANOVA) and Tukey’s post hoc anal-
ysis, two-way ANOVA and Bonferroni’s post hoc test, or Student’s 
t test where appropriate, with statistical significance at p < 0.05.
 Results 
 ATP, Lipid Peroxidation and TAC Assays Indicate 
Oxidative Stress with All Treatments 
 API, alone or in combination with H 2 O 2 , significantly 
increased MDA (p < 0.05;  fig. 1 a) and reduced TAC (p < 
0.05;  fig. 1 b). Both API and H 2 O 2 resulted in loss of ATP; 
however, both treatments were necessary for a significant 
loss ( fig. 1 c).
 Confocal Fluorescence Microscopy and Live Cell 
Imaging Indicate Loss of Mitochondrial Function with 
All Treatments 
 MitoTracker Red fluorescence was significantly re-
duced following API and/or H 2 O 2 exposure ( fig.  2 a–e;
p < 0.05). There was no additive effect when H 2 O 2 was 
delivered with API. Live-cell imaging captured the loss of 
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 Fig. 1. Lipid peroxidation, TAC and ATP generation following ox-
idative stress and cell senescence.  a Lipid peroxidation was mea-
sured by MDA assay. Cells exposed to API, H 2 O 2 or API + H 2 O 2 
had a significant increase in MDA compared to DMSO vehicle 
controls ( *  p < 0.05 compared to DMSO).  b TAC was measured by 
colorimetric assay. Cells exposed to API or API + H 2 O 2 had a sig-
nificant reduction in TAC compared to DMSO controls. H 2 O 2 in-
duced a small but significant increase in TAC ( *  p < 0.05 compared 
to DMSO and  #  p < 0.05 compared to untreated controls).  c ATP 
generation was measured by luminescence assay; 1 m M H 2 O 2 was 
used to demonstrate maximal ATP loss. Compared with untreated 
controls, API + H 2 O 2 caused the greatest ATP loss ( *  p < 0.05 com-
pared to DMSO and  #  p < 0.05 compared to all). 
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mitochondrial membrane permeability in the kidney 
cells with oxidative stress (H 2 O 2 ). Results of time-lapse 
photography ( fig. 2 f–h) using JC-1 demonstrated healthy 
polarised mitochondrial membrane (red fluorescence) 
transitioning to green fluorescence and dysfunctional mi-
tochondria. Fixed cells (JC-1,  fig. 2 i–k) also showed mi-
tochondrial depolarisation in response to oxidative stress. 
Concomitant apoptosis is indicated (arrow,  fig. 2 k).
 Oxidative Stress as a Mechanism Unifies Outcomes 
of Increased Renal Cell Apoptosis, Decreased Mitosis 
and Cell Senescence 
 Apoptosis was increased and mitosis decreased by all 
treatments. API in association with H 2 O 2 produced great-
est effect ( fig. 3 a; p < 0.05). These results were supported 
by the cytotoxicity assay ( fig. 3 b). Representative photo-
micrographs of morphological characteristics of apopto-
sis, mitosis and senescence are demonstrated in  figure 3 c 
(control) and  3 d (API + H 2 O 2 ). ApopTag labelling is 
demonstrated in  figure 3 e–g. Ki67 immunocytochemis-
try is demonstrated in  figure 3 h–j. Representative West-
ern immunoblots of Bax and Bcl-X L ( fig. 4 a) and densi-
tometry ( fig.  4 b) demonstrated increased Bax and de-
creased Bcl-X L , with a pro-apoptotic ratio of Bax:Bcl-X L 
increased, with all treatments. The greatest increase was 
observed with API + H 2 O 2 (all p < 0.05).
 Senescent cell morphology ( fig. 5 b) and SA-β-gal im-
munofluorescence ( fig. 5 a) are presented. API and API + 
H 2 O 2 produced significant morphological senescence 
changes (p < 0.001 compared to DMSO), but all treat-
ments caused increased SA-β-gal immunofluorescence 
(p < 0.05 compared to DMSO). Examples of immuno-
fluorescence demonstrated little SA-β-gal in controls 
( fig.  5 c) versus extensive punctuate green cytoplasmic 
fluorescence in  figure 5 d (API treatment). Expression of 
the cell cycle regulator p16 Ink4a ( fig. 6 a–c) did not change 
with API or H 2 O 2 treatments after 2 h of exposure. How-
ever, a significant increase was demonstrated at 24 h after 
H 2 O 2 treatment.
 The Antioxidant NAC Protects Renal Cells from 
Oxidative Stress and Senescence 
 NAC significantly modulated apoptosis for all treat-
ments, restored the mitotic potential of H 2 O 2 -treated 
cells and decreased senescence morphology induced by 
API and H 2 O 2 ( fig. 7 a–c; p < 0.05).
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 Fig. 2. Live- and fixed-cell imaging verified mitochondrial dys-
function with oxidative stress and cell senescence.  a–d MitoTrack-
er Red CMXRos confocal fluorescence microscopy is demonstrat-
ed.  e Fluorimetry is presented graphically as arbitrary fluorescence 
units (AFU). Compared with control cultures ( a ), all treatments ( b 
API,  c H 2 O 2 and  d API + H 2 O 2 ) had decreased MitoTracker Red. 
 e AFU were significantly decreased in all treatments ( *  p < 0.05 
compared to untreated controls).  f–h Confocal fluorescence mi-
croscopy using live-cell imaging and JC-1 labelling.  f Control cells 
during 20-min exposure to H 2 O 2 .  g ,  h Mitochondrial membrane 
depolarisation during 20-min exposure to H 2 O 2 . There was a grad-
ual decrease in red fluorescence (polarised mitochondria, approx. 
590 nm) to predominantly green fluorescence (depolarised mito-
chondria, approx. 525 nm).  i–k Mitochondrial depolarisation was 
also demonstrated by JC-1 pre-treatment, oxidative stress, and 
then fixing the cells before confocal microscopy.  i Control cells 
have red fluorescing mitochondria.  j ,  k The predominance of 
green fluorescence after exposure to H 2 O 2 , again demonstrating 
mitochondrial membrane depolarisation.  k Apoptosis is also seen 
(DAPI-stained nuclear condensation and fragmentation, arrow). 
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 Fig. 3. Increased apoptosis and decreased mitosis occur with oxi-
dative stress and senescence.  a The mean ± SEM of % apoptosis 
and mitosis. Apoptosis increased significantly with all treatments 
compared with control or DMSO but was greater than the addition 
of counts for API and H 2 O 2 in the API + H 2 O 2 treatment, indicat-
ing a synergistic effect of the treatments ( *  p < 0.05 compared to 
control). Mitosis decreased in all treatments compared to control 
and DMSO ( #  p < 0.05 compared to control).  b The mean ± SEM 
of lactate dehydrogenase (as % maximal cytotoxicity of HK2 cells 
exposed to 5 m M of H 2 O 2 ). API and API + H 2 O 2 produced the 
greatest % cytotoxicity compared with untreated cells and DMSO 
controls ( *  p < 0.05 compared to untreated control).  c–j Represen-
tative histology. The morphological characteristics of apoptosis 
(arrows), mitosis ( * ) and senescence (#) are shown in HE-stained 
cells ( c control and  d API treatment as an example).  e–g Verifica-
tion of apoptosis with ApopTag (brown nuclei, arrows; colours 
refer to the online version only).  e Negative control.  f ApopTag in 
untreated controls.  g ApopTag in H 2 O 2 treatment as an example. 
 h–j Proliferative activity was identified using Ki67 immunocyto-
chemistry ( * positive nuclei as intense brown).  h Negative control 
for Ki67.  i Untreated controls where mitosis was high.  j API + 
H 2 O 2 as an example where mitosis was negated. 
Control
6
4
2
Fo
ld
 c
ha
ng
e 
Ba
x:
Bc
l-X
L r
at
io
0
DMSO API H2O2 API +
H2O2
Control DMSO API H2 O2 API + H2O2
Bax
GAPDH
Bcl-XL
GAPDH
ba
*
 Fig. 4. Western immunoblot and densitometry for Bax and Bcl-XL 
expression.  a Representative examples of Western immunoblots 
for pro-apoptotic Bax and anti-apoptotic Bcl-X L plus the GAPDH 
loading controls for these blots. All treatments resulted in in-
creased Bax and decreased Bcl-X L .  b Relative densitometry was 
normalised to GAPDH, calculated as a fold-change of controls and 
presented graphically as a ratio of Bax:Bcl-X L . The pro-apoptotic 
ratio of Bax:Bcl-X L increased with all treatments compared with 
DMSO with the greatest increase observed in the API + H 2 O 2 treat-
ment ( *  p < 0.05). 
Co
lo
r v
er
si
on
 a
va
ila
bl
e 
on
lin
e
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
ity
 o
f Q
ue
en
sla
nd
13
0.
10
2.
15
8.
15
 - 
6/
18
/2
01
3 
4:
01
:0
7 
AM
 Small  /Bennett  /Roy  /Gabrielli  /Johnson  /
Gobe  
 
Nephron Exp Nephrol 2012;122:123–130 
DOI: 10.1159/000350726
128
 Discussion 
 Although oxidative stress and cell senescence may con-
tribute to renal cell dysfunction and attrition in CKD, the 
involvement of the mitochondria and their health or dys-
function in the pathogenesis of CKD has not yet been well 
defined. This study used an in vitro kidney disease model 
with oxidative stress and cell senescence to investigate mi-
tochondria involvement in the loss of renal tubular epi-
thelial cells, as a cell culture model of oxidative stress in 
CKD. The results have provided evidence that oxidative 
stress and cell senescence combine to cause most renal cell 
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 Fig. 6. Western immunoblot and densi-
tometry for p16 Ink4a .  a Western immuno-
blots for the cell cycle regulator p16 Ink4a 
at 2 h ( b ) and 24 h ( c ) after treatment, plus 
the GAPDH loading controls. Suberohy-
droxamic acid (+) was used as a positive 
control for induction of p16 Ink4a expres-
sion. Blots and densitometry are labelled 
with control, DMSO vehicle, API, H 2 O 2 or 
API + H 2 O 2 . p16 Ink4a expression did not 
change significantly at 2 h following all 
treatments; however, after 24-hour expo-
sure to H 2 O 2 there was significantly in-
creased p16 Ink4a expression ( * * *   p < 0.05 
compared to controls). 
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 Fig. 5. Induction of senescence in HK2 cells.  a ,  b Senescence was 
identified and quantified using morphology (enlarged cells with 
reduced staining saturation).  c ,  d Senescence was identified and 
quantified using immunofluorescence of SA-β-gal.  b API and API 
+ H 2 O 2 produced significant changes in senescence morphology 
( *  p < 0.05 compared with controls); however, SA-β-gal ( a ) was 
significantly increased by all treatments ( * p < 0.05 compared to 
DMSO and  #  p < 0.05 compared to untreated controls).  c ,  d Im-
munofluorescence for controls ( c ) had little labelling versus exten-
sive punctuate green fluorescence in the cytoplasm of API-treated 
cells (d). DAPI-stained nuclei are blue. 
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loss as well as decrease the proliferative activity of renal 
cells; both involve mitochondrial destabilization.
 One of the unusual outcomes was that the flavonoid 
API, used successfully here and elsewhere  [19] to induce 
renal cell senescence, also caused increased lipid peroxi-
dation (increased MDA), decreased TAC and the greatest 
mitochondrial dysfunction with or without concurrent 
H 2 O 2 . Lagoa et al.  [24] recently reported, using mitochon-
dria isolated from rat brain and heart, that API (10 μ M ) 
inhibited the activity of Complex I of the electron trans-
port chain by affecting the binding of the coenzyme sub-
strate. Increased reliance on Complex I–III electron trans-
fer reduces the efficiency of oxidative phosphorylation, 
perhaps leading to mitochondrial dysfunction. These re-
sults and our own suggest that the oxidative stress pro-
duced by API may exhaust antioxidant stores. In our 
study, API did not alter the expression of the cell cycle 
regulator p16 Ink4a after 2 or 24 h, indicating that API-in-
duced kidney cell senescence occurs via p16 Ink4a -indepen-
dent mechanisms. The apparent lack of p16 Ink4a activity 
may indicate a protective mechanism, thereby ceasing 
their progression to transcription. Transcriptional regula-
tion by API may need to be investigated, such as was pub-
lished by Liu et al.  [25] for the inhibitory action of API on 
vascular endothelial growth factor and angiogenesis.
 Apoptosis and mitosis contribute to renal homeostasis 
by ensuring adequate cell numbers for healthy renal func-
tion. Loss of functioning renal cells (increased apoptosis), 
decreased mitosis and increased cell senescence reflect a 
decreased ability for the kidney to metabolise and repair 
in CKD  [26, 27] . All of these characteristics featured in 
the current experiments. API and H 2 O 2 were pro-apo-
ptotic, notably with a synergistic effect seen on renal cell 
apoptosis when the treatments were combined. The pro-
apoptotic effect of API has been recorded previously, but 
mostly in investigations of cancer treatments, where it 
caused apoptosis in cervical and prostate cancer cell lines 
when trialled as a therapy against cancer growth  [28, 29] .
 Apoptosis, as a result of oxidative damage, is well rec-
ognised. In CKD, apoptosis may initially act as a cellular 
adaptive response to oxidative stress to eliminate dysfunc-
tional cells. The outcome for the whole kidney, however, 
is likely to be renal atrophy with loss of renal function. The 
Bcl-2 family proteins, including pro-apoptotic Bax and 
anti-apoptotic Bcl-X L , regulate the intrinsic, mitochon-
drial-dependent pathway of apoptosis  [7, 30] . Changes in 
the ratio of pro-apoptotic Bax to anti-apo ptotic Bcl-X L fol-
lowing oxidative insult have been seen previously in renal 
epithelium  [5, 31] . In the current experiments, there was 
a similar pro-apoptotic change with all treatments.
 NAC is a free-radical scavenger that has been used suc-
cessfully to reduce injury in a variety of nephrotoxic and 
ischemic experimental and clinical renal models, and has 
had some success in CKD patients  [32] . When it was used 
concurrently with API and/or H 2 O 2 , it significantly re-
duced apoptosis and senescence and also restored the re-
generative capacity of the kidney. However, antioxidant 
therapy is sometimes disappointing in models of CKD 
 [33] and more studies are now being completed compar-
ing multiple antioxidants.
 In conclusion, the cellular and biomolecular altera-
tions in the kidney during CKD are undoubtedly very 
complex, but our investigation provides evidence that ox-
idative stress and cell senescence together produce the 
greatest renal cell loss and mitochondrial destabilisation. 
The antioxidant NAC attenuated many of the character-
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 Fig. 7. The antioxidant NAC ameliorates effects of oxidative stress 
and senescence. Percentage apoptosis ( a ), mitosis ( b ) and senes-
cence ( c ) are shown. Cells were pre-treated with NAC (10 m M ), or 
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changes are indicated by an asterisk (p < 0.05). NAC significantly 
modulated apoptosis for all treatments, restored the mitotic poten-
tial of H 2 O 2 -treated cells and decreased senescence induced by API 
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istics that likely contribute to CKD. A more targeted ap-
proach to antioxidant therapy in CKD may limit mito-
chondrial dysfunction, with an improved outcome for 
CKD patients. The model may serve as a baseline to test 
the role of mitochondria after various putative causes of 
CKD, and to further analyse the benefits of antioxidants 
in ameliorating mitochondrial dysfunction in CKD.
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Small DM, Morais C, Coombes JS, Bennett NC, Johnson DW,
Gobe GC. Oxidative stress-induced alterations in PPAR- and asso-
ciated mitochondrial destabilization contribute to kidney cell apopto-
sis. Am J Physiol Renal Physiol 307: F814–F822, 2014. First pub-
lished August 13, 2014; doi:10.1152/ajprenal.00205.2014.—The
mechanism(s) underlying renoprotection by peroxisome proliferator-
activated receptor (PPAR)- agonists in diabetic and nondiabetic
kidney disease are not well understood. Mitochondrial dysfunction
and oxidative stress contribute to kidney disease. PPAR- upregulates
proteins required for mitochondrial biogenesis. Our aim was to deter-
mine whether PPAR- has a role in protecting the kidney proximal
tubular epithelium (PTE) against mitochondrial destabilisation and
oxidative stress. HK-2 PTE cells were subjected to oxidative stress
(0.2–1.0 mM H2O2) for 2 and 18 h and compared with untreated cells
for apoptosis, mitosis (morphology/biomarkers), cell viability (MTT),
superoxide (dihydroethidium), mitochondrial function (MitoTracker
red and JC-1), ATP (luminescence), and mitochondrial ultrastructure.
PPAR-, phospho-PPAR-, PPAR- coactivator (PGC)-1, Parkin
(Park2), p62, and light chain (LC)3 were investigated using Western
blots. PPAR- was modulated using the agonists rosiglitazone, piogli-
tazone, and troglitazone. Mitochondrial destabilization increased with
H2O2 concentration, ATP decreased (2 and 18 h; P  0.05), Mito-
tracker red and JC-1 fluorescence indicated loss of mitochondrial
membrane potential, and superoxide increased (18 h, P  0.05).
Electron microscopy indicated sparse mitochondria, with disrupted
cristae. Mitophagy was evident at 2 h (Park2 and LC3 increased; p62
decreased). Impaired mitophagy was indicated by p62 accumulation at
18 h (P  0.05). PPAR- expression decreased, phospho-PPAR-
increased, and PGC-1 decreased (2 h), indicating aberrant PPAR-
activation and reduced mitochondrial biogenesis. Cell viability de-
creased (2 and 18 h, P  0.05). PPAR- agonists promoted further
apoptosis. In summary, oxidative stress promoted mitochondrial de-
stabilisation in kidney PTE, in association with increased PPAR-
phosphorylation. PPAR- agonists failed to protect PTE. Despite
positive effects in other tissues, PPAR- activation appears to be
detrimental to kidney PTE health when oxidative stress induces
damage.
peroxisome proliferator-activated receptor-; thiozolidinediones; mi-
tochondria; oxidative stress
ALTERATIONS IN THE BIOENERGETIC CONTROLS of kidney cells can
lead to a failure in oxidant handling, leading to a state of
oxidative stress in kidney disease. The causes are multiple,
from high glucose in diabetes to ischemia-reperfusion, toxins,
and acute kidney injury to the long-term effects of aging and
the development of chronic kidney disease (CKD). Kidney
tubular atrophy, mainly due to tubular cell apoptosis of the
proximal tubule, is a common characteristic of these diseases
and therefore presents a crucial target to preserve kidney health
(36, 37). Oxidative stress is a mediating factor in mitochondrial
dysfunction and subsequent cell dysregulation and death dur-
ing kidney disease (16, 41, 47). The importance of mitochon-
drial dysregulation comes from the large number of mitochon-
dria in proximal tubular epithelial (PTE) cells and their heavy
reliance on oxidative phosphorylation for ATP-dependent ac-
tive solute transport in the nephron (19). Identifying oxidant-
handling pathways that are perturbed in the kidney during
oxidative stress is necessary for the development of reliable
therapies.
Peroxisome proliferator-activated receptor (PPAR)- is a
member of the highly conserved nuclear hormone receptor
superfamily of ligand-dependent transcription factors that play
central roles in lipid metabolism, glucose homeostasis, cell
proliferation, and inflammation (1). Ligand binding induces
heterodimer formation with the retinoic acid receptor and
complex binding to the peroxisome proliferator response ele-
ment within the promoter region of target genes (18). Phos-
phorylation may modulate the activity of PPAR- through
activating multiple kinase signaling pathways, including ERK
and AMP-activated protein kinase (AMPK). However, PPAR-
phosphorylation does not always indicate the activation of
PPAR- (5, 23, 51). Its inhibition may also be important for the
overall outcome, which largely depends on tissue type and the
mode of PPAR- modulation.
The family of thiozolidinediones (TZDs) consists of potent
pharmacological agonists of PPAR-, commonly used in the
treatment of type 2 diabetes. The targeting of PPAR-, how-
ever, is not limited to diabetes and its effect or dependence on
insulin. For example, PPAR- mRNA expression is increased
in kidney biopsies of CKD patients of diverse etiologies (32)
raising the possibility of mechanisms not dependent on insulin;
the TZD rosiglitazone attenuated kidney structural and func-
tional damage in a mouse model of diabetes, yet no change was
observed in glucose, insulin, or lipid levels (4), and a reduction
in proteinuria was achieved in patients with nondiabetic kidney
disease of various etiologies after 4 mo of rosiglitazone treat-
ment (27). A possible explanation for the diverse outcomes
from PPAR- agonist success is that PPAR- also positively
regulates mitochondrial biogenesis through the activation of
PPAR- coactivator (PGC)-1. Thus, PPAR- may influence
mitochondrial function (6, 12). This is important given the vital
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role mitochondria play in regulating the intracellular redox
environment (50). Healthy mitochondrial function relies on the
degradation of defective mitochondria via the activation of
selective autophagy pathways (mitophagy) and upregulation of
mitochondrial biogenesis pathways to restore a healthy pool
of functioning mitochondria (44). PPAR-, an alternate iso-
form of PPAR, also plays a role in mitochondrial biogenesis,
but is more widely expressed in the skeletal muscle and liver
(17) than in the kidney.
Several molecular pathways may be involved for the influ-
ence of PPAR- on mitochondrial function. A major pathway
for injury-induced mitochondrial degradation is the phosphate
and tensin homology-induced kinase-Parkin 2 (Park2) path-
way. Park2 is an E3 ubiquitin ligase that translocates to
mitochondria and mediates mitochondrial degradation (3, 35).
The adaptor protein p62 facilitates selective autophagy into the
light chain (LC)3-regulated machinery for lysosomal degra-
dation (2, 13). p62 is not required for Park2 translocation to
damaged mitochondria but is essential for final autophagic
clearance (13). PGC-1 is a nuclear transcription factor that
has been shown to mediate almost all aspects of mitochondrial
biogenesis and is therefore considered a master regulator of
biogenesis (21). Failure to restore mitochondrial homeostasis
and function can lead to a progressive increase in ROS and
ensuing oxidative stress. Therefore, PGC-1 activation pres-
ents a crucial target for mitochondrial preservation. Previous
studies (22, 39) have demonstrated TZD induction of mito-
chondrial biogenesis.
This study sought to 1) investigate the role of PPAR- in
oxidative stress and mitochondrial destabilization in damage
and loss of human kidney proximal tubular cells and 2)
determine whether PPAR- modulation can protect human
kidney PTE cells from oxidative stress-induced damage by
preserving mitochondrial function.
METHODS AND MATERIALS
Experimental design. HK-2 PTE cells were maintained in DMEM-
F-12 Ham’s medium containing 10% FBS and 1% penicillin-strepto-
mycin. Cells were grown at 37°C in a humidified atmosphere of 95%
O2 and 5% CO2, in 25- or 75-cm2 flasks. Cells were treated with H2O2
(0.2–1.0 mM) for 2 and 18 h to induce oxidative stress. In some
treatments, the PPAR- agonists troglitazone, rosiglitazone, and pi-
oglitazone were used as treatments for 2 h before and during H2O2
exposure. Troglitazone (T2573) and pioglitazone (E6910) were pur-
chased from Sigma-Aldrich (Castle Hill, NSW, Australia); rosiglita-
zone (no. 71740) was purchased from Cayman Chemical (Ann Arbor,
MI). All agonists were dissolved as stock solutions in DMSO and
stored frozen as small aliquots. A vehicle control was always used for
these experiments.
Western blot analysis. Western blots were performed from whole
cell lysates dissociated in lysis buffer (0.15M sodium chloride,
0.025M sodium fluoride, 0.5M EDTA, 0.1% SDS, and 1.0% Igepal in
50 mM Tris·Cl, pH 7.5) containing phosphatase and protease inhibi-
tors (10 g/ml aprotinin, 10 g/ml leupeptin, 1 mM sodium or-
thovanidate, and 100 g/ml phenylmethylsulfonyl chloride). Protein
was separated by SDS-PAGE on 10% acrylamide gel and electropho-
retically transferred onto polyvinyldodecylfluoride membranes. Mem-
branes were blotted using antibodies against PPAR-, phosphorylated
(p-)PPAR- (phosphorylation site: Ser112), PPAR-, PGC-1, Park2,
p62, LC3, and GAPDH as a loading control. Ponceau S was also
used as a dye on the polyvinyldodecylfluoride membrane to indicate
even loading of protein. Appropriate secondary antibodies were used
and visualised using chemiluminescent enhancer and X-ray film.
Scion software (Release Alpha 4.0.3.2) was used to quantify bands for
densitometry, which was normalized to GAPDH.
Light and fluorescence microscopy. Cells were grown to 70%
confluence on 12-mm glass coverslips. Immunofluorescence and cy-
tochemistry were used to assess p62 cellular localization. The primary
antibody for p62 (1:500, Santa Cruz Biotechnologies, Santa Cruz,
CA) was used with a secondary anti-rabbit Alexa fluor green fluores-
cence conjugate (1:300, Cell Signaling Technologies, Danvers, MA).
Apoptosis and mitosis were assessed using morphology (14) after
hematoxylin and eosin staining and digital scanning using Aperio
ImageScope histology software. Data were obtained by counting 10
frames (200) of cells for each treatment and calculating the percent-
age of apoptotic or mitotic cells. The morphological characteristics for
apoptosis were 1) shrunken eosinophilic cells with condensed, mar-
ginated nuclear chromatin and an intact cell membrane; 2) discrete
apoptotic bodies compromising large, dense, pyknotic nuclear frag-
ments surrounded by a narrow eosinophilic cytoplasm; and 3) clusters
of small apoptotic bodies (assessed as a single apoptotic occurrence)
(14). The morphological characteristics used to distinguish mitosis
were 1) the formation of mitotic spindles occurring during metaphase
and remaining visible in anaphase or 2) cells in the later stages of
mitosis, telophase, or undergoing cytokinesis. Morphological verifi-
cation of quantification has been confirmed in a similar experimental
protocol using molecular biomarkers for apoptosis (ApopTag) and
mitosis (proliferating cell nuclear antigen) in parallel with morphol-
ogy (41).
Oxidative stress and mitochondrial function. Oxidative stress was
determined and quantified using microfluorimetry detection of the
oxidation of dihydroethidium (DHE) to ethidium. Superoxide selec-
tively oxidizes this reaction and is an essential precursor to harmful
cellular oxidants, such as the hydroxyl radical and peroxynitrite. Cells
were cultured in black 96-well plates and treated as previously
described. The growth medium was then replaced with 5M DHE in
serum-free DMEM-F-12 and incubated for 30 min. Fluorescence
intensity was measured at 536-nm excitation and 610-nm emission
(Synergy Mx Multi-Mode Microplate reader, BioTek, Winooski, VT).
Fluorescence values were normalized to protein content for the cor-
responding wells and expressed as DHE fluorescence per microgram
of protein. JC-1 is a cationic fluorophore that possesses a mitochon-
drial membrane-dependent accumulation in mitochondria and was
quantified using the same technique. A decrease in red fluorescence
(JC-1 aggregate uptake into healthy mitochondria) and increase in
green fluorescence (JC-1 in the cytoplasm) indicates mitochondrial
membrane depolarization. JC-1 (3 M) was used posttreatment, and
fluorescence intensity was measured at 525-nm excitation and 590-nm
emission (red) and 490-nm excitation and 530-nm emission (green)
and normalized to protein content. ATP production was measured
using a luciferase-based luminescence assay (Promega). Cells were
seeded into white opaque 96-well plates and treated as previously
described. Chemiluminescent reagent was added, and cell lysis was
induced before luminescence was measured at an integration time of
0.5 s using a Titertek-Berthold Luminometer (Titertek-Berthold De-
tection Systems, Pforzheim, Germany).
Mitochondrial viability. MitoTracker red CMXRos (Invitrogen)
and confocal fluorescence microscopy were used to determine mito-
chondrial density. MitoTracker localizes to mitochondria with a
healthy mitochondrial membrane potential. Cells were grown on glass
coverslips and exposed to 100 nm MitoTracker red CMXRos for 30
min after treatments as previously described. Coverslips were
mounted after fixation in 4% paraformaldehyde and 4=,6-diamidino-
2-phenylindole nuclear staining. Cells were observed at 63 with a
Zeiss 510 Meta confocal fluorescence microscope using Zen 2008
software. Transmission electron microscopy was used to visualize the
ultrastructure of mitochondria. Briefly, cells were grown on sapphire
disks in growth media and exposed to treatments. High-pressure
freezing fixation was performed, and samples were imaged with a Jeol
1010 transmission electron microscope.
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Cell viability. Cell viability was measured using the assay based on
the reduction 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT; Sigma). Briefly, cells were treated as previously
described in 96-well plates, and 100l MTT solution was prepared in
DMEM-F-12 solution (0.5 mg/ml), added to wells, and incubated for
90 min at 37°C. MTT culture media were removed, and formazan
crystals that had formed during the assay were dissolved in 200 l
DMSO. Absorbance was measured in a microplate reader at 570 nm
with background collection at 690 nm.
Statistical analysis. Values are reported as means 	 SE. Data were
analyzed using one-way ANOVA and Tukey’s post hoc analysis,
two-way ANOVA and Bonferroni’s post hoc test, or Student’s t-test
where appropriate. Significance was established at P  0.05.
RESULTS
Oxidative stress decreased PPAR- expression and in-
creased PPAR- Ser112 phosphorylation. HK-2 cells displayed
a dose-dependent significant increase in apoptosis and dose-
dependent decrease in mitosis after oxidative stress at both 2
and 18 h (Fig. 1, A and B). This was associated with a decrease
in PPAR- protein levels (P  0.001 starting at 0.4 mM H2O2;
Fig. 2A) and a dose-dependent increase in p-PPAR- levels
(P  0.001 starting at 0.4 mM H2O2; Fig. 2A) after 2 h of
exposure to H2O2. After 18 h of H2O2 exposure (Fig. 2B),
PPAR- and p-PPAR- returned to basal levels, indicating that
oxidative stress promotes the phosphorylation of PPAR- as an
early response. Conversely, PPAR- expression decreased in a
dose-dependent manner after 2 h of exposure to H2O2 (P 
0.05 starting at 0.4 mM H2O2; Fig. 2A) and returned to control
levels after 18 h of H2O2 exposure (Fig. 2B).
Oxidative stress induced mitochondrial dysfunction. Mi-
tochondrial function was significantly reduced after exposure
to H2O2 for both 2 and 18 h (Fig. 3). H2O2 (0.6 mM)
significantly increased DHE fluorescence, indicating enhanced
levels of superoxide production and confirming an intracellular
state of oxidative stress (P 0.05; Fig. 3A). The mitochondrial
membrane potential significantly decreased, as indicated by a
decrease in JC-1 red fluorescence intensity (P  0.01 starting
at 0.4 mM H2O2; Fig. 3B) and an increase in JC-1 green
fluorescence intensity (P  0.01 starting at 0.4 mM H2O2; Fig.
3C). Confocal microscopy revealed that, compared with un-
treated HK-2 cells (Fig. 3H), uptake of MitoTracker red
CMXRos fluorescence was impaired after H2O2 exposure at
both 2 h (Fig. 3I) and 18 h (Fig. 3J). Mitochondrial ultrastruc-
ture (Fig. 3, D–G) revealed abundant elongated mitochondria
with clear cristae in untreated HK-2 cells (Fig. 3, D and E)
compared with segmented and swollen mitochondria (Fig. 3F)
and absent cristae (Fig. 3G) after H2O2 exposure. These
changes relate to a significant dose-dependent decrease in ATP
production by mitochondria after H2O2 exposure at both 2 h
(P  0.001 at 0.4 mM H2O2; Fig. 4A) and 18 h (P  0.001 at
0.4 mM H2O2; Fig. 4B), indicating impaired oxidative phos-
phorylation.
Oxidative stress-induced PPAR- dysregulation impaired
mitochondrial autophagy (mitophagy) and biogenesis. After
oxidative stress and the initial insult affecting mitochondrial
function (Figs. 3 and 4), the cellular autophagy machinery
needed for selective mitochondrial clearance was upregulated.
These results are shown in Fig. 5. Two hours of H2O2 exposure
significantly increased Park2 expression (P  0.01 at 0.4 mM
H2O2; Fig. 5A), indicating effective tagging of defective/
damaged mitochondria for autophagic clearance. Simultane-
ously, expression of the adapter protein p62 was significantly
downregulated (P  0.05 at 0.4 mM H2O2; Fig. 5B), and a
significant increase was seen in LC3 protein levels (P  0.01
at 0.6 mM H2O2; Fig. 5C), demonstrating early selective
autophagy of mitochondria (mitophagy). Park2 expression was
not significantly altered after extended (18 h) H2O2 exposure
(Fig. 5D), yet there was a significant increase in p62 and LC3
protein levels, indicating impaired p62 degradation with intra-
cellular accumulation. Altered p62 expression, as seen by
Western immunoblot analysis and assumed intracellular accu-
mulation, was verified using confocal microscopy (Fig. 5,
G–I). There was a decrease in the PPAR- coactivator and
mitochondrial biogenesis marker PGC-1 after 2 h of H2O2
exposure (P  0.05 at 0.4 mM H2O2; Fig. 6A) that corre-
sponded with the changes in Park2, p62, and LC3. The
cumulative results demonstrate impaired PPAR--dependent
mitochondrial biogenesis.
PPAR- activation does not protect kidney proximal tubular
cells from oxidative stress-induced damage. PPAR- expres-
sion and phosphorylation changes with selective PPAR- TZD
agonists were tested to determine whether this protected cells
Fig. 1. Oxidative stress promotes apoptosis and impairs mitosis in HK-2 cells.
HK-2 cells were exposed to H2O2 at concentrations ranging from 0.2 to 1.0
mM. Percentages of apoptotic and mitotic cells were imaged at 200 and
quantified using morphology after hematoxylin and eosin staining. Apoptosis
significantly increased in a dose-dependent manner after H2O2 exposure at
both 2 and 18 h (A). Mitosis significantly decreased in a dose-dependent
manner after H2O2 exposure at both 2 and 18 h (B). Results are expressed as
means 	 SE. ***P  0.001 compared with 18-h controls; #P  0.05 and
##P  0.01 compared with 2-h controls.
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from oxidative stress. The TZD agonists were delivered 2 h
before H2O2 (0.6 mM) exposure and during the 2- and 18-h
H2O2 treatment periods. Concentrations of the TZD agonists
(rosiglitazone and troglitazone at 10 M and pioglitazone at 1
M) were chosen from our preliminary data (not shown) and
were consistent with concentrations used in similar previous
studies (6, 11, 22, 33, 34). Expression of p-PPAR- was
calculated as a ratio of PPAR, and the fold change compared
with control cells was then compared for each of the TZDs at
2 h (Fig. 7, A–C) and 18 h (Fig. 7, G–I). H2O2 exposure alone
caused a significant increase in Ser112 phosphorylation of
PPAR- at both 2 and 18 h (P  0.05, Fig. 7, A–C; and P 
0.001, Fig. 7, G–I). This occurred in conjunction with a
significant decrease in cell viability compared with control
cells at 2 and 18 h (P  0.001, Fig. 7, D–F; and P  0.001,
Fig. 7, J–L). Cell viability was not improved above H2O2 levels
when each of the PPAR- agonists was used in combination
with H2O2 for 2 h (Fig. 7, D–F). Thus, these results demon-
strate a lack of protection by TZDs against oxidative stress-
induced loss of viability at a time when the p-PPAR--to-
PPAR ratio was significantly increased. After extended expo-
sure to PPAR- agonists and H2O2 (18 h), cell viability levels
remained significantly low (P  0.001; Fig. 7, J–L), with the
cell viability of the dual TZD and H2O2 treatment showing a
further significant reduction with rosiglitazone and troglitazone
(P  0.05; Fig. 7, J and K). Expression of the p-PPAR--to-
Fig. 2. Peroxisome proliferator-activated receptor (PPAR)- and PPAR- respond early (2 h) after oxidative stress. HK-2 cells were exposed to a range of H2O2
concentrations (0.2–1.0 mM) for 2 and 18 h. A: representative Western blots. There was a dose-dependent significant increase in PPAR- phosphorylation
[phosphorylated (p-)PPAR-] after 2 h of H2O2 exposure that corresponded to a decrease in PPAR- expression. PPAR- significantly increased in a
dose-dependent manner after 2 h of H2O2 exposure. B: results for 18 h. H2O2 exposure for 18 h did not significantly alter PPAR- phosphorylation or PPAR-
expression. p-PPAR- and PPAR- are expressed as a ratio, and PPAR- protein expression was normalized to GAPDH expression. Results are expressed as
means 	 SE. *P  0.05, **P  0.01, and ***P  0.001 compared with controls.
Fig. 3. Oxidative stress induces mitochondrial dys-
function. HK-2 cells were exposed to a range of
H2O2 concentrations (0.2–0.6 mM) for 2 and 18 h.
Dihydroethidium (DHE) and JC-1 fluorescence was
quantified by fluorimetry at 18 h. A: DHE fluores-
cence significantly increased after 0.6 mM H2O2
exposure, demonstrating ROS generation at 18 h. B
and C: JC-1 red fluorescence significantly decreased
in a dose-dependent manner (B) while increasing in
green fluorescence (C), indicating mitochondrial
membrane depolarization at 18 h. D–G: transmis-
sion electron microscopy revealed elongated mor-
phologically healthy mitochondria with cristae in
untreated HK-2 cells (D and E) and segmented,
swollen mitochondria (F) often with absent cristae
(G) in 0.6 mM H2O2-treated HK-2 cells at 18h
(arrow heads). H–J: MitoTracker red CMXRos up-
take was visualized with confocal microscopy and
shown to decline after both 2 h (I) and 18 h (J) of 0.6
mM H2O2 exposure compared with untreated HK-2
cells (H). Results are expressed as means 	 SE.
*P  0.05, **P  0.01, and ***P  0.001 com-
pared with controls.
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PPAR- ratio remained significantly increased at 18 h for
rosiglitazone combined with H2O2 (P  0.001; Fig. 7G),
whereas the ratio returned to that observed in untreated con-
trols after troglitazone cotreatment (Fig. 7H) and was lower
than untreated controls with pioglitazone cotreatment (P 
0.01; Fig. 7I). Extended exposure of TZD agonists for 18 h
before H2O2 exposure also demonstrated no protection to cell
viability (data not shown).
Fig. 4. Oxidative stress impaired cellular ATP pro-
duction. HK-2 cells were exposed to a range of
H2O2 concentrations (0.2–1.0 mM) for 2 and 18 h.
An ATP assay was performed based on lumines-
cence. ATP levels significantly decreased in a dose-
dependent manner after H2O2 exposure for both 2 h
(A) and 18 h (B). Results are expressed as means 	
SE. ***P  0.001 compared with controls.
Fig. 5. Oxidative stress promotes selective mitochondrial autophagy (mitophagy). HK-2 cells were exposed to a range of H2O2 concentrations (0.2–1.0 mM) for
2 and 18 h. Cells were lysed, and Western blot analysis was performed. Immunofluorescence of p62 was performed (anti-p62 is green fluorescence and nuclear
4=,6-diamidino-2-phenylindole is blue). Protein levels of Parkin (Park2; A) and p62 (B) significantly increased and decreased, respectively, in a dose-dependent
manner, whereas light chain (LC)3 (C) significantly increased after 2 h of H2O2 exposure. Park2 protein levels returned to control levels after 18 h of H2O2
(D), whereas p62 (E) and LC3 (F) expression significantly increased in a dose-dependent manner. Immunofluorescence revealed decreased cytoplasmic
localisation of p62 after 2 h of H2O2 (H) compared with untreated HK-2 cells (G), which increased after 18 h of H2O2 (I) to show a punctate perinuclear
cytoplasmic pattern (white arrowhead). Protein expression was normalized to GAPDH expression. Results are expressed as means	 SE. *P 0.05, **P 0.01,
and ***P  0.001, compared with controls.
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DISCUSSION
Oxidative stress and mitochondrial dysfunction have been
implicated in the pathogenesis of kidney disease of diverse
causes, including diabetes and CKD, two diseases of increasing
incidence (8, 15, 16). However, the molecular mechanisms are
still unclear. Here, oxidative stress-induced PPAR- alterations
were associated with mitochondrial destabilization and a fail-
ure to restore mitochondrial health due to defective activation
of PPAR--dependent biogenesis pathways. Furthermore, se-
lective PPAR- activation enhanced oxidative stress-mediated
tubular cell damage that was associated with PPAR- Ser112
phosphorylation. The results suggest that, despite positive
benefits in other tissues, PPAR- activation may be detrimental
to kidney PTE cells in the scenario of oxidative stress-induced
injury.
Our results demonstrate that PPAR- is present in kidney
PTE cells and is responsive early in oxidative stress-induced
injury. The associated increase in Ser112-phosphorylation of
PPAR- (p-PPAR-) was not beneficial to cellular outcome in
these cells. The increase in the p-PPAR--to-PPAR- ratio
may be injurious to cells via the development of mitochondrial
dysfunction. However, at 18 h of exposure to oxidative stress,
the p-PPAR--to-PPAR- ratio was not elevated, perhaps
demonstrating that early stress-induced PPAR- dysregulation
stimulates a series of persistent negative cellular events, pri-
marily targeting mitochondrial homeostasis.
Oxidative stress-induced posttranslational modifications to
PPAR-, including phosphorylation, have had little study in
kidney PTE cells. In adipocytes, MAPK-induced phosphory-
lation of PPAR- at Ser112 was linked to decreased transcrip-
tional activity of PPAR- by inhibition of ligand binding and
cofactor recruitment (5, 23, 51). In addition, PPAR- phos-
phorylation at Ser87 by AMP kinase in baby hamster kidney
cells repressed the transactivating function of the receptor (31).
Our data, demonstrating a decrease in PPAR- transcriptional
activity along with a failure to upregulate PGC-1 and mito-
chondrial biogenesis, at a time of increased Ser112 PPAR-
phosphorylation in human kidney PTE cells, agree with those
reports. The decrease in total functional PPAR- is likely due
to phosphorylation. Similar results have been shown in kidney
mesangial cells exposed to a high-glucose environment (45), a
mechanism of kidney injury involving increased oxidative
stress (40, 42).
PTE cells of the kidney have a high density of mitochondria
(20). It is likely, therefore, that the relationship between
PPAR- and mitochondrial function will be especially impor-
tant. Yang and colleagues (48) have previously shown, in an in
vivo rat model of aging, that PPAR- activation attenuates
age-related mitochondrial injury in the kidney by maintaining
the integrity of the mitochondrial membrane potential. How-
ever, these results represent an outcome from the heteroge-
neous renal cell population and not specifically mitochondria
from PTE cells. The majority of in vitro studies that have
demonstrated protective actions of PPAR- have done so in
glomerular cell types, namely, podocytes and mesangial cells
(26, 34, 49). Our results demonstrate oxidative stress-induced
PTE cell mitochondrial dysfunction that is associated with a
decreased p-PPAR--to-PPAR- ratio. This alteration is per-
sistent, indicating that PPAR- induces negative downstream
effects. We hypothesized that PPAR- phosphorylation in-
duced disruptions to the mitochondrial homeostatic machinery
and was responsible for this persistent cumulative dysfunction.
Autophagy is a highly conserved protective response to
eliminate damaged cellular components. Mitochondrial ho-
meostasis relies on the degradation of defective mitochondria
and upregulation of mitochondrial biogenesis to restore a
healthy pool of functioning mitochondria (9). Our results
demonstrate significant perturbation to these pathways during
oxidative stress. The induction of selective mitophagy medi-
ated by the Park2-p62-LC3 pathway is evident after the initial
(2 h) response to oxidative stress. However, long-term (18 h)
oxidative stress facilitates significant impairments to this sys-
tem, as indicated by p62 aggregation. Park2 upregulation after
2 h of oxidative stress demonstrates labeling and translocation
of the E3 ligase Parkin to depolarized mitochondria and the
initiation of polyubiquination to signal p62 binding (13). p62
degradation has been shown to be a consistent marker of
selective autophagy due to its clearance within the autophago-
some (25, 28, 29, 43), and our results further confirm this with
enhanced LC3 expression. Mitophagy has received little
study in the kidney, with Parkin-mediated mitophagy previ-
ously shown to be dependent upon p62 in HeLa and neuro-
blastoma cell lines (13). Recently, Ishikawa and colleagues
(24) used rat acute kidney injury models to demonstrate that
increased mitophagy in the kidney was highly influenced by
ROS. The results of the present investigation show an increase
in p62 after 18 h of oxidative stress, demonstrating impaired
selective turnover and accumulation of p62. A previous study
(30) has demonstrated liver injury accompanied by the forma-
tion of p62-positive inclusions and that the removal of p62
Fig. 6. Oxidative stress impairs PPAR- coactivator
(PGC)-1-dependent mitochondrial biogenesis that
persists long term. HK-2 cells were exposed to a
range of H2O2 concentrations (0.2–1.0 mM) for 2
and 18 h. Cells were lysed, and Western blot anal-
ysis was performed. Protein levels of PGC-1 sig-
nificantly decreased in a dose-dependent manner
after both 2 h (A) and 18 h (B) of H2O2 exposure.
Protein expression was normalized to GAPDH ex-
pression. Results are expressed as means 	 SE.
*P  0.05, **P  0.01, and ***P  0.001 com-
pared with controls.
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attenuated this injury. Impaired selective mitochondrial au-
tophagy caused by persistent ROS production and ensuing
oxidative damage results in p62 accumulation, which further
contributes to cellular dysfunction. This result was com-
pounded by the failure of PPAR- to activate PGC-1 to
stimulate mitochondrial biogenesis and restore the cellular
redox environment. This change would have provided a con-
tinuation of negatively regulating intracellular signaling, with
persistent oxidative stress and reduced mitochondria-depen-
dent ATP production. This demonstrates early, persistent, and
indirect mitochondrial dysfunction resulting from a failure of
PGC-1 activity after oxidative stress.
PPAR- agonist treatment has previously been shown to
protect against mitochondrial dysfunction in other cell types,
including neuronal cells (10, 46) and endothelial cells (11). In
the kidney, disparate results have been previously described
and largely depend on the cell type and insult used (26, 45, 46).
Important to note is that PPAR- Ser112 phosphorylation has
been shown to modify PPAR- activity rather than act as a
marker of PPAR- activation. PPAR- agonists can inhibit
Fig. 7. PPAR- activation does not protect HK-2 cells against oxidative stress-induced injury. HK-2 cells were exposed for 2h with either rosiglitazone (Rosi;
10M), troglitazone (Trog; 10 M), or pioglitazone (Piog; 1 M) followed by 2 h of exposure to H2O2 (0.6 mM) in combination with Rosi, Trog, or Piog.
Western blot analysis and MTT assay were performed. At 2 h, H2O2 alone and in combination with Rosi significantly increased the fold difference in the
p-PPAR--to-PPAR- ratio compared with controls (A). H2O2 and Trog treatment alone or in combination significantly increased the p-PPAR--to-PPAR- ratio
(B). H2O2 treatment alone or in combination with Piog significantly increased the p-PPAR--to-PPAR- ratio (C). Cell viability significantly decreased after
H2O2 treatment alone and in combination with Rosi (D), Trog (E), or Piog (F). At 18 h, H2O2 exposure alone and in combination with Rosi significantly increased
the p-PPAR--to-PPAR- ratio, whereas Rosi treatment alone significantly decreased the p-PPAR--to-PPAR- ratio (G). H2O2 exposure alone significantly
increased, whereas Trog treatment alone significantly decreased, the p-PPAR--to-PPAR- ratio (H). H2O2 treatment alone significantly increased the
p-PPAR--to-PPAR- ratio, which was significantly decreased when H2O2 was used in combination with Piog (I). Cell viability was significantly decreased after
H2O2 exposure alone, and this was significantly enhanced when combined with Rosi (J) or Trog (K). Piog treatment in combination with H2O2 significantly
decreased cell viability compared with control (L). Results are expressed as means 	 SE. *P  0.05, **P  0.01, and ***P  0.001 compared with controls;
#P  0.05 compared as indicated.
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obesity-linked Ser273 phosphorylation of PPAR- by cyclin-
dependent kinase 5 in adipose tissue (7). Our results show an
inability of rosiglitazone to inhibit PPAR- Ser112 phosphor-
ylation during oxidative stress, therefore preventing classical
downstream actions of PPAR-, primarily the upregulation of
PGC-1 and maintenance of mitochondrial homeostasis (21,
39). This finding appears to be unique to kidney tubular cells.
Of note is that PPAR- is an alternate inducer of PGC-1-
dependent mitochondrial biogenesis (38, 44), and its down-
regulation in response to oxidative stress further impairs
the restoration of mitochondrial homeostasis. The ability of
rosiglitazone and troglitazone to decrease PTE cell viability
after extended oxidative stress is a novel finding and may result
from the inability to prevent PPAR- phosphorylation, not
only at Ser112 but on other sites of phosphorylation, including
Ser273 and Ser82, that were not studied here.
In summary, our findings describe oxidative stress-induced
PPAR- alterations and resulting mitochondrial destabilization
and a failure to restore mitochondrial health due to defective
activation of PPAR--dependent biogenesis pathways. These
changes may contribute to the pathogenesis of diverse kidney
disease, including CKD. A novel finding is that activation of
PPAR- by TZD enhances oxidative stress-mediated tubular
cell damage that is associated with PPAR- Ser112 phosphor-
ylation. This may account for the tubular damage and a lack of
therapeutic benefit of TZDs seen in some human trials.
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Abstract. The structural and functional heterogeneity of the kidney ensures a diversity of response in health and
disease. Multiphoton microscopy has improved our understanding of kidney physiology and pathophysiology by
enabling the visualization of the living kidney in comparison with the static view of previous technologies. The use
of multiphoton microscopy with rodent models in conjunction with endogenous fluorescence and exogenous
infused dyes permits the measurement of renal processes, such as glomerular permeability, juxtaglomerular
apparatus function, tubulointerstitial function, tubulovascular interactions, vascular flow rate, and the intrarenal
renin-angiotensin-aldosterone system. Subcellular processes, including mitochondrial dynamics, reactive oxy-
gen species production, cytosolic ion concentrations, and death processes apoptosis and necrosis, can also be
measured by multiphoton microscopy. This has allowed valuable insight into the pathophysiology of diabetic
nephropathy, renal ischemia-reperfusion injury, hypertensive nephropathy, as well as inflammatory responses
of the kidney. The current review presents an overview of multiphoton microscopy with a focus on techniques for
imaging the kidney and gives examples of instances where multiphoton microscopy has been utilized to study
renal pathophysiology in the living kidney. With continued advancements in the field of biological optics and
increased adoption in experimental nephrology, multiphoton microscopy will undoubtedly continue to create
new paradigms in kidney disease. © The Authors. Published by SPIE under a Creative Commons Attribution 3.0 Unported License.
Distribution or reproduction of this work in whole or in part requires full attribution of the original publication, including its DOI. [DOI: 10.1117/1
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1 Introduction
Over the past decade, fluorescence microscopy has provided
visual insight into the temporal and spatial interactions of mol-
ecules at a cellular and subcellular level. Continuing advance-
ments into fluorescence microscopy have led to imaging that is
less damaging to biological material, thus enabling visualization
of living tissues at a greater penetration depth. Multiphoton
microscopy (MPM) is such a technology. It has brought the
visualization and localization of cellular interactions, typically
seen only in cell culture models, to living animals. Conventional
confocal microscopy relies on a stream of single photons to pro-
cure two- and three-dimensional (3-D) images, whereas MPM
uses rapidly pulsed photons at half of the single photon energy
required to excite the fluorophore. MPM is sometimes referred
to as two-photon excitation microscopy or two-photon fluores-
cence. The simultaneous absorption of two lower-energy photons
excites the fluorophore, reduces background fluorescence due to
a narrow focal volume, and minimizes toxicity to the biological
material due to photo bleaching. The use of lower-energy pho-
tons together with infrared lasers increases the effective tissue
depth of imaging. MPM imaging has been used to study the
structure and function in numerous systems, including liver,1–3
skin,4–8 cornea,9,10 thymus,11,12 and kidney.13–16
The kidney has a complex internal three-dimensional structure
and a heterogeneous cell population, with glomeruli, tubules,
interstitial space, and vasculature interacting in the vital kidney,
an organ that is ideal for imaging with MPM. The renal inter-
stitium, situated between the basement membranes of nephrons
and the vessels, contains interstitial fibroblasts, dendritic cells,
and occasional macrophages that quickly react to stress and
damage of the intrinsic functioning tissues of the kidney.
Developments in image reconstruction and analysis software
have provided additional advancement to bring MPM imaging
to its potential for analyzing the kidney in health and disease.
This review will present an overview of the principles of MPM,
MPM techniques for imaging the kidney, and examples of
instances where MPM has been able to explain novel aspects
of renal pathophysiology.
2 Principles and Advantages of Multiphoton
Microscopy
The basic principles of fluorescence apply to MPM imaging.
Fluorescence occurs by the absorption of a photon by a fluoro-
phore that brings an electron from the fluorophore to an excited
state. The electron returning to its ground state causes the release
of a photon (fluorescence emission photon), which is then effi-
ciently detected.17,18 The initial excitation photon is typically of
a high energy. This is known as single-photon fluorescence.
MPM fluorescence is based on the simultaneous absorption
of two low-energy, near-infrared wavelength photons by a fluo-
rophore, and hence, the alternative name two-photon fluores-
cence (Fig. 1). Three-photon excitation and second harmonic*Address all correspondence to: Glenda C. Gobe, E-mail: g.gobe@uq.edu.au
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generation work on similar principles and can also be used to
visualize fluorescent optical sections.19
Although the energy of either of these photons is too low to
raise an electron to an excited state, it is the combination of the
two energies that is sufficient to excite and thus release a fluo-
rescence emission photon. However, the two photons must meet
the fluorophore at exactly the same time, within approximately
an attosecond (10−18 s) of one another. During the early stages
of development of MPM, this was difficult to achieve since
simultaneous electronic stimulation at a single specified point
was very unlikely. It was not until the development of higher-
powered lasers (∼10 mW) that could produce the necessary
photon flux,21,22 as well as ultrashort pulsed laser systems22 that
greatly reduced the power, that MPM became possible with bio-
logical material.
A further advantage of using near-infrared wavelengths,
instead of ultraviolet light, for fluorescence excitation was
the reduction of scattering and increase in imaging penetration
depth in the sample (from ∼20 to 500 to 600 μm). Additionally,
single-photon microscopy uses a pinhole detection device to
remove out-of-focus and out-of-plane light. Removal of the pin-
hole allows fluorescence emission detectors to be placed closer
to the microscope objective to optimize collection of scattered
light, as well as enhance imaging depth.
3 Techniques for Imaging the Kidney
Various MPM approaches have been utilized to analyze the
functioning kidney at the subcellular level. These include in
vitro imaging,23,24 imaging of live isolated microperfused prep-
arations of tubules, vessels, and glomeruli,25,26 and live perfused
kidney slice preparations.27 Although MPM can produce signifi-
cant information from in vitro experimental models, it is the
whole live kidney where MPM techniques are used to their
full potential. The interplay between segments of the nephron
(glomeruli, tubule segments), the vasculature, and its contents,
and the interstitium can be observed in detail.
The choice of animal, microscope settings, surgical or phar-
macological methods, autofluorescence and fluorescent dyes are
all important considerations for the application of MPM to nor-
mal and diseased kidney. Limitations that have been discovered
in other tissues apply equally in kidney research, and in some
cases, the kidney presents its own set of problems. For example,
early studies in neural tissue had demonstrated that the maximal
tissue depth for two-photon excitation was 500 to 600 μm.28,29
The main problem of MPM in the kidney was that the depth was
limited to a maximum of 150 to 200 μm. This is primarily due to
substantial scattering of emission photons from the high refrac-
tive index and heterogeneity of kidney tissue. In addition, the
ability of cytochrome c oxidase and hemoglobin to absorb
light, and the spherical aberration (a deviation of rays of light
through a spherical lens from the expected focal point) seen in
the kidney, all contributed to a reduction in the maximal exci-
tation depth.30,31 Another important consideration of intravital
MPM is the possibility of photodamage and cytotoxicity due
to extended periods of excitation, and adequate controls need
to be included.
The limitation in maximal excitation depth is important since
glomerular depth from the renal capsule differs among rodents.
For example, the kidneys of Munich-Wistar rats possess super-
ficial glomeruli that are easily imaged with MPM. The afferent
and efferent capillaries and Bowman’s space, as well as the con-
tiguous S1 segment of the proximal tubule, can be seen in this
model.32 In comparison, imaging of mouse kidneys is usually
restricted to tubular and vascular structures because of the
depth of their glomeruli. A quantitative analysis of glomerular
depths from 10 commonly used mouse strains was performed by
Schiessl and colleagues,33 who found that the BALB/c and
C57Bl6 mouse strains contained the most superficial glomeruli
at both 4 and 10 weeks of age, regardless of sex. However, it still
remains challenging to visualize glomeruli in mice, and the use
Fig. 1 Pictorial representation of one-photon and two-photon fluores-
cence. Two-photon excitation demonstrates simultaneous absorption
of infrared laser pulses at a single point compared to one-photon exci-
tation, which uses visible or ultraviolet light lasers that excite photons
throughout the biological material. Adapted from Ref. 20.
Fig. 2 Close-to-surface glomeruli from hydronephrotic mouse kid-
neys. Capillary endothelium is stained with isolectin B4-conjugated
to Alexa Fluor 488 (green), neutrophils are stained using anti-Gr1-
conjugated to phycoerythrin (arrows—orange/red), and surface mye-
loperoxidase (MPO) is stained with polyclonal anti-MPO-conjugated
to Alexa-647 (arrow—blue) demonstrating activated neutrophils.
Bright autofluorescence from remnants of the tubulointerstitium can
be seen outside of glomeruli. Excitation wavelength was 810 nm
and emitted signal was collected by three nondescanned detectors:
500 to 550 nm (Alexa 488), 575 to 605 nm (phycoerythrin), and 625 to
675 nm (Alexa 647). A 20× 1.0 NA water immersion objective (Leica)
was used. Scale bar represents 30 μm. Methods of glomerular prepa-
ration have been described within text and in detail elsewhere.35
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of MPM for studying the functional significance of certain glo-
merular genes or proteins, in specific gene knock-in and
knockout strains of mice, is limited. Khoury and colleagues34
demonstrated podocyte biology in female nephrin knockout/
green fluorescent protein (GFP) knock-in heterozygote
(Nps1tm1Rkl∕J) mice using superficially located glomeruli.
Close-to-surface glomeruli have also been imaged using MPM
in C57Bl6 mice;35 however, this was only possible in three- to
four-week-old mice of ∼12 g weight. These mice have smaller
kidneys and some glomeruli are sufficiently superficial in the
cortex to be visualized via MPM. Another approach for visual-
izing glomeruli in mice is to use the posthydronephrosis
model.36 In this model, one kidney undergoes ureteric ligation
for 12 weeks to allow dilatation of the renal pelvis and marked
tubulointerstitial atrophy. The remaining thin rim of transparent
cortical tissue has clear glomeruli, and these can be visualized
by both transmission and confocal microscopy. This approach
also allows assessment of numerous glomeruli in the same ani-
mal and is particularly amendable for assessment of leukocyte
recruitment during models of glomerular inflammation2–4
Table 1 Types of fluorescent probes, their characteristics, and functions.
Probe Characteristic Function References
Hoecsht 33342 Labels cell nuclei blue Nuclear change (apoptosis, mitosis) 23, 32, 39 to 50
Propidium iodide Labels cell nuclei red,
membrane-impermeable
Necrotic change of nuclei 32, 51, 52
Octadecyl rhodamine
B chloride R-18
Labels cell membrane Single cell size and structure 23, 42, 48, 49
Calcein-acetoxymethyl
(AM)
Labels cytosol of tubular and
endothelial cells
Cell viability 27, 40
Quinacrine Loads preferentially into brush
border and subapical vesicles
Endo- and exocytosis, and apical
shedding. Renin granules in the
juxta-glomerular apparatus
16, 23 to 25, 39
to 41, 48 to 50,
53, 54
Tetramethyl rhodamine
methyl ester
Mitochondrial membrane-
dependent dye
Mitochondrial density and health that
loads well into proximal and distal
tubules, and glomeruli
14, 27, 40
Monochlorobimane Forms a fluorescent adduct in
the presence of glutathione
Indicates levels of intracellular glutathione 14, 27, 40
Rhod-2 AM Calcium-sensitive dye that is
generally localized to the
mitochondria
Indicates levels of intracellular calcium 40 to 42, 55
Seminaphthorhodafluor
(SNARF)-1 AM
pH-sensitive dye Indicated changes in pH levels 42
Dihydroethidium Superoxide-sensitive dye that
fluoresces red and binds to DNA
Indicates levels of reactive oxygen species
production
14, 27, 35
Rhodamine-123 Mitochondrial membrane-
dependent dye
Mitochondrial density and health that
loads preferentially into the proximal tubule
14
Rhodamine B hexyl
ester
Endothelial cell mitochondrial
membrane-dependant dye
Labels metabolically active endothelial cells 32
Lucifer yellow Stains endothelium yellow,
endocytosed from the plasma
Indicates endocytosis 15, 25, 41, 42, 49
Fura-red AM Calcium-sensitive dye Fluorescence intensity decreases on calcium
binding
23, 54 to 56
Fluo-4 AM Calcium-sensitive dye Fluorescence intensity increases on calcium
binding
23, 54 to 56
ANNINE-6 Voltage-sensitive dye Vascular smooth muscle cell selective
(afferent arteriole)
38, 41
Sulfonefluorescein Organic ion secreted by
proximal tubules
Marker of proximal tubule derived renal cysts 57, 58
3000 to 4000-Da
dextran-fluorophore
conjugate
Freely filtered by the glomerulus Indicates glomerular permeability and
proximal tubule endocytosis
15, 32, 42, 45, 59
10,000-Da dextran-
fluorophore conjugate
Freely filtered by the glomerulus
and somewhat permeant in the
vasculature
Indicates glomerular permeability,
proximal tubule endocytosis, and
vascular permeability
32, 40
40,000-Da dextran-
fluorophore conjugate
Slowly filtered by the kidney, and
largely impermeant in the vasculature
Indicates glomerular permeability,
vascular flow, and vascular permeability
32, 45, 59
7000 to 500,000-Da
dextran fluorophore
conjugate
Not filtered by the kidney, but
retained in the vasculature
Indicates glomerular permeability,
vascular flow, and vascular permeability
15, 16, 25, 32, 34,
39 to 41, 45, 48 to
50, 54, 59
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(Fig. 2). We have found that glomeruli in the C57Bl6 mouse
kidney, made atrophic and fibrotic after ischemia-reperfusion
injury (IRI), may be located superficially and visualized using
MPM because of the atrophy of the tubulointerstitium (unpub-
lished data). Thus, MPM offers enhanced knowledge of kidney
pathophysiology from experimental studies, especially where
modulation of mouse genetics is also used.
The infusion of fluorescent, or fluorescence-conjugated,
probes for live cell imaging allows differentiation of structures
in the kidney, as well as study of the function at the single neph-
ron level. Table 1 identifies common MPM probes that will be
discussed here. The spatial organization of the nucleus in the cell
is paramount not only as a point of reference for cellular sub-
compartments, but also for detailed information on internal
kidney structure when used in conjunction with endogenous
autofluorescence. Hoechst 33342 is a membrane permeable
dye that may be used to stain nuclei blue. Gene delivery
with adenovirus-cDNA constructs containing GFP have been
microinfused successfully into the tubule or vascular space of
the rat kidney and visualized with MPM imaging.37 Although
this approach has not had wide application, it offers a unique
way to study the behavior of any fluorescently tagged protein
in the kidney. Intrarenal blood flow, both glomerular and peri-
tubular, has an intimate relationship with tubular function and
glomerular filtration. The renal microvasculature can now be
imaged at greater depth in real time with MPM. This technique
relies on performing a line scan along the central axis of a vessel
of interest in conjunction with a high molecular weight nonfil-
terable fluorescent dextran (70 kDa).32 Red blood cells do not
take up fluorescent dye and, therefore, present apparent dark
areas for which movement can be measured through time.
This technique has been utilized to study the electronic vascular
signal conduction with nephron synchronization.38 Furthermore,
Kang and colleagues39 have confirmed a significantly higher
flow rate occurs in intraglomerular capillaries compared with
peritubular capillaries with similar diameters and the same
systolic blood pressure. The measured red blood cell speed
in the kidney was found to be higher than in most other vascular
beds, which is consistent with the higher blood flow to the
kidneys.28
3.1 Practical Considerations of In Vivo MPM
The commercialization of MPM has provided a greater degree
of automation compared to earlier models that were based on a
conventional confocal microscope equipped with a secondary
laser. Current systems can be either inverted or upright.
Upright systems need to employ a stabilization device, such
as a kidney cup, to prevent respiratory movement distorting
live images. Inverted systems limit the need for kidney stabili-
zation devices, however, these devices may still be necessary.
Two excellent step-by-step protocols provide a detailed descrip-
tion of effective preparation of the rat kidney and microscope
stage for MPM imaging.32,60 The first decision is whether to
image using objectives in the inverted or conventional mode.
Subsequently, high-quality image acquisition and data reproduc-
ibility of kidney imaging require two important considerations:
(1) the size of the inner muscle layer incision and (2) the imple-
mentation of a kidney stabilization device. Three layers must be
incised to reach the peritoneal cavity to externalize the kidney in
both the rat and mouse: skin, thin outer muscle layer, and thick
inner muscle layer. The incision of the inner muscle layer should
be smaller than the length of the kidney, so that externalization
of the kidney through the incision stabilizes the kidney without
stretching the renal pedicle and reducing renal perfusion. In
some cases (for example, with the objective set to image
from below the animal), a kidney stabilization device may
not be needed because the body weight of the animal effectively
stabilizes the kidney. However, where the body weight of the
animal is small, as for a mouse, stabilization devices may
still be needed. The devices can range in complexity from a sim-
ple cue-tip cotton bud placed near the renal pedicle to a custom-
made kidney cup (for example, for imaging from above the kid-
ney). Suturing the kidney capsule to a fixed point has also been
used to stabilize the kidney. Effective temperature control devi-
ces are also essential for real-time imaging of anaesthetized
Fig. 3 Schematic diagram showing a common setup for intravital imaging of a mouse or rat kidney. The
animal is placed on its side with the exposed kidney lying in a shallow coverslip dish. Appropriate stabi-
lization devices may need to be employed (depicted here are small pieces of autoclave tap stacked upon
each other). The coverslip dish is filled with warm physiological saline, and a heated blanket is placed
over the animal to maintain physiological temperature. Further temperature control devices may be
employed, such as heating pads underneath the animal’s torso and hind limbs and around the micro-
scope objective. Adapted from Ref. 60.
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animals. Figure 3 gives an example of a setup for intravital
MPM, visualizing from below the kidney and employing a cov-
erslip-bottom dish to stabilize the kidney.
3.2 Quantifying Kidney Function
MPM provides an alternate technique to quantify kidney func-
tion during physiological and diseased states. An important
measure of kidney function is its ability to filter molecules,
which may also provide information regarding the site of dam-
age. Quantifying renal permeability of any macromolecule with
intravital MPM requires conjugation of a fluorphore to a known
molecule and identification of kidney microstructure compart-
ments. Two excellent descriptions of methods are available:
ratiometric determination of glomerular filtration rate (GFR)
was applied during physiological and acute kidney injury
conditions,61 and similar use has been made of the glomerular
sieving coefficient (GSC).60 When quantiying changes in fluo-
rescence from specific compartments, it is important to compen-
sate for background fluorescence for each image by subtracting
the average fluorescence intensity within the compartment of
interest prior to injection of fluorescent biomarkers from the
average intensity from the same region taken after infusion.
The fundamental principle for assessing GFR using intravital
MPM is to monitor the decay of a fluorescent reporter molecule
from the vascular lumen or extracellular space over time
following a bolus injection, and not neccesarily only from
within the glomerulus and Bowman’s space. The procedure
relies on the use of one compartment, and one reporter molecule,
and is known as a one-compartent model. The process is greatly
enhanced by incorporating a second, larger (kDa), species of
fluorescently labeled conjugate infused into the aminal at the
same time, thereby having the larger-size conjugate confined
to the vascular space and the other freely filterable by the kidney.
Measuring the fluorescence ratio of the larger to the smaller
molecule, rather than purely relying on measuring the fluores-
cence only from the freely filterable smaller molecule, signifi-
cantly enhances the accuracy of GFR measurment by reducing
the fluctuation of the signal caused by movement of the focal
point.62 Using this method, GFR may be rapidly quantified;
however, a large number of data points are needed to assess
the kinetics of conjugated molecules adequately. GFR values
obtained via this method using fluorescein isothiocyanate
(FITC)-inulin (reporter) and 500-kDa Texas Red-dextran
(large molecule) were found to have a Pearson correlation coef-
ficient of 0.85 when compared to GFR values obtained via stan-
dard inulin clearance from blood and urine.61
Determining the GSC is another useful quantitative measure
based on the fundamental concept of fluorescence decay
between compartments. This method requires 3-D data sets
acquired from glomeruli, and localization of glomerular capil-
lary loops, Bowman’s space, and the S1 segment of the proximal
tubule. Serum albumin, conjugated to Texas Red, has been used
extensively to quantify the GSC of albumin in rats, and prepa-
ration of the conjugated fluorphore has been described.60 During
rat intravital MPM preparations, prior to infusion of reporter
molecules, glomeruli appear as dark circular spaces surrounded
by autofluorescent proximal tubules, and these should be demar-
cated in situ to allow ease of transition between glomeruli.
Following infusion of the fluorescent reporter, an appropriate
time is allowed for systemic distribution of the fluorophore
before aquiring 3-D volumes of selected glomeruli at ∼1-μm
intervals. 3-D data image analysis software (for example,
MetaMorph Microscopy Automation and Image Analysis
Software; Volocity 3D Image Analysis Software; and Imaris
Scientific 3D/4D Processing and Analysis Software) is available
and often free, and facilitates export of 3-D volumetric data. To
obtain the volumetric data, the capillary loop containing the
fluorescent marker and the empty space (Bowman’s space)
between its margins and Bowman’s capsule need to be identi-
fied, taking note of the average intensity reading within the
capillary loop and the average intensity reading in Bowman’s
space from the same focal plane. Adequate background readings
prior to fluorescence marker infusion are necessary. The GSC
can then be determined using the equation
GSC ¼ ðraw Bowman’s space intensity−background Bowman’s space intensityÞðraw capillary loop intensity−background capillary loop intensityÞ .
Similar principles can be applied to the reabsorption of the
fluorescent marker within the S1 segment of the proximal
tubule.
Four-dimensional cell tracking over time, combined with
MPM, has also produced novel data in the field of immunology
and immune cell tracing,5,63,64 and has been used in the kidney to
describe a new paradigm of leukocyte recruitment in the glo-
merulus.35 A detailed methodology for the data acquisition
and analysis is available.65 The possibility of the visualization
and quantitation of kidney myofibroblast proliferation during
profibrotic processes in the kidney presents an interesting oppor-
tunity that remains untapped.
3.3 Significance of Endogenous Fluorescence
Autofluorescence is commonly a hindrance of routine fluores-
cence microscopy, yet it is used to advantage in MPM. The
reduced form of nicotinamide adenine dinucleotide (NADH)
is a useful and plentiful endogenous fluorophore in the kidney
due to the high density of mitochondria of which NADH is a
metabolic substrate.27 Images captured without the infusion of
fluorescent dyes can rely on this signal for basic information of
tubular structure. As the fluorescence excitation, emission, and
fluorescence lifetime of NADH and NADPH overlap, these two
molecules are measured together and referred to as NAD(P)H.66
Hall and colleagues40 have demonstrated that the mitochondrial
membrane-dependent fluorophore tetremethyl rhodamine methyl
ester (TMRM) colocalizes with the endogenous fluorescence
pattern of NAD(P)H. Changes in the intensity of NAD(P)H
fluorescence can provide valuable information regarding cell
metabolism, given that the oxidized form (NADþ) is nonfluor-
escent (see Fig. 4, comparing the healthy kidney with ischemia-
reperfused kidney; our data). NAD(P)H is a respiratory substrate
for complex I of the mitochondrial electron transport chain. The
total emitted fluorescence is, therefore, equal to the total NAD
pool in a reduced state. A quantitative measure of this fluores-
cence provides information of the mitochondrial redox state,
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which is dependent on factors such as substrate supply and mito-
chondrial respiratory chain function. Detailed measurements
can also be made using fluorescence lifetime imaging (FLIM)
techniques, which are discussed in more detail below. Flavins,
which only fluoresce in their oxidative state, can provide further
information of the cellular redox state. The autofluorescent
properties of NAD(P)H can also be a problem when using
MPM, especially in proximal tubules, as it can interfere with
quantitative analysis when using some fluorophores that have
overlapping excitation/emission.
Functional autofluorescent markers have also been used to
detect accumulation of the so-called aging or wear and tear pig-
ment, lipofuscin, in retinal pigment epithelial cells and the
brain.67,68 To our knowledge, this has not been carried out in the
kidney, despite the presence of lipofuscin in the atrophic kidney.
In addition, aberrant indoleamines, such as serotonin (5-HT)
and melatonin, under conditions of oxidative stress can form
dimerized indolamine oxidation products producing intrinsic
fluorescence that can be detected by three-photon excitation.
This approach has been used to image 5-HT granules induced
in mucosal mast cells by oxidative stress.19
3.4 Multiphoton Microscopy and FLIM
The fluorescence lifetime of a fluorophore is the mean time a
fluorophore remains in an excited state before emitting a photon
(fluorescence) and returning to the initial ground state. The
fluorescence lifetime of a fluorophore, either endogenous or
synthetic, depends on the type of molecule, its conformation,
and the way the molecule interacts with the surrounding micro-
environment.69 FLIM constructs a spatial distribution map of
fluorescence lifetimes of a sample imaged by confocal, multipho-
ton, endoscopic, or wide-field microscopy.70 Importantly, FLIM
microscopy can be used to measure molecular environmental
parameters, the metabolic state of cells and tissues via endog-
enous autofluorescence, drug distribution and interactions, and
protein-interactions by fluorescence resonance energy trans-
fer (FRET).
There are two major approaches used to measure the fluores-
cence lifetime of a sample: time-domain and frequency-domain.
For time-domain FLIM, the fluorescence of a sample is acquired
by time-correlated single-photon counting (TCSPC) to generate
a lifetime decay curve. The lifetime curve is generated by repeat-
edly measuring the appearance of an emitted photon following
an excitation pulse from the confocal or multiphoton laser
source. This approach allows for the direct measurement of
the decay curve, which is modeled to an exponential function
according to the number of estimated components (i.e., indepen-
dent physiochemical states of one or more fluorophores). The
advantages of time-domain FLIM include the direct measure-
ment of the decay curve, calculation of fluorescence lifetimes of
the major components (typically a maximum of three to four),
and relatively simple analysis compared to frequency-domain
FLIM. Time-domain FLIM in multiphoton microscopy may
require longer acquisition times compared to frequency-domain
in order to generate an accurate decay curve. However, time-
domain FLIM by TCSPC delivers excellent signal-to-noise
ratio for weak signal samples.70,71
For frequency-domain FLIM, the intensity of the excitation
light source is modulated sinusoidally at a radio frequency. The
resulting emission fluorescence has the same frequency as the
excitation light, but demonstrates changes in phase and ampli-
tude (demodulation) relative to the incident light depending on
the fluorescence lifetime.72 For multiphoton frequency-domain
FLIM, an image intensifier is used to modulate the gain of the
detector at the same frequency as the incidence light. Ideally, the
fluorescence lifetime of a single molecule with one physiochem-
ical state will be identical to both the phase and modulation
Fig. 4 Endogenous fluorescence of NAD(P)H excited at 740 nm (green) in the healthy (a) and ischemia-
reperfused mouse kidney (b). Seven-week-old C57Bl6 mice were anesthetized, a lateral flank incision
made, and 20 min ischemia-reperfusion performed. Images were captured using a Lavision Biotec Nikon
multiphoton microscope to a depth of 71 μm from the kidney capsule. Imaris 7.6.0 software was used to
adjust images to normalized fluorescence. 740-nm two-photon excitation clearly demonstrates the cort-
ical tubular network with distal tubules, proximal tubules with associated brush border, and interstitial
space (a). In (b), tubular pathology during the 20 min following renal ischemia demonstrates tubular
cell effacement (white arrow), formation of cast material (*), and epithelial cell striations (black
arrow). Excitation wavelength was 740 nm and emission was detected using three nondescanned filters:
447 to 460 nm (blue), 485 to 550 nm (green), and 593 to 600 nm (red). A 20× 0.95 NA water immersion
objective (Olympus) was used. Scale bar represents 50 μm.
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lifetimes.71,72 The advantage of the frequency-domain FLIM is
comparatively better signal-to-noise ratio than time-domain FLIM
via TCSPC for complex systems with multiple fluorophores.
3.5 Multiphoton FLIM Applications
A useful application of FLIM in conjunction with MPM in the
kidney is measuring the fluorescence lifetime of NAD(P)H.
NAD(P)H lifetime measurements are widely used for metabolic
and redox imaging in vitro and in vivo.2,7,73–76 The lifetime of
NAD(P)H is resolved as a two-component system with the short
(∼0.3 to 4 ns) and long (∼2.3 ns) lifetimes represented as
the free and protein-bound conformations, respectively.72,77,78
As previously mentioned, the reduced form of NADH, NAD
+, is not fluorescent and the ratio of NADH:NAD+ has been
used previously as a measure of the redox state of the cell.
Bird and colleagues demonstrated that the free-to-bound ratio
of NAD(P)H, represented by the ratio of the amplitude coeffi-
cients for the short and long lifetimes (i.e., α1∕α2), is related to
the NADH/NAD+ ratio and can be used as an indicator for redox
changes within the cell.73 While the free-to-bound ratio of NAD
(P)H can be used to measure redox changes within the cells,
this ratio should not be confused with the widely used redox
ratio that is calculated by measuring the ratio of flavin adenine
dinucleotide (FAD) to NADH intensity.79
FAD is also examined routinely by FLIM for intracellular
metabolic and redox analysis. While FAD can be found in
a free and protein-bound conformation, the former has a signifi-
cantly higher quantum yield with a lifetime of 2.91 ns.72 In con-
trast to NAD(P)H, only the oxidized form of FAD is fluorescent
and is used to measure changes in the redox state of the cell in
combination with NADH.79
Figure 5 shows a depth- and spectrally resolved stack of mul-
tiphoton FLIM images and corresponding lifetime histograms
measured from a healthy mouse kidney. TCSPC was used to
generate the lifetime decay curve for each image (depth range:
120 μm) and fit to a two-component exponential function. Two
spectral windows were used to simultaneously isolate the fluo-
rescence lifetimes of NAD(P)H (350 to 450 nm) and FAD (515
to 620 nm). The data show a relatively consistent average life-
time of NAD(P)H as the imaging depth increases. Similarly, the
FAD lifetime shows a tendency for a minimal decrease in aver-
age lifetime with depth. As expected, the total fluorescence
intensity decreased with depth. This figure demonstrates that
multiphoton FLIM yields consistent lifetime data, which can
be used to assess changes in the metabolic and redox states
of the tissue, with increasing depth imaging of the kidney.
Cellular autofluorescence lifetime has also been used to dis-
tinguish between normal, dysplastic, and cancerous tissues,
including oral,74 breast,80 basal cell carcinoma,81 and head
and neck squamous cell carcinoma.82 In addition, FLIM was
used to characterize morphological features of basal cell carci-
noma within in vivo human skin.83,84 The fluorescence lifetime
properties of FAD and porphyrin were used to distinguish
between normal kidney and renal cell carcinoma within the liv-
ing rat kidney.85 The fluorescence lifetime of NAD(P)H and
FAD is a viable indicator of IRI within the liver1,2 and kidney86
in vivo. The fluorescence lifetime changes associated with
necrosis76 and apoptosis87,88 have also been described and
can be used to measure tissue responses to drug treatments
and disease states89 within the kidney.
FRET describes the energy transfer from a donor to an
acceptor fluorophore with overlapping emission and excitation
spectra, respectively.90 However, the two substrates must be
within a critical distance of each other so that the donor energy
is quenched by the acceptor.91 Therefore, measuring the fluores-
cence lifetime of the donor substrate can provide quantitation of
protein–protein proximity and interactions.92,93 This technique
has been harnessed in conjunction with MPM and FLIM in stud-
ies of renin synthesis in the kidney: by utilizing fluorescence-
based fluorogenic renin substrates, the direct visualization of
the enzyme activity of renin in vivo, rather than only the granular
content, has been seen.24,41 These fluorogenic renin substrates
contain donor and acceptor fluorophores connected by a
sequence of rodent angiotensinogen, which includes the renin
cleavage site. In the absence of renin activity, the donor fluores-
cence is quenched by the acceptor molecule due to its close
proximity and FRET. In the presence of renin and subsequent
cleavage of angiotensinogen producing separation of the donor
and acceptor, fluorescence is recovered and can be visualized.
This technology potentially offers unique insight into disease
models of altered renin-angiotensin-aldosterone system (RAAS)
activation. More recently, Baird and coworkers have developed
a quantitative FRET system using MPM to investigate the
interaction of NF-E2 p45-related factor 2 (Nrf2) and its in-
hibitor Kelch-like erythroid-cell-derived protein with CNC
homology [ECH]-associated protein 1 (Keap1).94 The Nrf2/
Keap1 complex is a master regulator of cytoprotective genes95
and has been shown to play a role in both acute and chronic
kidney pathologies.96–98
4 Utilization of Multiphoton Fluorescence
Microscopy in the Kidney
4.1 Multiphoton Microscopy and Renal Physiology
The ability of MPM to provide high-resolution real-time optical
sections that can produce 3-D images has led to significant
improvements in our understanding of kidney physiology.
Interactions between hormones, tubular cells, and vessels can
all be observed. In particular, our understanding of the functions
of the juxtaglomerular apparatus (JGA), tubular transport, and
glomerular filtration have all improved. Powerful studies have
utilized single nephrons to demonstrate tubulovascular inter-
actions, the intrarenal RAAS, renal vascular flow rate, and
permeability. Subsequently, this has uncovered subcellular proc-
esses that can also be visualized and include apoptosis, necrosis,
mitochondrial dynamics, reactive oxygen species (ROS) pro-
duction, cytosolic ion concentrations, pH, signal propagation,
and protein expression.32,42
Some of the first insights into kidney function using MPM
were found after imaging of the JGA.26 The JGA is a critical
structure that regulates renal blood flow and glomerular filtra-
tion for a single nephron, and the multiple cell types of the JGA
make real-time MPM 3-D reconstruction of living kidney prep-
arations an ideal tool for studying the structure. The cell types
include mesangial cells, secretory granular epithelioid cells, vas-
cular smooth muscle cells, vascular endothelium, and macula
densa tubular epithelial cells. Macula densa cells in the thick
ascending limb detect changes in fluid osmolality and/or NaCl
concentration via specific transport mechanisms and send sig-
nals through mesangial cells to the glomerulus (tubuloglomer-
ular feedback), resulting in vascular resistance and renin release
by granular mesangial cells.99
Initial MPM approaches utilized in situ isolation of glomeruli
with attached afferent and efferent arterioles, S1 segments of the
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proximal tubule, and the cortical thick ascending limb of the
loops of Henle. By increasing the osmolality and NaCl concen-
tration of tubular perfusate, this approach allowed direct visu-
alization of the tubuloglomerular feedback mechanism. It was
noted that macula densa cells swelled significantly, most likely
due to increased NaCl transport, and that membrane blebbing
of the apical membrane of the macula densa also occurred,
resulting in afferent arteriole constriction.26 The inclusion of
angiotensin II (AngII) in the perfusate also decreased the glo-
merular capillary diameter and increased the calcium concentra-
tion in cells of the JGA.26 Liu and Persson100 then demonstrated
that macula densa cells could regulate their volume and that cal-
cium elevation, due to decreased tubular NaCl and osmolarity,
was not dependent on cell volume. Furthermore, physiological
Fig. 5 Fluorescence lifetime imaging (FLIM) of (a) NAD(P)H and (b) flavin adenine dinucleotide (FAD) in
healthy mouse kidney. Seven-week-old C57BI6 mice were sacrificed and the kidney excised prior to
multiphoton FLIM imaging on the JenLab DermaInspect microscope at an excitation wavelength of
740 nm. Endogenous fluorescence was separated into two emission channels, (a) 350 to 450 nm
and (b) 515 to 620 nm, corresponding to NAD(P)H and FAD, respectively. Z-stack FLIM images
were taken from a depth of ∼20 μm below the kidney surface and are pseudo-colored according to
average weighted τm lifetime (0 to 2000 ps; blue-green-red). Scale bare represents 40 μm.
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increases in luminal NaCl concentration and osmolality could
result in macula densa cell shrinkage, a change that may
have implications for cell signaling.101
Studies using MPM fully show the integrated nature of cell-
to-cell communication in the kidney. MPM on live kidney tissue
and confocal microscopy on fixed kidney tissue have combined
to give a novel understanding of JGA physiology. MPM allowed
the visualization of endothelial fenestrations of the JGA portion
of the afferent arteriole for the first time.25 The release of renin
into the JGA interstitium, a common and integral component for
endocrine function, was therefore demonstrated. Using tech-
niques similar to that of MPM, standard confocal microscopy
has highlighted that tubuloglomerular feedback relies on a cal-
cium-dependent vasoconstriction caused by extracellular ATP
and gap junction communication in the JGA.56 Electronic vas-
cular signal propagation in isolated JGA preparations has also
been visualized with a fluorescent voltage-sensitive dye loaded
into tubular-vascular preparations highlighting nephron syn-
chronization.38 Recently, Peppiatt-Wildman and colleagues55
have taken a subcellular approach to calcium handling in the
kidney to complement these studies. Using calcium-sensitive
fluorophores and transgenic mice expressing the GCaMP2-
calcium sensor, they were able to record calcium dynamics
from endothelial, glomerular, and tubular origins.
Another primary role of JGA cells is to release renin into the
vasculature to activate the RAAS, which maintains body salt and
water balance. Renin release is slow and, therefore, is the rate-
limiting step of the RAAS pathway. As such, the temporal infor-
mation that MPM provides adds value onto more conventional
methods of analysis. Specific labeling of JGA granular cells
containing renin with acidotrophic fluorophores that are highly
membrane-permeant, therefore accumulating in acidic cellular
organelles, allows temporal and spatial tracking of renin activity
at a cellular level. The JGA is the classic anatomical site of renin
synthesis and its biosynthetic precursor prorenin; however,
significant amounts of renin have been found in the principal
cells of the connecting tubule as well as the cortical and medul-
lary collecting ducts.16,102,103 The study of renin dynamics
using acidotrophic fluorophores, such as quinacrine and Lyso
Tracker-Red, must be interpreted with caution given that
these studies rely on surrogate molecules being observed rather
than renin itself.
4.2 New Paradigms in Renal Physiology
The postglomerular uptake of selected glomerular filtrates con-
tributes to the complex process of urine production. The simul-
taneous visualization of tubular uptake and glomerular filtration
provided by MPM has allowed direct quantification of single
nephron filtration. These measurements utilize dextrans of
varying molecular weights conjugated to fluorophores. The
approach has already challenged our understanding of the eti-
ology of albuminuria. Russo and colleagues43 used a puromycin
aminonucleoside nephrosis rodent model. They administered
fluorescent serum albumin to rats and demonstrated that the glo-
meruli filter albumin at nephrotic levels in both controls and
rats with nephrosis (albumin excretion rate >300 mg∕day);
however, a rapid retrieval of almost all albumin occurred at
the epithelium of the S1 segment of the proximal tubule in con-
trol rats, but not nephrotic rats. This result is in direct contrast
with previous studies that measured glomerular-tubular filtration
using micropuncture techniques.104,105
The proximal tubule apical endocytotic machinery megalin,
vacuolar H+-ATPase A subunit, and clathrin were shown to
decrease in expression in nephrotic rats, and this provides a pos-
sible mechanism for albuminuria.43,106 Quantitative MPM
studies were performed to validate the result, with some finding
the GSC of albumin much lower than reported.44,53,107 However,
the issue remains controversial,108–111 with debate on the ability
of MPM to identify multiple factors that influence glomerular
albumin permeability, including the depth of image acquisition,
the selection of fluorophore, genetic strain of rat, and dietary
status.53,112 The generalized polarity concept, whereby the inten-
sity difference between two fluorescent molecules is normalized
to the total intensity of the two dyes, has revealed further
differences in proximal tubule uptake following glomerular
filtration. Specifically, negatively charged 40-kDa dextran is
more readily absorbed in the proximal tubule than neutral
40-kDa dextran.45
4.3 Multiphoton Microscopy and Renal
Pathophysiology
Significant advancements have been achieved using MPM in
experimental models of kidney disease. Possibly, the most valu-
able aspect of the utilization of MPM in models of kidney path-
ophysiology is the temporal and spatial imaging of subcellular
processes, such as apoptosis, necrosis, and mitochondrial
dynamics. Renal IRI,14,27,40,113,114 kidney cyst development,57
diabetic nephropathy,16,39,44,115 renal inflammation,35,116,117 and
gentamicin toxicity14 have been investigated using MPM.
Renal IRI is the most common form of acute kidney injury
and has been studied extensively. As an experimental model,
this has a translational focus for transplant nephrology and is a
useful model to study cellular responses to IRI. IRI is charac-
terized by tubular swelling, cell death (apoptosis and necrosis),
mitochondrial dysfunction, inflammatory responses, and
deregulated vascular function.46 Microvascular and tubular com-
ponents of the kidney have mutual, as well as unique, responses
to IRI, which contribute to decreased kidney function. Given
that IRI is potentially reversible, MPM can be used to image
these cellular processes and then determine the success, or fail-
ure, of novel interventions. Recently, Hall and colleagues14 have
usedMPM to demonstrate the role of redox alterations occurring
as a result of IRI. By using endogenous NADH fluorescence,
mitochondrial selective probes (TMRM), ROS-sensitive dyes
[dihydroethidium (DHE)], and glutathione indicators, they
have shown that IRI mainly affects the distribution of mitochon-
dria in the proximal tubular epithelium, with increased superox-
ide levels. Although increased ROS have been implicated in the
pathophysiology of IRI before, MPM has allowed direct visu-
alization of ROS in conjunction with cell damage. MPM image
analysis of IRI during two models of kidney transplantation has
revealed cast formation in the tubular profiles, mainly from
increased tubular injury, necrosis, and apoptosis.51 This study
also assessed the efficacy of p53 siRNA during rodent kidney
transplantation and found that it significantly improved kidney
function and decreased cast formation, perhaps by increasing
blood flow through the vasculature.
Inflammation within the kidney may be reparative or profi-
brotic; however, the underlying mechanisms remain poorly
understood. Routine histological analysis, of necessity at a sin-
gle point in time, often fails to uncover important cellular inter-
actions given the high motility of circulating inflammatory cells
in a time-dependent manner. Recently, MPM revealed a new
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leukocyte recruitment paradigm in the glomerulus of the
inflamed kidney.35 This has implications for glomerular base-
ment membrane disease and other forms of immune cell-medi-
ated glomerulonephritis, common causes of end-stage kidney
disease, associated with inflammatory cell recruitment to the
glomerulus. Devi et al.35 used MPM of glomeruli in mice in
combination with fluorescence-based approaches for labeling
leukocytes to demonstrate that even in the absence of inflamma-
tion, neutrophils and monocytes undergo transient (∼5 min)
periods of retention and migration in the glomerular capillaries
before returning to the bloodstream. In addition, in three sepa-
rate models of glomerular inflammation, neutrophils increased
their dwell time in the glomerulus in response to inflammation.
This model also spatially tracked neutrophils and monocytes,
separating them into static and crawling groups. In addition,
∼30% of intravascular neutrophils in the inflamed glomeruli
generated ROS that were detected by DHE, which also dis-
played increased dwell time.35
The manipulability of mouse genetics combined with intra-
vital microscopy is especially useful in the field of renal immu-
nology. Soos and colleagues118 used conventional intravital
confocal microscopy in the CX3CR1GFP∕þ mouse in the normal
kidney to examine interstitial macrophages and dendritic cells in
the normal kidney. This demonstrated the contiguous network
and probing dendritic behavior throughout the entire kidney.
Using a robust model of kidney inflammation and fibrosis
[unilateral ureteral obstruction (UUO)] and MPM, renal den-
tritic cells identified via endogenous expression of yellow fluo-
rescent protein (YFP) in CD11c-YFP mice were seen to adapt to
a proinflammatory phenotype to activate T-cells. However, fol-
lowing dentritic cell depletion, UUO mice continued to develop
fibrosis, indicating that these cells do not directly contribute to
fibrosis.116 Fluorescently labeled Escherichia Coli has been
used in a model of upper urinary tract infection and visualized
using MPM. This study revealed the initial stages of neutrophil
infiltration with the Hoechst 33342 fluorophore and morphol-
ogy as well as vascular, tubular, and lymphatic structural inter-
actions.117 The use of GFP-labeled immune components in these
murine models, as well as fluorophore-conjugated antibodies,
have fully utilized immunological analyses using MPM.
Diabetic nephropathy is the leading cause of chronic kidney
disease worldwide and comprises a large proportion of nephrol-
ogy research. The progressive nature of diabetes-induced kidney
damage, coupled with the quantitative aspects of MPM image
acquisition and analysis, allows structural and functional rela-
tionships to be explored. The previously mentioned controversy
of the nonglomerular origin of albuminuria has been further sup-
ported in models of streptozotocin-induced diabetes in rats.44,115
The GSC of albumin was found to be unaltered in 12-week-old
diabetic rats compared to controls. Infusion of a 69-kDa FITC-
dextran (which has the same GSC as albumin) in control rats
was not retained in the plasma following 24 h; however, albu-
min-Alexa568 (used to image albumin with MPM) was well
retained in the plasma.44 This supported the theory that filtered
albumin was reabsorbed by the proximal tubule epithelium and
returned to the circulation. This system of reabsorption appears
to be disturbed early in diabetes within the proximal tubular
cells captured in vivo using MPM, showing a marked reduction
in intracellular uptake of albumin-Alexa568. However, despite
albuminuria being an outcome in diabetic nephropathy, the
question still remains as to what causes a disruption of the proxi-
mal tubule endocytosis machinery. Studies have shown that
proximal tubule albumin uptake relies on clathrin- and recep-
tor-mediated mechanisms.119,120 Proximal tubule endocytosis
is modulated by AngII through AngII (type 2) receptor mediated
protein kinase B activation and may present a target for
albuminuria.121
Diabetes also increases collecting duct prorenin levels,
observed by quinacrine-labeled renin/prorenin granules and
MPM, suggesting that prorenin content and release from collect-
ing duct cells may be more important than the JGAwhen regu-
lating levels ofAngII in diabetes.16 This alternate pattern ofAngII
renin stimulationmakesMPMan ideal tool, compared with fixed
whole kidney or cortex preparations, and provides a theoretical
pathway for inhibiting proximal tubular albumin endocytosis
early in diabetes. Using the same rodent model of diabetes (strep-
tozotocin-induced diabetic rat), Satoh and colleagues115 demon-
strated early morphological changes in glomeruli at four and
eight weeks, including glomerular hypertrophy and an increased
diameter ratio of afferent and efferent arterioles, which correlated
to hyperfiltration of a 40-kDa dextran fluorophore. However, the
hyperfiltration of the glomeruli had already occurred before the
diabetic rats developed albuminuria. A novel finding relating to
established proteinuric kidney disease has shown significant
alterations to endothelial surface layer of the glomerulus.122
This endothelial glycocalyx composed of glycosaminoglycans,
proteoglycans, absorbed plasma components, and a loose matrix
is significantly reduced in old spontaneously proteinuric kidney
disease rats. This technique utilized MPM in conjunction with
various fluorochrome-conjugated lectins to specifically label
the glomerular glycocalyx in conjunction with physiological
microvascular permeability measurements.
Polycystic kidney disease is an autosomal dominant genetic
disorder that often leads to destructive renal cyst development.
Studies into the pathophysiology of autosomal dominant poly-
cystic kidney disease (ADPKD) using MPM are limited, yet
provide an untapped opportunity, given that the tubule-derived
cysts often lack important transport functions. Sulfonefluores-
cein, which is a fluorescent organic anion that has been
shown to be secreted from kidney proximal tubular cells,58 pro-
vides a useful tool to study tubule-derived cysts. Tanner and col-
leagues57 have demonstrated in heterozygous Han:SPRD rat
with ADPKD that sulfonefluorescein accumulation in proximal
tubules was diminished compared with control proximal tubules
in control rats. However, the proximal tubule epithelial cells of
cysts were variable in accumulating sulfonefluorescein, sug-
gesting a broad deficiency in transport functions.
5 Conclusion: Future Advances in
Multiphoton Microscopy in the Kidney
The use of MPM imaging has rapidly increased over the past
decade and with this comes an unprecedented possibility for
advancements in our knowledge in live cell physiology and
pathophysiology. A major limitation to current MPM technol-
ogies in the kidney is the limitation of imaging depth in the
cortex. Continuing efforts toward imaging at greater depths,
possibly into the medulla, are needed. New infrared dyes with
longer wavelengths that penetrate deeper due to less absorption
and scattering appear to be the next step. Researchers are also
continuing to find new applications for MPM technology. The
use of a compact and flexible microendoscope utilizing multi-
photon excitation has been used to visualize rodent colon, kid-
ney, and liver in vivo.123 This opens the possibility of in vivo
imaging in human organs. MPM has already been applied in
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a clinical setting to assess skin diseases124 and gastric cancer.125
Peti-Peterdi and colleagues42 have now demonstrated the uncon-
ventional use of multiphoton lasers as micromanipulators in the
kidney. By focusing the multiphoton excitation laser beam at a
small site, such as the capillary wall in the glomerulus, the local
tissue damage can cause a disruption and may help to study
the local effects of this damage. Recently, Corridon and col-
leagues126 developed a method to facilitate and monitor the
expression of exogenous genes in the rat kidney using plasmid
and viral vectors, which can be visualized with MPM.
In conclusion, the ability to visualize and quantify cellular and
intracellular processes in multiple dimensions in living animals
offers endless rewards in experimental nephrology research.
MPM provides an avenue to answer some unknown kidney
processes both in terms of physiology and pathophysiology.
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APPENDIX B 
 
General Reagents and Solutions 
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B.1 Trypsin / Versene 
10x Versene (500 mL) 10x PBS (1 L) 
NaCl 40 g NaCl 80 g 
KCL 1 g KCl 2 g 
NaHPO4.12H2O 14.14 g NaHPO4 14.4 g 
KH2PO4 1 g KH2PO4 2.4 g 
EDTA 10 g  
 
 In a 1 L beaker: 
10 mL of 10x versene (above) 
100 mL of 10x PBS (above) 
 Make up to 1 L with MilliQ water and pour into a 2 L bottle. 
 Autoclave and leave to cool. 
 Add 20 mL of 2.5 % trypsin (10x) liquid (Gibco, Catalogue no. 15090) at 37 ºC to 
versene/PBS solution pre-cooled to room temperature.  
 Aliquot into 50 mL falcon tubes and store at -20 ºC. 
B.2 1 x PBS 
 In a 1 mL beaker: 100 mL of 10x PBS (above) 
 Make up to 1 L with MilliQ water. 
 Autoclave for sterility if required. 
B.3 1 x TBST (high salt) 
TBST - High Salt (4 L) 
Tris 9.69 g 
NaCl 116.88 g 
10% Tween 20 20 mL 
pH 7.4 – 7.5 using HCl 
 
B.4 4% buffered paraformaldehyde (PF) in sodium phosphate buffer 
4 % PF (2 L) 
Paraformaldehyde pellets 80 g 
NaH2PO4 6.2 g 
Na2H PO4 28.5 g 
Barnstead water 1600 mL 
 
 In a beaker, add reagents as stated above. 
 In a fume hood, heat at 60 ºC while stirring. Do not let the temperature of the solution roise 
above 80 ºC. Add approximately 15-20 NaOH pellets to assist dissolving solids. 
 pH the solution to 7.2. 
 Make the total volume up to 2 L using MilliQ water. 
 Filter the solution with a 0.2 µm filter and aliquot into 50 mL falcon tubes and store at -20 
ºC. Defrost in refrigerator before use. 
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B.5 Radioimmuno precipitation (RIPA) buffer 
 Prepare 50 mM Tris-Cl (pH 7.5) by dissolving 6.06 g of Tris in 900 mL of sterile water, 
adjusting the pH to 7.5 and making up to 1 L. Autoclave and store at room temperature. 
 Add the following to 200 mL of 50 mM Tris-Cl (pH 7.5): 
RIPA buffer (200 mL in 50 mM Tris-Cl, pH 7.5) 
NaCl (150 mM) 1.75 g 
NaF (25 mM) 0.21 g 
EDTA (0.5 mM) 0.037 g 
SDS (0.1 % w/v) 0.2 g 
Sodium deoxycholate (0.5 % w/v) 1.0 g 
IGEPAL CA-630 (1 %) 2 mL 
 
 Prior to use, add the following proteinase and phosphatase inhibitors to 10 mL of RIPA 
buffer and mix well (vortex): 
RIPA additives prior to use 
Phenylmethylsulfonyl fluoride (PMSF) (100 µg/mL) 200 µL 
Leupeptin (10 mg/mL) 10 µL 
Aprotinin (10 mg/mL) 10 µL 
Sodium orthovanadate (Na3VO4) (200 mM) 50 µL 
 
B.6 SDS-PAGE buffer solutions and gel recipes 
 Resolving gel buffer – 48 mL 1M HCl + 36.33 g Tris base per 100 mL (pH 8.9). Store at 
room temperature. 
 12% ammonium persulfate – (w/v), store in dark at 4 ˚C. 
 Spacer gel buffer – 6.055 g Tris base (pH 6.7) per 100 mL, store at 4 ˚C. 
 Running buffer – 3 g Tris base + 14.4 g glycine + 10 mL 10 % SDS per 1 L of H2O 
 4X Sample buffer – 1.25 mL spacer gel buffer + 1 mL 10 % SDS + 1.5 mL glycerol + 0.1 
mL β-mercaptoethanol + 1.15 mL H2O + 0.25 g bromophenol blue to colour the solution. 
 Transfer buffer – 3 g Tris base +14.4 g glycine + 10-20 % methanol per 1 L of H2O. 
 
B.7.1 Resolving Gel (25 mL) 
 
Resolving Gel (25 mL – 4 Gels) 
% Gel 8 10 12 15 20 
30% acrylamide 6.664 mL 8.33 mL 9.996 mL 12.495 mL 16.66 mL 
H2O 14.806 mL 13.14 mL 11.474 mL 8.975 mL 4.81 mL 
Resolving gel buffer 3.13 mL 3.13 mL 3.13 mL 3.13 mL 3.13 mL 
10% SDS 250 µL 250 µL 250 µL 250 µL 250 µL 
12% ammonium 
persulphate 
143 µL 143 µL 143 µL 143 µL 143 µL 
TEMED 12 µL 12 µL 12 µL 12 µL 12 µL 
 
 
292 
 
B.7.2 Spacer Gel (10 mL) 
Spacer Gel (10 mL – 4 Gels) 
% Gel 4 7 
30% acrylamide 1.33mL 2.3275mL 
H2O 6.115mL 5.1175mL 
Spacer gel buffer 2.4mL 2.4mL 
10% SDS 75µL 75µL 
12% ammonium 
persulphate 
75µL 75µL 
TEMED 5µL 5µL 
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APPENDIX C 
 
Dose-Response Validation 
  
294 
 
 
 
 
 
